

**LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY D/B/A
BLUE CROSS AND BLUE SHIELD OF LOUISIANA**

*a mutual insurance company organized
and existing under the laws of the State of Louisiana*

**PLAN OF REORGANIZATION
REGARDING THE CONVERSION
FROM A MUTUAL INSURANCE COMPANY
TO A STOCK INSURANCE COMPANY**

under LSA-R.S. §§ 22:72 and 22:236 *et seq.*

**Proposed by the Board of Directors of
Louisiana Health Service & Indemnity Company d/b/a
Blue Cross and Blue Shield of Louisiana on
January 23, 2023**

TABLE OF CONTENTS

	Page
ARTICLE I. Manner of Reorganization.....	4
Section 1.1. Reorganization to a Stock Insurance Company.....	4
Section 1.2. Establishment and Funding of the Foundation.....	4
Section 1.3. Purchase and Sale of BCBSLA Shares	5
Section 1.4. Effectiveness of this Plan	6
Section 1.5. ERISA Plans; Tax-Qualified Policies	6
Section 1.6. Continuation of Corporate Existence	6
ARTICLE II. Extinguishment of Membership Interests	6
ARTICLE III. Distribution of Consideration.....	7
ARTICLE IV. Determination of the Equitable Consideration for Extinguishment of Membership Interests.....	7
ARTICLE V. Form and Amount of Consideration to be Distributed.....	7
ARTICLE VI. Method or Formula for the Allocation of Consideration	7
ARTICLE VII. BCBSLA Pays No Dividends	8
ARTICLE VIII. Address and Telephone Number of BCBSLA.....	8
ARTICLE IX. Approval by the Commissioner	8
Section 9.1. Commissioner’s Public Hearing on this Plan; Commissioner’s Order.....	8
Section 9.2. Notice of Public Hearing	8
Section 9.3. Findings Required for Approval.....	9
Section 9.4. Notice of Approval Order.....	9
ARTICLE X. Approval by Members.....	9
Section 10.1. Voting	9
Section 10.2. Notice of Special Meeting	9
ARTICLE XI. Additional Provisions.....	10
Section 11.1. Policyholders	10
Section 11.2. In Force.....	10
Section 11.3. Confidentiality	11
Section 11.4. Additional Acquisitions of Ownership.....	11
Section 11.5. Director and Officer Compensation	11
Section 11.6. Amendment or Withdrawal of this Plan.....	12
Section 11.7. Corrections	12
Section 11.8. Notices	12
Section 11.9. Costs and Expenses	12
Section 11.10. Captions and Headings	12
Section 11.11. Governing Law	12
Section 11.12. Judicial Review	12
ARTICLE XII. Definitions.....	13

TABLE OF CONTENTS
(continued)

	Page
Section 12.1. General Terms	13
Section 12.2. Specific Terms	13
EXHIBIT A – Third Amended and Restated Articles of Incorporation of BCBSLA	
EXHIBIT B – Amended and Restated Bylaws of BCBSLA	
EXHIBIT C – Acquisition Agreement	
EXHIBIT D – Fairness Opinion	
EXHIBIT E – Eligible Member Payment Methodology	
EXHIBIT F – Actuarial Opinion	
EXHIBIT G – Foundation Directors and Advisory Board Members	
EXHIBIT H – Note Amount Calculation	

**LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY
D/B/A
BLUE CROSS AND BLUE SHIELD OF LOUISIANA**

**PLAN OF REORGANIZATION REGARDING THE CONVERSION
FROM A MUTUAL INSURANCE COMPANY TO A STOCK INSURANCE COMPANY**

This Plan of Reorganization Regarding the Conversion from a Mutual Insurance Company to a Stock Insurance Company (this “Plan”) has been approved and is being proposed by the Board of Directors (the “Board”) of Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana, a mutual insurance company organized and existing under the laws of the State of Louisiana (“BCBSLA”), by resolutions of the Board duly adopted and effective as of January 23, 2023 (the “Adoption Date”). Capitalized terms used herein have the respective meanings set forth in Article XII.

Affirmations Related to the Proposed Reorganization

A. This Plan provides for:

(1) the conversion/reorganization of BCBSLA from a mutual insurance company into a stock insurance company pursuant to LSA-R.S. § 22:72, LSA-R.S. § 22:236 *et seq.* and the other applicable provisions of the Louisiana Insurance Code (such statutory provisions are referred to herein collectively as the “Louisiana Demutualization Law”);

(2) prior to the effectiveness of the Reorganization (as defined below) and in furtherance of the purposes and policies set forth in the currently existing Second Amended and Restated Articles of Incorporation of BCBSLA (the “Current Articles”) (including promoting the health and welfare of the constituencies to be served pursuant to such Current Articles), the contribution by BCBSLA of the Approved Excess Surplus to The Accelerate Louisiana Initiative, Inc., a newly formed nonprofit nonstock corporation organized to work to improve the health and lives of the people of the State of Louisiana and intended to qualify as a Code Section 501(c)(4) social welfare organization (the “Foundation”);

(3) prior to the effectiveness of the Reorganization, and in furtherance of the purposes and policies set forth in the Current Articles (including promoting the health and welfare of the constituencies to be served pursuant to the Current Articles), the issuance by BCBSLA to the Foundation of a note payable substantially in the form attached as Exhibit A to the Acquisition Agreement (the “Note”), to be paid immediately following the closing of the transactions contemplated by the Acquisition Agreement (the “Closing”) in accordance with the terms of the Acquisition Agreement and this Plan;

(4) contemporaneously with the effectiveness of the Reorganization, the issuance of 100% of the shares of Common Stock to be issued pursuant to this Plan to ATH Holding Company, LLC, an Indiana limited liability company (“Purchaser”), which is a wholly owned subsidiary of Elevance Health, Inc., an Indiana corporation (“Elevance”), such that, following such issuance upon the effectiveness of the Reorganization, Purchaser shall directly own

(and Elevance shall indirectly own) 100% of the issued and outstanding shares of Common Stock;
and

(5) contemporaneously with the effectiveness of the Reorganization, the deposit by Purchaser with the Paying Agent (for distribution to the Eligible Members) of the Eligible Member Payment as consideration for the extinguishment of the Membership Interests of the Eligible Members;

in each case, in accordance with this Plan, the Acquisition Agreement and the Louisiana Demutualization Law, as applicable. The transactions set forth in clauses (1)–(5) above are collectively referred to herein as the “Proposed Reorganization” and, in the form approved by the Commissioner, the “Reorganization”.

B. The Board believes that the Proposed Reorganization will not, in any way, adversely impact policy premiums or health care benefits to Members.

C. The Board believes that the Proposed Reorganization will provide BCBSLA with greater financial resources and flexibility. The Board believes that this financial flexibility will improve BCBSLA’s access to capital to permit BCBSLA to expand existing business, develop new business opportunities and enhance its competitive position in the health benefits industry through Elevance’s more than \$100 billion market capitalization and one of the most diversified asset portfolios in the entire industry. The Board believes that the Proposed Reorganization will permit BCBSLA to continue to improve service to customers and grant BCBSLA members the ability to utilize tools already available to Elevance and its affiliates that will enhance the availability of health care services and benefits to members, including Elevance’s digital tools which give members 24-hour digital support and includes text and video visits with integrated healthcare providers, integrated pharmacy support, at-home diagnostics solutions, and care navigation. Elevance has developed a portfolio of whole health solutions, and capabilities with over \$4 billion in investments in recent years. This portfolio provides solutions for a variety of member needs, including condition-specific needs regarding diabetes, cancer, heart conditions, and several others. Having condition-specific solutions that complement the care delivered by health care providers enables members to focus on what will improve their health and lives. Increasingly, health care is being delivered digitally and outside of the traditional physician’s office when appropriate, especially in rural parts of Louisiana where health care services can be located hours away from a member’s home or work. Elevance’s digital platforms and health care delivery assets dramatically improve access via mobile devices, internet, and phone at the convenience of members. These whole health capabilities have demonstrated success in improving Elevance members’ health. Elevance has recently developed a ‘whole health index’, a dynamic model to better understand drivers of health and measure the impacts of its various solutions on health outcomes in a community. This index also helps identify the most promising future opportunities to improve the health of members and their communities. Further, Elevance plans to continually invest over \$1.2 billion annually in building new capabilities – capabilities that the Board desires to bring to BCBSLA members. Among the whole health solutions that Elevance offers are:

(1) Elevance's Cancer Care Navigator and Concierge Care solutions to support members with cancer, and their families, with personalized one-to-one support as they navigate the complex landscape of cancer care. Examples include connecting and aligning with the appropriate health care providers, matching with appropriate clinical trials, traveling to a center of excellence, and getting second opinions when needed. These solutions already serve members in Elevance's existing markets and ensure that Elevance members understand their options, get high quality care, and minimize unnecessary hospital visits.

(2) Personalized care programs for diabetes patients, including remote patient monitoring and AI-powered coaching that recommends specific actions members can take to better manage their health. These solutions help diabetic members maintain the right nutrition and activity levels to proactively minimize any disease complications. As a testament to the effectiveness of these tools, Elevance's Medicare Advantage members have 19% lower A1C (blood sugar levels) for diabetic Medicare seniors nationally.

(3) Maternal health solutions focused on maternal morbidity and prenatal and postpartum care, with a goal to reduce health disparities in Louisiana such as low birth weight and pre-term births, especially among Black women. Example whole health solutions include incentives for pregnant women for timely pre-natal visits, postpartum depression screening and follow-up, dedicated clinical liaisons who collaborate with health care providers and advocate for the right care for the member, and a comprehensive suite of digital tools to support future moms as they journey through their pregnancies. Together, these solutions among current Elevance members have helped reduce the number of pre-term births by 25% and decrease the number of low-birth weight babies by 26%, metrics in which Louisiana currently ranks 50th among all states.

(4) A full suite of market-leading behavioral health services through a broad network of experts, that already serve 1 out of every 6 people in the United States of America. Elevance is committed to bringing to BCBSLA members enhanced access to clinical mental health support, substance use disorder treatment, specialty programs such as autism and depression, crisis programs, support for children in foster care, virtual counselling, 24-hour chat service and more. These services are integrated into medical product design. Through improved data and analytics capabilities, BCBSLA will be able to proactively identify members at risk and in need of health interventions. The behavioral health capabilities of Elevance will complement the behavioral health capabilities currently enjoyed by BCBSLA members.

The Board, therefore, has determined that (1) this Plan properly protects and serves the best interests of the Members of BCBSLA, and is fair and equitable to the Members of BCBSLA, (2) there are no material risks associated with the Proposed Reorganization and (3) the financial condition of BCBSLA will not be diminished upon the effectiveness of the Proposed Reorganization.

D. The Board believes that the benefits of the Proposed Reorganization to BCBSLA Members are plentiful and that all Members and covered persons, not just Eligible Members, will be able to access a portfolio of solutions and capabilities developed by Elevance and its affiliates, including its healthcare services organization, Carelon. As described in more detail above, these solutions have demonstrated success in improving members' health while reducing costs and

complexity. The Proposed Reorganization will result in the delivery of these more effective and efficient solutions, such as integrated pharmacy, care navigation, and member advocacy, which would help improve member health outcomes while working to lower the cost trend of care. The large and continual investment in expanding capabilities simultaneously improves member experience and reduces the inflationary rise in health care costs and health insurance premiums.

E. The Board has not identified any risks of the Proposed Reorganization that would outweigh the benefits described in clauses “C” and “D” above.

F. The Board believes that the expansion of capabilities and services to be made available to BCBSLA Members and other covered persons as a result of the Proposed Reorganization will materially improve the member experience, including improving the likelihood that health coverage offered by BCBSLA after the effectiveness of the Proposed Reorganization will be more effective at improving the health and lives of Members, which is the purpose of BCBSLA as espoused in the Current Articles. BCBSLA expects that the availability of certain capabilities can occur shortly after the effectiveness of the Proposed Reorganization, and will be followed in the medium or long term with additional improvements such as expanded care management programs and further integration of health care information, analytics and clinical insights to improve the health outcomes of Members. In addition, there will be greater resources available to grow, refine and improve analytics following the effectiveness of the Proposed Reorganization. The Proposed Reorganization ultimately ensures that Members receive more value for their premium dollars.

G. Following the effectiveness of the Proposed Reorganization, BCBSLA will be in a strong financial position as part of the well-capitalized Elevance holding company system. Further, BCBSLA will continue to exceed the minimum statutory requirements for capital and surplus and will maintain an authorized control level risk-based capital ratio of at least 375% immediately following the Reorganization.

ARTICLE I.

Manner of Reorganization

The manner in which the Proposed Reorganization will occur, and the insurance and other companies that will result from or be directly affected by the Proposed Reorganization, are as follows:

Section 1.1. Reorganization to a Stock Insurance Company. In accordance with the Acquisition Agreement and the Louisiana Demutualization Law, BCBSLA will as of and following the Effective Date become a stock insurance company, organized and existing under the laws of the State of Louisiana. The Articles of Incorporation of BCBSLA, and Bylaws of BCBSLA, as amended and effective upon the Effective Date, will be substantially in the forms attached hereto as Exhibit A and Exhibit B, respectively. The transaction set forth in Affirmation A(1) of this Plan is intended to qualify as a tax-free reorganization described in Section 368 of the Internal Revenue Code of 1986, as amended (the “Code”).

Section 1.2. Establishment and Funding of the Foundation. The Foundation has been formed by BCBSLA in connection with the Proposed Reorganization. Prior to the effectiveness of

the Reorganization, in furtherance of the purposes delineated in the Current Articles to work to improve the health and lives of the citizens of the State of Louisiana, and in accordance with the Louisiana Demutualization Law and subject to the approval of the Commissioner, and in exchange for the right to become a stock insurance company under the Louisiana Demutualization Law with the approval of the Commissioner, BCBSLA shall (a) pay or transfer the Approved Excess Surplus to the Foundation and (b) issue the Note to the Foundation. Immediately following the Closing, Purchaser shall (i) contribute, or cause to be contributed, to BCBSLA an amount equal to the Note Amount, and (ii) cause BCBSLA to pay to the Foundation the Note Amount and thereby satisfy its obligations under the Note.

Section 1.3. Purchase and Sale of BCBSLA Shares. At the Closing, all of the shares of BCBSLA's Common Stock will be issued to Purchaser such that, following the Effective Date, BCBSLA will be a direct wholly owned subsidiary of Purchaser and an indirect wholly owned subsidiary of Elevance (the "Acquisition"). Further, following the Effective Date, BCBSLA shall be a continuation of the existence of BCBSLA as it existed prior to the effectiveness of the Reorganization and shall be treated as such pursuant to the applicable provisions of the Louisiana Demutualization Law (including, LSA-R.S. § 22:236.9(A)).

(a) On the Effective Date, the Eligible Members will be entitled to receive the Eligible Member Payment as further described in Article V.

(b) The Reorganization will be effected through the following structure or series of transactions in the following order:

- (i) BCBSLA will reorganize, or convert, from a Louisiana mutual insurance company into a Louisiana stock insurance company and issue to Purchaser all of the shares of its Common Stock being issued.
- (ii) Purchaser shall pay to the Paying Agent, for distribution to the Eligible Members in full consideration for the extinguishment of their Membership Interests, the Eligible Member Payment, by wire transfer of immediately available funds to the account designated in the Paying Agent Agreement.
- (iii) The transaction set forth in Affirmation A(1) of this Plan is intended to qualify as a tax-free reorganization within the meaning of Section 368 of the Code.

(c) Common Stock. The Common Stock will not be registered under the Securities Act or applicable state securities laws (collectively, the "Securities Laws"), and Purchaser agrees not to sell, encumber or otherwise transfer shares of Common Stock unless (i) there is an effective registration statement under the Securities Laws covering the transaction, (ii) Purchaser receives an opinion of counsel satisfactory to Purchaser that such registration is not required under the Securities Laws, or (iii) Purchaser otherwise satisfies itself that registration is not required under the Securities Laws. Each certificate (if any) representing shares of Common Stock shall bear a legend substantially to the foregoing effect. Neither BCBSLA nor Purchaser

will have any obligation to provide a procedure for the disposition of shares of Common Stock, except as expressly stated in this Plan.

Section 1.4. Effectiveness of this Plan. This Plan and the amendment and restatement of the Current Articles contemplated by Section 1.1 (the “Articles Amendment”) will become effective upon the date and time of filing of appropriate Articles of Amendment by the Recorder of Mortgages for the Parish of East Baton Rouge, Louisiana, and a Certificate of Compliance with the Louisiana Department of Insurance as provided in the Louisiana Demutualization Law unless a later date and time are specified in the Articles Amendment, in which event this Plan and the Articles Amendment will become effective and take place at the later date and time (which shall not be later than the tenth day after the Articles Amendment is recorded in accordance with LSA-R.S. § 22:236.8.(C)). The effectiveness of this Plan is conditioned upon, among other things, (1) approval of this Plan by the Commissioner, (2) approval of this Plan by the Members at the Special Meeting, as further described in Article X, (3) approval of the Acquisition by the Commissioner, and (4) the satisfaction of the conditions set forth in Article VI of the Acquisition Agreement (a copy of which is attached hereto as Exhibit C).

Section 1.5. ERISA Plans; Tax-Qualified Policies.

(a) To the extent necessary, BCBSLA shall engage an independent fiduciary to (i) exercise the vote with respect to this Plan for any Eligible Members which are affiliates of BCBSLA, and (ii) determine how to allocate any consideration received under this Plan with respect to any employee benefit welfare plan among plan participants and the sponsoring employer identified in proviso (i) herein.

(b) There are no Policies issued by BCBSLA that are part of tax-qualified retirement funding arrangements or individual retirement annuities described in Sections 401(a), 403(a), 403(b), 408 or 408A of the Code.

Section 1.6. Continuation of Corporate Existence. Upon BCBSLA’s Reorganization from a mutual insurance company into a stock insurance company pursuant to this Plan, BCBSLA shall continue its corporate existence as a stock insurance company as provided in LSA-R.S. § 22:236.9.

ARTICLE II.
Extinguishment of Membership Interests

All Membership Interests will be extinguished and will cease as of the Effective Date. The extinguishing of Membership Interests will occur by operation of law under the Louisiana Demutualization Law on the Effective Date. All other contractual rights and obligations under every Policy will continue in force under the terms of the Policy.

ARTICLE III.
Distribution of Consideration

The Eligible Members will, upon the extinguishment of their Membership Interests, become entitled to receive consideration equal to each Eligible Member's equitable share of the Eligible Member Payment as provided in Article V of this Plan.

ARTICLE IV.
Determination of the Equitable Consideration for Extinguishment of Membership Interests

BCBSLA has, with the assistance of its Qualified Investment Banker and other advisors retained in connection with the Proposed Reorganization, structured the Proposed Reorganization to provide that consideration paid to the Eligible Members for the extinguishment of the Membership Interests of the Eligible Members as of the Effective Date is fair to the Eligible Members, as a group, from a financial point of view, as provided in Article V. In that regard, the Board has received a written fairness opinion from the Qualified Investment Banker attached hereto as Exhibit D (the "Fairness Opinion") confirming, subject to the limitations and qualifications in such opinions (which opinions will be reaffirmed to the Board as of the Effective Date), that the method for the provision of aggregate consideration to the Eligible Members upon the extinguishing of the Membership Interests under this Plan is fair to the Eligible Members, as a group, from a financial point of view consistent with LSA-R.S. § 22:236.3(A).

ARTICLE V.
Form and Amount of Consideration to be Distributed

The Board has received the Fairness Opinion confirming the fairness of the method for the provision of aggregate consideration to the Eligible Members, as a group, from a financial point of view, consistent with LSA-R.S. § 22:236.3(A). The aggregate consideration to be distributed to the Eligible Members in exchange for the extinguishment of their Membership Interests will be cash in an amount equal to approximately \$180,000,000.00, subject to the reconciliation of the member months on the Adoption Date and the methodology and conditions set forth on Exhibit E hereto (the "Eligible Member Payment"). The aggregate value of the Eligible Member Payment was determined by tabulating the member months attributable to Eligible Members, divided by the number of member months of all Members and all members of BCBSLA's subsidiaries since BCBSLA's corporate formation in 1975, in accordance with the methodology set forth on Exhibit E hereto. The tabulation does not take into account the member months attributable to self-insured customers, which currently constitutes a majority of BCBSLA's Members and customers and related member months, and is a significant contributor to the value of BCBSLA. The exclusion of self-insured customer member months in the tabulation increases the value that is attributable to Eligible Members to the benefit of the Eligible Members (as compared to the value if the self-insured customer member months were included).

ARTICLE VI.
Method or Formula for the Allocation of Consideration

The Board has received a written actuarial opinion from the Actuary attached hereto as Exhibit F (the "Actuarial Opinion") as to the reasonableness and appropriateness of the

methodology or formula and underlying assumptions used to allocate the Eligible Member Payment among Eligible Members and stating that the resulting allocation is fair and equitable, consistent with LSA-R.S. § 22:236.3(B). The method or formula for allocating the Eligible Member Payment among the Eligible Members is to make a uniform payment of consideration, a fixed component under LSA-R.S. § 22:236.3(B)(1), to each Eligible Member. In the event that an individual or entity is an Eligible Member pursuant to multiple Policies, such Eligible Member(s) shall receive the uniform payment of consideration for each In Force Policy. The payment of uniform, fixed consideration for each In Force Policy is fair and equitable because each In Force Policy furnishes an Eligible Member with a Membership Interest that is identical for each Eligible Member. Each Eligible Member will be allocated a cash amount equal to a portion of the Eligible Member Payment referred to in Article V, which such amount is reflected in Exhibit E and has been determined as reasonable and appropriate in the Actuarial Opinion.

ARTICLE VII.
BCBSLA Pays No Dividends

The Current Articles prohibit the payment of dividends and since BCBSLA's incorporation, its articles of incorporation, as amended (and the articles of incorporation, as amended, of all relevant predecessors), have never included provisions providing for the payment of dividends. BCBSLA has no Policies that provide for the payment of dividends and, heretofore, no dividends have been paid. Accordingly, no method or procedure need be established to provide for the determination and preservation of dividends.

ARTICLE VIII.
Address and Telephone Number of BCBSLA

The address and telephone number of BCBSLA will be unchanged by the Proposed Reorganization, and each Member of BCBSLA will receive notification of such information along with a notice of hearing outlined in Section 9.2 and in LSA-R.S. § 22:236.4.

ARTICLE IX.
Approval by the Commissioner

Section 9.1. Commissioner's Public Hearing on this Plan; Commissioner's Order. This Plan, the Proposed Reorganization and the Acquisition are subject to the approval of the Commissioner. The Commissioner will hold a public hearing on these matters pursuant to LSA-R.S. 22:236.4 (the "Public Hearing").

Section 9.2. Notice of Public Hearing. Written notice of the Public Hearing, in a form satisfactory to the Commissioner, will be mailed by first class mail at BCBSLA's expense at least 30 days prior to the Public Hearing to BCBSLA's Members. Such notice will be mailed to the address of each Member of BCBSLA as such address is shown on BCBSLA's records on the Adoption Date (or such other address as may be provided in writing to BCBSLA by the Member within a reasonable period of time prior to the mailing of the notice). Such notice of Public Hearing will include a brief statement of the subject of the Public Hearing, the date, time and location of the Public Hearing, and such additional information as the Commissioner may require.

Section 9.3. Findings Required for Approval. Pursuant to LSA-R.S. § 22:236.4(B), the Commissioner shall approve this Plan and the Proposed Reorganization if the Commissioner is satisfied, following the Public Hearing: (a) that the interests of the Eligible Members and the other Members of BCBSLA are properly protected; (b) that this Plan serves the best interests of the Eligible Members and the other Members of BCBSLA; and (c) that this Plan is fair and equitable to the Eligible Members and the other Members of BCBSLA.

Section 9.4. Notice of Approval Order. In the event that the Commissioner approves this Plan, the Proposed Reorganization and the Acquisition (such approval, the “Commissioner’s Order”), notice of the Commissioner’s Order will be mailed by first class mail following the issuance of the Commissioner’s Order to BCBSLA’s Members. Such notice will be mailed to the address of each Member of BCBSLA as such address is shown on BCBSLA’s records on the Adoption Date (or such other address as may be provided in writing to BCBSLA by the Member within a reasonable period of time prior to the mailing of the notice).

ARTICLE X. **Approval by Members**

Section 10.1. Voting.

(a) BCBSLA will hold a special meeting of Members (the “Special Meeting”) within a time period that complies with LSA-R.S. § 22:236.5, which shall occur after the Public Hearing. At the Special Meeting, the Members qualified to vote will be entitled to vote in person or by proxy on this Plan. The Members eligible to vote at the Special Meeting will be the Members of BCBSLA as of the Adoption Date (the “Voting Members”), which will be the record date for the Special Meeting.

(b) This Plan shall be approved at the Special Meeting by a vote of not less than two-thirds of the Voting Members present or represented by special ballot or special proxy at the Special Meeting. The Voting Members will vote as a single class.

(c) A quorum for the Special Meeting shall consist of the Voting Members present or represented by special ballot or special proxy at the Special Meeting.

Section 10.2. Notice of Special Meeting.

(a) BCBSLA will mail or cause to be mailed notice of the Special Meeting by first class mail at BCBSLA’s expense to all of the Voting Members. The notice will comply with the Current Articles and LSA-R.S. § 22:236.5 and set forth the date, time and place of the Special Meeting. Such notice will be mailed, at least 30 days prior to the Special Meeting, to the address of each Voting Member as it appears on the records of BCBSLA on the Adoption Date (or such other address as may be provided in writing to BCBSLA by the Voting Member within a reasonable period of time prior to the mailing of the notice). The notice will be in a form satisfactory to the Commissioner.

(b) Such notice of the Special Meeting will be accompanied by a proxy form and a copy or summary of this Plan as required by LSA-R.S. § 22:236.5 and approved by the Commissioner.

ARTICLE XI.
Additional Provisions

Section 11.1. Policyholders. The Policyholder of a Policy as of any date specified in this Plan will be determined by BCBSLA on the basis of BCBSLA's records as of such date in accordance with the following provisions:

(a) The Policyholder of a Policy that is an individual insurance policy is the Person specified in such Policy as the policyholder, unless no policyholder is so specified, in which case the Policyholder will be deemed to be the Person that signed the application for the Policy or, in the case of applications made on behalf of minor children, the Person who signed the application.

(b) The Policyholder of a group insurance policy is the Person or Persons specified in such Policy as the policyholder unless no policyholder is so specified, in which case the Policyholder is the Person sponsoring the group health care benefits plan. For the avoidance of doubt, certificates or other evidences of insurance issued under a group Policy are not and shall not be treated as Policies.

(c) In no event may there be more than one Policyholder of a Policy, although more than one Person may be entitled to health benefits under a Policy.

(d) Self-funded or administrative services-only contracts are not contracts of insurance and do not create Membership Interests for the contract holders or participants of such groups.

(e) Except as otherwise set forth in this Section 11.1, the identity of the Policyholder is determined by BCBSLA without giving effect to any interest of any other Person in such Policy. For the avoidance of doubt, certificates or other evidences of insurance issued under a group policy are not and shall not be treated as Policies.

(f) In any situation not expressly covered by the foregoing provisions of this Section 11.1, or as to which application of the foregoing provisions is unclear, the Policyholder reflected on the records of BCBSLA and determined in good faith by BCBSLA, will be presumed to be the Policyholder for purposes of this Section 11.1, and, except for administrative errors, BCBSLA will not be required to examine or consider any other facts or circumstances.

(g) The mailing address of a Policyholder as of any date for purposes of this Plan will be the Policyholder's last known address as shown on the records of BCBSLA as of such date.

(h) Any dispute as to the identity of a Policyholder or the right to vote or receive consideration will be determined in accordance with the foregoing and the relevant provisions of

the Louisiana Demutualization Law, applicable provisions of the Louisiana Insurance Code or such other procedures as may be acceptable to the Commissioner.

Section 11.2. In Force. A Policy will be deemed to be in force (“In Force”) as of any date if, as shown on BCBSLA’s records on such date, the effective date of such Policy occurs on or prior to such date, and as of such date the required premium has been received by BCBSLA and such Policy, as shown on BCBSLA’s records on such date, has not expired or otherwise been surrendered or terminated; provided that a Policy will be deemed to be In Force during any applicable grace period for non-payment of premiums as administered by BCBSLA; provided further however that for the avoidance of doubt such Policy will no longer be deemed to be In Force if such applicable grace period expires without the applicable premium having been paid.

(a) Any dispute as to whether a Policy is In Force will be resolved in accordance with the foregoing or such other procedures as may be acceptable to the Commissioner.

Section 11.3. Confidentiality. BCBSLA will request the confidential treatment of documents in accordance with the Louisiana Insurance Code (Title 12) and the Louisiana Public Records Law (Title 44).

Section 11.4. Additional Acquisitions of Ownership. Except for the Acquisition, for five years following the Effective Date, no Person or Persons acting in concert (other than BCBSLA, Purchaser, any other company that is directly or indirectly wholly-owned by Elevance, or any employee benefit plans or trusts sponsored by BCBSLA, Purchaser or Elevance) may directly or indirectly acquire, or agree or offer to acquire, in any manner the beneficial ownership of five percent (5%) or more of the outstanding shares of any class of a voting security of BCBSLA or Purchaser, other than in compliance with LSA-R.S. § 22:236.6 or any regulations promulgated thereunder.

Section 11.5. Director and Officer Compensation. As is typical in change of control transactions such as the series of transactions contemplated by the Plan of Reorganization, all of the current members of the BCBSLA Board, except for the President and Chief Executive Officer of BCBSLA (who is also a member of the BCBSLA Board), are expected to resign immediately prior to the Closing. Certain of the resigning directors set forth on Exhibit G are currently directors of the Foundation or will become directors of the Foundation at or prior to the Closing, and such directors set forth on Exhibit G will continue as directors of the Foundation following the Closing. The Foundation has not yet determined the compensation structure for the members of its board of directors following the Closing and intends to engage a compensation consultant following the Closing to advise the board of directors of the Foundation on this and other matters. It is intended that any compensation of members of the board of directors of the Foundation will comply with all provisions of applicable law, including any regulations promulgated thereunder applicable to organizations organized and operated for charitable purposes. Other resigning directors of the BCBSLA Board set forth on Exhibit G will become members of the Advisory Board (as defined in the Acquisition Agreement) of BCBSLA effective as of the Closing. The members of the Advisory Board will receive compensation in an initial amount not in excess of the amount they currently receive as compensation for serving as members of the BCBSLA Board, which amounts may be adjusted during the term of the Advisory Board’s existence in accordance with the

provisions of the Advisory Board Charter (as defined in the Acquisition Agreement). Except as described above, no director, officer, agent or employee of BCBSLA will receive any fee, commission, or other valuable consideration, other than his or her usual regular salary and compensation, that is contingent upon the Plan of Reorganization becoming approved or effective or is based upon aiding, promoting, or assisting in the approval or effectuation of the Plan of Reorganization. If the transactions contemplated by the Plan of Reorganization are not consummated, the members of the BCBSLA Board will continue to receive the compensation and benefits that they currently receive as members of the BCBSLA Board.

Section 11.6. Amendment or Withdrawal of this Plan. This Plan may be amended or abandoned only as provided by the Louisiana Demutualization Law and by action of two-thirds of the members of the BCBSLA Board in accordance with the Acquisition Agreement. This Plan shall be promptly abandoned upon any valid termination of the Acquisition Agreement. This Plan may not be amended after the Public Hearing referred to in Article IX unless the Commissioner determines that the amendment is not materially disadvantageous to Members. If the Commissioner determines that the amendment is materially disadvantageous to Members, another Public Hearing must be held regarding this Plan as amended.

Section 11.7. Corrections. BCBSLA may, until the Effective Date and in accordance with the Acquisition Agreement, by an instrument executed by its President and Chief Executive Officer, the Senior Vice President, Strategy and Business Development, Senior Vice President and Secretary and Chief Financial Officer, attested by its Secretary or Assistant Secretary under BCBSLA's corporate seal and submitted to and approved by the Commissioner, make such modifications as are appropriate to correct clerical errors, clarify existing items or make additions to correct manifest omissions in this Plan (including the Exhibits) so long as such corrections or modifications do not materially disadvantage Members. BCBSLA may in the same manner also make such corrections or modifications as may be required by the Commissioner before or after the Public Hearing as a condition of approval of this Plan. No such corrections or modifications will require approval by the Voting Members unless such corrections or modifications materially disadvantage Members or such approval is otherwise required by the Board or the Commissioner.

Section 11.8. Notices. Pursuant to LSA-R.S. § 22:236.5(C), if BCBSLA complies substantially and in good faith with the Louisiana Demutualization Law with respect to any required notice to Members, the failure of any Person to actually receive any such notice that such Person was entitled to receive will not impair the validity of any action taken under the Louisiana Demutualization Law or this Plan.

Section 11.9. Costs and Expenses. BCBSLA will pay the expenses of any accountants, actuaries, attorneys, and other experts hired by the Commissioner to review any matter under the Louisiana Demutualization Law with respect to this Plan.

Section 11.10. Captions and Headings. The captions and headings of this Plan have been inserted for convenience of reference only and will not affect the meaning or interpretation of this Plan.

Section 11.11. Governing Law. The terms of this Plan will be governed by and construed in accordance with the laws of the State of Louisiana.

Section 11.12. Judicial Review. Pursuant to LSA-R.S. § 22:236.4, all petitions for judicial review of, and any action challenging the validity of or arising out of the approval or disapproval of or any action proposed to be taken under any order or determination of the Commissioner in connection with this Plan or the Reorganization must be filed not later than 30 days after the order or determination is issued by the Commissioner.

ARTICLE XII. **Definitions**

Section 12.1. General Terms. For all purposes of this Plan, except as otherwise expressly provided or unless the context otherwise requires:

- (1) The terms defined in this Article XII will, when used in this Plan, have the meanings assigned to them in this Article XII and include the plural as well as the singular.
- (2) The words “herein,” “hereof,” “hereunder” and other words of similar import refer to this Plan as a whole and not to any particular article, section, subsection or other subdivision.

Section 12.2. Specific Terms. For all purposes of this Plan, except as otherwise expressly provided in this Plan, the following terms will have the meanings set forth below:

“Acquisition” shall have the meaning set forth in Section 1.3.

“Acquisition Agreement” shall mean that certain Agreement and Plan of Acquisition, dated as of January 23, 2023, by and among BCBSLA, Purchaser, Elevance and the Foundation, as it may be amended from time to time in accordance with the provisions thereof.

“Actuarial Opinion” shall have the meaning set forth in Article VI.

“Actuary” shall mean Brian M. Collender, FSA, MAAA associated with the firm of Deloitte Consulting LLP.

“Adoption Date” shall have the meaning specified in the first paragraph of this Plan.

“Approved Excess Surplus” shall have the meaning specified in the Acquisition Agreement.

“Articles Amendment” shall have the meaning set forth in Section 1.4.

“BCBSLA” shall have the meaning specified in the first paragraph of this Plan.

“Board” shall have the meaning specified in the first paragraph of this Plan.

“Closing” shall have the meaning specified in Affirmation A(3) of this Plan.

“Code” shall have the meaning specified in Section 1.1.

“Commissioner” shall mean the Commissioner of Insurance of the State of Louisiana, his deputy or the Louisiana Department of Insurance, as appropriate.

“Commissioner’s Order” shall have the meaning specified in Section 9.4.

“Common Stock” shall mean the common stock of BCBSLA, par value \$0.01 per share, following the effectiveness of the Reorganization.

“Current Articles” shall have the meaning specified in Affirmation A(2) of this Plan.

“Effective Date” shall mean the date on which the Reorganization contemplated by this Plan becomes effective in accordance with the Louisiana Demutualization Law and Section 1.4.

“Elevance” shall have the meaning specified in Affirmation A(4) of this Plan.

“Eligible Member” shall mean a Person who is a Member of BCBSLA on the Adoption Date and continues to be a Member of BCBSLA on the Effective Date.

“Eligible Member Payment” shall have the meaning set forth in Article V.

“ERISA” shall have the meaning specified in the Acquisition Agreement.

“Fairness Opinion” shall have the meaning set forth in Article IV.

“Foundation” shall have the meaning specified in Affirmation A(2) of this Plan.

“In Force” shall have the meaning specified in Section 11.2.

“Louisiana Demutualization Law” shall have the meaning specified in Affirmation A(1) of this Plan.

“Member” shall mean as of any specified date any Person who, in accordance with the records, BCBSLA’s Current Articles and currently effective Amended and Restated Bylaws of BCBSLA, is the Policyholder of an In Force Policy.

“Membership Interests” shall mean all of the rights and interests of Policyholders as Members of BCBSLA as arising under and provided by law and by BCBSLA’s Current Articles and currently effective Amended and Restated Bylaws, which rights include, but are not limited to, the rights, if any, to vote and the rights, if any, with regard to the surplus of BCBSLA.

“Note” shall have the meaning specified in Affirmation A(3) of this Plan.

“Note Amount” shall mean the amount calculated in accordance with Exhibit H hereto.

“Paying Agent” shall have the meaning specified in the Acquisition Agreement.

“Paying Agent Agreement” shall mean a paying agent agreement to be entered into by and among Purchaser, BCBSLA and the Paying Agent, in the form mutually agreed to pursuant to the Acquisition Agreement prior to Closing.

“Person” shall mean an individual, a corporation, a partnership, an association, a joint stock company, a trust, an unincorporated organization, a limited liability company, a limited liability partnership, a government or governmental agency, a state or political subdivision of a state, board, estate, trustee or fiduciary, or any other legal entity.

“Plan” shall have the meaning specified in the first paragraph of this Plan.

“Policy” shall mean any individual insurance policy or group health care benefits contract that has been issued by BCBSLA and under which the Policyholder thereof is a Member with Membership Interests.

“Policyholder” shall mean the Person or Persons specified or determined pursuant to Section 11.1.

“Proposed Reorganization” and “Reorganization” shall have the meaning specified in Affirmation A of this Plan.

“Public Hearing” shall have the meaning specified in Section 9.1.

“Purchaser” shall have the meaning specified in Affirmation A(4) of this Plan.

“Qualified Investment Banker” shall mean Chaffe & Associates, Inc.

“Securities Act” shall mean the Securities Act of 1933, as amended.

“Securities Laws” shall have the meaning specified in Section 1.3(c).

“Special Meeting” shall have the meaning specified in Section 10.1.

“United States” shall mean the States of the United States, the District of Columbia, the Commonwealth of Puerto Rico and Territories of the United States within the meaning of Section 2(6) of the Securities Act.

“Voting Member” shall have the meaning specified in Section 10.1.

EXHIBIT A
Third Amended and Restated Articles of Incorporation of BCBSLA

[See attached]

**AMENDED AND RESTATED
ARTICLES OF INCORPORATION
OF
[LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY]¹**

Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (hereinafter referred to as the “Corporation”), duly existing under the Louisiana Insurance Code and desiring to amend and restate its Articles of Incorporation in connection with its conversion from a mutual insurance company to a stock insurance company pursuant to LSA-R.S. 22:72, LSA-R.S. 22:236 *et seq.* and the other applicable provisions of the Louisiana Insurance Code (collectively, the “Louisiana Demutualization Law”) submits the following Amended and Restated Articles of Incorporation:

**ARTICLE 1
NAME AND PRINCIPAL OFFICE**

Section 1.01. Name. The name of the corporation is [Louisiana Health Service & Indemnity Company].

Section 1.02. Address. The principal address of the Corporation's principal office at the time of the effectiveness of these Amended and Restated Articles of Incorporation is:

5525 Reitz Avenue
Baton Rouge, LA 70809²

**ARTICLE 2
REGISTERED AGENT INFORMATION**

Section 2.01. Registered Agent. The name and address of the Corporation's registered agent at the time of effectiveness of these Amended and Restated Articles of Incorporation is:

Louis Patalano, IV
5525 Reitz Avenue
Baton Rouge, LA 70809³

**ARTICLE 3
PURPOSES AND POWERS**

Section 3.01. Purposes. The purpose or purposes for which the Corporation has been formed are as follows: to make or write all or any one or more of the kinds of insurance set forth in La. Stat. Ann. § 22:47 of the Louisiana Insurance Code, including, but not limited to, insurance of human beings against bodily injury, disablement, or death by accident or accidental means, or the expense thereof, or against disablement, or expense resulting from sickness or old age, as identified in La. Stat. Ann. § 22:47(2) of the Louisiana Insurance Code, and to do all things necessary and appropriate for carrying on the business of such an insurance company. The Corporation shall have and may exercise all of the rights, privileges and powers set forth in the Louisiana Insurance Code and the Louisiana Business Corporation Act, as applicable, and shall have the power to do all acts and things necessary, convenient or expedient to carry out the purposes for which it was formed.

¹ To be confirmed.
² To be confirmed.
³ To be confirmed.

Section 3.02. Powers. In addition to the powers and privileges conferred upon the Corporation by law and those incidental thereto, the Corporation shall possess and may exercise all the rights, powers and privileges that are necessary or convenient to carry out its business and affairs.

ARTICLE 4
PERIOD OF EXISTENCE

Section 4.01. Period. The period during which the Corporation will continue as a corporation shall be perpetual.

ARTICLE 5
STOCK

Section 5.01. Authorized Shares. Upon the effectiveness of these Amended and Restated Articles of Incorporation, the Corporation shall have the authority to issue [1,000] shares of stock, at [0.01]⁴ par value per share, all of which shall be designated as Common Stock. Upon the effectiveness of these Amended and Restated Articles of Incorporation, and the Corporation's conversion from a mutual insurance company to a stock insurance company under the Louisiana Demutualization Law, the Corporation has issued and outstanding a total of [#] shares of its Common Stock and has additional paid-in capital or additional paid-in surplus in respect of that issued and outstanding Common Stock of not less than [\$]⁵.

Section 5.02. Terms. All shares of Common Stock are of one and the same class with equal rights, privileges, powers, obligations, liabilities, duties and restrictions. Shares of Common Stock may be issued for cash or property, tangible or intangible, at such price and amount per share as may be determined by the Board of Directors.

ARTICLE 6
INCORPORATOR, OFFICERS AND DIRECTORS

Section 6.01. Original Incorporators and Directors. The name and address of each of the incorporators and Directors at the time of the original incorporation of the Corporation is included within the original incorporation documents of the Corporation, which are hereby incorporated by reference.

Section 6.02. Current Directors. The name and address of each Director of the Corporation as of the effectiveness of these Amended and Restated Articles of Incorporation are as follows:

<u>Name</u>	<u>Address</u>
I. Steven Udvarhelyi, M.D.	5525 Reitz Avenue, Baton Rouge, LA 70809
Kathleen S. Kiefer	220 Virginia Avenue, Indianapolis, IN 46204
Heather C. Steinmeyer	220 Virginia Avenue, Indianapolis, IN 46204
Ronald W. Penczek	220 Virginia Avenue, Indianapolis, IN 46204
Jay H. Wagner	220 Virginia Avenue, Indianapolis, IN 46204

⁴ To be confirmed.

⁵ To be confirmed.

Section 6.03. Current Officers. The name, title and address of each officer of the Corporation as of the effectiveness of these Amended and Restated Articles of Incorporation are as follows:

<u>Name</u>	<u>Title</u>	<u>Address</u>
I. Steven Udvarhelyi, M.D.	President & CEO	5525 Reitz Avenue, Baton Rouge, LA 70809
Vincent E. Scher	Treasurer	220 Virginia Avenue, Indianapolis, IN 46204
Adam Short	Assistant Treasurer	5525 Reitz Avenue, Baton Rouge, LA 70809
Eric (Rick) K. Noble	Assistant Treasurer	220 Virginia Avenue, Indianapolis, IN 46204
Kathleen S. Kiefer	Secretary	220 Virginia Avenue, Indianapolis, IN 46204
Louis Patalano, IV	Assistant Secretary	5525 Reitz Avenue, Baton Rouge, LA 70809
Korey Harvey	Assistant Secretary	5525 Reitz Avenue, Baton Rouge, LA 70809

ARTICLE 7 **BYLAWS**

Section 7.01. Bylaws. The Board of Directors shall have the power to adopt, amend or repeal the Bylaws of the Corporation or adopt new Bylaws.

ARTICLE 8 **BOARD OF DIRECTORS**

Section 8.01. Management. A Board of Directors shall manage the Corporation's business. The Directors shall have all of the qualifications, powers and authority and shall be subject to all applicable limitations as set forth in the Louisiana Insurance Code and the Louisiana Business Corporation Act, as applicable. The number of Directors of the Corporation shall not be less than five (5) nor more than twelve (12), the exact number to be specified from time to time in the manner provided by the Corporation's By-Laws. The number of Directors at the time of effectiveness of these Amended and Restated Articles of Incorporation is five (5).

Section 8.02. Vacancy. Any vacancy on the Board of Directors caused by death, resignation, disqualification, increase in the number of Directors, or otherwise may be, at the discretion of the Board, filled by a majority vote of the remaining Directors (whether or not such Directors constitute a quorum) or left unfilled until the next annual meeting of shareholders. If the Directors fill such a vacancy, the new Director shall serve until the next annual meeting of the shareholders. The failure of the Board of Directors or the shareholders to fill one or more vacancies on the Board of Directors or to elect a full Board of Directors shall not in any way prevent or restrict the Board of Directors from exercising the powers of the Corporation or from directing its business and affairs.

Section 8.03. Removal of Directors. A Director may be removed, with or without cause, only at a meeting of the shareholders or Directors called expressly for that purpose. Removal by the shareholders requires an affirmative vote of the shareholders representing at least a majority of all the votes then entitled to be cast at an election of Directors. Removal by the Board of Directors requires an affirmative vote of at least one-half of all Directors. No Director may be removed except as provided in this Section.

ARTICLE 9 **SHAREHOLDER MEETINGS**

Section 9.01. Shareholder Meetings. All meetings of shareholders shall be held at any place within or outside of the State of Louisiana, or may be held solely by means of remote communication, as

may be specified in the Bylaws of the Corporation, as from time to time in effect, or as may be designated by the Board of Directors or the Officer of the Corporation calling the meeting.

Section 9.02. Voting Rights. Every shareholder of the Corporation shall have the right, at every shareholder meeting, to one vote for each share outstanding in his name on the books of the Corporation. Voting for Directors shall not be cumulative.

Section 9.03. Action Without Meeting. Any action required or permitted to be taken at any meeting of the shareholders may be taken without a meeting, if the action is taken by all shareholders entitled to vote on the action. The action must be evidenced by one or more written consents describing the action taken, signed by each shareholder and delivered to the Corporation for inclusion in the minutes for filing with the corporate records. The record date for determining the shareholders entitled to take action without a meeting is the date the first shareholder signs the consent. Action taken under this section is effective when the last shareholder signs the consent, unless the consent specifies a different prior or subsequent effective date, in which case the action is effective on or as of the specified date. Such consent shall have the same effect as a unanimous vote of all shareholders and may be described as such in any document.

ARTICLE 10 **INDEMNIFICATION**

Section 10.01. Indemnification. To the maximum extent permitted by law, the Company shall indemnify every Eligible Person (certain capitalized terms used in this Article are defined in Section 10.02) against all Liability and Expense that may be incurred by him or her in connection with or resulting from any Claim to the fullest extent authorized or permitted by the Louisiana Insurance Code and the Louisiana Business Corporation Act, as applicable, or otherwise consistent with the public policy of the State of Louisiana. In furtherance of the foregoing, and not by way of limitation, every Eligible Person shall be indemnified by the Company against all Liability and reasonable Expense that may be incurred by him or her in connection with or resulting from any Claim, (a) if such Eligible Person is Wholly Successful, on the merits or otherwise, with respect to the Claim, or (b) if not Wholly Successful, then if such Eligible Person is determined to have acted in good faith, in what he or she reasonably believed to be the best interests of the Company or at least not opposed to its best interests and, in addition, with respect to any criminal Claim is determined to have had reasonable cause to believe that his or her conduct was lawful or had no reasonable cause to believe that his or her conduct was unlawful. The termination of any Claim, by judgment, order, settlement (whether with or without court approval), or conviction or upon a plea of guilty or of *nolo contendere*, or its equivalent, shall not create a presumption that an Eligible Person did not meet the standards of conduct set forth in this Section. The actions of an Eligible Person with respect to an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 shall be deemed to have been taken in what the Eligible Person reasonably believed to be the best interests of the Company or at least not opposed to its best interest if the Eligible Person reasonably believed he or she was acting in conformity with the requirements of such Act, or he or she reasonably believed his or her actions to be in the interests of the participants in or beneficiaries of the plan.

Section 10.02. Definitions.

- (a) The term “Claim” as used in this Article shall include every pending, threatened or completed claim, action, suit or proceeding and all related appeals (whether brought by or in the right of this Company or any other corporation or otherwise), civil, criminal, administrative or investigative, formal or informal, in which an Eligible Person may become involved as a party or otherwise (i) by reason of his or her being or having been an Eligible Person or (ii) by reason of any action taken or not taken by him or her in his or her capacity as an Eligible Person, whether or not he or she continued in that capacity at the time the Liability or Expense shall have been incurred.
- (b) The term “Eligible Person” as used in this Article shall mean every person (and the estate, heirs and personal representatives of such person) who is or was a Director, Officer or employee of the Company or who, while a Director, Officer or employee of the Company, is or was serving at the request of the Company as a Director, Officer, partner, trustee, employee, member, manager, agent or fiduciary of any other corporation, partnership, joint venture, trust, employee benefit plan, limited liability company or other organization or entity, whether for profit or not. An Eligible Person shall also be considered to have been serving as a Director, Officer, trustee, employee, agent or fiduciary of an employee benefit plan at the request of the Company if his or her duties to the Company also imposed duties on, or otherwise involved services by, him or her to the plan or to participants in or beneficiaries of the plan.
- (c) The terms “Liability” and “Expense” as used in this Article shall include, but shall not be limited to, counsel fees and disbursements and amounts of judgments, fines or penalties against (including excise taxes assessed with respect to an employee benefit plan), and amounts paid in settlement by or on behalf of, an Eligible Person.
- (d) The term “Wholly Successful” as used in this Article shall mean (i) termination of any Claim, whether on the merits or otherwise, against the Eligible Person in question without any finding of liability or guilt against him or her, (ii) approval by a court or agency, with knowledge of the indemnity herein provided, of a settlement of any Claim, or (iii) the expiration of a reasonable period of time after the threatened making of any Claim without commencement of an action, suit or proceeding and without any payment or promise made to induce a settlement.
- (e) As used in this Article, the term “Company” includes all constituent entities in a consolidation or merger and the new or surviving corporation of such consolidation or merger, so that any Eligible Person who is or was a Director, Officer or employee of such a constituent entity or is or was serving at the request of such constituent entity as a Director, Officer, partner, trustee, employee, member, manager, agent or fiduciary of any other corporation, partnership, joint venture, trust, employee benefit, limited liability company or other organization or entity, whether for profit or not, shall stand in the same position under this Article with respect to the new or surviving corporation as he would if he had served the new or surviving corporation in the same capacity.

Section 10.03. Advancement of Expenses.

- (a) Expenses incurred by an Eligible Person who is a Director or Officer of the Company in defending any Claim shall be paid by the Company in advance of the final disposition of that Claim promptly as they are incurred upon receipt of an undertaking by or on behalf of such Eligible Person to repay such amount if he or she is determined not to be entitled to indemnification.
- (b) Expenses incurred by any other Eligible Person with respect to any Claim may be advanced by the Company (by action of the Board of Directors, whether or not a disinterested quorum exists) prior to its final disposition upon receipt of an undertaking by or on behalf of the Eligible Person to repay such amount if he or she is determined not to be entitled to indemnification.

Section 10.04. Non-Exclusivity and Insurance. The rights of indemnification and advancement of expenses provided in Article 10 shall be in addition to any rights to which any Eligible Person may otherwise be entitled. The Board of Directors may, at any time and from time to time:

- (a) approve indemnification of any Eligible Person to the fullest extent authorized or permitted by the provisions of applicable law or otherwise consistent with the public policy of the State of Louisiana, whether on account of past or future transactions, and
- (b) authorize the Company to purchase and maintain insurance on behalf of any Eligible Person against any Liability or Expense asserted against or incurred by him or her in such capacity or arising out of his or her status as an Eligible Person, whether or not the Company would have the power to indemnify him or her against such Liability or Expense.

Section 10.05. Contract. The provisions of this Article shall be deemed to be a contract between the Company and each Eligible Person, and an Eligible Person's rights under this Article shall not be diminished or otherwise adversely affected by any repeal, amendment, or modification of this Article that occurs subsequent to that person becoming an Eligible Person.

If the Louisiana Insurance Code or the Louisiana Business Corporation Act, as applicable, is amended after the effective date of these Amended and Restated Articles of Incorporation to authorize corporate action further eliminating or limiting the personal liability of an Eligible Person, then the liability of an Eligible Person of the Company automatically shall be eliminated or limited to the fullest extent permitted by the Louisiana Insurance Code or the Louisiana Business Corporation Act as so amended.

ARTICLE 11
AMENDMENT OF ARTICLES

Section 11.01. Amendment. The Corporation reserves the right to amend, alter, change or repeal any provision contained in these Amended and Restated Articles of Incorporation or in any amendment hereto or to add any provision to these Amended and Restated Articles of Incorporation or to any amendment hereto in any manner now or hereafter prescribed or permitted by the provisions of the Louisiana Insurance Code or the Louisiana Business Corporation Act, as applicable, as from time to time in effect or by the provisions of any other applicable statute of the State of Louisiana; and all rights

conferred upon shareholders in these Amended and Restated Articles of Incorporation or any amendment hereto are granted subject to this reservation.

EXHIBIT B
Amended and Restated Bylaws of BCBSLA

[See attached]

**AMENDED AND RESTATED
BYLAWS
OF
[LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY]¹**

[Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana] (the “Company”) consistent with the Louisiana Insurance Code and the Louisiana Business Corporation Act, as applicable, as from time to time amended (the “Louisiana Laws”), submits the following Bylaws:

**ARTICLE I
OFFICES**

The Company shall have such offices, either within or outside of the State of Louisiana, as the Board of Directors may designate or as the Company’s business may from time to time require.

**ARTICLE II
SHAREHOLDERS**

2.1 Annual Meetings. The annual shareholders' meeting for the election of Directors and for the transaction of other business that properly may come before that meeting shall be held each year on such date as may be designated by the Board of Directors, and at the time and place, if any, within or outside the State of Louisiana, or may be held solely by means of remote communication, as shall be designated by the Board of Directors.

2.2 Special Meetings. For any proper purpose(s), the Board of Directors or the President may call at any time a special shareholders' meeting. Special shareholders' meetings shall be held on the dates, at the times, and at the places, if any, within or outside of the State of Louisiana, or may be held solely by means of remote communication, as whomever calls such meetings directs. The President shall call a special shareholders' meeting whenever a written request is delivered to the President by a majority of the Board of Directors and upon the written request of one-fourth of the shareholders of the Company. All such written requests must state a proper purpose or purposes for the special meeting.

2.3 Notice of Meeting.

- (a) Written notice of every shareholders' meeting stating the date, time, and place of such meeting, the means of remote communication, if any, by which shareholders may be deemed to be present in person and vote at such meeting, and signed by the President, any Vice President, the Secretary, or any Assistant Secretary shall be delivered either personally or by mail or sent by electronic transmission to each shareholder entitled to vote at that meeting. The notice of a special meeting also must state the purpose or purposes for which such meeting is called. The notice of an annual meeting may state the purpose or purposes for which such meeting is called.
- (b) Written notices shall be delivered not less than ten (10) nor more than sixty (60) days before the date of a meeting, except as otherwise provided by law.

¹ To be confirmed.

- (c) If mailed, all notices shall be sent to shareholders' addresses as they appear in the Company's stock books, unless a shareholder has filed with the Secretary a written request that notices to that shareholder be mailed to some other address. In such a case, notices shall be mailed to the address designated in the shareholder's written request.

2.4 Waiver of Notice. Whenever the Louisiana Laws, the Company's Amended and Restated Articles of Incorporation or these Amended and Restated Bylaws require any notice to be given to a shareholder, a written waiver of notice shall be deemed equivalent to notice if the waiver is signed by the shareholder entitled to notice (whether before or after the time stated in the waiver) and delivered to the Company for inclusion in the minutes or other corporate records. A shareholder's attendance at a meeting, or participation by remote communication in a meeting in accordance with these Amended and Restated Bylaws, whether in person or by proxy, shall be deemed equivalent to a written waiver of notice of the meeting by the shareholder unless the shareholder at the beginning of the meeting objects to holding the meeting or transacting business or consideration of a particular matter at the meeting.

2.5 Voting Lists. At least ten (10) days before each shareholders' meeting, the officer or agent responsible for the Company's stock transfer books shall make a complete list of the shareholders entitled to vote at the meeting or any adjournment of the meeting. The list, arranged in alphabetical order, shall identify each eligible shareholder's name, address, and number of shares. For a period of ten (10) days prior to the meeting, the list shall be kept on file at the Company's principal office and shall be subject to inspection by any shareholder at any time during usual business hours. The list also shall be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any shareholder during the whole time of the meeting. If the meeting is held solely by means of remote communication, the list shall be open to examination by any shareholder at any time during the meeting on a reasonably accessible electronic network, and information required to access this list shall be provided with the notice to the meeting. The Company's original stock transfer book shall be prima facie evidence as to which shareholders are entitled to examine shareholders' lists and transfer books or to vote at shareholders' meetings.

2.6 Quorum. Except as otherwise required by law, to transact business at any shareholders' meeting, holders of record of a majority of the then-issued and outstanding shares of capital stock of the Company and who are entitled to vote must be present in person or by proxy.

2.7 Adjournments. In the absence of a quorum, a majority of the shareholders present at the meeting (in person or by proxy) or, if no shareholder entitled to vote is present (in person or by proxy), any officer entitled to preside at or act as secretary of a shareholders' meeting, may adjourn such meeting from time to time until a quorum is present. If an annual or special shareholders' meeting is adjourned to a different date, time or place, notice need not be given of the new date, time or place, if any, if the new date, time or place and the means of remote communication, if any, by which shareholders may be deemed to be present in person and vote at such meeting are announced at the meeting before adjournment, unless a new record date is or must be established for the adjourned meeting.

2.8 Voting. Directors shall be chosen by a plurality of eligible shareholder votes cast in an election, and, except as otherwise provided by law or by the Company's Amended and Restated Articles of Incorporation, all other questions before the shareholders shall be determined by a majority of the eligible votes cast on such question.

2.9 Proxies. Any shareholder entitled to vote may vote by proxy, provided that the instrument authorizing the proxy to act shall have been executed in writing (which shall include telegraphing or cabling or transmitting or authorizing the transmission of an electronic submission) by the shareholder himself or by the shareholder's duly authorized attorney. Shares standing in the name of a

business entity (other than the Company) may be voted by any officer, agent, or proxy as the board of directors or other managers of that entity may appoint or as the governing documents of that entity may prescribe. All proxies must be filed with the Company's Secretary before or at the time of a meeting. A proxy may be revoked at any time by the shareholder upon written notice to the Secretary or the presiding officer at any shareholder meeting.

2.10 Judges of Election. The Board of Directors may appoint judges of election to serve at any election of Directors and at balloting on any other matter that may properly come before a shareholders' meeting. If no such appointment is made or if any of the judges so appointed fail, refuse or are unable to attend, then the presiding officer at a meeting may make such appointments.

2.11 Conduct of Meetings. Shareholders' meetings shall be presided over by the President, and in his or her absence, by a person chosen by the Board of Directors. The Company's Secretary, and in his or her absence, an Assistant Secretary, and if none is present, a person chosen at the meeting by the Board of Directors, shall act as secretary of a shareholders' meeting.

2.12 Participation in Meetings by Remote Communication. The President or the Board of Directors may permit any or all shareholders to participate in an annual or special meeting of shareholders by, or through the use of, any means of remote communication. The Board of Directors, acting in its sole discretion, may establish guidelines and procedures in accordance with applicable provisions of the Louisiana Laws and any other applicable law for the participation by shareholders in a meeting of shareholders by means of remote communication. A shareholder participating in a meeting by such means who complies with such guidelines and procedures and is otherwise entitled to vote at the meeting shall be deemed to be present in person and may vote at the meeting, whether such meeting is held at a designated place or solely by means of remote communication.

2.13 Informal Action by Shareholders.

- (a) Unless otherwise provided by law, any action required or permitted to be taken at a shareholders' meeting may be taken without a meeting if all the shareholders entitled to vote on the action sign a written consent that describes the action taken and the written consent is delivered to the Company for inclusion in the shareholders' minute book.
- (b) The record date for determining which shareholders are entitled to take action without a meeting is the date the first shareholder signs the written consent.
- (c) Action taken under this Section is effective when the last shareholder signs the written consent, unless the written consent specifies a prior or subsequent effective date.
- (d) A written consent signed under this Section has the effect of a meeting vote and may be described as a meeting vote in any document.

ARTICLE III
BOARD OF DIRECTORS

3.1 Number. The authorized number of Directors which shall constitute the whole Board of Directors shall be fixed from time to time by resolution of the Board of Directors or shareholders (any such resolution of either the Board of Directors or shareholders being subject to any resolution of either of them). The Board of Directors at the effective date of these Amended and Restated Bylaws shall consist of five (5).

3.2 Eligibility of Directors. Requirements as to eligibility shall be determined by the Board of Directors, but in determining the eligibility of persons to become Members of the Board of Directors, consideration shall be given to the individual's knowledge and experience as to general business issues.

3.3 Election and Term of Office. Directors shall be elected at the annual shareholders' meeting, except as provided otherwise in this Article. Each director, before being qualified to act, shall file with the Secretary a written acceptance of his trust. A Director (whether elected at an annual meeting or otherwise) shall continue in office until his or her successor has been elected and qualified or until, if earlier, his or her death, resignation, or removal as provided below.

3.4 Vacancies and Additional Directorships. If any vacancy shall occur in the Board of Directors by reason of death, resignation, disqualification, increase in the number of Directors, or otherwise, a majority of the remaining Directors (whether or not a quorum), may fill the vacancy. A Director selected by the Directors to fill a vacancy shall be elected to hold office until the next annual shareholders' meeting.

3.5 Regular Meetings. A meeting of the Directors shall be held each year immediately following the annual meeting of the shareholders; and in addition thereto, meetings of the Directors shall be held no less than quarterly during the year. Notice of the meetings, giving the time and place thereof, shall be mailed by the Secretary to each of the Directors not less than three (3) days before the date of the meeting.

3.6 Special Meetings. The President or any two (2) Directors may call a special meeting of the Board of Directors. Except as otherwise required by law, special meetings of the Board of Directors must be preceded by at least two (2) days' notice of the date, time, and place of the meeting. The notice need not describe the purpose of the special meeting. Notice may be provided by mail, to each Director's residence or usual place of business, by email, or telephoned or delivered personally. A Director may participate in a special meeting by telephone, video conference call, or any other means of communication by which the Director may simultaneously hear and participate in the meeting, and will be considered present at such meeting unless the Director, at the beginning of the meeting, or promptly upon arrival, object to holding the meeting or transacting business at the meeting.

3.7 Waiver of Notice. Whenever the Louisiana Laws, the Company's Amended and Restated Articles of Incorporation or these Amended and Restated Bylaws require any notice to be given to a Director, a written waiver of notice shall be deemed equivalent to notice if the waiver is signed by the Director entitled to the notice (whether before or after the time stated in the notice) and delivered to the Company for inclusion in the minutes or other Corporate records. A Director's attendance at a meeting shall be deemed equivalent to his or her written waiver of notice of the meeting.

3.8 Quorum. At each Board of Directors' meeting, a majority of the total number of Directors must be present to constitute a quorum to transact business.

3.9 Adjournments. In the absence of a quorum, a majority of those Directors present at a meeting may adjourn the meeting from time to time until a quorum is present, and the meeting may be held as so adjourned without further notice or waiver.

3.10 Voting. A majority of the Directors present at any meeting at which a quorum is present may decide any question brought before the meeting, except as otherwise provided by applicable law, the Company's Amended and Restated Articles of Incorporation, or these Amended and Restated Bylaws.

3.11 Interest of Directors.

- (a) A “conflict of interest transaction” is a transaction with the Company in which a Director of the Company has a direct or indirect interest. A conflict of interest transaction is not voidable by the Company solely because of the Director's interest in the transaction if any one of the following is true:
- (1) The material facts of the transaction and the Director's interest were disclosed or known to the Board of Directors or to a committee of the Board of Directors, and the Board of Directors or committee authorized, approved, or ratified the transaction;
 - (2) The material facts of the transaction and the Director's interest were disclosed or known to the shareholders entitled to vote, and they authorized, approved, or ratified the transaction; or
 - (3) The transaction was fair to the Company.
- (b) For purposes of this Section, a Director of the Company has an “indirect interest” in a transaction if:
- (1) one party to the transaction is another entity in which the Director has a material financial interest or in which the Director is a general partner; or
 - (2) one party to the transaction is another entity of which the Director is a Director, officer, or trustee and the transaction is, or is required to be, considered by the Company's Board of Directors.
- (c) For purposes of Subsection (a)(1), a conflict of interest transaction is authorized, approved, or ratified if it receives the affirmative vote of a majority of the Directors on the Board of Directors (or on the committee) who have no direct or indirect interest in the transaction (“Disinterested Directors”). However, a transaction may not be authorized, approved, or ratified under this Section by a single Director. If a majority of the Disinterested Directors vote to authorize, approve, or ratify a transaction, a quorum shall be deemed present for the purpose of taking action under this Section. The presence of, or a vote cast by, a Director with a direct or indirect interest in the transaction does not affect the validity of any action taken under Subsection (a)(1), if the transaction is otherwise authorized, approved, or ratified as provided in this Subsection.
- (d) For purposes of Subsection (a)(2), shares owned by or voted under the control of a Director who has a direct or indirect interest in the transaction and shares owned by or voted under the control of an entity described in Subsection (b) may be counted in a vote of shareholders to determine whether to authorize, approve, or ratify a conflict of interest transaction.

3.12 Resignation of Directors. Any Director may resign at any time by giving written notice of resignation to the Board of Directors, the President, or the Secretary. Unless otherwise specified in the notice, a resignation shall take effect upon receipt of the notice by the Board of Directors or by any such officer. Acceptance of a resignation is not necessary to make the resignation effective.

3.13 Removal of Directors. A Director may be removed, with or without cause, only at a meeting of the shareholders or Board of Directors called expressly for that purpose. Removal by the shareholders requires an affirmative vote of the shareholders representing at least a majority of all the

votes then entitled to be cast at an election of Directors. Removal by the Board of Directors requires an affirmative vote of at least one-half of all Directors.

3.14 Compensation of Directors. Directors may receive such reasonable compensation for their services, whether in the form of salary or a fixed fee for attendance at meetings, and for their expenses, if any, as the Board of Directors may determine from time to time. This Section shall not be construed to preclude any Director from serving the Company in any other capacity and receiving compensation for such services.

3.15 Informal Action by Directors.

- (a) Unless otherwise provided by law, any action required or permitted to be taken at a Directors' meeting may be taken without a meeting if all the Directors sign a written consent that sets forth the action taken and the written consent is filed in the Directors' minute book.
- (b) Action taken under this Section is effective when the last Director signs the written consent, unless the written consent specifies a prior or subsequent effective date.
- (c) A written consent signed under this Section has the effect of a meeting vote and may be described as a meeting vote in any document.

3.16 Committees. The Board of Directors may designate one or more committees, and, to the extent required by applicable law, the Board of Directors shall establish (i) a committee that shall have the responsibility for recommending the selection of independent certified public accountants and reviewing the Corporation's financial condition ("Audit Committee"), and (ii) one or more committees that shall have the responsibility for (a) recommending candidates to be nominated by the Board of Directors in addition to any other nominations by shareholders for election as Directors by shareholders, (b) evaluating the performance of officers deemed to be principal officers of the Corporation, and (c) recommending to the Board of Directors the selection and compensation of such principal officers (collectively, the "Nomination and Compensation Committees"). Each committee shall consist of one or more of the Directors, and, to the extent required by law, not less than one-third of such Directors shall be persons who are not officers or employees of the Company or any entity controlling, controlled by or under common control with the Company (each such person, an "Independent Committee Director"); provided, however, to the extent required by applicable law, the Audit Committee and Nomination and Compensation Committees shall be composed solely of persons who are Independent Committee Directors. Except for the Audit Committee and Nomination and Compensation Committees, to the extent any committee is composed of any Independent Committee Directors, at least one Independent Committee Director must be included in any quorum for the transaction of business at any meeting of such committee. The Board of Directors may designate one or more Directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Company, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority as to the following:

- (a) authorize distributions;
- (b) approve or propose to shareholders actions that require shareholder approval;
- (c) fill vacancies on the Board of Directors or any of its committee(s); or

- (d) adopt, amend or repeal the Bylaws.

3.17 Duties. The Board of Directors shall be the governing entity and generally manage the fiscal and business affairs of this Corporation and discharge such duties as are required of it by applicable law. Every Director, when elected, shall take and subscribe an oath that he or she will, insofar as the duty devolves upon such person, faithfully, honestly and diligently administer the affairs of the Corporation, and that he or she will not knowingly violate or willingly permit to be violated any of the provisions of law applicable to the Corporation, all as required by the laws of the State of Louisiana.

3.18 Additional Duties of Directors. In addition to such other duties as may be imposed upon the Directors, the Directors shall keep a record of the attendance of Directors at the meetings of the Board and shall make a report, showing the names of the Directors, the number of meetings of the Board, regular and special, the number of meetings attended and the number of meetings from which each Director was absent, which report shall be read at the annual meeting of shareholders and incorporated into the minutes thereof.

ARTICLE IV OFFICERS

4.1 Officers. The officers of the Company shall be a President, a Secretary, a Treasurer, and such other officers as may be appointed in accordance with the provisions of Section 4.3.

4.2 Election, Term of Office, and Qualifications. Each officer (except officers appointed in accordance with the provisions of Section 4.3) shall be elected annually by the Board of Directors and shall hold such office until a successor has been elected and qualified or until, if earlier, the officer dies, resigns pursuant to Section 4.4, or is removed pursuant to Section 4.5.

4.3 Subordinate Officers and Agents. The Board of Directors from time to time may appoint other officers or agents (including one or more Vice Presidents, Assistant Secretaries and Assistant Treasurers), to hold office for such periods, have such authority, and perform such duties as are provided in these Amended and Restated Bylaws or as may be provided in the resolutions appointing them. The Board of Directors may delegate to any officer or agent the power to appoint such subordinate officers or agents and to prescribe their respective terms of office, authorities, and duties. Any authority to appoint subordinate officers or agents delegated by the Board of Directors to any officer or agent includes the authority to remove any subordinate officer or agent appointed.

4.4 Resignations. An officer may resign at any time by giving written notice of resignation to the Board of Directors, the President, or the Secretary. Unless otherwise specified in such notice, a resignation shall take effect upon receipt of the notice by the Board of Directors or by any such officer. Acceptance of a resignation is not necessary to make the resignation effective. An officer's resignation does not affect the Company's contract rights, if any, with that officer.

4.5 Removal.

- (a) An officer specifically designated in Section 4.1 may be removed, with or without cause, at any Board of Directors' meeting by an affirmative vote of a majority of the Directors then in office.
- (b) An officer or agent appointed in accordance with the provisions of Section 4.3 may be removed, with or without cause, at any Board of Directors' meeting by an affirmative

vote of a majority of the Directors present at such meeting or at any time by a superior officer or agent upon whom the Board of Directors or these Amended and Restated Bylaws have conferred such removal power.

- (c) The removal of an officer does not affect that officer's contract rights, if any, with the Company.

4.6 Vacancies. A vacancy in any office by reason of death, resignation, removal, disqualification, or otherwise shall be filled for the unexpired portion of the term in the manner prescribed by these Amended and Restated Bylaws for the regular election or appointment to such office.

4.7 The President. The President is the chief executive officer of the Company, subject to the direction of the Board of Directors. The President shall, unless the Board of Directors provides otherwise in a specific instance or generally, preside at all meetings of the shareholders and the Board of Directors, have general and active management of the business of the Company and see that all orders and resolutions of the Board of Directors are carried into effect. The President shall execute bonds, mortgages, and other contracts requiring a seal, under the seal of the Company, if adopted, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof shall be expressly delegated by the Board of Directors to some other officer or agent of the Company.

4.8 The Vice Presidents. In the absence of the President or in the event of the President's inability or refusal to act, the Vice President, or if there be more than one Vice President, the Vice Presidents in the order designated by the Board of Directors or the President (or in the absence of any designation, then in order determined by their tenure in office) shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President. The Vice Presidents shall perform such other duties and have such other powers as the Board of Directors or the President may from time to time prescribe.

4.9 The Secretary. The Secretary shall have such powers and perform such duties as are incident to the office of Secretary. Unless the Amended and Restated Articles of Incorporation or these Amended and Restated Bylaws designate another officer, the Secretary shall have authority to certify these Amended and Restated Bylaws, resolutions of the Board and the shareholders and committees thereof, and other documents of the Company as true and correct copies thereof. The Secretary shall maintain a stock ledger and prepare lists of shareholders and their addresses as required and shall be the custodian of corporate records. The Secretary shall attend all meetings of the Board of Directors and all meetings of the shareholders and record all the proceedings of the meetings of the Company and of the Board of Directors in a book to be kept for that purpose and shall perform like duties for the standing committees when required. The Secretary shall give, or cause to be given, notice of all meetings of the shareholders and special meetings of the Board of Directors, and shall perform such other duties as may be from time to time prescribed by the Board of Directors or President, under whose supervision the Secretary shall be. If the Board of Directors adopts a corporate seal for the Company, the Secretary shall have custody of the corporate seal of the Company and the Secretary, or an Assistant Secretary, shall have authority to affix the same to any instrument requiring it and when so affixed, it may be attested by the signature of the Secretary or by the signature of such assistant Secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Company and to attest the affixing by the signature of the Secretary.

4.10 The Treasurer. The Treasurer shall perform such duties and shall have such powers as may be assigned to the Treasurer by the Board of Directors or the President. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of Treasurer. The Treasurer

shall have the custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Company and shall deposit all moneys and other valuable effects in the name and to the credit of the Company in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Company as may be ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render to the President and the Board of Directors, when the President or Board of Directors so requires, an account of all transactions as Treasurer and of the financial condition of the Company.

4.11 Salaries. The salaries of the Company's officers shall be fixed from time to time by the Board of Directors. The Board of Directors, though, may delegate to any person the power to fix the salaries or other compensation of any officers or agents appointed in accordance with the provisions of Section 4.3. No officer shall be prevented from receiving a salary by reason of the fact that such officer is also a Director of the Company.

ARTICLE V

EXECUTION OF INSTRUMENTS AND

DEPOSIT OF CORPORATE FUNDS

5.1 Execution of Instruments Generally. Subject to the Board of Directors' approval, the President, any Vice President, the Secretary, or the Treasurer may enter into any contract or execute and deliver any instrument in the name and on behalf of the Company. The Board of Directors may authorize any officer, officers, agent, or agents to enter into any contract or execute and deliver any instrument in the name and on behalf of the Company, and such authorization may be general or confined to specific instances.

5.2 Borrowing. No loans or advances shall be obtained or contracted for, by, or on behalf of the Company, and no negotiable paper shall be issued in the Company's name, unless and except as authorized by the Board of Directors. Such authorization by the Board of Directors may be general or confined to specific instances. Any officer or agent of the Company so authorized may obtain loans and advances for the Company, and for such loans and advances, the authorized officer or agent may make, execute, and deliver promissory notes, bonds, or other evidences of indebtedness of the Company. Any officer or agent of the Company so authorized also may pledge, hypothecate, or transfer as security for the payment of any and all loans, advances, indebtedness, and liabilities of the Company any and all stocks, bonds, other securities, and other personal property at any time held by the Company and, to that end, may endorse, assign, and deliver the same and do every act and thing necessary or proper in connection therewith.

5.3 Deposits. All funds of the Company not otherwise employed shall be deposited from time to time to the Company's credit in such banks or trust companies or with such bankers or other depositories as the Board of Directors may select or as may be selected by any officer, officers, agent, or agents authorized to do so by the Board of Directors. Endorsements for deposit to the credit of the Company in any of its duly authorized depositories shall be made in such manner as the Board of Directors may determine from time to time.

5.4 Checks, Drafts, etc. All checks, drafts, or other orders for the payment of money and all notes or other evidences of indebtedness issued in the Company's name shall be signed by such officer, officers, agent, or agents of the Company and in such manner as determined by the Board of Directors from time to time.

5.5 Shares of Other Corporations; Proxies. Whenever the Company holds shares of any other corporation, any and all rights and powers of the Company as shareholder (including the attendance, acting, and voting at shareholders' meetings and execution of waivers, consents, and proxies) may be exercised on behalf of the Company by the President, any Vice President, the Secretary or by such other person as the Board of Directors may authorize.

ARTICLE VI **CAPITAL STOCK**

6.1 Certificates of Stock. The shares of stock of the Company may be represented by certificates or may be issued in uncertificated form pursuant to the customary arrangements for issuing shares in such form. The Secretary of the Company shall ensure that records of issuance of all uncertificated shares, and the transfer, exchange, conversion, surrender or redemption thereof, shall be maintained at all times by agents of the Company, through a direct registration system or other book-entry record keeping system as the Secretary may approve. Any shares issued in uncertificated form shall not affect shares already represented by certificates until they are surrendered to the Company. Certificates for shares of the capital stock of the Company, if any, shall be signed by, or in the name of the Company by, (i) the President or a Vice President, and (ii) the Treasurer or the Secretary of the Company, certifying the number of shares owned by such shareholder in the Company. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Company with the same effect as if such officer, transfer agent or registrar were such officer, transfer agent or registrar at the date of issue.

6.2 Lost Certificates. The Board of Directors may direct a new certificate or certificates to be issued in place of any certificate or certificates theretofore issued by the Company alleged to have been lost, stolen or destroyed. When authorizing such issue of a new certificate or certificates, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate or certificates, or such owner's legal representative, to give reasonable evidence of such loss, theft or destruction, to advertise the same in such manner as it shall require and/or to give the Company a bond in such sum as it may direct as indemnity against any claim that may be made against the Company with respect to the certificate alleged to have been lost, stolen or destroyed or the issuance of such new certificate.

6.3 Transfer of Stock. Upon surrender to the Company or the transfer agent of the Company of a certificate for shares, duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, and proper evidence of compliance with other conditions to rightful transfer, it shall be the duty of the Company to cancel the old certificate, register such transfer through the book-entry record keeping system of the Company or issue a new certificate to the person entitled thereto and record the transaction upon its books.

6.4 Registered Shareholders. The Company shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Louisiana.

ARTICLE VII
RECORD DATES

In order that the Company may determine the shareholders entitled: (1) to notice of or to vote at any shareholders' meeting or any adjournment thereof, (2) to express consent to corporate action in writing without a meeting, (3) to receive payment of any dividend or other distribution or allotment of any rights, or (4) to exercise any rights in respect of any change, conversion, or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting nor more than sixty (60) days prior to any other action. Only those shareholders of record on the date so fixed shall be entitled to any of the foregoing rights, notwithstanding the transfer of any such stock on the Company's books after any such record date fixed by the Board of Directors.

ARTICLE VIII
FISCAL YEAR

The fiscal year of the Company shall be the calendar year.

ARTICLE IX
CORPORATE SEAL

The Board of Directors may adopt a corporate seal for the Company. Absent adoption of a corporate seal by the Board of Directors, there shall be no corporate seal.

ARTICLE X
AMENDMENT OF BYLAWS

At any meeting of the Board of Directors, the Board of Directors may amend or repeal the Company's Bylaws or approve Amended and Restated Bylaws by an affirmative vote of a majority of all of the Directors.

EXHIBIT C
Agreement and Plan of Acquisition

[See attached]

Dated January 23, 2023

Agreement and Plan of Acquisition

by and among

Elevance Health, Inc.,
as Parent,

ATH Holding Company, LLC,
as Purchaser,

The Accelerate Louisiana Initiative, Inc.,
as the Foundation,

and

Louisiana Health Service & Indemnity Company
(d/b/a Blue Cross and Blue Shield of Louisiana),
as the Company

Table of Contents

Page

ARTICLE I The Transactions	2
Section 1.1 The Reorganization	2
Section 1.2 Purchase and Sale of the Company Shares	3
Section 1.3 The Closing	3
Section 1.4 Payment of Indebtedness.....	3
Section 1.5 Deliveries at the Closing	3
Section 1.6 Closing Payments.....	4
Section 1.7 Adjustment.....	5
Section 1.8 Withholding Rights	7
ARTICLE II Representations and Warranties of the Company and the Foundation	8
Section 2.1 Organization and Power	8
Section 2.2 Foreign Qualifications.....	8
Section 2.3 Authorization.....	8
Section 2.4 Enforceability	8
Section 2.5 Subsidiaries	9
Section 2.6 Governmental Authorizations	9
Section 2.7 Non-Contravention.....	9
Section 2.8 Capitalization	10
Section 2.9 Financial Statements	10
Section 2.10 Accounting Controls; Books and Records	11
Section 2.11 Absence of Certain Changes	11
Section 2.12 Litigation	12
Section 2.13 Material Contracts.....	12
Section 2.14 Benefit Plans	14
Section 2.15 Labor Relations	16
Section 2.16 Taxes	17
Section 2.17 Environmental Matters.....	19
Section 2.18 Intellectual Property; Information Technology.....	19
Section 2.19 Real Property; Personal Property	22
Section 2.20 Permits; Compliance with Law	23
Section 2.21 Insurance Policies.....	25
Section 2.22 Insurance Operations.....	25
Section 2.23 Healthcare and Regulatory Matters.....	27
Section 2.24 Capital or Surplus Maintenance	29
Section 2.25 Affiliated Transactions.....	29
Section 2.26 Brokers	29
Section 2.27 Fairness Opinion	29
Section 2.28 No Other Representations or Warranties.....	29
ARTICLE III Representations and Warranties of Purchaser and Parent	30
Section 3.1 Organization and Power	30
Section 3.2 Authorization of Transactions.....	30
Section 3.3 No Breach.....	30
Section 3.4 Litigation	31
Section 3.5 Brokerage	31
Section 3.6 Sufficiency of Funds	31

Table of Contents

	Page
Section 3.7 Permits; Compliance with Law	31
Section 3.8 Insurance Operations.....	31
Section 3.9 Healthcare and Regulatory Matters.....	32
Section 3.10 No Other Representations or Warranties.....	33
ARTICLE IV Pre-Closing Covenants.....	33
Section 4.1 Operation of Business	33
Section 4.2 Access	37
Section 4.3 Notification	38
Section 4.4 Negotiations with Other Parties	38
Section 4.5 Regulatory Matters.....	39
Section 4.6 Reorganization Matters	41
Section 4.7 Resignations	43
ARTICLE V Additional Agreements.....	43
Section 5.1 Further Assurances.....	43
Section 5.2 Press Releases	43
Section 5.3 Directors' and Officers' Indemnification.....	43
Section 5.4 Tax Matters.	44
Section 5.5 Certain Employee and Employee Benefits Matters	46
Section 5.6 Consents	48
Section 5.7 Advisory Board Matters.....	48
ARTICLE VI Conditions to Closing.....	48
Section 6.1 Conditions to the Obligations of the Company and the Foundation	48
Section 6.2 Conditions to Purchaser's Obligations.....	49
ARTICLE VII Termination.....	50
Section 7.1 Termination.....	50
Section 7.2 Effect of Termination.....	51
Section 7.3 Termination Fee	52
ARTICLE VIII Indemnification.....	53
Section 8.1 Survival	53
Section 8.2 Indemnification Related to Member Proceedings	53
Section 8.3 Indemnification Related to Tax Claims.....	54
Section 8.4 Limitation on Indemnification	54
Section 8.5 Indemnification Procedures for Claims Relating to Member Proceedings	54
Section 8.6 Indemnification Procedures for Certain Tax Claims.....	55
Section 8.7 Recovery Under Insurance Policies	56
Section 8.8 Net of Tax Benefits	56
Section 8.9 Sole Recourse.....	56
ARTICLE IX Miscellaneous.....	57
Section 9.1 No Survival	57
Section 9.2 Fees and Expenses.....	57
Section 9.3 Amendment and Waiver.....	57
Section 9.4 Notices.....	57
Section 9.5 Assignment.....	59
Section 9.6 Severability	59
Section 9.7 Construction and Interpretation.....	59

Table of Contents

	Page
Section 9.8 Purchaser Deliveries.....	60
Section 9.9 No Third-Party Beneficiaries	60
Section 9.10 Specific Performance; Damages	60
Section 9.11 Complete Agreement.....	60
Section 9.12 Counterparts	61
Section 9.13 Governing Law.....	61
Section 9.14 Waiver of Jury Trial	61
Section 9.15 Exclusive Jurisdiction and Venue	61
Section 9.16 Non-Recourse.....	61
Section 9.17 No Presumption Against Drafter	62
Section 9.18 Time of Essence	62
Section 9.19 No Right of Set-Off.....	62
Section 9.20 Parent Guarantee	62
Section 9.21 Representation of Foundation; Privilege.....	62
ARTICLE X Definitions.....	63
Schedule 1 Statutory Capital Schedule	83
Schedule 2 Required Approvals.....	84
Schedule 3 Commitments	85
Schedule 4 Hypothetical Scenarios for Tax Claims	86
Exhibit A Form of Note	87
Exhibit B Proposed Plan of Reorganization	88
Exhibit C Example Estimated Closing Statement.....	89
Exhibit D Advisory Board Charter	90

AGREEMENT AND PLAN OF ACQUISITION

THIS AGREEMENT AND PLAN OF ACQUISITION (this “Agreement”) is made and entered into as of January 23, 2023, by and among Elevance Health, Inc., an Indiana corporation (“Parent”), ATH Holding Company, LLC, an Indiana limited liability company (“Purchaser”), Louisiana Health Service & Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana), a Louisiana mutual insurance company (the “Company”), and The Accelerate Louisiana Initiative, Inc., a newly established Delaware nonprofit nonstock corporation organized to work to improve the health and lives of the people of the State of Louisiana and intended to qualify as a Code Section 501(c)(4) social welfare organization (the “Foundation”). Each of the above-referenced parties is sometimes herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in Article X.

WHEREAS, the Company proposes to reorganize from a mutual insurance company to a stock insurance company pursuant to the Plan of Reorganization and in accordance with LSA-R.S. 22:72, LSA-R.S. 22:236 *et seq.* and the other applicable provisions of the Louisiana Insurance Code (collectively, the “Demutualization Statutes”) (the transactions contemplated by such reorganization, collectively, the “Reorganization”);

WHEREAS, the Foundation has been formed by the Company in connection with the Reorganization;

WHEREAS, in connection with the Reorganization, Parent desires to indirectly acquire one hundred percent (100%) of the issued and outstanding shares of capital stock of the Company in accordance with this Agreement and the Plan of Reorganization;

WHEREAS, contemporaneously with the effectiveness of the Reorganization, the Company shall issue to Purchaser one hundred percent (100%) of the shares of its capital stock (the “Company Shares”) in accordance with the Plan of Reorganization and subject to the terms and conditions set forth in this Agreement;

WHEREAS, immediately prior to the effectiveness of the Reorganization and in exchange for the right to operate as a stock insurance company following the Reorganization in accordance with the Demutualization Statutes and subject to approval of the Commissioner and in furtherance of the purposes of the constituencies to be served pursuant to the Amended and Restated Articles of Incorporation of the Company, the Company shall (i) pay or transfer, as applicable, to the Foundation the Approved Excess Surplus and (ii) issue to the Foundation a note payable substantially in the form attached as Exhibit A (the “Note”), to be repaid immediately following the Closing in accordance with the terms thereof and the Plan of Reorganization;

WHEREAS, the Proposed Plan of Reorganization provides that, concurrently with the effectiveness of the Reorganization, Purchaser will deposit with the Paying Agent for distribution to the Eligible Members and Purchaser and the Company shall cause the Paying Agent to distribute to the Eligible Members, the Eligible Member Payment as consideration for the extinguishment of their membership interests in the Company, on the terms and subject to the conditions of the Plan of Reorganization and in accordance with the Demutualization Statutes;

WHEREAS, the Company Board has determined, subject to approval of the Commissioner, to recommend to the Company’s Qualified Voters the approval and adoption of the Plan of Reorganization, this Agreement and the transactions contemplated hereby (the “Transactions”); and

WHEREAS, the Company Board has duly approved and adopted the Proposed Plan of Reorganization, this Agreement and the Transactions;

NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ARTICLE I

The Transactions

Section 1.1 The Reorganization.

(a) Subject to the terms and conditions hereof, on the Closing Date, the Company shall effectuate the Reorganization, whereupon the Company shall reorganize from a mutual insurance company to a stock insurance company in accordance with the Plan of Reorganization and the Demutualization Statutes.

(b) Prior to the execution of this Agreement, the Company Board, by at least a two-thirds affirmative vote of the entire Company Board, has adopted the Proposed Plan of Reorganization attached as Exhibit B hereto, complying with the Demutualization Statutes and including or providing for the following:

(i) a statement analyzing the benefits and risks attendant to the Reorganization, including the rationale for the Reorganization;

(ii) a statement indicating how the Reorganization will protect the immediate and long-term interests, and serve the best interests of, the policyholders of the Company;

(iii) copies of the articles of incorporation and bylaws (or their equivalents) of the Company, in each case in the form to be effective immediately following the Reorganization;

(iv) information sufficient to demonstrate that the financial condition of the Company will not be diminished upon the Reorganization;

(v) a description of the plan for the issuance of the Company Shares by the Company to Purchaser;

(vi) that all membership interests in the Company shall be extinguished as of the Reorganization;

(vii) the manner in which the Eligible Member Payment was determined and the method by which the Eligible Member Payment is to be allocated among the Eligible Members;

(viii) that all consideration or proceeds distributed to Eligible Members pursuant to the Plan of Reorganization and this Agreement shall be in the form of cash;

(ix) payment or transfer, as applicable, of the Approved Excess Surplus and issuance of the Note to the Foundation;

(x) the distribution of the Eligible Member Payment in a fair and equitable manner to all Eligible Members in consideration of the extinguishment of their membership interests in the Company;

(xi) that the Company following the Reorganization shall be a continuation of the existence of the Company prior to the Reorganization and shall be treated as such pursuant to §236.9.A of the Louisiana Insurance Code (LSA-R.S. 22:236.9.A);

(xii) that the effectiveness of the Plan of Reorganization is conditioned upon, among other things, (x) approval of the Reorganization and Plan of Reorganization by the Commissioner, (y) approval of the Reorganization and Plan of Reorganization at a meeting convened for that purpose by a vote of not less than two-thirds of the Qualified Voters of the Company entitled to vote on matters and present or represented by special ballot or special proxy, and (z) the satisfaction of the conditions set forth in Article VI hereof; and

(xiii) such additional terms and provisions as are agreed upon in writing by the Parties and not inconsistent with the provisions set forth herein.

Section 1.2 Purchase and Sale of the Company Shares. Upon the terms and subject to the conditions set forth herein, and pursuant to the Plan of Reorganization, at the Closing, Purchaser shall deposit with the Paying Agent for distribution to the Eligible Members pursuant to the Paying Agent Agreement, an amount equal to the Eligible Member Payment, and the Company shall transfer and deliver to Purchaser or an Affiliate of Purchaser so designated by Purchaser, one hundred percent (100%) of the Company Shares, free and clear of all Liens (other than any restrictions under the Securities Laws or Liens created by or resulting from actions of Purchaser).

Section 1.3 The Closing. The closing of the Transactions (the “Closing”) shall take place by electronic exchange of documents, commencing at 10:00 a.m. New York City time on the third Business Day following the satisfaction or waiver of all conditions to each Party’s obligation to consummate the Transactions (other than the conditions which by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at the Closing), or at such other place or on such other date as is mutually agreeable to Purchaser and the Company. The date of the Closing is referred to herein as the “Closing Date.” All matters to be calculated as of the Closing Date pursuant to this Agreement shall be calculated as of 12:01 a.m. on the Closing Date.

Section 1.4 Payment of Indebtedness. The Parties contemplate that, upon the Closing, all Indebtedness set forth in Section 1.4 of the Company Disclosure Letter (“Closing Repaid Indebtedness”) will be fully repaid and that such repayment will be funded by Purchaser in accordance with this Agreement. In order to facilitate such repayment, no later than two Business Days prior to the Closing Date, the Company shall obtain payoff letters for all such Closing Repaid Indebtedness, which payoff letters shall (i) acknowledge the aggregate principal amount and all accrued but unpaid interest constituting such Indebtedness of the Company Entities as of the Closing Date and (ii) confirm that upon payment of such amount, each party to whom such Closing Repaid Indebtedness is owed shall release any and all Liens with respect thereto and agree to execute and file Uniform Commercial Code Termination Statements and such other documents or endorsements reasonably necessary to release such Liens in respect of the assets and properties of the Company Entities (the “Payoff Letters”).

Section 1.5 Deliveries at the Closing.

(a) At the Closing, Purchaser shall deliver, or cause to be delivered, to the Company each of the following:

(i) a certificate from an officer of Purchaser, dated as of the Closing Date and in a form reasonably acceptable to the Company, stating that the conditions specified in Section 6.1(a) and Section 6.1(b) have been satisfied;

(ii) certified copies of the resolutions duly adopted by the board of directors (or equivalent governing body) of Purchaser authorizing the execution, delivery and performance of this Agreement and the consummation of the Transactions; and

(iii) a counterpart signature page to the Paying Agent Agreement duly executed by Purchaser.

(b) At the Closing, the Company or the Foundation, as applicable, shall deliver, or cause to be delivered, to Purchaser each of the following:

(i) a certificate from an officer of the Company, dated as of the Closing Date and in a form reasonably acceptable to Purchaser, stating that the conditions specified in Section 6.2(a) and Section 6.2(b) with respect to the Company have been satisfied;

(ii) certified copies of the resolutions duly adopted by Company Board authorizing the execution, delivery and performance of this Agreement and the consummation of the Transactions;

(iii) a certificate certifying that the Company was not a “United States real property holding corporation” within the meaning of Section 897(c)(2) of the Code at any time during the five-year period ending on the Closing Date;

(iv) the Payoff Letters; and

(v) a certified copy of the certificate filed with the Commissioner pursuant to §236.8.A of the Louisiana Insurance Code (LSA-R.S. 22:236.8.A).

Section 1.6 Closing Payments.

(a) No less than three Business Days, but no more than ten Business Days prior to the Closing Date, the Company shall deliver to Purchaser (i) an estimated unaudited balance sheet of the Company (the “Estimated Closing Balance Sheet”), (ii) a certificate signed by the Chief Financial Officer of the Company containing a statement (the “Estimated Closing Statement”) setting forth the Company’s good faith calculation of (a) the Estimated Closing Indebtedness (if applicable), (b) the Estimated Company Transaction Expenses (if applicable) and (c) the Estimated Closing Surplus (including the estimates of Statutory Capital and Minimum Regulatory Capital and including a line item calculation schedule for each Estimated UTP Accrual that has been reflected in the calculation of the Estimated Closing Surplus through reflection as liabilities in the Financial Statements, as updated in the Estimated Closing Balance Sheet), and (iii) any supporting documentation used to prepare the Estimated Closing Balance Sheet and the Estimated Closing Statement reasonably requested by Purchaser. The Estimated Closing Statement shall be prepared in a manner consistent with SAP, consistently applied; provided that the Closing Indebtedness and Company Transaction Expenses, in each case, if applicable, shall be calculated in accordance with GAAP and without duplication of any amounts included in the calculation of the Estimated Closing Surplus. An example Estimated Closing Statement setting forth the Company’s good faith estimate of the components thereof as of September 30, 2022 is attached hereto as Exhibit C. Following delivery of the Estimated Closing Statement and prior to the Closing Date, the Company shall provide Purchaser and its Representatives with reasonable access during normal business hours to the books, records and personnel of the Company Entities used in or responsible for, as applicable, the preparation of the Estimated Closing Statement; provided, that such access or related activities may be limited to the extent reasonably necessary due to COVID-19 Actions or COVID-19 Measures, and the Company shall (A) consider in good faith any potential adjustments to the Estimated Closing Statement raised by Purchaser reasonably and in good faith prior to the Closing, and (B) make any corresponding changes to the Estimated Closing Statement that the

Company reasonably agrees are appropriate. All payments to be made by Purchaser pursuant to this Section 1.6 shall be made in accordance with the Estimated Closing Statement, as applicable.

(b) At the Closing, immediately prior to the effectiveness of the Reorganization and in exchange for the right to operate as a stock insurance company following the Reorganization in accordance with the Demutualization Statutes and subject to approval of the Commissioner and in furtherance of the purposes of the constituencies to be served pursuant to the Amended and Restated Articles of Incorporation of the Company, the Company shall (i) cause the Approved Excess Surplus to be paid or transferred, as applicable, to the Foundation and (ii) issue the Note to the Foundation pursuant to the terms of the Plan of Reorganization. Notwithstanding anything in this Agreement to the contrary, payment or transfer, as applicable, of the Approved Excess Surplus by the Company may be made wholly or partly in kind, instead of in cash, with any such transfer in kind to be made by transferring Marketable Securities.

(c) At the Closing, Purchaser shall pay to the Paying Agent as consideration for the purchase by Purchaser of the Company Shares and for the extinguishment of the membership interests of the Company held by the Eligible Members, the Eligible Member Payment, by wire transfer of immediately available funds to the account designated in the Paying Agent Agreement.

(d) At the Closing, Purchaser shall pay, on behalf of the Company Entities, the Closing Repaid Indebtedness to the recipients thereof in accordance with Section 1.4.

(e) At the Closing, Purchaser shall pay to the Company, for distribution through the Company's payroll system, any amounts due to employees and officers of any Company Entity constituting Company Transaction Expenses and shall pay all other Company Transaction Expenses for which invoices have been submitted to Purchaser at least three Business Days prior to the Closing Date. No less than three Business Days, but no more than ten Business Days prior to the Closing Date, the Company shall provide a statement which sets forth the amount of the Company Transaction Expenses and instructions for payment thereof.

(f) Immediately following the Closing, Purchaser shall (i) contribute, or cause to be contributed, to the Company an amount equal to the Note Amount, (ii) cause the Company to pay to the Foundation the Note Amount in satisfaction of its obligations to the Foundation under the Note and (iii) cause the Paying Agent to distribute the Eligible Member Payment to the Eligible Members pursuant to the Plan of Reorganization and the Paying Agent Agreement.

Section 1.7 Adjustment.

(a) Determination of Foundation Amount. No later than 120 days after the Closing Date, Purchaser shall prepare and deliver to the Foundation (i) an unaudited consolidated balance sheet of the Company Entities (the "Closing Balance Sheet"), and (ii) a certificate signed by an authorized officer of Purchaser containing a statement (the "Final Closing Statement") setting forth Purchaser's good faith calculation of (A) the Closing Indebtedness (if applicable), (B) the Company Transaction Expenses (if applicable), and (C) the Closing Surplus (including Statutory Capital and Minimum Regulatory Capital and including a line item calculation schedule for each UTP Accrual that has been reflected in the calculation of the Closing Surplus through reflection as a liability in the Financial Statements, as updated in the Closing Balance Sheet), together with a calculation of the Final Foundation Amount based on such calculations, and (iii) any supporting documentation used to prepare the Closing Balance Sheet and the Final Closing Statement reasonably requested by the Foundation. The Final Closing Statement shall be prepared in a manner consistent with SAP, consistently applied; provided, that the Closing Indebtedness and Company Transaction Expenses, in each case, if applicable, shall be calculated in accordance with GAAP and without duplication of any amounts included in the calculation of the Closing Surplus. Following delivery of the Final Closing Statement and prior to the expiration of the 45-day period referred to in Section 1.7(b) below,

Purchaser shall provide the Foundation and its Representatives with reasonable access upon reasonably advanced written request during normal business hours to the books, records and personnel of Purchaser and the Company Entities, as applicable, used in or responsible for, as applicable, the preparation of the Final Closing Statement; provided, that such access or related activities may be limited to the extent reasonably necessary due to COVID-19 Actions or COVID-19 Measures. If Purchaser fails to deliver the Final Closing Statement in accordance with this Section 1.7(a), the amounts set forth in the Estimated Closing Statement shall be deemed final and binding upon the Parties.

(b) Dispute Resolution Procedures. In the event that the Foundation does not object by written notice of objection (a “Notice of Objection”) to the Closing Balance Sheet or the Final Closing Statement within 45 days after the Foundation’s receipt thereof, the Closing Balance Sheet and the Final Closing Statement, as applicable, shall be deemed final and binding. A Notice of Objection shall set forth in reasonable detail the Foundation’s alternative calculations for any amount in dispute (a “Contested Adjustment”) and a recalculation of the Final Foundation Amount, based on such amounts.

(c) If the Foundation delivers a Notice of Objection to Purchaser within the applicable 45-day period referred to in Section 1.7(b), then any element of the Closing Balance Sheet and the Final Closing Statement that is not in dispute on the date such Notice of Objection is given shall be treated as final and binding and any Contested Adjustment shall be resolved as set forth in this Section 1.7(c):

(i) The Foundation and Purchaser shall promptly endeavor in good faith to resolve their dispute regarding the Contested Adjustments, but if a final resolution thereof is not obtained within ten Business Days after delivery to Purchaser of the Notice of Objection, the resolution of such Contested Adjustments shall be submitted to KPMG LLP (the “Independent Accountant”).

(ii) The Independent Accountant shall act as an arbitrator to determine, based upon the provisions of this Section 1.7(c), only the Contested Adjustments and the determination of each amount of the Contested Adjustments shall be made in accordance with the procedures set forth in Section 1.7(b) hereof. The Independent Accountant shall only decide the specific items under dispute by the Parties and its decision for each Contested Adjustment must be within the range of values proposed for such item in the Final Closing Statement and the Notice of Objection.

(iii) The Foundation and Purchaser shall use their commercially reasonable efforts to cause the Independent Accountant to render a decision in accordance with this Section 1.7(c) along with a statement of reasons therefor within 30 days of the submission of the Contested Adjustments, or as promptly as practicable thereafter. The decision of the Independent Accountant shall be final, binding and non-appealable upon each Party and the decision of the Independent Accountant shall constitute an arbitral award that is final, binding and non-appealable and upon which a judgment may be entered by a court having jurisdiction thereover.

(iv) The Foundation and Purchaser shall each pay their own costs and expenses incurred under this Section 1.7(c). The Foundation shall be responsible for that fraction of the fees and costs of the Independent Accountant where (A) the numerator is the absolute value of the difference between the Foundation’s aggregate position with respect to the Final Foundation Amount and the Final Foundation Amount as recalculated based upon Independent Accountant’s final determination with respect to the Contested Adjustments and (B) the denominator is the absolute value of the difference between the Foundation’s aggregate position with respect to the Final Foundation Amount and

Purchaser's aggregate position with respect to the Final Foundation Amount, and Purchaser shall be responsible for the remainder of such fees and costs.

(v) The Foundation, Purchaser, and their respective Representatives shall cooperate fully with the Independent Accountant during its engagement.

(d) Settlements. The difference between the Final Foundation Amount and the Closing Foundation Amount as finally determined, and payable pursuant to this Section 1.7(d), is referred to herein as the "Adjustment". Upon the determination, in accordance with Section 1.7(b) or Section 1.7(c), of the Final Foundation Amount, the Foundation or Purchaser, as the case may be, shall make or cause or direct to be made, as applicable, the payment required by this Section 1.7(d) as follows:

(i) if the Final Foundation Amount is greater than the Closing Foundation Amount, then Purchaser shall within three Business Days of the determination of the Final Foundation Amount (A) contribute, or cause to be contributed, to the Company an amount equal to the Adjustment and (B) cause the Company to pay to the Foundation an amount equal to the Adjustment by wire transfer of immediately available funds to an account designated by the Foundation in writing;

(ii) if the Final Foundation Amount is less than the Closing Foundation Amount, then within three Business Days after the determination of the Final Foundation Amount, then the Foundation shall within three Business Days of the determination of the Final Foundation Amount, pay an amount equal to the Adjustment by wire transfer of immediately available funds to an account designated by Purchaser in writing; or

(iii) if the Final Foundation Amount is equal to the Closing Foundation Amount, no payments shall be made pursuant to this Section 1.7(d).

Section 1.8 Withholding Rights. Each of Purchaser, the Foundation and the Company shall be entitled to deduct and withhold from amounts otherwise payable to any Person pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under any provision of applicable Law. If Purchaser, the Foundation or the Company, as the case may be, so withholds any amounts, and if such amounts are paid over to the relevant Governmental Authority, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person that otherwise would have received such amount but for such withholding, except as otherwise required by applicable Law. Prior to deducting or withholding any amounts from the Closing Foundation Amount or the Final Foundation Amount, Purchaser shall use commercially reasonable efforts to provide the Foundation notice prior to the date on which such proposed deduction or withholding is anticipated to occur. Purchaser and the Foundation shall cooperate in good faith to reduce or eliminate any amounts that would otherwise be deducted or withheld pursuant to this Section 1.8. Notwithstanding the foregoing, Purchaser shall not withhold U.S. federal income Taxes on any payments of the Closing Foundation Amount or the Final Foundation Amount to the Foundation in the event it provides Purchaser with a properly executed IRS Form W-9 on or prior to the Closing unless the adoption or taking effect of or any change in any Law, rule, regulation or treaty, any change in the administration, interpretation, implementation or application thereof by any Governmental Authority or the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority after the date of this Agreement requires Purchaser to deduct or withhold from any payments to the Foundation despite its delivering a properly executed IRS Form W-9.

ARTICLE II

Representations and Warranties of the Company and the Foundation

As a material inducement to Purchaser to enter into this Agreement and to consummate the Transactions, the Company, as to itself and the other Company Entities, and the Foundation, as to itself only, hereby represent and warrant to Purchaser as follows as of the date hereof and as of the Closing Date, except as set forth on the Company Disclosure Letter delivered to Purchaser pursuant to the terms of this Agreement:

Section 2.1 Organization and Power.

(a) Each of the Company and the Foundation (i) is duly organized, validly existing and in good standing under the Laws of its jurisdiction of organization and (ii) has the requisite power and authority to own, lease and use its assets and properties in all material respects in a manner in which its properties and assets are currently owned, leased and used and carry on its business as it is now being conducted, except where the failure to have such requisite power and authority would not, individually or in the aggregate, reasonably be expected to be material to the Company Entities, taken as a whole.

(b) Each of the Subsidiaries of the Company (i) is duly organized, validly existing and in good standing under the Laws of its jurisdiction of organization and (ii) has the requisite power and authority to own, lease and use its assets and properties in all material respects in a manner in which its properties and assets are currently owned, leased and used and carry on its business as it is now being conducted, except where the failure to have such requisite power and authority would not, individually or in the aggregate, reasonably be expected to be material to the Company Entities, taken as a whole. The Company has made available to Purchaser true, correct and complete copies of the Organizational Documents of each Company Entity, as in effect on the date hereof (reflecting all amendments and modifications made thereto prior to the date hereof). No Company Entity is in violation of such Organizational Documents in any material respects.

Section 2.2 Foreign Qualifications. Each Company Entity is duly qualified to do business as a foreign corporation, limited liability company or other legal entity and is in good standing in each jurisdiction where such qualification is necessary or where the conduct of its business or the ownership or leasing of its properties or assets requires it to be so qualified or licensed, except in such jurisdictions where the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

Section 2.3 Authorization. Subject to the receipt of all Required Approvals and the Member Approval, each of the Company and the Foundation has all requisite power and authority and has taken all corporate or other action necessary to execute and deliver this Agreement and the other agreements contemplated hereby and to perform its obligations (including the consummation of the Transactions) hereunder and thereunder. The execution and delivery of this Agreement by each of the Company and the Foundation, each such Person's performance of its obligations hereunder and the consummation of the Transactions have been duly authorized by all requisite corporate or other action, and except for the Member Approval, no other act or proceeding on the part of the Company or the Foundation or their respective governing bodies, stockholders or members, as applicable, is necessary to authorize the execution, delivery or performance of this Agreement or the other agreements contemplated hereby and the consummation of the Transactions. Each of the Company and the Foundation has duly executed and delivered this Agreement.

Section 2.4 Enforceability. Assuming the due authorization, execution and delivery by the respective other parties thereto, this Agreement and each Related Agreement to which the Company, any other Company Entity or the Foundation is or will be a party at the Closing constitute or will constitute at

the Closing, as applicable, legal, valid and binding agreements and obligations of such Person, enforceable against such Person in accordance with their respective terms, subject to the Enforceability Exceptions.

Section 2.5 Subsidiaries. Section 2.5 of the Company Disclosure Letter sets forth a true, accurate and complete list of each Subsidiary of the Company, listing for each such Subsidiary its name, type of entity, a list of each Subsidiary's officers and directors (or the equivalent), the jurisdiction of its incorporation or organization, its authorized capital stock or other equity instruments, the number and type of its issued and outstanding shares of capital stock or other equity instruments and the current ownership of such capital stock or other equity instruments. Except as set forth in Section 2.5 of the Company Disclosure Letter, each of the Subsidiaries of the Company is wholly owned by the Company, directly or indirectly, free and clear of any Liens (other than Permitted Liens). Except for securities held as part of its investment portfolio which, in each case, constitute no more than 1% of the issued and outstanding capital stock of any Person, the Company does not own, directly or indirectly, any capital stock of, or any other securities convertible into or exercisable or exchangeable for or evidencing the right to subscribe for or acquire, at any time, capital stock of any Person other than the Subsidiaries of the Company.

Section 2.6 Governmental Authorizations. The execution, delivery and performance of this Agreement and the Related Agreements by each of the Company and the Foundation and the consummation by each such Person of the Transactions and the Related Agreements to which such Person is or will be a party at the Closing, do not and will not require any consent, approval or other authorization of, or filing with or notification to, any Governmental Authority, other than:

- (a) filings and notices to be made with, and consent or approval to be received from, applicable state insurance regulatory authorities, including the LDI Approval;
- (b) compliance with the pre-acquisition notification requirements of the HSR Act;
- (c) compliance with the post-Closing notice requirements of CMS applicable to the Transactions; and
- (d) any other Required Approvals.

Section 2.7 Non-Contravention. The execution, delivery and performance of this Agreement and the Related Agreements to which it is or will be a party to at the Closing, by such Person and the consummation by such Person of the Transactions do not and will not (with or without notice, lapse of time, or both) (a) contravene or conflict with, or result in any violation or breach of, or constitute a default (with or without due notice or lapse of time or both) under any provision of, the Organizational Documents of such Person in any material respect, (b) contravene or conflict with, or result in any violation or breach of, any Law applicable to any Company Entity or by which any assets of any Company Entity ("Company Assets") are bound, assuming that all Required Approvals, the Member Approval and the other authorizations described in Section 2.6 have been obtained or made, or (c) result in any violation or breach of, acceleration of, loss of right or benefit under, give rise to any right to amend, terminate, modify, accelerate or cancel, result in the creation of any Lien (other than a Permitted Lien) or constitute a default (with or without notice or lapse of time or both) under, any Material Contract or require any consent, approval, clearance, exemption, waiver, Permit or other authorization of, registration, declaration or filing with or notification to, any Person under any Material Contract, other than in the case of clauses (b) and (c) of this Section 2.7 as would not, individually or in the aggregate, reasonably be expected to materially impair or delay the ability of such Person to consummate the Transactions or perform its obligations under this Agreement, the Related Agreements or any other documents and instruments to be executed and delivered by such Person pursuant hereto and thereto.

Section 2.8 Capitalization.

(a) At Closing, the Company Shares (i) will constitute 100% of the issued and outstanding shares of capital stock of the Company and (ii) will be duly authorized, validly issued and fully paid and nonassessable.

(b) The authorized, issued and outstanding capital stock or other equity interests of each of the Company's Subsidiaries, and each record owner thereof, in each case free and clear of any Lien (other than Permitted Liens), are set forth in Section 2.8(b) of the Company Disclosure Letter.

(c) As of the Closing Date after giving effect to the Reorganization, except for Securities owned by Purchaser or the Company, there will be no outstanding (i) shares of capital stock of or other voting or equity interests in any Company Entity, (ii) securities, bonds, debentures or Indebtedness of any Company Entity convertible into or exercisable or exchangeable for shares of capital stock of or other voting or equity interests in any Company Entity, (iii) options, warrants or other Rights or agreements, commitments or understandings of any kind to acquire from any Company Entity, or other obligation of any Company Entity to issue, transfer or sell, any shares of capital stock of or other voting or equity interests in any Company Entity, or securities, bonds, debentures or Indebtedness convertible into or exercisable or exchangeable for shares of capital stock of or other voting or equity interests in any Company Entity (the items in clauses (i), (ii) and (iii) being referred to collectively as the "Securities"), (iv) voting trusts, proxies or other similar agreements or understandings to which any Company Entity is a party or by which any Company Entity is bound with respect to the voting of any shares of capital stock of or other voting or equity interests in any Company Entity, or (v) contractual obligations or commitments of any character restricting the transfer of, or requiring the registration for sale of, any shares of capital stock of or other voting or equity interests in any Company Entity. As of the Closing, after giving effect to the Reorganization, there will no outstanding obligations of any Company Entity to repurchase, redeem or otherwise acquire any Securities.

(d) Each outstanding share of capital stock (or equivalent equity interest) of each Subsidiary of the Company (i) is duly authorized, validly issued, fully paid and non-assessable (in each case to the extent such concepts are applicable to such capital stock or equivalent equity), (ii) is not subject to any pre-emptive rights, rights of first refusal, restrictions on transfer or other similar Rights, (iii) is free and clear of all Liens (other than Permitted Liens), (iv) was not issued in violation of any material Contract, restrictions on transfer or other similar right and (v) was issued in compliance in all material respects with all applicable Securities Laws.

(e) There are no outstanding obligations of the Company Entities (i) to repurchase, redeem or otherwise acquire any shares of capital stock (or equivalent equity interest) of any Subsidiary of the Company or (ii) to provide any funds to or make any investment (including in respect of any unsatisfied subscription obligation or capital contribution or capital account funding obligation) in (x) any Subsidiary of the Company or (y) any other Person.

(f) There are no voting trusts, proxies or other agreements, arrangements or commitments to which any Company Entity is a party with respect to the issuance, sale, voting or transfer of any shares of capital stock of the Company Entities. There are no bonds, debentures, notes or other instruments or evidence of Indebtedness issued by any Company Entity that entitle the holder thereof to vote together with stockholders of such Person on any matters with respect to such Person.

Section 2.9 Financial Statements.

(a) The Company has furnished Purchaser with true, complete and accurate copies of (i) the audited consolidated balance sheets of the Company Entities for the years ended December 31, 2019, December 31, 2020 and December 31, 2021, and the related audited consolidated statements of operations

and comprehensive income, equity and cash flows of the Company Entities for the fiscal years then ended, together with the notes thereto and the reports of the Company's independent accountants with respect thereto (the "Audited Financial Statements") and (ii) the unaudited consolidated balance sheets of the Company Entities as of September 30, 2022 (the "Interim Financial Statements" and together with the Audited Financial Statements, the "Financial Statements"). The Financial Statements (i) have been prepared in accordance with GAAP and (ii) present fairly, in all material respects, the financial position of the Company Entities included in such Financial Statements as of their respective dates and the results of operations for the Company Entities included in such Financial Statements for the respective periods then ended, subject, in the case of the Interim Financial Statements to the absence of footnote disclosures and other presentation items and changes resulting from normal year-end adjustments.

(b) The Company has furnished Purchaser with copies of the financial or statutory statements, as applicable, of the Regulated Entities that are listed in Section 2.9(b) of the Company Disclosure Letter (collectively, the "Regulated Entity Statements"). The Regulated Entity Statements (i) were prepared in accordance with GAAP or SAP (as applicable) on a consistent basis during the periods presented and (ii) present fairly, in all material respects, the GAAP or SAP (as applicable) financial position, assets, Liabilities, capital and surplus of the corresponding Regulated Entities as of their respective dates and the GAAP or statutory (as applicable) results of operations for the corresponding Regulated Entities for the respective periods then ended. No material deficiency has been asserted to the Regulated Entities by any Governmental Authority with respect to any Regulated Entity Statements and no Governmental Authority has requested the refile or amending of any Regulated Entity Statement. The Regulated Entities comply in all material respects with all applicable solvency requirements, including risk-based capital requirements, under applicable Laws.

(c) No Company Entity has any material Liabilities, other than (v) Liabilities disclosed, reflected or reserved against on any of the Financial Statements or Regulated Entity Statements, (w) Liabilities incurred in the ordinary course of the business of the Company Entities consistent with past practice since the Balance Sheet Date, (x) Liabilities incurred under or in accordance with this Agreement or in connection with the Transactions that will constitute Company Transaction Expenses or that will be paid or satisfied prior to the Closing, (y) liabilities for Taxes and (z) other liabilities that would not constitute a Material Adverse Effect.

Section 2.10 Accounting Controls; Books and Records. The Company maintains a system of internal controls and procedures that are sufficient to provide reasonable assurance (i) that transactions are executed only with management's authorization, (ii) that transactions are recorded as necessary to permit preparation of the financial statements in accordance with GAAP and SAP and to maintain accountability for assets of the Company Entities, and (iii) regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets of the Company. The Company has not identified or been made aware of (x) any significant deficiency or material weakness in the system of internal accounting controls utilized by the Company Entities, (y) any fraud, whether or not material, that involves the management of such Company Entity who have a role in the preparation of financial statements or the internal accounting controls utilized by any Company Entity or (z) any claim or allegation regarding any of the foregoing. The Company maintains an adequate system of internal controls pursuant to the requirements of SAP and the applicable state insurance regulatory authorities.

Section 2.11 Absence of Certain Changes. Since the Balance Sheet Date through the date of this Agreement, there has not occurred any Material Adverse Effect. Except as otherwise expressly required by this Agreement or for any COVID-19 Actions or as required by any COVID-19 Measures, since the Balance Sheet Date through the date hereof, (a) the Company Entities have conducted their business, in all material respects, in the Ordinary Course of Business and (b) except as set forth in Section 2.11(b) of the Company Disclosure Letter, no Company Entity has taken any action that, if taken after the date of this Agreement, would require the consent of Purchaser pursuant to Section 4.1.

Section 2.12 Litigation. There are no Proceedings pending against any Company Entity and, to the Knowledge of the Company, there are no Proceedings threatened to be brought against any Company Entity, or any of their respective properties, assets, operations or Rights or any of their respective officers, directors, employees or agents in their capacities as such, that, individually or in the aggregate, would reasonably be expected to be material to the Company Entities, taken as a whole, or the Company's ability to consummate the Transactions. There are no, and since the Look-Back Date there have not been any, Orders outstanding against any Company Entity that, individually or in the aggregate, would reasonably be expected to be material to the Company Entities taken as a whole.

Section 2.13 Material Contracts. Section 2.13 of the Company Disclosure Letter sets forth a list of all of the following Contracts (x) to which any Company Entity is a party as of the date of this Agreement or (y) by which any Company Entity or any of their respective properties or assets are bound as of the date of this Agreement (in each case, other than any Company Benefit Plan) (such Contracts, collectively, the "Material Contracts"):

(a) Contracts imposing any restrictions, restraints or limitation on the freedom of any Company Entity to (i) freely engage in any line of business, or future business activities, or in any market or geographic area or (ii) to compete with any Person or in any line of business;

(b) Contracts (i) under which any Company Entity has directly or indirectly incurred, created, assumed or guaranteed outstanding Liabilities of any Person (other than any Company Entity), excluding endorsements for the purpose of collection in the Ordinary Course of Business, (ii) under which any Company Entity has directly or indirectly granted a Lien (including pursuant to any credit support or similar agreement) on any asset or group of assets of any Company Entity, or (iii) that are letter of credit arrangements or performance bond arrangements;

(c) Contracts under which a Company Entity has borrowed any money from, or issued any note, bond, debenture or other evidence of Indebtedness to, any Person (other than trade payables incurred in the Ordinary Course of Business that are not more than 90 days past due);

(d) Contracts under which a Company Entity, directly or indirectly, has agreed to make any advance, loan, extension of credit or capital contribution to, or other investment in, any Person (other than extensions of advances to hospitals, trade credit and advances of expenses to employees in the Ordinary Course of Business);

(e) Contracts entered into for the acquisition from another Person or disposition to another Person of assets (other than in the Ordinary Course of Business) or capital stock or other equity interest of another Person (however structured) which contain "earn-out" obligations with respect to any Company Entity which may become payable from and after the date of this Agreement;

(f) Contracts evidencing any obligations of any Company Entity with respect to the issuance, sale, repurchase or redemption of any equity securities of such Company Entities;

(g) (x) Contracts with CMS or with any other Governmental Authority relating to a Health Care Program, including any agreements relating to the Medicare Shared Savings Program or the Next Generation ACO Model and (y) settlement agreements and corporate integrity agreements, in the case of each of clauses (x) and (y), with CMS or any Health Care Program or Governmental Authority;

(h) ACO, partnership, joint venture, consortium or alliance agreement or other similar Contracts (including any agreement providing for joint research, development or marketing);

- (i) any agent, sales representative, sales or distribution Contract involving payments by any Company Entity in excess of \$1,000,000 per annum (or which, in the case of payments based upon sales commissions, is reasonably likely to be in excess of such amount);
- (j) any Contract with any commercial or governmental payor (including Medicare) involving payments to any Company Entity in excess of \$500,000 per annum;
- (k) any Contract with any Provider (x) involving annual revenues in excess of \$15,000,000 in the fiscal year ended December 31, 2021 or expected to involve annual revenues in excess of \$15,000,000 in the fiscal year ending December 31, 2022 or (y) whereby any Company Entity sends (i.e., down streams) financial risk to the counterparty;
- (l) any Contract (x) for the engagement or employment of any individual employee or individual service-provider on a full-time, part-time, consulting or other basis with annual base compensation in excess of \$175,000 that is not terminable at will without the payment of severance or provision of notice, or (y) providing for the payment of severance or a retention, change in control or other similar payment;
- (m) any collective bargaining agreement or other Contract with a labor union, works council, or other labor organization;
- (n) any Contract that is a settlement, conciliation, or similar agreement (i) with any Governmental Authority or (ii) that imposes any monetary or other material obligation upon any Company Entity in excess, in the case of any monetary obligation, of \$250,000;
- (o) any Contract or group of related Contracts with the same party or group of affiliated parties (other than Providers) for the purchase of supplies, products, equipment or other personal property or for the receipt of services that (i) have a term of more than six months from the date or dates thereof, (ii) are not terminable by any Company Entity party thereto upon 90 days' or less notice without penalty, and (iii) involved annual payments to or from any Company Entity in excess of \$750,000 in the fiscal year ended December 31, 2021 or that are expected to involve annual payments to or from any Company Entity in excess of \$750,000 in the fiscal year ending December 31, 2022;
- (p) any Contract under which any Company is lessee of, or holds or operates any personal property owned by any other party, for which the annual rental exceeds \$1,000,000, other than Contracts with Providers;
- (q) any Real Property Lease for which the annual rental exceeds \$125,000;
- (r) Contracts containing any requirement, supply or exclusivity provision or any "most-favored nation", "most favored pricing" or similar clause;
- (s) any Contract (w) involving the exclusive licensing of any Owned Intellectual Property, (x) under which any Company Entity is granted any license, right, covenant, or immunity under any Intellectual Property of a Person that is not a Company Entity (other than non-exclusive end user licenses of uncustomized, commercially available, off-the-shelf Software used for the Company's internal use with fees of less than \$500,000 annually), (y) under which any Company Entity grants to a Person that is not a Company Entity any license, right, covenant, or immunity under any Intellectual Property (other than end user agreements that grant non-exclusive licenses of Company Software to end users in the Ordinary Course of Business on terms in all material respects the same as the form end user Contracts that have been previously provided to Purchaser), or (z) under which a Person that is not a Company Entity develops or assigns any Intellectual Property for the benefit of any Company Entity (other than agreements with employees or

contractors (who are natural persons, not entities) entered into in the Ordinary Course of Business on terms in all material respects the same as the forms of such Contracts that have been previously provided to Purchaser);

(t) any Contract with any Governmental Authority, other than Contracts for the provision of administrative services for self-insured, or Contracts of insurance for fully-insured, employee welfare benefit arrangements of employees of Governmental Authorities; or

(u) any Contract between any Company Entity, on the one hand, and any other Company Entity or equityholder, officer or director of any Company Entity, on the other hand (other than Contracts related to employment or engagement relationships and compensation, travel advances and employee loans in the Ordinary Course of Business).

Each Material Contract, whether or not set forth in Section 2.13 of the Company Disclosure Letter, is, subject to the Enforceability Exceptions, a valid and binding agreement of the relevant Company Entity and, to the Knowledge of the Company, each other party thereto and is, subject to the Enforceability Exceptions, in full force and effect, enforceable in accordance with its terms, and will continue to be enforceable following Closing. No Company Entity and, to the Knowledge of the Company, any other party thereto, is in material breach or violation of, default under or has repudiated any such Material Contract. No Company Entity has received written notification of the intention of any other Person to cancel, terminate or amend in any material respect the terms of any Material Contract, or accelerate the obligations of any Company Entity thereunder. A true, correct and complete copy of each Material Contract has been delivered or made available to Purchaser. No event has occurred, is pending or, to the Knowledge of the Company, is threatened which, after the giving of notice, lapse of time or otherwise, would constitute a breach, violation or default by any Company Entity under any Material Contract or, to the Knowledge of the Company, any other party to any Material Contract or would permit acceleration, termination or material modification of any Material Contract.

Section 2.14 Benefit Plans.

(a) Section 2.14(a) of the Company Disclosure Letter lists all material Company Benefit Plans. “Company Benefit Plans” means all “employee benefit plans” within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974 (“ERISA”), and all Company Benefit Plans, stock purchase, stock option, stock appreciation right, stock-based or other equity-based, profit-sharing, employment, severance, consulting, termination, change-of-control, retention, bonus, incentive, deferred compensation, retirement, supplemental retirement, welfare, post-employment welfare, vacation, sick leave, paid time off, insurance, medical, fringe benefit, and any other benefit plans, agreements, programs, policies, commitments or arrangements, whether or not in writing, whether or not funded and whether or not subject to ERISA, which are maintained, sponsored or contributed to by any Company Entity or to which any Company Entity is required to make contributions or with respect to which any Company Entity has any Liability, in each case with respect to current or former directors, officers, employees or consultants of any Company Entity.

(b) With respect to each Company Benefit Plan set forth, or required to be set forth, in Section 2.14 of the Company Disclosure Letter, the Company has made available to Purchaser true and complete copies of the following, to the extent applicable: (i) the plan document, including all amendments thereto and all related trust documents, insurance Contracts or other funding vehicles, (ii) the most recent summary plan description, together with a summary or summaries of material modifications thereto, (iii) the most recent annual report on Form 5500 (including all schedules), (iv) the most recent annual audited financial statements and opinion, (v) if the Company Benefit Plan is intended to qualify under Section 401(a) of the Code, the most recent determination letter received from the IRS, and (vi) all material non-routine correspondence to or from the IRS, the United States Department of Labor, the Pension

Benefit Guaranty Corporation or any other Governmental Authority received since the Look-Back Date with respect to any Company Benefit Plan.

(c) No Company Entity, nor any entity that would be treated together with any Company Entity as a single employer within the meaning of Section 414 of the Code, maintains, sponsors, contributes to or has any Liability and has not within the preceding six years maintained, sponsored, contributed to or had any Liability (including, in each case, on account of any employer (whether or not incorporated) that would be treated together with any Company Entity as a single employer within the meaning of Section 414 of the Code) with respect to any employee benefit plan subject to Section 412 of the Code or Title IV of ERISA, including any “multiemployer plan” (as such term is defined under Section 3(37) of ERISA).

(d) Except as would not result in material Liability to the Company Entities, taken as a whole: (i) each Company Benefit Plan has been administered, funded and maintained, in form and operation, in compliance in all respects with its terms and ERISA, the Code, and all other applicable Law, (ii) all contributions, premiums or other payments that are due have been paid on a timely basis with respect to each Company Benefit Plan, (iii) with respect to each Company Benefit Plan that is intended to qualify under Section 401(a) of the Code (or any similar provision of Law) (A) a favorable determination letter has been issued by the IRS with respect to such qualification or a timely application for such determination is now pending or is not yet required to be filed, (B) its related trust has been determined to be exempt from taxation under Section 501(a) of the Code (or any similar provision of Law) and (C) to the Knowledge of the Company, no event has occurred since the date of such qualification or exemption that would reasonably be expected to adversely affect such qualification or exemption, (iv) no Company Entity has incurred or expects to incur any penalty or Tax (whether or not assessed) under Sections 4980H, 4980D, 6721 or 6722 of the Code and no circumstances or events have occurred that could result in the imposition of any such penalties or Taxes, and (v) no Company Entity has engaged in any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) with respect to any Company Benefit Plan that would subject any Company Entity to any Tax or penalty imposed by ERISA or the Code.

(e) No Company Benefit Plan provides health, medical, life insurance or death benefits to current or former employees of any Company Entity beyond their retirement or other termination of service, other than coverage mandated by COBRA or Section 4980B of the Code, or any similar state group health plan continuation Law, the premium cost of which is fully paid by such current or former employees or their dependents.

(f) Neither the execution and delivery of this Agreement nor the consummation of the Transactions would reasonably be expected to (either alone or in combination with another event), directly or indirectly, (i) result in any payment or benefit becoming due, or increase the amount of any payment or benefit due, to any current or former employee, officer, director, or other individual independent contractor of any Company Entity, (ii) increase any compensation or benefits otherwise payable under any Company Benefit Plan, (iii) result in the acceleration of the time of payment, funding or vesting of any compensation or benefits due to any current or former employee, officer, director or other individual independent contractor of any Company Entity, (iv) directly or indirectly cause any Company Entity to transfer or set aside any assets to fund any material benefits under any Company Benefit Plan, (v) otherwise give rise to any material liability under any Company Benefit Plan, (vi) limit or restrict the right to merge, materially amend, terminate or transfer the assets of any Company Benefit Plan on or following the consummation of the Transactions, or (vii) give rise to any payment that could, alone or in the aggregate, be characterized as an “excess parachute payment” as defined in Section 280G of the Code or subject to an excise tax under Section 4999 of the Code.

(g) Except as would not result in material Liability to the Company Entities, taken as a whole: each Company Benefit Plan subject to Code Section 409A (if any) has at all relevant times been

in material compliance with applicable document requirements of, and has been operated in material compliance with, Code Section 409A and the Treasury Regulations and other official guidance promulgated thereunder.

(h) No Company Entity has any commitment to reimburse, make-whole, indemnify or otherwise “gross-up” any Person for Tax set forth under Section 409A of the Code, Section 280G of the Code, or Section 4999 of the Code (or any similar provision of state, local or foreign Law) or any other Tax.

(i) Except as would not result in material Liability to the Company Entities, taken as a whole: there do not exist any pending or, to the Company’s Knowledge, threatened claims (other than routine claims for benefits in the Ordinary Course of Business), suits, actions, disputes, audits or investigations with respect to any Company Benefit Plan, including any pending or, to the Company’s Knowledge, threatened claims, suits, actions, disputes, audits, investigations, by the IRS, the United States Department of Labor or other Governmental Authority with respect to any Company Benefit Plan.

Section 2.15 Labor Relations.

(a) No employee of any Company Entity is represented by a labor union, works council, or other labor organization and, to the Knowledge of the Company, no union or employee organizing efforts have occurred since the Look-Back Date or are now underway. No Company Entity is a party to or bound by any collective bargaining agreement or other Contract with a labor union, works council or other labor organization. No Company Entity is, or since the Look-Back Date has been, subject to any pending or, to the Knowledge of the Company, threatened, strike, picket, work stoppage, work slowdown or other organized labor dispute. Excluding the effect of any actions that may be taken by Purchaser from and after Closing, the Company Entities have satisfied all notice, consultation, bargaining, and consent obligations owed to their employees and their employees’ representatives under applicable Law or labor Contract, to the extent any such obligations exist, with respect to the Transactions.

(b) Each Company Entity is, and since the Look-Back Date has been, in compliance in all material respects with all applicable Laws relating to the employment of labor and employment practices (including equal employment opportunity Laws), including all applicable Laws relating to wages, hours, collective bargaining, employment discrimination, civil rights, safety and health, workers’ compensation, immigration, worker and employee classification, plant closings and mass layoffs, pay equity and the collection and payment of withholding or social security Taxes, except where the failure to so comply would be material to the Company Entities taken as a whole. No Company Entity has incurred any material Liability or obligation under the WARN Act or any similar state or local Law since the Look-Back Date that remains unsatisfied. Except as would not result in material Liability to the Company Entities taken as a whole: (i) each Company Entity has fully and timely paid all wages, salaries, wage premiums, prevailing wages, commissions, bonuses, fees, and other compensation not in dispute which have come due and payable to its current and former employees and independent contractors under applicable Law, Contract, or Company policy; and (ii) each individual who has provided services to any Company Entity since the Look-Back Date and was classified and treated by the Company Entities as an independent contractor, consultant, or other service provider is and was properly classified and treated for all applicable purposes. To the Knowledge of the Company, no officer or executive of any Company Entity: (i) has any present intention to terminate his or her employment with the Company Entities; or (ii) is a party to or bound by any confidentiality, non-competition, proprietary rights or other agreement that would materially restrict the performance of such employee’s employment duties or the ability of Company Entities to conduct their business. There are no pending or, to the Company’s Knowledge, threatened charges, complaints, arbitrations, audits, or investigations before any Governmental Authority brought against any Company Entity by or on behalf of any current or former employee (or any person alleging to be an employee), any applicant for employment, any class of the foregoing, or any Governmental Authority, that

involve the labor or employment relations and practices of any Company Entity, that would reasonably be expected to result, individually or in the aggregate, in material Liability to the Company Entities taken as a whole.

(c) In the past three years, (i) no allegations of sexual harassment or sexual misconduct have been made in writing, or, to the Knowledge of the Company, threatened to be made against or involving any current or former officer, director or other employee at the level of vice president or higher by any current or former officer, employee or individual service provider of any Company Entity, and (ii) no Company Entity has entered into any settlement agreements resolving, in whole or in part, allegations of sexual harassment or sexual misconduct by any current or former officer, director or other employees with a title of vice president or higher.

Section 2.16 Taxes.

(a) All income and other material Tax Returns required to be filed by or with respect to any Company Entity have been timely filed (taking into account any valid extension of time within which to file) with the appropriate tax authorities, and all such Tax Returns are true, complete and correct in all material respects and were prepared in compliance with applicable Law.

(b) Each Company Entity has fully and timely paid all income and other material Taxes due and owing by it (regardless of whether shown to be due on any Tax Returns referred to in Section 2.16(a)).

(c) There are no outstanding agreements extending or waiving the statutory period of limitations applicable to any Tax Return, or any claim for, or the period for the collection, assessment or reassessment of, Taxes with respect to any Company Entity for any taxable period, and no written request for any such waiver or extension is currently pending.

(d) No audit, investigation, arbitration, litigation, complaint, suit, charge, inquiry, investigation, or other Proceeding by any Governmental Authority has occurred within the past five years, is pending or has been threatened in writing (or, to the Knowledge of the Company, other than in writing) with respect to any Taxes or material Tax Returns of or with respect to any Company Entity.

(e) No deficiencies for Taxes have been proposed, asserted or assessed in writing (or, to the Knowledge of the Company, other than in writing) against any Company Entity that are still pending. No Company Entity is subject to any rulings or determinations of any Governmental Authority in respect of any Tax, and no requests for any such rulings or determinations are pending between any Company Entity, on the one hand, and any Governmental Authority, on the other hand.

(f) No Company Entity has (i) been a member of an Affiliated Group filing a combined, consolidated, unitary or other similar Tax Return (other than an Affiliated Group the common parent of which is a Company Entity) or (ii) any liabilities for Taxes of any Person (other than a Company Entity), as a transferee or successor, by contract, or otherwise.

(g) No written claim has been made within the past five years by any Taxing Authority in a jurisdiction where a Company Entity does not file Tax Returns that such Company Entity is or may be subject to taxation by that jurisdiction.

(h) Section 2.16(h) of the Company Disclosure Letter sets forth the classification of each Company Entity for U.S. federal income tax purposes.

(i) No Company Entity will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (v) change in or use of an improper method of accounting

for a taxable period ending on or prior to the Closing Date, (w) closing agreement under Section 7121 of the Code (or any similar provision of Law) entered into prior to the Closing, (x) intercompany transaction or any excess loss account described in Treasury Regulations under Section 1502 of the Code (or any similar provision of Law) that occurred, or existed, prior to the Closing, (y) installment sale or open transaction disposition made prior to the Closing, or (z) prepaid amount received or deferred revenue accrued prior to the Closing.

(j) There are no Liens for Taxes on any assets of any Company Entity, other than Permitted Liens.

(k) No Company Entity is party to any Tax sharing or similar agreement with any other Person other than agreements with customers, vendors, lenders, lessors and the like entered into in the Ordinary Course of Business for which Taxes are not the principal subject matter.

(l) The unpaid Taxes of the Company Entities (i) did not, as of the Balance Sheet Date, exceed the reserve for Tax liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the Interim Financial Statements (rather than in any notes thereto) and (ii) do not exceed that reserve as adjusted for the passage of time through the Closing Date in accordance with the past custom and practice of the Company Entities in filing their Tax Returns. Since the Balance Sheet Date, No Company Entity has incurred any liability for Taxes arising from extraordinary gains or losses, as that term is used in GAAP, or from transactions outside the Ordinary Course of Business.

(m) Each Company Entity has properly (i) collected and remitted all material sales, use, valued added and similar Taxes with respect to sales or leases made or services provided to its customers and (ii) for all sales, leases or provision of services that are exempt from sales, use, valued added and similar Taxes and that were made without charging or remitting sales, use, valued added or similar Taxes, received and retained any appropriate Tax exemption certificates and other documentation qualifying such sale, lease or provision of services as exempt.

(n) [Reserved.]

(o) Each Company Entity, and all intercompany transactions between any Company Entities, are in compliance with the relevant transfer pricing requirements under applicable Law and, in the case of reinsurance transactions, result in the transfer of insurance risk, as determined for purposes of Section 482 or 845 of the Code, as applicable, and any similar provision of state, local, and non-U.S. Law. On or prior to the Closing Date, each Company Entity will have properly and in a timely manner documented its transfer pricing methodology in compliance with applicable Tax Laws.

(p) All material Taxes that each Company Entity is (or was) required by Law to withhold or collect in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, member or other Persons have been duly withheld or collected, and have been timely paid over to the proper authorities to the extent due and payable. Each Company Entity has complied in all material respects with all Tax information reporting requirements (including any IRS Form 1099 reporting requirements) with respect to payments (or deemed payments) to independent contractors, creditors, stockholders, members or other Persons.

(q) No Company Entity has constituted a “distributing corporation” or a “controlled corporation” (within the meaning of Section 355(a)(1)(A) of the Code) in a distribution of stock purported or intended to be governed in whole or in part by Section 355(a) or 361(c) of the Code in the two years prior to the date of this Agreement.

(r) No Company Entity is or has been a party to any “reportable transaction” within the meaning of Section 6707A(c)(1) of the Code and Section 1.6011-4(b) of the Treasury Regulations.

(s) The Company satisfied the requirements set forth in Section 833(c)(2) of the Code for all taxable periods for which the statute of limitations has not yet expired, and the Company has not taken any action or omitted to take any action which would prevent the application of Section 833(c) of the Code to the Company. No Company Entity intends to take any deduction described under Section 833 of the Code with respect to the 2021 or 2022 taxable year.

(t) Each Company Entity is subject to taxation as an “insurance company other than a life insurance company” under Part II of Subchapter L of the Code.

(u) No Company Entity qualifies or has ever qualified as a life insurance company within the meaning of Section 816 of the Code. The Transactions, including the Reorganization, will not cause any Company Entity to have any income or gain or Tax liability as a result of an intercompany transaction or any excess loss account described in Treasury Regulations under Section 1502 of the Code (or any similar provision of Law) that occurred prior to or existed as of the Closing.

(v) No Company Entity has incurred or will incur any material liability under any “hold harmless” indemnification agreements respecting the Tax qualification or treatment of any insurance Contract, product or plan sold, issued, entered into or administered by any Company Entity prior to the Closing Date.

(w) Each insurance Contract that is an “annuity contract” within the meaning of Section 817(g) of the Code is “adequately diversified”, as contemplated by Section 817(h) of the Code.

Section 2.17 Environmental Matters. Each Company Entity and each of their facilities is in compliance, and since the Look-Back Date has complied, in all material respects with all applicable Laws relating to Hazardous Substances, pollution, contamination, public or worker health and safety, or protection of the environment or natural resources (collectively, “Environmental Law”). The Company Entities and their facilities possess, and since the Look-Back Date have possessed, all Permits required under Environmental Law for their respective operations, and such operations are, and since the Look-Back Date have been, in compliance in all material respects with such Permits. No Proceeding arising under or pursuant to Environmental Law is pending, or to the Knowledge of the Company, threatened, against any Company Entity, except for such Proceedings as would not be material to the Company Entities taken as a whole, and since the Look-Back Date, no Company Entity has received any other written (or, to the Knowledge of the Company, other) notice of any material violation of or Liability under Environmental Law. Except as has not resulted and would not reasonably be expected to result in material Liability relating to Hazardous Substances matters or pursuant to Environmental Laws for any Company Entity, (i) no Company Entity has released, produced, sold, used, stored, transported, handled, discharged or disposed of Hazardous Substances at the Real Property or at any other location, (ii) there are no Hazardous Substances present at any Real Property or, to the Knowledge of the Company, any real property formerly owned, leased or operated by any Company Entity, and (iii) there has been no exposure of any Person to any Hazardous Substances arising from the operation of the business of any Company Entity, including at any Real Property.

Section 2.18 Intellectual Property; Information Technology.

(a) Section 2.18(a) of the Company Disclosure Letter sets forth a true, complete and accurate list, specifying, where applicable, the respective Patents, registration or application numbers and the names of all registered owners, of all (i) Owned Intellectual Property that is registered, issued or the subject of a pending application for registration with a Governmental Authority, (ii) material unregistered Trademarks owned by any Company Entity, (iii) material social media accounts owned by any Company

Entity, and (iv) domain names owned by any Company Entity. The Intellectual Property required to be listed on Section 2.18(a) of the Company Disclosure Letter is valid, subsisting, enforceable, and has not been deemed by any Governmental Authority to be invalid or unenforceable and has not been cancelled or abandoned and the Company Entities have taken each action required to be taken and paid all amounts due for all such Intellectual Property to be in compliance with all registration requirements of Law.

(b) A Company Entity (i) possesses and is the sole and exclusive legal and beneficial owner of all right, title and interest in and to all Owned Intellectual Property, free and clear of all Liens (other than Permitted Liens) and (ii) has a valid and enforceable right to use all other Intellectual Property and Computer Systems used in or necessary for the operation of the business of the Company Entities. The Owned Intellectual Property and Licensed Intellectual Property constitute all Intellectual Property that is used in or necessary for the operation of the business of the Company Entities. No Company Entity nor any of the Owned Intellectual Property is subject to any outstanding Order (including any motion or petition therefor) or any settlement agreement that does or would restrict or impair the validity, enforceability, ownership, use, practice, or exploitation of any Intellectual Property by any Company Entity.

(c) The Company Entities and the operation of the business of the Company Entities (including any products or services or the manufacture, use, importation, sale, offering for sale, marketing, distribution, or other commercialization thereof) did not and do not (nor will the conduct proposed under the Related Agreements) (i) infringe, misappropriate, dilute or otherwise violate the Intellectual Property Rights of any Person or (ii) engage in unfair competition or trade practices. No Company Entity has received any written (or, to the Knowledge of the Company, other) notices, requests for indemnification, or claims from any Person related to the foregoing (including any invitations to license), nor has any Company Entity requested or received any opinions of counsel related to the same.

(d) There are no Proceedings pending or, to the Knowledge of the Company, threatened, against any Company Entity (i) alleging that any Company Entity has infringed, misappropriated or otherwise violated any Intellectual Property, or other proprietary Right of any Person that is not a Company Entity or has engaged in unfair competition or trade practices, (ii) relating to the use of any Intellectual Property in the conduct of the business of any Company Entity and (iii) contesting the validity, scope, use, enforceability, ownership, patentability or registerability of any Owned Intellectual Property.

(e) To the Knowledge of the Company, no Person is infringing upon, misappropriating or otherwise violating any Owned Intellectual Property (or has done so since January 1, 2016).

(f) The execution, delivery, and performance of this Agreement and the Related Agreements and the consummation of the Transactions will not, with or without notice or lapse of time, result in, or give any other Person the right or option to cause or declare (i) any alteration, impairment, adverse impact, or extinguishment of any Rights of any Company Entity in any Intellectual Property or Company Systems (nor will require any consent, notification, approval, waiver, the payment or grant of additional amounts or consideration as a result thereof); (ii) the grant, assignment or transfer to any other Person of any license, immunity, covenant not to assert or compete, or other right, title, or interest in, to or under any Owned Intellectual Property or any Intellectual Property Rights owned or controlled by Purchaser or any of its Affiliates; or (iii) any Company Entity being bound by or subject to, any exclusivity obligation, non-compete or other restriction on the conduct, operation or scope of its business as currently conducted or as currently contemplated to be conducted or any of its products or services.

(g) The Company Entities have taken all commercially reasonable actions to maintain and protect all of the Owned Intellectual Property, including the secrecy, confidentiality and value of Trade Secrets and other confidential information of the Company Entities (including source code and algorithms for Company Software), and the Company Entities have not disclosed any confidential Owned Intellectual

Property to any Person that is not a Company Entity other than pursuant to a written confidentiality agreement pursuant to which such Person agrees to protect such confidential information. All Persons who have contributed, developed or conceived any Intellectual Property on behalf of any Company Entity have done so pursuant to a valid and enforceable agreement that adequately protects the Trade Secrets of the Company Entities and grants to the Company Entities (by way of a present grant of assignment) exclusive ownership of the Person's contribution, development or conception (or all such Rights have vested in such Company Entity by operation of Law). To the Company's Knowledge, (i) each party to any such confidentiality agreement or proprietary rights agreement is and has been in full compliance with all applicable terms and requirements thereof and (ii) there has occurred no event that, with notice or the passage of time or otherwise, would constitute a default thereunder or grounds for termination or modification thereof or for the imposition of any charge or penalty thereunder.

(h) The Company Entities have not developed, and are not under any obligation to develop, any Intellectual Property for any Person that is not a Company Entity.

(i) Section 2.18(i) of the Company Disclosure Letter sets forth a true, complete and accurate list of all Software owned (or purported to be owned) by any Company Entity ("Company Software") as of the date hereof. Except with respect to Licensed Intellectual Property, no Person that is not a Company Entity owns any Intellectual Property in any Software incorporated in or used with any Company Software.

(j) (i) Section 2.18 of the Company Disclosure Letter sets forth a true, complete and accurate list of all Open Source Software that has been used in, incorporated into, integrated or bundled with any Company Software, and for each such item of Open Source Software: (A) the name and version number of the applicable license and (B) whether the item was modified or distributed; (ii) no Company Software is subject to Copyleft Terms; and (iii) each Company Entity is in full compliance with the terms and conditions of all relevant licenses for Open Source Software used in their business.

(k) Except for matters that have been resolved or as set forth in Section 2.18(k) of the Company Disclosure Letter, there are, and since the Look-Back Date have been, no defects in any of the Company Software that would prevent the same from performing in accordance with their user specifications or functionality descriptions.

(l) No Person other than the Company Entities possesses, or has an actual or contingent right to access or possess, a copy in any form of any source code for any Company Software and no Company Entity, nor any other Person acting on their behalf, has disclosed, delivered or licensed to any Person that is not a Company Entity, or permitted the disclosure or delivery to any escrow agent of, any source code for any Company Software, except for disclosures to any employees, contractors or consultants of any Company Entity under binding written agreements that prohibit use or disclosure of such source code except in the performances of services for the Company. All such source code is in their sole possession and has been maintained as strictly confidential.

(m) No Owned Intellectual Property was developed with funding from, or using the facilities or resources of, any Governmental Authority or university, college or other educational institution.

(n) The Company Systems (i) are sufficient for the immediate and currently anticipated future needs of the Company Entities' business; (ii) are maintained and in good working condition and have functioned consistently and accurately in all material respects in conformance with their documentation and functional specifications since being installed; and (iii) do not contain any disabling codes or instructions, "time bombs," "Trojan horses," "back doors," "trap doors," "Easter eggs," "logic bombs," "cancelbots," worms, viruses, spyware, keylogger software, or other vulnerability, faults, or other Software or programming routines or malicious code or damaging devices designed or reasonably expected to materially adversely impact the functionality of or permit unauthorized access or to disable or otherwise

harm any computer, systems, or Software (collectively, “Contaminants”). The Company Entities maintain commercially reasonable security, disaster recovery and business continuity plans, procedures and facilities, and the most recent testing of such plans and procedures did not identify any deficiencies therein that would be material to any Company Entity, and there has not been any material failure with respect to any of the Company Systems that has not been remedied or replaced.

(o) The Company Entities have implemented and required that third-party vendors implement adequate policies and commercially reasonable security regarding the confidentiality, availability and integrity of the Company Systems and the data stored or contained therein or transmitted thereby. The Company Systems do not contain any Contaminants, and there has been no unauthorized taking and storing on-site and off-site of back-up copies of critical data.

(p) The Company Entities and the conduct of their respective businesses are and have been in material compliance with all Data Security Requirements and there have not been any actual or alleged data security breaches, nor any loss, damage, unauthorized access, disclosure, use, or security incidents impacting the confidentiality, integrity and availability or uses of any of the Company Systems and the data stored or contained therein or transmitted thereby. There have been no claims, actions, investigations, inquiries or notices received by the Company Entities from a Person that is not a Company Entity (including any Governmental Authority) relating to Data Security Requirements or information security related incidents, including any notices of unauthorized access, acquisition, destruction, damage, disclosure loss, corruption or alternation of data or the Computer Systems on which they are stored. The consummation of the Transactions will not result in any violations of any applicable Data Security Requirements.

Section 2.19 Real Property; Personal Property.

(a) Section 2.19(a) of the Company Disclosure Letter sets forth a complete and correct list of all real property owned in whole or in part by any Company Entity, including the fee owner and the address thereof (such real property, together with all buildings, structures, fixtures and improvements erected or located thereon, the “Owned Real Property”). The Owned Real Property identified in Section 2.19(a) of the Company Disclosure Letter comprises all of the real property owned by any Company Entity. The Company Entities have good, valid and insurable fee simple title to the Owned Real Property free and clear of all Liens, except for Permitted Liens. There are no outstanding options, rights of first offer or rights of first refusal to purchase any Owned Real Property or any portion thereof or interest therein. No Company Entity is a party to any Contract to purchase any real property or interest therein relating to, or intended to be used in the operation of, their respective businesses. Except as set forth in Section 2.19(a) of the Company Disclosure Letter, no Company Entity has leased or licensed for use any Owned Real Property, in whole or in part, to any Person that is not another Company Entity, and no Company Entity nor, to the Knowledge of the Company, any counterparty is in material default with respect to any such lease or license. No condemnation proceeding is pending or, to the Knowledge of the Company, threatened with respect to any Owned Real Property or material portion thereof. All buildings, structures, fixtures, building systems and other improvements located on the Owned Real Property are in good condition and repair in all material respects, except for reasonable wear and tear, and are supplied with utilities necessary for the operation of the business as currently conducted at such facilities. There are no imminent material capital repairs or replacements required at any Owned Real Property for which no or inadequate reserves have been established under GAAP.

(b) Each of the leases, subleases, licenses, concessions and other occupancy agreements (written or oral) to which any Company Entity is a party as of the date of this Agreement, including all amendments, extensions, renewals and other agreements with respect thereto and the right to all security deposits and other amounts and instruments deposited by or on behalf of any Company Entity thereunder, and any guaranties thereof (collectively, the “Real Property Leases”) is, subject to the

Enforceability Exceptions, a legal, valid, binding enforceable agreement of the applicable Company Entity. Section 2.19(b) of the Company Disclosure Letter sets forth a list of all real property leased by the Company Entities (the “Leased Real Property”), including the address of each Leased Real Property, and the date and names of the parties to the Real Property Lease to which such Leased Real Property is subject. The Company has made available to Purchaser a true and complete copy of each written Real Property Lease and a summary of each oral Real Property Lease, if any. The Company Entities have a valid and enforceable leasehold interest in all Leased Real Property (including all buildings, structures, land, fixtures and other improvements thereto) held by them. As of the date of this Agreement, no Company Entity leasehold interest in any such Leased Real Property is subject to any Lien, except for Permitted Liens. No material breach or material default on the part of any Company Entity, or to the Knowledge of the Company, any counterparty thereto, exists under any Real Property Lease, and to the Knowledge of the Company, no event has occurred or circumstance exists which, with or without the delivery of notice, the passage of time or both, would constitute such a breach or default or would permit the termination, modification or acceleration of rent under such any Real Property Lease. No Company Entity’s possession and quiet enjoyment of the Leased Real Property has been disturbed and, to the Knowledge of the Company, there are no material disputes with respect to the Real Property Leases. Except as set forth in Section 2.19(b) of the Company Disclosure Letter, no Company Entity has subleased, licensed or otherwise granted any Person that is not another Company Entity the right to use or occupy any Leased Real Property or any portion thereof and no Company Entity or, to the Knowledge of the Company, any counterparty is in material default with respect to any such sublease, license or other grant, nor has any Company Entity assigned or transferred its interest in any Real Property Lease or any portion thereof. The Company Entities have not collaterally assigned or granted any other security interest in any Real Property Lease or any interest therein except in connection with any Indebtedness that has been discharged or will be discharged at Closing. No condemnation proceeding is pending or, to the Knowledge of the Company, threatened with respect to any Leased Real Property or material portion thereof. No Company Entity has received notice that any counterparty to any Real Property Lease has exercised its right to terminate and, to the Knowledge of the Company, no such counterparty intends to terminate any such Real Property Lease.

(c) The Leased Real Property identified in Section 2.19(b) of the Company Disclosure Letter comprises all of the real property leased or subleased by any Company Entity.

(d) All buildings, structures, fixtures, equipment, and building systems and equipment, and all components thereof that constitute the Leased Real Property that are required, pursuant to the Real Property Leases, to be maintained or repaired by any Company Entity have been so maintained and/or repaired in all material respects (subject to ordinary wear and tear), and are supplied with utilities necessary for the operation of the business as currently conducted at such facilities. There are no imminent material capital repairs or replacements required at any Leased Real Property for which no or inadequate reserves have been established under GAAP.

(e) Each Company Entity owns good and marketable title to, or holds pursuant to valid and enforceable (except as enforceability may be limited by the Enforceability Exceptions) leases, all of the tangible and material personal property shown to be owned by it on the Financial Statements, free and clear of all Liens, except for Permitted Liens. The property and assets currently owned and leased by the Company Entities (i) comprise all of the property and assets of the Company Entities used for or held for use in, the conduct of their respective business as currently conducted and (ii) are, in all material respects, in usable condition for the operation of the businesses of the Company Entities, ordinary wear and tear and aging excepted.

Section 2.20 Permits; Compliance with Law.

(a) Section 2.20(a) of the Company Disclosure Letter sets forth a list of all material franchises, grants, accreditations, qualifications, registrations, clearances, permissions, authorizations,

licenses, easements, variances, exceptions, consents, certificates, approvals, membership privileges, waivers, exemptions received, certifications, identification numbers and other permits of any Governmental Authority (“Permits”) necessary for each Company Entity to own, lease, use and operate their respective properties and assets or to carry on their respective business (collectively, the “Company Permits”). Each Company Entity is, and since the Look-Back Date has been, in possession of and compliance with all Company Permits. All such Company Permits are, and since the Look-Back Date have been, in good standing and full force and effect in all material respects and there are no written (or, to the Knowledge of the Company, oral) notices of noncompliance, judgments, consent decrees, Orders or judicial or administrative actions materially and adversely affecting or that could materially and adversely affect any of the Company Permits and no suspension, limitation, revocation or cancellation of any of the Company Permits is pending or, to the Knowledge of the Company, has been threatened against any Company Entity. Except for past violations for which the Company Entities are not subject to any current liability, to the Knowledge of the Company, each Company Entity’s respective Representatives is and has been in material compliance with such Company Permits.

(b) Each Company Entity is and has at all times since the Look-Back Date been in compliance with (i) all Laws applicable to such Company Entity or by which any of the Company Assets is bound, and (ii) all Laws applicable to, and the terms and conditions of, all Company Permits, except in each case as would not reasonably be expected to be, individually or in the aggregate, material to the Company Entities taken as a whole. To the Company’s Knowledge, each of their respective directors, officers, members, partners or managers (as it relates to the Company Entities) is, and has at all times since the Look-Back Date, been in compliance in all material respects with all applicable Laws applicable to their responsibilities concerning the Company.

(c) To the Knowledge of the Company, each employee and any other authorized Person acting for or on behalf of any Company Entity, who is required by applicable Law to hold a Permit or other qualification to perform his or her duties in acting for or on behalf of any Company Entity, (i) holds such Permit or other qualification, (ii) such Permit or other qualification is in good standing in each applicable jurisdiction to perform such duties as required by applicable Law and, (iii) in the course and scope of such Person’s duties for or on behalf of any Company Entity, is performing only those services which are permitted by such Permit or other qualification.

(d) The Company Entities have in place, and, to the Knowledge of the Company, all of the Company Entities’ respective directors, officers, agents and employees, are in compliance with, procedures and internal controls designed to provide reasonable assurances that material violations of Laws would be prevented, detected and deterred.

(e) Without limiting the generality of the foregoing, since the Look-Back Date, each Company Entity, and, to the Knowledge of the Company, each Company Entity’s Representatives, in their individual capacities or otherwise, have been in compliance in all material respects with applicable Trade Control Laws and Anti-Corruption Laws. Without limiting the foregoing, since the Look-Back Date, the Company Entities, and, to the Knowledge of the Company, each Company Entity’s Representatives, in their individual capacities or otherwise, have not (i) engaged in any business or dealings with a Sanctioned Person or Sanctioned Country in violation of applicable Trade Control Laws; (ii) made, offered or promised to make any unlawful payment or given, offered, promised, or authorized or agreed to give, any money or thing of value to any Governmental Authority or other Person in violation of applicable Anti-Corruption Laws; or (iii) received from any Governmental Authority or any other Person any written (or, to the Knowledge of the Company, other) notice, inquiry, or internal or external allegation, made any voluntary or involuntary disclosure to a Governmental Authority, or conducted any internal investigation or audit concerning any alleged violation of applicable Trade Control Laws or Anti-Corruption Laws.

(f) Each Company Entity is in compliance in all material respects with all material rules and regulations of the BCBSA.

Section 2.21 Insurance Policies. The Company Entities are covered by valid and currently effective insurance policies and all premiums payable under such policies have been paid to date. No Company Entity has received any written notice of default or cancellation of any such policy. All material fire and casualty, general liability, business interruption, product liability, and sprinkler and water damage and other material insurance policies maintained by or on behalf of the Company Entities (“Insurance Policies”) provide adequate coverage for all normal risks incident to the business of the Company Entities and their respective properties and assets. Since the Look-Back Date, no claim for coverage under any Insurance Policy has been denied or disputed by the underwriters of such Insurance Policy. No Company Entity has any self-insurance program or co-insurance programs. The Company has made available to Purchaser accurate and complete copies of each Insurance Policy. Except as would not reasonably be expected, individually or in the aggregate, to be material to the Company Entities, taken as a whole, or the Company’s ability to consummate the Transactions, (a) all premiums due under such Insurance Policies have been timely paid as of the date hereof and will be timely paid through the Closing Date, and the Company Entities have otherwise complied with the terms and conditions of such Insurance Policies and (b) (i) the Insurance Policies are in full force and effect and are legal, valid, binding and enforceable with their respective terms, and (ii) no Company Entity is in default under any such Insurance Policy. The Company Entities have received no written notice of any actual or threatened cancellation, non-renewal or termination of, or material premium increase with respect to any such Insurance Policies. To the Knowledge of the Company, there is no event, occurrence, condition or act (including the Transactions) that would entitle any insurer to cancel, terminate or non-renew any Insurance Policy. Each Insurance Policy will continue in full force and effect immediately following the Closing in accordance with its terms.

Section 2.22 Insurance Operations.

(a) The Company and each Subsidiary through which the Company conducts insurance and health maintenance organization operations is listed in Section 2.22(a) of the Company Disclosure Letter (the “Regulated Entities”). Since the Look-Back Date, each of the Regulated Entities has timely filed all annual and quarterly statements, together with all material exhibits, interrogatories, notes, schedules, risk capital reports and any actuarial opinions, affirmations or certifications or other supporting documents in connection therewith, in each case required to be filed by the Company or any such Subsidiary with or submitted by the Company or any such Subsidiary to the appropriate insurance regulatory Governmental Authorities of the jurisdiction in which it is domiciled or commercially domiciled on forms prescribed or permitted by such authority (collectively, the “SAP Statements”). The Company has delivered or made available to Purchaser copies of all such annual SAP Statements for the periods beginning on the Look-Back Date and through the date hereof, each in the form (including exhibits, annexes and any amendments thereto) filed with state insurance Governmental Authorities and true and complete copies of all examination reports of insurance departments and any insurance Governmental Authorities received by the Company on or after the Look-Back Date and through the date hereof relating to the Regulated Entities. The financial statements included in the SAP Statements and prepared on a statutory accounting basis, including the notes thereto, were prepared in conformity with SAP prescribed or permitted by applicable state insurance Governmental Authorities, in each case, consistently applied for the periods covered thereby (except as may be indicated in the notes to those financial statements) and fairly present in all material respects the statutory financial position of the relevant Regulated Entity as at the respective dates thereof and the results of operations of such Regulated Entity for the respective periods then ended. The SAP Statements complied in all material respects with all applicable Laws when filed. No material deficiency has been reported or asserted to the Regulated Entities by any Governmental Authority with respect to any SAP Statements or the operations of the Regulated Entities or the Company. Except as indicated therein, all assets that are reflected as admitted assets on SAP Statements have been calculated and presented in compliance in all material respects with all Laws (including the filing of any required reports) regulating

the business of insurance and all Orders and directives of insurance Governmental Authorities (collectively, the “Insurance Laws”) with respect to admitted assets, as applicable. The statutory balance sheets and income statements included in the SAP Statements have been audited by the Company’s independent auditors, and the Company has delivered or made available to Purchaser true and complete copies of all audit opinions related thereto for periods beginning on the Look-Back Date. The Regulated Entities comply in all material respects with all applicable solvency requirements, including risk-based capital requirements under applicable Insurance Laws. The loss reserves of the Regulated Entities recorded in the SAP Statements for periods beginning on the Look-Back Date: (i) were determined in all material respects in accordance with ASOPs in effect on that date (except as may be indicated in the notes thereto), (ii) were computed on the basis of methodologies consistent in all material respects with those used in computing the corresponding reserves in the prior fiscal year (except as may be indicated in the notes thereto) and (iii) include provisions for all actuarial reserves that were required at that time to be established in accordance with applicable Laws based on facts known to the Company as of such date.

(b) Since the Look-Back Date, the business of the Company Entities (including, to the Knowledge of the Company, business, marketing, operations, sales and issuances of insurance Contracts conducted by or through agents) has been conducted in compliance with applicable Insurance Laws except in each case as would not reasonably be expected to be, individually or in the aggregate, material to the Company Entities, taken as a whole, or the Company’s ability to consummate the Transactions. In addition, (i) there is no (and since the Look-Back Date there has not been any) pending or, to the Knowledge of the Company, threatened charge by any Governmental Authority that any of the Regulated Entities has violated in any material respect, nor is there (and since the Look-Back Date there has not been) any pending or, to the Knowledge of the Company, threatened investigation by any Governmental Authority with respect to any possible violations in any material respect by the Regulated Entities of, any applicable Insurance Laws, (ii) each Regulated Entity has been duly authorized by the relevant state insurance Governmental Authorities to issue the policies and/or Contracts of insurance related to the business of the Company Entities that it is currently writing and in the states in which it conducts its business, and (iii) since the Look-Back Date, the Regulated Entities have filed all material reports required to be filed by the Regulated Entities with the relevant Governmental Authorities. None of the Regulated Entities is subject to any order, decree or notice of deficiency of any insurance Governmental Authority relating to such Regulated Entity that relates to material marketing, sales, trade or underwriting practices (other than routine correspondence) from and after the Look-Back Date or seeks the revocation or suspension of any license or other permit issued pursuant to applicable Insurance Laws. No Proceeding is (or since the Look-Back Date has been) pending or, to the Knowledge of the Company, threatened that would reasonably be expected to result in the revocation or suspension of any such material license or permit.

(c) To the extent applicable, Section 2.22(c) of the Company Disclosure Letter sets forth the following information with respect to each reinsurance policy to which any Company Entity is a party: (i) the name of the reinsurer; (ii) the policy number and the period of coverage; (iii) the scope and amount (including a description of how deductibles and ceilings are calculated and operate) of coverage; and (iv) a description of any retroactive premium adjustments or other loss-sharing arrangements. With respect to such reinsurance policy: (i) the policy is legal, valid, binding, enforceable and in full force and effect with respect to such Company Entity, subject to the Enforceability Exceptions, and, to the Knowledge of the Company, is legal, valid, binding and enforceable and in full force and effect with respect to the other parties thereto; (ii) no Company Entity nor, to the Knowledge of the Company, any other party to the policy is in breach or default in any material respect (including with respect to the payment of premiums or the giving of notices), and, to the Knowledge of the Company, no event has occurred which, with notice or the lapse of time, would constitute such a breach or default, or permit termination, modification, or acceleration, under the policy; and (iii) no Company Entity, nor, to the Knowledge of the Company, any other party to the policy has repudiated any material provision thereof in writing or has provided such Company with any written notice of any intention to materially modify or terminate any such agreement in any material respect.

Section 2.23 Healthcare and Regulatory Matters.

(a) (i) The Company Entities currently conduct, and have at all times since the Look-Back Date conducted, their respective businesses in all material respects in compliance with all Health Care Laws applicable to their respective operations, activities or services, any agreements executed with any Governmental Authorities as they relate to any Health Care Program and any Orders to which they are a party or are subject, including any settlement agreements or corporate integrity agreements, (ii) since the Look-Back Date, no Company Entity, nor any officer, manager or director of any Company Entity or, to the Company's Knowledge, any independent contractor of any Company Entity, has received any written notice, citation, suspension, revocation, limitation, warning, or request for production of information or repayment or refund issued by a Governmental Authority that alleges or asserts that any Company Entity or any officer, manager, director or independent contractor of any Company Entity has violated any Health Care Laws or which requires or seeks to adjust, modify or alter any Company Entity's operations, activities, services or financial condition that has not been fully and finally resolved to the Governmental Authority's satisfaction without further liability to the Company Entities, (iii) except for the Contracts described in Section 2.13(g), if any, since the Look-Back Date, no Company Entity is a party to any corporate integrity agreement, monitoring agreement, consent decree, deferred prosecution agreement, settlement order or similar agreement with any Governmental Authority with respect to any actual or alleged violation in any material respect of any applicable Health Care Law with material obligations (other than confidentiality obligations) remaining to be performed, (iv) no Company Entity has made a voluntary disclosure pursuant to any Governmental Authority self-disclosure protocol or similar procedure, including, but not limited to, the U.S. Department of Health and Human Services Office of Inspector General's Health Care Fraud Self-Disclosure Protocol or the Centers for Medicare and Medicaid Services' Self-Referral Disclosure Protocol, and any similar state self-disclosure protocols, or has made a material disclosure to a Governmental Authority regarding potential repayment obligations arising from actual or potential violations of any Health Care Law and (v) there are no restrictions imposed by any Governmental Authority upon any Company Entity's business, activities or services that would restrict or prevent in any material respect any Company Entity from operating as it currently operates.

(b) Each Company Entity, and all of their respective directors, officers and employees and, to the Knowledge of the Company, agents, is in material compliance with, and each Company Entity has, compliance programs, including policies and procedures reasonably designed to cause the Company Entities and their respective directors, officers, agents and employees to be in material compliance with, to the extent applicable, all Health Care Laws. Since the Look-Back Date, no Governmental Authority or Health Care Program has imposed a material fine, material penalty or other material sanction on any Company Entity nor, to the Company's Knowledge, is any such fine, penalty or other sanction pending. Since the Look-Back Date, no Company Entity, or any officers, directors and employees, or to the Knowledge of the Company, agents, of the Company Entities has been: (i) excluded, suspended, debarred or otherwise ruled ineligible from participation in any Health Care Program, or (ii) party to or subject to any Proceeding concerning any of the matters described in the foregoing clause (i).

(c) Each of the Company's insurance and health maintenance Subsidiaries (i) meets, in all material respects, the requirements for participation in the provision of services to, and the receipt of payment from, the respective Health Care Programs in which it participates and (ii) is a party to one or more valid CMS agreements and agreements with applicable state Medicaid Governmental Authorities authorizing such participation and is in compliance with the terms of such agreements. No Company Entity, nor any of its respective equity holders, directors, officers, managers, managing employees (as such term is defined in 42 U.S.C. § 1320a-5(b)), vendors or other personnel (whether employees or independent contractors) has, for itself or for any other Person, (i) submitted or caused to be submitted to a Governmental Authority a knowingly false, fraudulent, abusive or improper claim for payment, (ii) billed any Governmental Authority for any service not rendered or not rendered as claimed, or (iii) received and

knowingly retained any payment or reimbursement from any Governmental Authority in excess of the proper amount allowed under applicable provider agreements or applicable Law.

(d) To the Company's Knowledge, no Company Entity is the subject of any material Proceedings, investigations, audits or focused reviews by a Governmental Authority regarding its compliance with applicable Health Care Laws other than audits in the Ordinary Course of Business. There has been no event since January 1, 2019 that would reasonably be concluded to give rise to any material Liability for noncompliance with applicable Health Care Laws by any Company Entity.

(e) Since the Look-Back Date, each Company Entity has timely filed all regulatory reports, schedules, statements, documents, filings, submissions, forms, registrations and other documents, including, to the extent required under applicable Law, with respect to bids, premium rates, rating plans, policy terms and other terms established or used by the Company Entities, together with any amendments required to be made with respect thereto, that each Company Entity was required to file with any Governmental Authority to the extent relating to Health Care Laws, including CMS, and including filings that it was required to file under the Patient Protection and Affordable Care Act (Pub. L. 111-148) as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152), with respect to its respective business activities and services (collectively "Health Care Law Filings"). All such Health Care Law Filings were complete, correct and in compliance with applicable Laws and Orders, and (i) no material deficiencies or material Liabilities have been asserted by any Governmental Authority and (ii) no Company Entity is the subject of any material plan of correction related to any such Health Care Law Filings.

(f) Since the Look-Back Date, each Company Entity and, to the Knowledge of the Company, each authorized broker, producer, consultant, agent, field marketing organization, or third-party service provider to the extent acting on behalf of Company Entities has marketed, administered, sold and issued insurance and health care benefit products with respect to the Company Entities' business activities and services in compliance in all material respects with all applicable Health Care Laws, including specifically applicable Laws that relate to the compensation of and licensing of Persons to sell health insurance and health care benefit products.

(g) Each Company Entity currently conducts, and has at all times since the Look-Back Date conducted, its business in compliance in all material respects with all applicable Laws related to the Medicare Advantage Program, also known as "Medicare Part C", and Medicare Prescription Drug Benefit Programs, also known as "Medicare Part D".

(h) Each Company Entity has established and implemented programs, procedures, policies, practices, Contracts and systems required to comply in all material respects with the applicable provisions of the Privacy Laws. Each Company Entity is, and has been at all times since January 1, 2019, in compliance in all material respects with the applicable Privacy Laws. Each Company Entity has complied in all material respects with all of its customer-facing policies with respect to data collection, use, processing, privacy, protection and security. Since January 1, 2019, no Company Entity has experienced any material incident in which confidential or sensitive information, payment card data, personally identifiable information or other protected information relating to individuals was or may have been stolen or improperly accessed, used or disclosed, including any breach of security or "breach" as defined at 45 C.F.R. §164.402. No Company Entity is in violation of the requirements of any "business associate" agreement entered into at the request of a covered entity or another "business associate" under the Privacy Laws.

(i) No Company Entity, nor any of its directors, officers or employees, or to the Knowledge of the Company, any of its agents, in their individual capacities, has in furtherance of or in connection with such Company Entity's business: (x) offered, promised or given any financial or other

advantage or inducement to any Person in violation of applicable Law; (y) requested, agreed to receive or accepted any financial or other advantage or inducement in violation of applicable Law; or (z) offered, promised or given any financial or other advantage or inducement to any public official or other representative of a Governmental Authority (or to any other Person at the request of, or with the acquiescence of, any public official or other representative of a Governmental Authority) with the intention of influencing any public official or other representative of a Governmental Authority in the performance of his, her or its public functions (whether or not that performance would be improper) in violation of applicable Laws.

(j) Each Company Entity that is an ACO participating in the Medicare Shared Savings Program (“MSSP ACOs”), and all of the arrangements that each such MSSP ACO has with its participants, provider/suppliers, and other entities, (i) qualifies for the protection of, and complies in all material respects with the terms and conditions of, the federal fraud and abuse waivers at 80 Fed. Reg. 66726 *et seq.* (Oct. 29, 2015), and (ii) qualifies for the protection of, and complies in all material respects with the terms and conditions of, the antitrust safety zone jointly adopted by the Federal Trade Commission and the United States Department of Justice, appearing at 76 Fed. Reg. 67026 *et seq.* (Oct. 28, 2011).

Section 2.24 Capital or Surplus Maintenance. No Regulated Entity is subject to any requirement imposed by a Governmental Authority to maintain capital or surplus amounts or levels or is subject to any restriction on the payment of dividends or other distributions on its surplus or shares of capital stock, except for any such requirements or restrictions under applicable Laws, including Insurance Laws and regulations and as imposed by a Governmental Authority in connection with the Transactions.

Section 2.25 Affiliated Transactions. No Affiliated Party (i) is a party to any Contract with any Company Entity (other than employment, retention or engagement agreements and other arrangements relating to compensation in the ordinary course), (ii) has any material interest in any property (real, personal or mixed), tangible or intangible, or assets owned or used by any Company Entity, (iii) is a party to any Proceeding against any Company Entity, or (iv) owes, or is owed, any amount to or from any Company Entity (other than compensation and advances made in the Ordinary Course of Business). No Company Entity or, to the Knowledge of the Company, their respective directors, managers or officers possesses, directly or indirectly, any material financial interest in, or holds any position as a director, officer or employee of, any Person that is a material client, supplier, customer, lessor, lessee, or competitor or potential competitor of any Company Entity.

Section 2.26 Brokers. No broker, finder, investment banker or other intermediary is entitled to any brokerage, finder’s or other similar fee or commission from any Company Entity in connection with the Transactions based upon arrangements made by or on behalf of any Company Entity, and Purchaser does not have and will not have any Liability or otherwise suffer or incur any Loss as a result of or in connection with any brokerage, finder’s or other similar fee or commission (contingent or otherwise) of any such Person retained by or on behalf of any Company Entity in connection with the Transactions.

Section 2.27 Fairness Opinion. The Company Board has received and made available to Purchaser the signed written opinion (“Fairness Opinion”) of Chaffe & Associates, Inc., as financial advisor to the Company, dated on or prior to the date hereof, confirming, subject to the limitations and qualifications in such opinion, that the method for the provision of aggregate consideration to the Eligible Members upon the extinguishing of their membership interests in the Company pursuant to the Plan of Reorganization is fair to the Eligible Members, as a group, from a financial point of view consistent with LSA-R.S. 22:236.3(A).

Section 2.28 No Other Representations or Warranties. Except for the representations and warranties contained in this Agreement, any Related Agreement to which the Company is or will be a party

at the Closing, and the certificate delivered pursuant to Section 1.5(b)(i), neither the Company nor any other Person makes any other express or implied representation or warranty on behalf of any Company Entity.

ARTICLE III

Representations and Warranties of Purchaser and Parent

As an inducement to the Company to enter into this Agreement and to consummate the Transactions, except as disclosed since January 1, 2020 in the reports, schedules, forms, statements or other documents filed by Parent pursuant to the Securities Laws (excluding any risk factor disclosure, contained in such documents under the heading “Risk Factors” and any disclosures of risks or other matters included in any “forward-looking statements”, disclaimers or other statements that are cautionary, predictive or forward-looking in nature), each of Purchaser and Parent, as applicable, represent and warrant to the Company as follows as of the date hereof and as of the Closing Date:

Section 3.1 Organization and Power

Purchaser (a) is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Indiana, and (b) has the requisite power and authority to carry on its business as it is now being conducted, except where the failure to have such requisite power and authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on Purchaser’s ability to consummate the Transactions.

Section 3.2 Authorization of Transactions. Purchaser has all requisite organizational power and authority to execute and deliver this Agreement and the other agreements contemplated hereby and to perform its obligations (including the consummation of the Transactions) hereunder and thereunder. The execution, delivery and performance by Purchaser of this Agreement, each Related Agreement and the consummation of the Transactions have been duly and validly authorized by Purchaser’s governing body and no other act or proceeding on the part of Purchaser or its governing body, stockholders or members, as applicable, is necessary to authorize the execution, delivery or performance of this Agreement or the other agreements contemplated hereby and the consummation of the Transactions. This Agreement has been duly executed and delivered by Purchaser and, assuming the due execution and delivery of this Agreement and the other agreements contemplated hereby by the other parties hereto and thereto, this Agreement constitutes, and the other agreements contemplated hereby upon execution and delivery by Purchaser will each constitute, a valid and binding obligation of Purchaser, enforceable in accordance with its terms, except as such enforceability may be limited by the Enforceability Exceptions.

Section 3.3 No Breach. The execution, delivery and performance by Purchaser of this Agreement and the other agreements contemplated hereby and the consummation of the Transactions will not (with or without notice, lapse of time, or both) (a) contravene or conflict with, or result in any violation or breach of, or constitute a default (with or without due notice or lapse of time or both) under any provision of, the Organizational Documents of Purchaser in any material respect, (b) contravene or conflict with, or result in any violation or breach of, any Law or other restriction of any Governmental Authority to which Purchaser or any of its Affiliates is subject or by which the assets of Purchaser or any of its Affiliates are bound, (c) violate, conflict with, result in a breach of, constitute a default under, result in the loss of any right or benefit under, give modification or result in the acceleration under, or result in the creation of any Lien (other than Permitted Liens) upon any of the assets or properties of Purchaser under, any permit or Contract to which Purchaser is a party or by which Purchaser’s assets are bound, or (d) require any authorization, consent, approval, exemption or notice to any Governmental Authority under the provisions of any Law (except for the filings, authorizations, consents, approvals and exemptions contemplated by Section 4.5(d)).

Section 3.4 **Litigation.** There are no Proceedings pending or, to the Knowledge of Purchaser, threatened against or affecting Purchaser or any of its Affiliates, at law or in equity, or before or by any Governmental Authority that would reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser's ability to consummate the Transactions.

Section 3.5 **Brokerage.** Purchaser does not have any liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the Transactions.

Section 3.6 **Sufficiency of Funds.** Purchaser has the financial capability and sufficient cash on hand necessary to consummate the Transactions on the terms and subject to the conditions set forth herein, and will have all such capability and cash on hand as of the Closing Date. Purchaser affirms that it is not a condition to Closing or to any of its obligations under this Agreement that Purchaser obtains financing for the Transactions.

Section 3.7 **Permits; Compliance with Law.**

(a) Each of Purchaser and Parent is and has at all times since the Look-Back Date been in compliance with all Laws applicable to Purchaser or Parent or by which any of the assets of Purchaser or Parent is bound, except as would not reasonably be expected to be, individually or in the aggregate, material to Purchaser and Parent taken as a whole.

(b) Each of Purchaser and Parent have in place, and, to the Knowledge of Purchaser, all of Purchaser's and Parent's respective directors, officers, agents and employees, are in material compliance with, procedures and internal controls designed to provide reasonable assurances that material violations of Laws would be prevented, detected and deterred.

(c) Without limiting the generality of the foregoing, since the Look-Back Date, each of Purchaser and Parent, and, to the Knowledge of Purchaser, each of Purchaser and Parent's respective Representatives, in their individual capacities or otherwise, have been in compliance in all material respects with applicable Trade Control Laws and Anti-Corruption Laws. Without limiting the foregoing, since the Look-Back Date, each of Purchaser and Parent, and, to the Knowledge of Purchaser, each of Purchaser's and Parent's respective Representatives, in their individual capacities or otherwise, have not (i) engaged in any business or dealings with a Sanctioned Person or Sanctioned Country in violation of applicable Trade Control Laws; (ii) made, offered or promised to make any unlawful payment or given, offered, promised, or authorized or agreed to give, any money or thing of value to any Governmental Authority or other Person in violation of applicable Anti-Corruption Laws; (iii) requested, agreed to receive or accepted any financial or other advantage or inducement in violation of applicable Law; or (iv) received from any Governmental Authority or any other Person any written (or, to the Knowledge of Purchaser, other) notice, inquiry, or internal or external allegation, made any voluntary or involuntary disclosure to a Governmental Authority, or conducted any internal investigation or audit concerning any alleged violation of applicable Trade Control Laws or Anti-Corruption Laws, in each case, except as would not reasonably be expected to be, individually or in the aggregate, material to Purchaser and Parent taken as a whole.

Section 3.8 **Insurance Operations**

Since the Look-Back Date, the business of Purchaser and Parent (including, to the Knowledge of Purchaser, business, marketing, operations, sales and issuances of insurance Contracts conducted by or through agents) has been conducted in compliance with applicable Insurance Laws except in each case as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions. In addition, (i) there is no (and since the Look-Back Date there has not been any) pending or, to the Knowledge of Purchaser, threatened charge by any Governmental Authority that any of Purchaser or Parent has violated in any material respect, nor is there (and since the Look-Back Date there has not been) any pending or, to

the Knowledge of Purchaser, threatened investigation by any Governmental Authority with respect to any possible violations in any material respect by Purchaser or Parent of, any applicable Insurance Laws, (ii) each of Purchaser and Parent has been duly authorized by the relevant state insurance Governmental Authorities to issue the policies or Contracts of insurance related to the business of Purchaser and Parent, as applicable that it is currently writing and in the states in which it conducts its business, and (iii) since the Look-Back Date, each of Purchaser and Parent have filed all material reports required to be filed by Purchaser and Parent, as applicable with the relevant Governmental Authorities, in each case, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions. Neither Purchaser nor Parent is subject to any order, decree or notice of deficiency of any insurance Governmental Authority relating to Purchaser or Parent that relates to material marketing, sales, trade or underwriting practices (other than routine correspondence) from and after the Look-Back Date or seeks the revocation or suspension of any material license or other material permit issued pursuant to applicable Insurance Laws. No Proceeding is (or since the Look-Back Date has been) pending or, to the Knowledge of Purchaser, threatened that would reasonably be expected to result in the revocation or suspension of any such material license or material permit, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions.

Section 3.9 Healthcare and Regulatory Matters

(a) (i) Purchaser and Parent each currently conduct, and have at all times since the Look-Back Date conducted, their respective businesses in all material respects in compliance with all Health Care Laws applicable to their respective operations, activities or services, any agreements executed with any Governmental Authorities as they relate to any Health Care Program and any Orders to which they are a party or are subject, including any settlement agreements or corporate integrity agreements, (ii) since the Look-Back Date, neither Purchaser nor Parent, nor any officer, manager or director of Purchaser or Parent or, to Purchaser's Knowledge, any independent contractor of Purchaser or Parent, has received any written notice, citation, suspension, revocation, limitation, warning, or request for production of information or repayment or refund issued by a Governmental Authority that alleges or asserts that either Purchaser or Parent or any officer, manager, director or independent contractor of Purchaser or Parent has violated in any material respect any Health Care Laws or which requires or seeks to adjust, modify or alter in any material respect Purchaser's or Parent's operations, activities, services or financial condition that has not been fully and finally resolved to the Governmental Authority's satisfaction without further liability to Purchaser or Parent, (iii) since the Look-Back Date, neither Purchaser nor Parent is a party to any corporate integrity agreement, monitoring agreement, consent decree, deferred prosecution agreement, settlement order or similar agreement with any Governmental Authority with respect to any actual or alleged violation in any material respect of any applicable Health Care Law with material obligations (other than confidentiality obligations) remaining to be performed, (iv) neither Purchaser nor Parent has made a voluntary disclosure pursuant to any Governmental Authority self-disclosure protocol or similar procedure, including, but not limited to, the U.S. Department of Health and Human Services Office of Inspector General's Health Care Fraud Self-Disclosure Protocol or the Centers for Medicare and Medicaid Services' Self-Referral Disclosure Protocol, and any similar state self-disclosure protocols, or has made a material disclosure to a Governmental Authority regarding potential repayment obligations arising from actual or potential violations of any Health Care Law, and (v) there are no restrictions imposed by any Governmental Authority upon Purchaser's or Parent's business, activities or services that would restrict or prevent in any material respect Purchaser or Parent from operating as it currently operates, in each case, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions.

(b) Each of Purchaser and Parent, and each of their respective directors, officers and employees and, to the Knowledge of Purchaser, agents, is in material compliance with, and each of Purchaser and Parent has, compliance programs, including policies and procedures reasonably designed to cause Purchaser and Parent and their respective directors, officers, agents and employees to be in material compliance with, to the extent applicable, all Health Care Laws, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions. Since the Look-Back Date, no Governmental Authority or Health Care Program has imposed a material fine, material penalty or other material sanction on Purchaser or Parent nor, to Purchaser's Knowledge, is any such material fine, material penalty or other material sanction pending, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions. Since the Look-Back Date, neither Purchaser nor Parent, or any officers, directors and employees, or, to the Knowledge of Purchaser, agents, of Purchaser or Parent has been: (i) excluded, suspended, debarred or otherwise ruled ineligible from participation in any Health Care Program, or (ii) party to or subject to any Proceeding concerning any of the matters described in the foregoing clause (i), in each case, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions.

(c) To Purchaser's Knowledge, neither Purchaser nor Parent is the subject of any material Proceedings, investigations, audits or focused reviews by a Governmental Authority regarding its compliance with applicable Health Care Laws other than audits in the Ordinary Course of Business, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions. There has been no event since the Look-Back Date that would reasonably be concluded to give rise to any material Liability for noncompliance with applicable Health Care Laws by either Purchaser or Parent, except as would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Purchaser and Parent, taken as a whole, or Purchaser's or Parent's ability to consummate the Transactions.

Section 3.10 No Other Representations or Warranties

Except for the representations and warranties contained in this Agreement, any Related Agreement to which Purchaser or Parent is or will be a party at the Closing and the certificate delivered pursuant to Section 1.5(a)(i), neither Purchaser, Parent nor any other Person makes any other express or implied representation or warranty with respect to Purchaser or Parent.

ARTICLE IV

Pre-Closing Covenants

Section 4.1 Operation of Business. From the date of this Agreement until the Closing (or until such earlier time as this Agreement is terminated in accordance with Section 7.1), except as required to effect the Reorganization or as otherwise expressly provided for by this Agreement including, without limitation, as set forth on Section 4.1 of the Company Disclosure Letter, or by the Plan of Reorganization, by applicable Law (including any COVID-19 Action or as required by any COVID-19 Measures), or consented to in writing by Purchaser (which consent will not be unreasonably withheld, conditioned or delayed), the Company shall (w) conduct its business, and cause the other Company Entities to conduct their respective operations, in the Ordinary Course of Business in all material respects, (x) use commercially reasonable efforts to conduct its business, and to cause the other Company Entities to conduct their respective operations, in compliance, in all material respects, with applicable Laws, and (y) maintain and

preserve intact, in all material respects, its and the other Company Entities' (1) business organization and (2) books and records and accounts in accordance with past practice, and (z) use commercially reasonable efforts to maintain relationships with key employees, suppliers, customers and other Persons with whom any Company Entity has material commercial dealings; provided, that, the Company Entities may use available cash to pay any Indebtedness prior to the Closing, for distributions or dividends or for any other purpose. From the date of this Agreement until the Closing (or until such earlier time as this Agreement is terminated in accordance with Section 7.1), except as otherwise expressly provided for by this Agreement (including the Company Disclosure Letter), by applicable Law (including any COVID-19 Action or as required by any COVID-19 Measures), or with the prior written consent of Purchaser (which consent will not be unreasonably withheld, conditioned or delayed), the Company will not, and will not permit any of the other Company Entities or its and their respective Representatives to, take any of the following actions:

(a) Organizational Documents. Amend, modify or restate the Organizational Documents of any Company Entity, other than de minimis amendments or modifications, or as contemplated by the Plan of Reorganization;

(b) Capital Stock. (i) Adjust, split, combine, subdivide or reclassify the Securities of any Company Entity, (ii) redeem, purchase or otherwise acquire, directly or indirectly, the Securities of any Company Entity, (iii) authorize, issue or grant any Person any right or option to acquire the Securities of any Company Entity other than in the Ordinary Course of Business pursuant to any equity plans in effect as of the date hereof, (iv) authorize, issue, purchase, redeem, deliver or sell the Securities of any Company Entity, or (v) declare, set aside, make or pay any dividends on or make other distributions in respect of the Securities of any Company Entity other than dividends or distributions by wholly owned Subsidiaries of the Company to the Company or another wholly owned Subsidiary of the Company;

(c) Compensation and Benefits. (i) Increase the compensation, bonus or benefits payable or to become payable to any of its current or former employees, individual independent contractors, directors or officers, except for increases in salary, bonus targets, hourly wage rates and benefits of employees, individual independent contractors, or directors, in each case, who are not Officers of the Company, in connection with the Company Entities' normal compensation adjustment process that do not exceed (A) 7.5% individually, or (B) 5.25% in the aggregate of the total annual compensation for all such employees, individual independent contractors or directors (as such value is approved by the Company Board in the Ordinary Course of Business consistent with past practice); (ii) other than in connection with the retention agreements to be entered into in connection with this Agreement as set forth on Section 4.1(c) of the Company Disclosure Letter, grant to any current or former employee, director, individual independent contractor or officer any change in control, retention, or transaction compensation or benefits; (iii) other than in connection with the retention agreements to be entered into in connection with this Agreement as set forth on Section 4.1(c) of the Company Disclosure Letter or the severance policy set forth on Section 4.1(c) of the Company Disclosure Letter, grant to any current or former employee any severance or termination compensation or benefits; (iv) establish, adopt, enter into, materially amend, or terminate any material Company Benefit Plan or any employee benefit plan, agreement, policy, program or commitment that, if in effect on the date of this Agreement, would constitute a material Company Benefit Plan, or accelerate the (A) vesting, (B) funding, (C) determination of value, or (D) payment of compensation or benefits thereunder, or otherwise except as set forth on Section 4.1(c) of the Company Disclosure Letter; (v) plan, implement, or announce any facility closings, employee layoffs, reductions-in-force, temporary layoffs, salary or wage reductions, work schedule changes or other actions that could implicate the WARN Act or any similar state or local applicable Law, or which could materially impact the business of any Company Entity, (vi)(A) hire or engage any new Officers of the Company, or (B) terminate (other than for cause) the employment or service of any current Officers of the Company, in either case of clauses (A) or (B), without advance notice

to Purchaser as set forth on Section 4.1(c) of the Company Disclosure Letter; (vii) enter into, amend or terminate any collective bargaining agreement or similar labor Contract, or (viii) waive or release any noncompetition, nonsolicitation, nondisclosure, noninterference, nondisparagement, or other restrictive covenant obligation of any current or former employee or individual independent contractor, except, in the case of each of clauses (i) through (viii), for actions (A) taken to the extent required by applicable Law, this Agreement or any Company Benefit Plan, or (B) set forth in Section 4.1 of the Company Disclosure Letter;

(d) Acquisitions. Acquire (by merger, consolidation, combination, acquisition of equity interests or assets, or otherwise) any material assets, debt or equity interests or other securities, business or any corporation, partnership, limited liability company, joint venture or other business organization or division thereof or enter into any Contract or letter of intent or similar arrangement (whether or not legally binding) with respect to the foregoing, except for (i) any such transaction pursuant to any Contract existing and in effect as of the date of this Agreement as set forth in Section 4.1 of the Company Disclosure Letter, or (ii) acquisitions made for aggregate consideration of \$5,000,000 or less in the Ordinary Course of Business;

(e) Dispositions. Sell, lease, license, sub-license, covenant not to assert, transfer, pledge, encumber, grant, cancel, abandon, allow to lapse, fail to maintain, or otherwise dispose of any Company Assets, including the capital stock of any Company Entity or other Securities of any Company Entity, or grant options, warrants, calls or other Rights to purchase or otherwise acquire (including upon conversion, exchange or exercise) equity interests or other securities (including appreciation rights, phantom stock or profit participation rights) or voting rights of any Company Entity, other than (i) the disposition of inventory or obsolete or excess equipment in the Ordinary Course of Business, (ii) pursuant to existing agreements in effect prior to the date of this Agreement as set forth in Section 4.1 of the Company Disclosure Letter, or (iii) dispositions of Company Assets (other than the capital stock, equity interests or other Securities of any Company Entity) made for aggregate consideration of \$5,000,000 or less, made in the Ordinary Course of Business;

(f) Liens. Permit any Company Entity's properties or assets to be subject to any Lien (other than Permitted Liens) not included in Section 2.13(b) of the Company Disclosure Letter;

(g) Indebtedness; Guarantees. Incur, assume, market, guarantee, cancel, modify in any material respect, pre-pay, forgive, write off or otherwise become liable for, or waive any Rights under, any Indebtedness in excess of \$500,000 in the aggregate, other than (i) Indebtedness that will be repaid at the Closing as Closing Repaid Indebtedness, (ii) performance bonds or letters of credit required to be issued pursuant to existing Contracts as set forth in Section 2.13(b) or Section 2.13(c) of the Company Disclosure Letter, and (iii) Indebtedness of the Company to any wholly owned Subsidiary of the Company or Indebtedness for borrowed money of any wholly owned Subsidiary of the Company to the Company;

(h) Accounting. Make any change to its accounting policies, principles, practices, methodologies, procedures or classifications, other than as required by GAAP, SAP, ASOP or applicable Law;

(i) Legal Actions. Waive, release, assign, settle or compromise any Proceedings to which a Company Entity is a party, or enter into any settlement agreement or understanding or agreement with any Governmental Authority, other than such waiver, release, assignment settlement or compromise (x) with any Person that is not a Governmental Authority that is limited only to the payment of money not in excess of \$1,250,000 individually or \$5,000,000 in the aggregate and does not admit liability by any Company Entity, (y) with respect to any matter set forth in Section 4.1(i) of the Company Disclosure Letter that is limited only to the payment of

money, or (z) funded, subject to payment of a deductible in an amount of \$500,000 or less, or self-insured retention, solely by insurance coverage maintained by the Company or a Subsidiary of the Company;

(j) Taxes. (i) Make, change or revoke any material Tax election, (ii) adopt or change any method of accounting for Tax purposes, (iii) amend any Tax Returns, (iv) enter into any closing agreement or other Contract with respect to Taxes with any Governmental Authority, (v) surrender any right to claim a refund of a material amount of Taxes, (vi) request any extension or waiver of the limitation period applicable to any Tax claim or assessment with respect to a material amount of Taxes, (vii) other than with respect to the Transactions, incur any material liability for Taxes outside the Ordinary Course of Business, (viii) fail to pay any material Taxes that become due and payable, (ix) change any U.S. federal income tax classification, (x) prepare or file any Tax Return in a manner inconsistent with past practice with respect to the treatment of items on such Tax Returns, except as required by Law, or (xi) settle or compromise any income or other Tax liability or claim, audit, assessment, dispute, proceeding or investigation in respect of Taxes if such settlement or compromise would reasonably be expected to have a materially adverse impact on Taxes relating to Post-Closing Tax Periods;

(k) Contracts. Enter into any Contract which, if in effect as of the date of this Agreement, would be a Material Contract or terminate, cancel, amend, waive any provision of or otherwise make any material change in any Material Contract, other than (i) in the Ordinary Course of Business, (ii) as permitted under another subsection of this Section 4.1, and (iii) terminations resulting from the expiration of any Material Contract in accordance with its terms;

(l) Intellectual Property. (i) Sell, transfer, assign, lease, license, sub-license, covenant not to assert, fail to maintain, allow to lapse, abandon, cancel or otherwise dispose of any material Owned Intellectual Property, except for end user agreements that grant non-exclusive licenses of Company Software to end users in the Ordinary Course of Business on terms in all material respects the same as the form end user Contracts that have been previously provided to Purchaser; (ii) disclose any Trade Secrets of any Company Entity to any Person (other than pursuant to written confidentiality agreements entered into in the Ordinary Course of Business that contain reasonable protections sufficient to preserve all rights in such Trade Secrets); or (iii) subject any Company Software to any Copyleft Terms;

(m) Related-Party Transactions. Except as otherwise permitted under another subparagraph of this Section 4.1, enter into any transaction or Contract with any Affiliated Party that would bind the Company after the Closing;

(n) Capital Expenditures. Make capital expenditures or commitments therefor that deviate from the Company's current annual budget, as made available to Purchaser prior to the date hereof, by more than \$2,000,000 in the aggregate;

(o) Loans and Advances. Make any loans, advances or capital contributions to, or investments in, any other Person (other than any Company Entity), including to any of the executive officers, directors, employees, agents, consultants or other Representatives of the Company Entities, other than advances to the executive officers, directors or employees of the Company Entities in the Ordinary Course of Business for travel and other normal business expenses or any advancement of expenses required under the Organizational Documents of any Company Entity;

(p) Insurance Policies. Cancel or terminate any insurance policy naming any Company Entity as a beneficiary or a loss payable payee unless the same shall be replaced with one or more insurance policies providing coverage reasonably comparable in scope and terms;

(q) Lines of Business. Enter into any business or new line of business or discontinue any material line of business or any business operations;

(r) Partnerships or Joint Ventures. Enter into or effect any partnership, joint venture or other similar Contract; or

(s) Other Actions. (i) Authorize, adopt or carry out a plan or agreement of complete or partial liquidation, dissolution, recapitalization, restructuring or reorganization of, or file a petition in bankruptcy under any provisions of federal or state bankruptcy Law on behalf of, any Company Entity, or make any other changes, whether directly or indirectly, to the capital structure of any Company Entity, or (ii) make any charitable contribution or pledge in excess of \$1,000,000 in the aggregate.

Notwithstanding anything to the contrary set forth in this Section 4.1, nothing in this Section 4.1 (i) shall restrict any actions relating to the formation or operation of a Management Services Organization or ACO on substantially the same terms as set forth on Section 4.1(ii) of the Company Disclosure Letter, or (ii) is intended to result in any Company Entity ceding control to Purchaser of any Company Entity's ordinary course of business and commercial decisions prior to the Closing Date.

For the avoidance of doubt, for purposes of this Section 4.1, it shall be considered an unreasonable delay in the event that Purchaser fails to provide its consent to or an affirmative rejection of any action the Company seeks to take pursuant to this Section 4.1 within ten Business Days of the date such consent is sought. For the avoidance of doubt, such consent by Purchaser may be subject to reasonable conditions and the existence of such conditions shall not be considered a failure to provide consent for purposes of the preceding sentence. In seeking consent, the Company shall provide written notice to Purchaser specifying in reasonable detail the action the Company seeks to take that is prohibited by this Section 4.1, which shall include any supporting documentation related thereto.

Section 4.2 Access.

(a) From the date of this Agreement until the Closing (or until such earlier time as this Agreement is terminated in accordance with Section 7.1), the Company shall permit (and shall cause each of the other Company Entities to permit), Representatives of Purchaser, including any third-party data privacy or cybersecurity auditor ("Security Auditor") engaged by Purchaser, to have reasonable access during normal business hours, and in a manner so as not to unreasonably interfere with the normal business operations of the Company Entities (and provided that such access is reasonable in light of COVID-19 and in accordance with applicable COVID-19 Measures), to, and will furnish all information reasonably requested concerning, the business and the premises, properties, assets, executive officers, Taxes and other key employees, books, accounts, records, contracts, documents, Software and Computer Systems of the Company Entities including to conduct a data privacy and information security audit ("Security Audit"); provided, however, the foregoing shall not apply with respect to any information the disclosure of which would, in the reasonable judgment of the Company, waive any privilege, violate any Law (including any COVID-19 Measures) or breach any duty of confidentiality owed to any Person, and shall not include any environmental sampling. Purchaser acknowledges that Parent is and remains bound by the Nondisclosure Agreement, and Purchaser agrees to comply with the terms of the Nondisclosure Agreement in the same manner as such terms are applicable to Parent. Purchaser agrees that any Security Auditor will be required to acknowledge in writing to be bound by confidentiality obligations at least as restrictive as those set forth in the Nondisclosure Agreement. The Company acknowledges and agrees that the access requirements and security policies of the Company Entities shall in no way materially impede Purchaser, or any Security Auditor, from conducting the Security Audit (in each case, except as may be required by applicable Law, including any COVID-19 Measures). The provision of any information pursuant to this Agreement by any Company Entity shall not expand the remedies available hereunder to Purchaser or its Affiliates under this

Agreement in any manner. From and after the date hereof until the Closing Date, the Company shall afford Purchaser and its Affiliates reasonable access to (i) information regarding employees of the Company Entities necessary for Purchaser and its Affiliates to onboard and integrate such employees; and (ii) the key employees of the Company Entities for the purpose of discussing and documenting (if applicable) the terms and conditions upon which each such employee may continue his or her employment with such Company Entity after the Closing.

(b) For each month following the date hereof, the Company shall provide Purchaser with an unaudited consolidated balance sheet and related unaudited consolidated statements of operations and cash flows for the month then ended within 45 days of the end of such month (the “Monthly Financial Statements”); provided, however, that any competitively-sensitive information contained in the Monthly Financial Statements will be on an outside-counsel-only basis and any material related to the valuation of the Company may be redacted. The Monthly Financial Statements, except as indicated therein, shall be prepared in accordance with GAAP applied on a basis consistent with the Financial Statements except that they need not contain footnotes and will be subject to year-end audit adjustments.

Section 4.3 Notification. Purchaser, on the one hand, and the Company and the Foundation, on the other hand, shall promptly notify each other of any material actions in connection with the Transactions commenced or, to the Knowledge of Purchaser or the Knowledge of the Company (as applicable), threatened against the Company, the Foundation, any of the other Company Entities or Purchaser, as the case may be. Additionally, Purchaser on the one hand, and the Company and the Foundation, on the other hand, may notify each other of the occurrence or non-occurrence of any fact or event that, in either case, would be reasonably likely to cause any condition set forth in Article VI not to be satisfied; provided, that no such notification, nor the obligation to make such notification, shall affect the representations, warranties, covenants or agreement of any Party or the conditions to the obligations of any Party; and provided, further, that the delivery of any notification pursuant to this Section 4.3 shall not limit or otherwise affect the remedies available hereunder to the Party receiving such notice.

Section 4.4 Negotiations with Other Parties.

(a) The Company agrees that, during the term of this Agreement, and except as otherwise expressly permitted by this Agreement, it shall not, and it shall cause its Subsidiaries and its and their respective Representatives not to, directly or indirectly, solicit, initiate, knowingly encourage or knowingly facilitate, any inquiries that would reasonably be expected to lead to, or the making of any proposal or offer to implement, any Alternative Transaction, or negotiate or otherwise engage in discussions with any Person (other than Purchaser or its Representatives) with respect to any Alternative Transaction, or approve, recommend or authorize any Alternative Transaction, or enter into any agreement, arrangement or understanding with respect to any Alternative Transaction or requiring it to abandon, terminate or fail to consummate the Transactions; provided, that, if the Company receives a bona fide written proposal from a Person for an Alternative Transaction that was not solicited after the date of this Agreement and is not otherwise prohibited by this Section 4.4, (i) the Company and the Company’s Representatives may (A) contact and engage in discussions with such Person solely in order to seek to clarify and understand the terms and conditions thereof in order to determine whether such inquiry, proposal or offer constitutes or could reasonably be expected to lead to a Superior Proposal, and (B) inform such Person of the provisions of this Section 4.4, and (ii) at any time prior to receipt of the Member Approval (and in no event after receipt of the Member Approval), the Company may furnish information to, and negotiate or otherwise engage in discussions with such Person, if and so long as the Company Board determines in good faith after consultation with its outside legal counsel that failure to provide such information or engage in such negotiations or discussions is reasonably likely to be inconsistent with the Company Board’s fiduciary duties under applicable Law and determines in good faith that such a proposal is, or would reasonably be expected to lead to, a Superior Proposal.

(b) The Company shall notify Purchaser promptly (but in any event within 24 hours) of such inquiries, proposals or offers received by, or any such discussions or negotiations sought to be initiated or continued with, any of its Representatives, indicating the name of such Person and providing to Purchaser a summary of the material terms of such proposal or offer for an Alternative Transaction. Prior to providing any information or data to, or entering into any negotiations or discussions with, any Person in connection with a proposal or offer for an Alternative Transaction, the Company shall receive from such Person an executed confidentiality agreement containing terms and provisions at least as restrictive as those contained in the Nondisclosure Agreement (which shall not preclude discussions or negotiations relating to the proposal or offer from such Person and which shall not contain any exclusivity provision or other term that would restrict, in any manner, the Company's ability to consummate the Transactions). The Company agrees that it will keep Purchaser informed, on a prompt basis, of the status and material terms of any such proposals or offers and the current basis of the status and details (including any material developments) in respect of any such discussions or negotiations.

(c) The Company agrees that it will immediately cease and cause to be terminated any existing activities, discussions or negotiations with any Third Parties conducted prior to the date of this Agreement with respect to any Alternative Transaction (and promptly terminate all physical and electronic data room access previously granted to any such Third Party) and will not terminate, amend, modify or waive any provision of any confidentiality or standstill agreement to which it is a party and shall enforce, to the fullest extent permitted under applicable Law, the provisions of any such agreement, including by obtaining injunctions to prevent any breaches of such agreements and to enforce specifically the terms and provisions thereof in any court having jurisdiction.

Section 4.5 Regulatory Matters.

(a) Antitrust Filings. As soon as practicable after the date hereof, but in no event later than ten Business Days after the date hereof, Purchaser and the Company will file or cause to be filed all requisite documents and notifications required under any Antitrust Law in connection with the Transactions (the "Antitrust Filings"). Each Party shall use its reasonable best efforts (and shall cause its Subsidiaries and Affiliates, as applicable, to use their respective reasonable best efforts) to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper or advisable to obtain all Required Approvals to consummate and make effective the Transactions as promptly as practicable, including using its reasonable best efforts to obtain or make all necessary or appropriate filings required under applicable Law and to lift any injunction or other legal bar to the consummation of the Transactions as promptly as practicable after the date of this Agreement. None of the Parties or their Affiliates shall knowingly take, cause or permit to be taken any action, including any mergers, acquisitions, joint ventures, or sales, that could reasonably be expected to materially delay or prevent consummation of the Transactions. For the avoidance of doubt, a merger, acquisition, joint venture or sale involving another plan in the State of Louisiana could reasonably be expected to materially delay or prevent consummation of the Transactions. Purchaser shall pay all filing fees for any required Antitrust Filings.

(b) LDI Filing and LA Form A Filing. As soon as practicable after the date hereof, but in no event later than twenty Business Days after the date hereof, (i) the Company shall file with the Commissioner the Proposed Plan of Reorganization, and thereafter shall promptly file such additional information, forms and other documents required under the Louisiana Insurance Code or requested by the Commissioner, requesting approval of the proposed Reorganization and the payment or transfer, as applicable, of the Approved Excess Surplus to the Foundation (the "LDI Filing") and (ii) Purchaser shall file with the Commissioner a Form A Statement Regarding the Acquisition of Control of a Domestic Insurer requesting approval of the proposed acquisition of control of the Company (the "LA Form A Filing"). Purchaser agrees to include in the LA Form A Filing, among other things, the matters set forth in Schedule 3. The filing fees to be paid in connection with the LDI Filing and the LA Form A Filing shall be evenly split between Purchaser and the Company. Notwithstanding anything herein to the contrary, in the

event the Commissioner requires any material changes to be made to the Proposed Plan of Reorganization, such changes shall be subject to the written consent of the Company, and in the event the Company does not provide such written consent, then the Company may terminate this Agreement pursuant to Section 7.1(j).

(c) Other Filings. In addition to, and separate from, the foregoing obligations of the Parties in this Section 4.5, from the date of this Agreement until the Closing (or until such earlier time as this Agreement is terminated in accordance with Section 7.1), Purchaser and the Company shall: (i) timely make or cause to be made all other notices, filings and applications, necessary in connection with obtaining the consents, approvals, permits or authorizations (including any Required Approvals) that are required to be obtained prior to the Closing from any Governmental Authority or any other Person in connection with the execution and delivery of this Agreement and the Transactions, and (ii) subject to and without limiting the specific obligations set forth herein, use their respective commercially reasonable efforts to take, or cause to be taken, all other actions and do, or cause to be done, all other things necessary or appropriate to consummate the Transactions as promptly as practicable; provided, that, subject to Section 4.1, no Indebtedness for borrowed money shall be repaid, except as otherwise required pursuant to the terms of the applicable loan agreement, and no Material Contract shall be amended to increase the amount payable thereunder or otherwise to be materially more burdensome to any Company Entity, in any such case to obtain any such consent, approval or authorization, without the prior written approval of Purchaser.

(d) Cooperation. Purchaser and the Company agree to (and the Company shall cause the Company Entities to) coordinate and cooperate with respect to each Required Approval and to promptly respond to any requests for information, inquiries or comment letters issued by any Governmental Authority in connection with a Required Approval and to promptly respond to any proposed undertakings or commitments sought by any Governmental Authority. Subject to such confidentiality restrictions as may be reasonably requested and applicable Laws relating to the exchange of information and the other terms and conditions of this Section 4.5, and without limiting the specific obligations set forth herein, each of Purchaser and the Company will use reasonable best efforts to: (i) promptly inform the other of any communication from any Governmental Authority regarding the Transactions; (ii) afford the other an opportunity to review and reasonably comment on drafts of any notices, filings and applications filed or made in connection with the Required Approvals; (iii) after affording the other such opportunity to review and reasonably comment thereon, obtain any consent required to be obtained (pursuant to any applicable Law, Contract, or otherwise) by such Party in connection with the Transactions; provided, however, that any competitively-sensitive information shared among the Parties will be on an outside-counsel-only basis and any material related to the valuation of the Company and evaluation of the Transactions may be redacted. Purchaser, subject to good faith consultations with the Company and good faith consideration of the Company's views and comments, and the inclusion of the Company at meetings with any Governmental Authority with respect to any substantive discussion related to the Transactions (unless otherwise requested by the Governmental Authority), shall take the lead in coordinating communications with any Governmental Authority and developing strategy for responding to any investigation or other inquiry by any Governmental Authority related to any Required Approval or any consent, approval, waiver or clearance by such Governmental Authority.

(e) Remedies. Purchaser agrees to, and will cause its Affiliates to, use reasonable best efforts to take any and all actions necessary to avoid, eliminate, and resolve any and all impediments under any Antitrust Law that may be asserted by any Governmental Authority or any other Person with respect to the Transactions and to obtain all consents, approvals, and waivers under any Antitrust Law that may be required by any Governmental Authority to enable the Parties to close the Transactions as promptly as practicable, including (i) proposing, negotiating, committing to, and/or effecting, by consent decree, hold separate order, or otherwise, the sale, divestiture, transfer, license, disposition, or hold separate (through the establishment of a trust or otherwise) of assets, properties, or businesses of Purchaser or its Subsidiaries or Affiliates, (ii) terminating, modifying, or assigning existing relationships, contracts, or obligations of

Purchaser or its Subsidiaries or Affiliates or those relating to any assets, properties, or businesses to be acquired pursuant to this Agreement, (iii) changing or modifying any course of conduct regarding future operations of Purchaser or its Subsidiaries or Affiliates or the assets, properties, or businesses to be acquired pursuant to this Agreement, including accepting non-structural remedies proposed by any Governmental Authority, such as prior notification and approval provisions, or (iv) otherwise taking or committing to take any other action that would limit Purchaser's or its Subsidiaries' or Affiliates' freedom of action with respect to, or their ability to retain, one or more of their respective operations, divisions, businesses, product lines, customers, assets or rights or interests, or their freedom of action with respect to the assets, properties, or businesses to be acquired pursuant to this Agreement; provided that Purchaser is not obligated to take any action contemplated in clauses (i) to (iv) unless such action is expressly conditioned upon the closing of the Transactions. In addition, if any Proceeding is instituted (or threatened) challenging the Transactions as violating any Antitrust Law or if any decree, order, judgment, or injunction (whether temporary, preliminary, or permanent) is entered, enforced, or attempted to be entered or enforced by any Governmental Authority that would make the Transactions illegal or otherwise delay or prohibit the consummation of the Transactions, the Parties and their respective Affiliates and Subsidiaries shall take any and all actions to contest and defend any such claim, cause of action, or proceeding to avoid entry of, or to have vacated, lifted, reversed, repealed, rescinded, or terminated, any decree, order, judgment, or injunction (whether temporary, preliminary, or permanent) that prohibits, prevents, or restricts consummation of the Transactions. Notwithstanding anything contained in this Agreement to the contrary, Purchaser shall not be obligated to, and no Company Entity shall without Purchaser's prior written consent, agree to any actions, restriction, condition, limitation, requirement or arrangement that would, individually or in the aggregate (x) reasonably be expected to have (A) a material adverse effect on the business, financial condition or the results of the operations of Parent and its Affiliates, taken as a whole but excluding the Company Entities, or (B) a Material Adverse Effect, or (y) be reasonably likely to have a material impact on the benefits reasonably expected to be derived by Purchaser in connection with the Transactions, taken as a whole (any such actions, restrictions, conditions, limitations, requirements, or arrangements, each a "Burdensome Term or Condition"); provided, however, that Purchaser's acceptance of a prior notification and approval provision shall not constitute a Burdensome Term or Condition if (a) required by a Governmental Authority to secure a Required Approval and (b) such action is expressly conditioned upon the closing of the Transactions.

Section 4.6 Reorganization Matters.

(a) Information Statement.

(i) In connection with solicitation of approval of the Reorganization by the Qualified Voters, as contemplated by this Agreement with respect to Qualified Voters who are present or represented at the Special Meeting by special ballot or special proxy in accordance with LSA-R.S. 22:236.5(A) (which solicitation shall be made either in person at the Special Meeting or prior to the Special Meeting), the Parties will prepare and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either Purchaser or the Company) an information statement relating to the Plan of Reorganization and the Transactions that complies with the Louisiana Insurance Code and all applicable Law (the "Information Statement"). As soon as practicable following execution of this Agreement but in no event before the scheduling of the Public Hearing, the Company shall deliver the Information Statement and all other applicable documents and information to its policyholders, including the Qualified Voters.

(ii) The Company will advise Purchaser reasonably promptly of the delivery of the Information Statement and all other applicable documents and information to its policyholders and any supplement or amendment. To the extent not prohibited by applicable Law, the Company shall provide Purchaser and its counsel with any comments or other communications, whether written or oral, that Company or its counsel may receive from time to time from any Governmental Authority or its staff with

respect to the Information Statement promptly after receipt of those comments or other communications and the Parties shall reasonably cooperate with each other with respect to and promptly respond to such comments, including by participating, directly or through counsel, in any discussions or meetings with such Governmental Authority.

(b) Public Hearing and Special Meeting. After the scheduling of the Public Hearing with respect to the Reorganization and the Plan of Reorganization, the Company shall, in accordance with the Louisiana Insurance Code and all applicable Law, provide to its policyholders, including the Qualified Voters and to such additional Persons and in such manner as may be specified by the Commissioner (i) timely notice (in no event less than 30 days' notice) of the Public Hearing and (ii) timely notice of the Special Meeting. As soon as practicable following the Public Hearing, the Company, acting through the Company Board, shall, in accordance with all applicable Laws, its Organizational Documents and the Plan of Reorganization, duly convene and hold the Special Meeting. Notwithstanding the foregoing provisions of this Section 4.6(b), if, on a date for which the Special Meeting is scheduled, the Company has not received special ballots or special proxies representing a sufficient number of votes to obtain the Member Approval, or if necessary to comply with applicable Law, the Company shall have the right to make one or more successive postponements or adjournments of the Special Meeting; provided that the Special Meeting is not postponed or adjourned to a date that is more than 30 days after the date for which the Special Meeting was originally scheduled (excluding any adjournments or postponements required by applicable Law). The Company, acting through the Company Board, shall (i) recommend to the Qualified Voters that they approve the Reorganization and approve and adopt the Plan of Reorganization (the "Board Recommendation"), (ii) use its reasonable best efforts to solicit and obtain the Member Approval, and (iii) shall not withhold, withdraw, amend, modify or qualify (or publicly propose to or publicly state that it intends to withdraw, amend, modify or qualify) in any manner adverse to Purchaser such recommendation (it being understood that publicly taking a neutral position or no position with respect to any Alternative Transaction shall be considered a modification to the Board Recommendation in a manner adverse to Purchaser) or abandon the Plan of Reorganization (collectively, a "Change in Recommendation"). In the event that during the five Business Days prior to the date that the Special Meeting is then scheduled to be held, the Company delivers a notice of an intent to make a Change in Recommendation, Purchaser may direct the Company, to the extent permissible under the Louisiana Insurance Code, to postpone the Special Meeting for up to six Business Days and the Company shall promptly, and in any event no later than the next Business Day, postpone the Special Meeting in accordance with Purchaser's direction. Without limiting Section 4.5, following the Member Approval, each Party shall use its commercially reasonable efforts to obtain the LDI Approval as promptly as possible and the Company, acting through the Company Board, shall not abandon the Plan of Reorganization.

(c) Change in Recommendation. Notwithstanding anything in Section 4.4 and this Section 4.6 to the contrary, at any time prior to the receipt of the Member Approval (and in no event after the receipt of the Member Approval), the Company Board may (i) effect a Change in Recommendation and, subject to compliance with this Section 4.6(c) and Section 7.1(h), terminate this Agreement in accordance with Section 7.1(h), following receipt of an unsolicited bona fide written proposal for an Alternative Transaction after the date of this Agreement which the Company Board determines in good faith after consultation with its financial advisors and outside legal counsel is a Superior Proposal, or (ii) effect a Change in Recommendation in response to a Company Intervening Event, in each case if and only if the Company Board determines in good faith by resolution duly adopted after consultation with its outside legal counsel that failure to take such action is reasonably likely to be inconsistent with the Company Board's fiduciary duties under applicable Law and the Company has complied in all material respects with the applicable provisions of Section 4.4 and this Section 4.6 with respect thereto. Prior to effecting a Change in Recommendation (by itself) or Change in Recommendation and termination of this Agreement in accordance with Section 7.1(h) as provided above, the Company shall provide Purchaser with four Business Days' prior written notice (it being understood and agreed that any amendment to the financial

terms or any other material term of such applicable Alternative Transaction shall, in each case, require a new written notice and a new period of four Business Days commencing at the time of such new notice) advising Purchaser of its intention to effect a Change in Recommendation (by itself) or Change in Recommendation and termination of this Agreement in accordance with Section 7.1(h) as provided above, and specifying in reasonable detail the material terms and conditions of, and the identity of any Person proposing, such Alternative Transaction, or a detailed written description of the material facts and circumstances relating to such Company Intervening Event, as applicable, and that the Company shall, during such time and if requested by Purchaser, engage in good-faith negotiations with Purchaser (including by making its officers and its financial and legal advisors reasonably available to negotiate) to amend this Agreement (x) such that the proposed Alternative Transaction would no longer constitute (or be reasonably expected to lead to) a Superior Proposal or (y) in a manner that obviates the need to effect a Change in Recommendation, as applicable. The Parties agree that nothing in this Section 4.6(c) shall in any way limit or otherwise affect Purchaser's right to terminate this Agreement pursuant to Section 7.1(g) at such time as the requirements of such subsection have been met. Any such Change in Recommendation shall not (1) change the approval of this Agreement or any other approval of the Company Board in any respect that would have the effect of causing any state corporate takeover statute or other similar statute to be applicable to the Transactions, or (2) change the obligation of the Company to present the Transactions at the Special Meeting as soon as practicable following the Public Hearing. Notwithstanding any Change in Recommendation, if this Agreement is not otherwise terminated by either the Company or Purchaser in accordance with the terms hereof, this Agreement shall be submitted to the Qualified Voters at the Special Meeting for the purpose of obtaining the Member Approval, and nothing contained herein, including any Rights of the Company to take certain actions pursuant to Section 4.4(a), shall be deemed to relieve the Company of such obligation.

Section 4.7 Resignations. At or prior to the Closing, at the request of Purchaser, Company shall deliver or cause to be delivered to Purchaser duly signed resignations, effective as of the Closing, of all directors of each of the Company Entities specified by Purchaser at least five Business Days prior to the Closing, or shall take such other action as is necessary to accomplish the removal of such persons from such positions; provided, that the person serving as President of the Company shall, subject to applicable Law and the applicable Organizational Documents of each Company Entity, at all times also be a director of the Company.

ARTICLE V

Additional Agreements

Section 5.1 Further Assurances. In case at any time after the Closing any further action is necessary to carry out the purposes of this Agreement, each of the Parties shall take, or cause to be taken, such further action (including the execution and delivery of such further instruments and documents) as any other Party reasonably may request.

Section 5.2 Press Releases. The Company and Purchaser each shall (a) consult with each other before issuing any press release or otherwise making any public statement with respect to the Transactions, (b) provide to the other Party for review a copy of any such press release or public statement, and (c) not issue any such press release or make any such public statement prior to such consultation and review and the receipt of the prior consent of the other Party, unless required by applicable Law or regulations of any applicable stock exchange.

Section 5.3 Directors' and Officers' Indemnification.

(a) From and after the Closing, Purchaser shall not, and shall cause each of its Subsidiaries and Affiliates (including the Company Entities) not to, amend, repeal or otherwise modify the

indemnification provisions or provisions regarding advancement of expenses of any such Person's Organizational Documents or the agreements set forth in Section 5.4 of the Company Disclosure Letter, in each case as in effect immediately prior to the Closing in any manner that would adversely affect the rights thereunder of individuals who, on or prior to the Closing, were directors, officers, managers, employees or holders of equity interests of such Person.

(b) At the Closing, Purchaser shall, or shall cause the Company to, obtain, maintain in effect for a period of six years thereafter, and fully pay for irrevocable "tail" insurance policies naming all Persons who are covered on the date of this Agreement by the Company Entities' existing policies as direct beneficiaries with respect to directors' and officers' liability insurance in an amount and scope that, in the aggregate, is no less advantageous than the Company Entities' existing policies with respect to matters existing or occurring at or prior to the Closing Date. Purchaser shall not, and shall cause the Company Entities not to, cancel or change such insurance policies in any respect.

(c) In the event Purchaser, any Company Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity in such consolidation or merger, or (ii) transfers all or substantially all of its properties and assets to any Person, then and in either such case, Purchaser shall make proper provision so that the successors and assigns of Purchaser or the applicable Company Entities, as the case may be, shall assume the obligations set forth in this Section 5.3.

Section 5.4 Tax Matters.

(a) Straddle Period Allocation. For purposes of this Agreement, in the case of any Straddle Period, the amount of Taxes attributable to the portion of the Straddle Period ending on the Closing Date shall be deemed to be (i) in the case of Taxes imposed on a periodic basis (such as certain franchise Taxes, and real or personal property Taxes), the amount of such Taxes for the entire period multiplied by a fraction, the numerator of which is the number of calendar days in the portion of the Straddle Period ending on and including the Closing Date and the denominator of which is the number of calendar days in the entire relevant Straddle Period, and (ii) in the case of Taxes not described in clause (i) above (such as Taxes that are based upon or related to income or receipts, based upon occupancy or imposed in connection with any sale or other transfer or assignment of property (real or personal, tangible or intangible)), the amount of any such Taxes shall be determined as if such taxable period ended as of the close of business on the Closing Date (and for such purposes, the taxable period of any partnership or other pass-through entity owned by any Person shall be deemed to end as of the close of business on the Closing Date). In the case of clause (ii) of the preceding sentence, exemptions, allowances or deductions that are calculated on an annual basis (including depreciation and amortization deductions computed as if the Closing Date was the last day of the Straddle Period) shall be allocated between the portion of the Straddle Period ending on the Closing Date and the portion of the Straddle Period thereafter in proportion to the number of days in each such portion.

(b) Transfer Taxes. Purchaser shall ensure that all sales and transfer Taxes, recording charges and similar Taxes, fees or charges imposed as a result of the Transactions (it being understood that such amounts shall not include any Taxes measured or calculated by reference to net or gross income or any fees or charges associated therewith), together with any interest, penalties or additions to such transfer Taxes, that are required to be paid under applicable Law and incurred in connection with the Transactions (collectively, the "Transfer Taxes") shall be timely paid in full to the applicable Taxing Authority. The Parties shall cooperate in the filing of any Tax Returns or other forms and documents as may be necessary or required by applicable Law and to obtain any exemption or refund of any such Transfer Tax.

(c) Tax Treatment of Transaction. For U.S. federal income Tax purposes (together with any applicable state and local income Tax purposes (collectively, "Tax Purposes")), the parties hereto

agree that none of the Transactions shall be treated as a taxable “recognition” event for any of the Company, the Foundation, Parent, or Purchaser (collectively, the “Intended Tax Treatment”). The Parties shall (and shall cause their respective Affiliates to) prepare all applicable books, records, and filings (and otherwise act) in a manner consistent with the Intended Tax Treatment.

(d) Certain Tax Payables. If and when the aggregate of all Taxes, penalties or interest relating to, or with respect to, any Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim paid by any of the Company Entities (and without regard to whether such Taxes, penalties or interest have been indemnified pursuant to this Section 5.4(d)) exceeds, in the aggregate, the Total UTP Accrual (as increased by all prior payments under this Section 5.4(d) and reduced by the aggregate amount paid by any of the Company Entities to the Foundation pursuant to Section 5.4(e) (regardless as to whether such payment pursuant to Section 5.4(e) is paid prior to, concurrently with, or after the time when any such Taxes, penalties or interest are incurred) other than a payment pursuant to Section 5.4(e) with respect to a cash Tax refund described in clause (i) of the definition of the term “Final Resolution Amount”), the Company will promptly notify the Foundation of such excess amount, and within ten Business Days of the Foundation’s receipt of such notice, the Foundation will reimburse the Company for such excess amount. The Company may offset any unpaid amount required to be paid to the Foundation pursuant to Section 5.4(e) by any unpaid amount the Foundation is required to pay to the Company pursuant to this Section 5.4(d) and, for the avoidance of doubt, no amounts shall be required to be paid to the Foundation pursuant to Section 5.4(e) (other than with respect to a cash Tax refund described in clause (i) of the definition of the term “Final Resolution Amount”) if the aggregate of all Taxes, penalties and interest relating to, or with respect to, any Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim paid by any Company Entity equals or exceeds the Total UTP Accrual as adjusted in accordance with the preceding sentence of this Section 5.4(d). For the avoidance of doubt, if any Company Entity is required to make a payment as a result of the disallowance of a Tax refund, credit or deduction that such Company Entity has previously received (including with respect to its U.S. Federal income Tax return for Tax year 2018 or 2019 and any cash Tax refund described in clause (i) of the definition of the term “Final Resolution Amount” that resulted in a payment pursuant to Section 5.4(e)), such payment (including any penalties and/or interest) will be considered as a payment of Taxes, penalties or interest relating to, or with respect to, any Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim. For the avoidance of doubt, Schedule 4 illustrates the operation of this Section 5.4(d) and of the last sentence of Section 5.4(e) using hypothetical scenarios.

(e) Certain Pending Tax Claims. From and after the Closing Date, Purchaser, Parent, and the Company Entities (as applicable) shall execute such limited powers of attorney, or other authorizations, documents or filings as are reasonably requested by the Foundation, as are necessary for the Foundation to control and administer (at its own expense) the Proceedings related to the Outstanding Tax Refund and Credit Claims and the Corporate Income Tax Claims. Furthermore, Purchaser, Parent, and the Company Entities (as applicable) shall otherwise cooperate with the Foundation as is necessary for the Foundation to diligently and effectively conclude the Proceedings related to the Outstanding Tax Refund and Credit Claims and the Corporate Income Tax Claims to its reasonable satisfaction, including the production of all necessary information or documents and the performance of any actions related thereto. The Foundation and its Representatives shall (i) keep Purchaser timely informed of the progress of the Proceedings related to the Outstanding Tax Refund and Credit Claim and the Corporate Income Tax Claim, (ii) allow Purchaser to participate, at Purchaser’s sole expense, in such Proceedings and to employ counsel of Purchaser’s choice for such purpose at Purchaser’s sole expense, (iii) permit Purchaser to attend any meetings or conferences with the relevant Taxing Authority pertaining to the Outstanding Tax Refund and Credit Claim or the Corporate Income Tax Claim, (iv) promptly provide Purchaser with copies of all material documents (including material submissions, notices, protests, briefs, written rulings and determinations and correspondence) pertaining to the Outstanding Tax Refund and Credit Claims or the Corporate Income Tax Claims, (v) permit Purchaser to comment on any material submissions to the relevant

Taxing Authority pertaining to the Outstanding Tax Refund and Credit Claims or the Corporate Income Tax Claims, and (vi) not agree to any settlement, compromise, adjustment, making any Tax election or otherwise resolving the Proceedings related to the Outstanding Tax Refund and Credit Claims or the Corporate Income Tax Claims, without Purchaser's prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). Upon the Final Resolution of an Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim, with respect to each particular year and line item as finally scheduled pursuant to Section 1.7 of this Agreement (or upon such later date as mutually agreed between Parent and the Foundation for payment with respect to a specific Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim as set forth in the finalized schedule prepared pursuant to Section 1.7 of this Agreement) Parent shall pay to the Foundation (or cause to be paid) the Final Resolution Amount (if a positive figure) that pertains to such Final Resolution in no event more than ten Business Days after the relevant Final Resolution (or such later date as mutually agreed between Parent and the Foundation in the finalized schedule prepared pursuant to Section 1.7 of this Agreement as the case may be), provided it is understood that Parent shall not be required to pay any amount to the Foundation hereunder with respect to any Tax refund or other Tax asset (including any interest related thereto) to the extent such Tax refund or other Tax asset was taken into account in the calculation of and resulted in an increase to the amount of Closing Surplus (including through a reduction or other offset to the UTP Accrual).

(f) Private Letter Ruling. The Parties shall use their respective reasonable best efforts to (i) to file or cause to be filed the PLR Request Submission within ten Business Days of the date hereof and (ii) to ultimately obtain from the IRS the private letter rulings set forth in the PLR Request Submission, unless both Purchaser and the Company mutually agree that the IRS will not grant a favorable private letter ruling related to the PLR Request Submission. In connection with the foregoing, the Parties shall cooperate in good faith in obtaining such private letter rulings, including using reasonable best efforts to take, or cause to be taken, all appropriate actions, and assist and cooperate with the other Parties in doing, all things necessary, proper or advisable to obtain such private letter rulings in the most expeditious manner practicable.

Section 5.5 Certain Employee and Employee Benefits Matters.

(a) From the Closing Date through the date that is the one-year anniversary of the Closing Date (the "Continuation Period"), Purchaser shall, or shall cause one of its Affiliates (including the Company Entities) to, provide each employee of each Company Entity who continues to be employed by a Company Entity, Purchaser or any of their respective Affiliates following the Closing (a "Continuing Employee") with (i) a salary or hourly wage rate not less than equal salary or hourly wage rate as provided to such employee immediately prior to the Closing Date; (ii) a target cash annual bonus opportunity, and a target cash long-term bonus opportunity that are substantially comparable in the aggregate to the target cash annual bonus opportunity and the target cash long-term bonus opportunity provided to such Continuing Employee immediately prior to the Closing Date; and (iii) other employee benefits (excluding any severance, annual and long term cash bonuses and equity or equity-based awards) that are substantially comparable in the aggregate to those provided to such Continuing Employee immediately prior to the Closing Date. From the Closing Date through the date that is the two-year anniversary of the Closing Date, Purchaser shall, or shall cause its Affiliates (including, for the avoidance of doubt, the Company Entities) to provide, each Continuing Employee with severance cash and benefits (excluding any equity or equity-based awards) entitlements and protections no less favorable than those set forth on Section 5.5(a) of the Company Disclosure Letter. The Parties acknowledge and agree that, following the date of this Agreement and effective at Closing, the Company shall offer and enter into retention and severance agreements with the officers of the Company identified on Section 4.1(c) of the Company Disclosure Letter, containing the terms and conditions set forth in Section 4.1(c) of the Company Disclosure Letter.

(b) Purchaser further agrees that, from and after the Closing Date, Purchaser shall use reasonable best efforts and shall cause each Company Entity and each of their respective Affiliates to use

reasonable best efforts to grant all of such employees credit for any service with a Company Entity earned prior to the Closing Date (A) for eligibility and vesting purposes and (B) for purposes of vacation accrual and severance benefit determinations under any benefit or compensation plan, program, policy, agreement or arrangement that may be established or maintained by Purchaser, any Company Entity or any of their respective Affiliates on or after the Closing Date (the “New Plans”), provided, that in no event will service be credited (x) for benefit accrual purposes under any defined benefit pension plan, frozen plan or post-retirement plan, (y) to the extent that crediting of service would result in duplication of benefits, or (z) in the case where similarly situated employees of Purchaser or its Affiliates do not receive credit for prior service under the applicable New Plan. In addition, Purchaser and the Company shall use reasonable best efforts to cause to be waived all pre-existing condition exclusions and actively-at-work requirements and similar limitations, eligibility waiting periods and evidence of insurability requirements under any New Plans to the extent waived or satisfied by an employee or his or her dependents under any Company Benefit Plan as of the Closing Date.

(c) Purchaser agrees that Purchaser and the Company Entities (following the Closing) shall be solely responsible for satisfying the continuation coverage requirements of Section 4980B of the Code for all individuals who are “M&A qualified beneficiaries” as such term is defined in Treasury Regulation Section 54.4980B-9.

(d) Purchaser and its Affiliates shall cause each Continuing Employee to receive (i) a 2023 stub period bonus calculated pursuant to Section 4.1(c) of the Company Disclosure Letter (less any applicable withholding Taxes) at the time such annual bonuses are ordinarily paid, but in no event later than March 15 of the calendar year following the calendar year to which such bonuses relate and (ii) any amounts outstanding as of the Closing under the Company’s long term incentive plans determined and paid as set forth on Section 4.1(c) of the Company Disclosure Letter.

(e) If requested by Purchaser at least five days prior to the Closing Date, the Company shall terminate any and all Company Benefit Plans intended to qualify under Section 401(k) of the Code (as applicable, a “Company 401(k) Plan”), effective not later than the day immediately preceding the Closing. In the event that Purchaser requests that any such Company 401(k) Plan be terminated, the Company shall provide Purchaser with evidence that such Company 401(k) Plan has been terminated pursuant to resolution of the Company Board (the form and substance of which shall be subject to review and approval by Purchaser) not later than the two days immediately preceding the Closing Date. To the extent the Company 401(k) Plan is terminated pursuant to Purchaser’s request, the affected Company employees shall be eligible to participate in a 401(k) plan maintained by Purchaser or one of its Subsidiaries effective as of the Closing Date, and such affected employees shall be entitled to effect a direct rollover of any eligible rollover distributions (as defined in Section 402(c)(4) of the Code), including any outstanding loans, to such 401(k) plan maintained by Purchaser or its Subsidiaries. Any such rollover will be subject to the administrative rules and procedures applicable to the Company 401(k) Plan and the 401(k) plan of Purchaser or its Subsidiaries, receipt of the documents evidencing any outstanding loans, the good standing of the loans at the time of the rollover, terms of the Company 401(k) Plan and the 401(k) plan of Purchaser or its Subsidiaries, and receipt of a timely participant election. To the extent that there are loans under the Company 401(k) Plan that will be rolled over into the 401(k) plan of Purchaser or its Subsidiaries, the Company shall take such actions as are reasonably necessary to ensure that such loans will not default as a result of the Transactions or plan termination if the participant makes a timely rollover election.

(f) At all times following the Closing, the Company shall, or Purchaser and its Affiliates shall, continue to maintain benefits for Directors Emeritus (and, to the extent applicable, their eligible dependents), including benefits for surviving spouses of deceased Directors Emeritus, as provided for under Article VIII of the Amended and Restated Articles of Incorporation of the Company as in effect immediately prior to the Closing (the “Director Benefit Provisions”) without regard to any discretion that the Director Benefit Provisions may provide to reduce such benefits. Any director of the Company who

retires or resigns from the Company Board as of or in connection with the Closing shall be designated as a Director Emeritus, including for the purposes of the Director Benefit Provisions.

(g) Nothing contained in this Section 5.5, express or implied, (i) shall constitute an amendment to or any other modification of any New Plan or Company Benefit Plan, or (ii) is intended to or shall confer upon any Person other than the Parties, including any Continuing Employee or their beneficiaries or dependents, any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement or (iii) shall create any obligation on the part of any Company Entity, Purchaser or any of their respective Affiliates to employ any Continuing Employee or retain the services of any other service provider for any period following the Closing.

Section 5.6 Consents. The Company shall give (and shall cause each of the other Company Entities to give) any required notices to Third Parties, and the Company will use commercially reasonable efforts (and will cause each of the Company Entities to use commercially reasonable efforts) to obtain any Third Party consents, in connection with the matters referred to in Section 2.7; provided, however, that nothing in this Section 5.6 shall require the Company or any other Company Entity to (i) expend any *non-de minimis* amount of money to obtain any such consent, (ii) commence any Proceeding or (iii) offer or grant any accommodation (financial or otherwise) to any Third Party.

Section 5.7 Advisory Board Matters. On or prior to the Closing Date (i) Parent shall execute and deliver counterpart signature pages to each of the Advisory Board Side Letters, and (ii) the Company shall cause each initial member of the Advisory Board to execute and deliver counterpart signature pages to each of the Advisory Board Side Letters.

ARTICLE VI

Conditions to Closing

Section 6.1 Conditions to the Obligations of the Company and the Foundation. The obligations of the Company and the Foundation to consummate the Transactions are subject to the satisfaction or waiver by the Company of the following conditions on or before the Closing Date:

(a) Representations and Warranties. The representations and warranties set forth in Article III shall be true and correct as of the date of this Agreement and as of the Closing Date as if made anew as of such date (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)), except for any failure of such representations and warranties to be true and correct that has not had a material adverse effect on the ability of Purchaser to consummate the Transactions.

(b) Performance of Covenants. Purchaser shall have performed in all material respects all of the covenants and agreements required to be performed by it under this Agreement prior to the Closing.

(c) No Restraint. (i) No Law shall have been enacted and no Order shall have been issued by a court or Governmental Authority of competent jurisdiction after the date hereof that would prevent the consummation of the Transactions; and (ii) no Governmental Authority of competent jurisdiction shall have instituted any Proceeding (which remains pending at what would otherwise be the Closing Date) before any United States court or other Governmental Authority of competent jurisdiction seeking to enjoin, restrain or otherwise prohibit consummation of the Transactions; provided, however, that for the avoidance of doubt, that by itself, a letter from the United States Federal Trade Commission or the Antitrust Division of the United States Department of Justice saying that its investigation into the

Transactions remains ongoing following expiration of the HSR Act waiting period is not a pending Proceeding to enjoin or restrain the Transactions under this Section 6.1(c).

(d) Antitrust; Required Approvals. Any applicable waiting period (and any extension thereof) under any Antitrust Law relating to the Transactions shall have expired or been terminated and all other Required Approvals shall have been obtained and remain in full force and effect.

(e) BCBSA. Any required approval of the BCBSA shall have been obtained, so that the right of the Company Entities to use the Blue Cross and Blue Shield name in the Company Entities' licensed service areas shall remain in full force and effect following the Transactions.

(f) Reorganization Approval. The LDI Approval shall have been obtained no fewer than 31 days prior to the Closing Date and remain in full force and effect and the Reorganization shall have occurred or shall be capable of occurring on the Closing Date in accordance with the Plan of Reorganization.

(g) Member Approval. The Member Approval shall have been obtained and remain in full force and effect.

Section 6.2 Conditions to Purchaser's Obligations. The obligation of Purchaser to consummate the Transactions is subject to the satisfaction or waiver by Purchaser of the following conditions on or before the Closing Date:

(a) Representations and Warranties. Except as would be untrue as to Section 2.16 as a result of the Transactions, (i) the representation and warranty of the Company set forth in the first sentence of Section 2.11 shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as if made anew as of such date; (ii) each of the Fundamental Representations shall be true and correct in all material respects as of the Closing Date as if made anew as of such date (except to the extent any such Fundamental Representation expressly relates to an earlier date (in which case as of such earlier date)); and (iii) each of the representations and warranties of the Company set forth in Article II (other than the Fundamental Representations and the representation and warranty in the first sentence of Section 2.11), respectively, disregarding all qualifications contained therein relating to materiality or Material Adverse Effect will be true and correct as of the date of this Agreement and as of the Closing Date as if made anew as of such date (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)), except for any failures of any such representation and warranty referred to in this clause (iii) to be true and correct that has not had, individually or in the aggregate, a Material Adverse Effect.

(b) Performance of Covenants. The Company and the Foundation shall have performed in all material respects all of the covenants and agreements required to be performed by them under this Agreement prior to the Closing.

(c) No Restraint. (i) No Law shall have been enacted and no order shall have been issued by a court or Governmental Authority of competent jurisdiction after the date hereof that would prevent the consummation of the Transactions; and (ii) no Governmental Authority of competent jurisdiction shall have instituted any Proceeding (which remains pending at what would otherwise be the Closing Date) before any United States court or other Governmental Authority of competent jurisdiction seeking to enjoin, restrain or otherwise prohibit consummation of any of the Transactions; provided, however, for the avoidance of doubt, that by itself, a letter from the United States Federal Trade Commission or the Antitrust Division of the United States Department of Justice saying that its investigation into the Transactions remains ongoing following expiration of the HSR Act waiting period is not a pending Proceeding to enjoin or restrain the Transactions under this Section 6.2(c).

(d) Antitrust. Any applicable waiting period (and any extension thereof) under any Antitrust Law relating to the Transactions shall have expired or been terminated.

(e) BCBSA. Any required approval of the BCBSA shall have been obtained, so that the right of the Company Entities to use the Blue Cross and Blue Shield name in the Company Entities' licensed service areas shall remain in full force and effect after the proposed Reorganization, and any such approval of the BCBSA shall not impose any Burdensome Term or Condition.

(f) Reorganization Approval. The LDI Approval shall have been obtained no fewer than 31 days prior to the Closing Date and remain in full force and effect and without the imposition of any Burdensome Term or Condition and the Reorganization shall have occurred or shall be capable of occurring on the Closing Date in accordance with the Plan of Reorganization.

(g) Member Approval. The Member Approval shall have been obtained and remain in full force and effect.

(h) Other Consents and Required Approvals. All other Required Approvals shall have been obtained and remain in full force and effect and shall not, individually or in the aggregate, impose any Burdensome Term or Condition.

(i) No Material Adverse Effect. Since the date hereof, there shall not have occurred any event, fact, occurrence, circumstance, development, change or effect that has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(j) Opelousas Settlement. The Opelousas Settlement shall be in full force and effect.

ARTICLE VII

Termination

Section 7.1 Termination. This Agreement may be terminated at any time prior to the Closing only as follows:

(a) by mutual written consent of Purchaser and the Company;

(b) by Purchaser upon written notice to the Company if there has been a breach of any covenant or agreement by, or inaccuracy of any representation or warranty of, the Company set forth in this Agreement, which would result in the failure of the conditions set forth in Section 6.2(a) or 6.2(b) to be satisfied (so long as Purchaser has provided the Company with written notice of such breach or inaccuracy and the breach or inaccuracy has continued without cure until 30 days following the date of such notice of breach);

(c) by the Company upon written notice to Purchaser if there has been a breach of any covenant or agreement by, or inaccuracy of any representation or warranty of, Purchaser set forth in this Agreement, which would result in the failure of the conditions set forth in Section 6.1(a) or 6.1(b) to be satisfied (so long as the Company has provided Purchaser with written notice of such breach or inaccuracy and the breach has continued without cure until 30 days following the date of such notice of breach or inaccuracy);

(d) by either Purchaser or the Company upon written notice to the other Party if the Transactions have not been consummated by January 23, 2024 (the "Termination Date"); provided, that (i) Purchaser shall not be entitled to terminate this Agreement pursuant to this Section 7.1(d) if Purchaser's breach of this Agreement has prevented the consummation of the Transactions at or prior to such time and

(ii) the Company shall not be entitled to terminate this Agreement pursuant to this Section 7.1(d) if the Company's breach of this Agreement has prevented the consummation of the Transactions at or prior to such time; provided, further, that (1) if, as of the Termination Date, the waiting period applicable to the Transactions under the Antitrust Laws shall not have expired or otherwise been terminated, or the LDI Approval, the Member Approval or any other Required Approval from a Governmental Authority shall not have been obtained, but all of the other conditions to the Closing shall have been satisfied or shall be capable of being satisfied, Purchaser or the Company may, upon written notice to the other Party, extend the Termination Date to a date not later than April 23, 2024 (the "Extension Date"), which date shall thereafter be deemed to be the Termination Date for purposes of this Agreement, and (2) if the Termination Date has been extended pursuant to Section 7.1(d)(1) and if, as of the Extension Date, the waiting period applicable to the Transactions under the Antitrust Laws shall not have expired or otherwise been terminated, or the LDI Approval, the Member Approval or any other Required Approval from a Governmental Authority shall not have been obtained, but all of the other conditions to the Closing shall have been satisfied or shall be capable of being satisfied, the Parties, may upon mutual agreement in writing, extend the Termination Date to a date not later than July 23, 2024, which date shall thereafter be deemed to be the Termination Date for purposes of this Agreement;

(e) by either Purchaser or the Company upon written notice to the other Party if any Order related to Antitrust Laws restraining, enjoining or otherwise prohibiting consummation of the Transactions shall become final and non-appealable;

(f) by either Purchaser or the Company upon written notice to the other Party if (i) any Governmental Authority which must grant a Required Approval has denied approval of such Required Approval as herein contemplated, and such denial has become final and non-appealable or any Governmental Authority of competent jurisdiction shall have issued a final non-appealable order permanently enjoining or otherwise prohibiting the consummation of the Transactions;

(g) by Purchaser upon written notice to the Company if the Company Board (i) fails to make the Board Recommendation, (ii) effects a Change in Recommendation, (iii) authorizes, approves or recommends to the LDI, the Qualified Voters, or otherwise authorizes, approves or publicly recommends, an Alternative Transaction, or (iv) shall fail to publicly confirm the Board Recommendation within ten Business Days after a written request by Purchaser that it do so following the Company's receipt of a proposal concerning an Alternative Transaction;

(h) by the Company, provided that the Company has complied with its obligations under Section 4.4 and Section 4.6, at any time prior to obtaining the Member Approval, in order to concurrently enter into a binding agreement for an Alternative Transaction that constitutes a Superior Proposal, if prior to or concurrently with such termination, the Company pays the Company Termination Fee due under Section 7.3; or

(i) by either Purchaser or the Company upon written notice to the other Party if, subject to any adjournment of the Special Meeting in accordance with Section 4.6(b) to a date no later than 30 days following the date for which the Special Meeting is initially scheduled, the Member Approval shall not be obtained at the Special Meeting.

(j) by the Company upon written notice to Purchaser if the Commissioner requires any material changes to be made to the Proposed Plan of Reorganization, and the Company does not provide the written consent specified in Section 4.5(b).

Section 7.2 Effect of Termination. Except for the provisions of Section 5.2, this Section 7.2, Section 7.3 and Article IX, which shall survive any termination of this Agreement, upon the valid termination of this Agreement in accordance with Section 7.1, this Agreement shall thereafter become void and have no effect, and no Party shall have any liability to any other Party or its members, stockholders,

managers or directors or officers in respect thereof; provided, that nothing herein will relieve any Party from any liability for any willful breach of the provisions of this Agreement prior to such termination.

Section 7.3 Termination Fee.

- (a) Without limiting Section 7.2, if this Agreement is terminated pursuant to:
 - (i) Section 7.1(g) (or Section 7.1(d) or Section 7.1(i)) at any time after Purchaser would have been permitted to terminate this Agreement pursuant to Section 7.1(g);
 - (ii) Section 7.1(i) and a proposal with respect to an Alternative Transaction shall have been publicly proposed or announced or otherwise publicly disclosed and not withdrawn after the date of this Agreement and prior to the date of the Special Meeting; or
 - (iii) Section 7.1(h);

then, (x) in the case of a termination contemplated by Section 7.3(a)(i), the Company shall pay to Purchaser within two Business Days following termination of this Agreement, a fee, by wire transfer in immediately available funds to an account specified by Purchaser, in the amount of \$75,000,000 (the “Company Termination Fee”), (y) in the case of termination contemplated by Section 7.3(a)(iii), the Company shall pay to Purchaser the Company Termination Fee on the date of termination of this Agreement and (z) in the case of a termination contemplated by Section 7.3(a)(ii), if the Company, within 12 months after such termination either consummates an Alternative Transaction or enters into a definitive agreement to implement an Alternative Transaction, the Company shall pay to Purchaser the Company Termination Fee simultaneously with such consummation or entering into such definitive agreement, as the case may be.

(b) If this Agreement is terminated pursuant to Section 7.1(b) or Section 7.1(c), then the non-terminating Party shall pay to the terminating Party, a fee by wire transfer in immediately available funds to an account specified by the terminating Party, in the amount of \$25,000,000 (the “Mutual Termination Fee”). Any such fee due under this Section 7.3(b) shall be paid on the second Business Day immediately following the date of termination of this Agreement.

(c) If (i) this Agreement is terminated by Purchaser or the Company pursuant to Section 7.1(d), Section 7.1(e), or Section 7.1(f), (ii) the failure to consummate the Transactions did not result from any breach by the Company of any covenant or obligations set forth in this Agreement and (iii) Purchaser or Parent has, subsequent to the date hereof, entered into a definitive agreement with respect to, or has otherwise publicly announced the consummation of, a Blue Plan Transaction, then Purchaser shall pay to the Company a non-refundable fee in the amount of \$75,000,000 (the “Purchaser Termination Fee”).

(d) The Company and Purchaser each acknowledge and agree that the agreements contained in this Section 7.3 are an integral part of the Transactions, and that, without these agreements, Purchaser and the Company would not enter into this Agreement and that any amounts payable pursuant to this Section 7.3 do not constitute a penalty. If either Party fails to pay to the other Party any amounts due under this Section 7.3, such Party shall pay the costs and expenses (including reasonable legal fees and expenses) of the other Party in connection with any Proceeding, including the filing of any lawsuit or other legal action, taken to collect payment. Any amounts not paid when due pursuant to this Section 7.3 shall bear interest from the date such payment is due until the date paid at a rate equal to the prime rate as published in The Wall Street Journal, Eastern Edition in effect on the date of such payment. In no event shall the Company be obligated to pay more than one Termination Fee pursuant to this Section 7.3.

(e) Notwithstanding anything to the contrary contained in this Agreement or any ancillary document or agreement delivered in connection herewith or otherwise (subject to Section 9.10), (i) in the event that this Agreement is terminated under circumstances where the Company Termination Fee

is payable, and except in the case of willful breach of this Agreement by the Company or the Foundation, payment of such Company Termination Fee shall constitute the sole and exclusive remedy (whether at law, in equity, in contract, in tort or otherwise, except as specifically contemplated by Section 9.10) of Parent and Purchaser in connection with any termination of this Agreement in the circumstances in which such Company Termination Fee became payable, and upon payment of such amount, (A) neither the Company nor the Foundation shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions and (B) neither Parent nor Purchaser shall have any further Rights or claims against any of the Company or the Foundation under this Agreement or otherwise, whether at law or equity, in contract, in tort or otherwise; (ii) in the event that this Agreement is terminated under circumstances where the Purchaser Termination Fee is payable, and except in the case of willful breach of this Agreement by Purchaser or Parent, payment of such Purchaser Termination Fee shall constitute the sole and exclusive remedy (whether at law, in equity, in contract, in tort or otherwise, except as specifically contemplated by Section 9.10) of the Company and the Foundation in connection with any termination of this Agreement in the circumstances in which such Purchaser Termination Fee became payable, and upon payment of such amount, (C) neither Purchaser nor Parent shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions and (D) neither the Company nor the Foundation shall have any further Rights or claims against any of Purchaser or Parent under this Agreement or otherwise, whether at law or equity, in contract, in tort or otherwise; and (iii) in the event that this Agreement is terminated under circumstances where the Mutual Termination Fee is payable, and except in the case of willful breach of this Agreement by the applicable Party responsible for payment of such Mutual Termination Fee, payment of such Mutual Termination Fee shall constitute the sole and exclusive remedy (whether at law, in equity, in contract, in tort or otherwise, except as specifically contemplated by Section 9.10) of the Party receiving such Mutual Termination Fee in connection with any termination of this Agreement in the circumstances in which such Mutual Termination Fee became payable, and upon payment of such amount, (E) neither the Company nor the Foundation, in the case of a Mutual Termination Fee payable by the Company, or Purchaser and Parent, in the case of a Mutual Termination Fee payable by Purchaser, as applicable, shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions and (F) neither the Company nor the Foundation, in the case of a Mutual Termination Fee payable by Purchaser, or Purchaser and Parent, in the case of a Mutual Termination Fee payable by the Company, as applicable, shall have any further Rights or claims against any of the applicable Party paying such Mutual Termination Fee under this Agreement or otherwise, whether at law or equity, in contract, in tort or otherwise.

ARTICLE VIII

Indemnification

Section 8.1 Survival. Notwithstanding anything to the contrary in this Agreement, the obligations to indemnify and hold harmless any party pursuant to Section 8.2 or Section 8.3 shall survive the Closing until the expiration of the applicable statute of limitations or repose (the “Survival Period”); provided, that any claim for indemnification under this Article VIII, notice of which has been validly delivered pursuant hereto prior to the expiration of the Survival Period, shall survive until such time as such claim is finally resolved pursuant to the terms hereof. Nothing herein shall be deemed to apply to, or limit in any way, any Party’s Rights and remedies in the case of fraud.

Section 8.2 Indemnification Related to Member Proceedings. Following the Closing and subject to the terms and conditions of this Article VIII:

(a) the Foundation (in such capacity, an “Indemnifying Party”) shall indemnify, defend and hold harmless Purchaser and its Affiliates (including the Company and its Subsidiaries) and each of their respective Representatives and Subsidiaries (collectively, the “Purchaser Indemnified Parties”)

from and against one-half (50%) of all Member Proceeding Indemnifiable Losses incurred by the Purchaser Indemnified Parties in excess of the Deductible (defined below).

(b) Purchaser and Parent (in such capacity, each an “Indemnifying Party”) shall each indemnify, defend and hold harmless the Foundation and its Affiliates and each of their respective Representatives and Subsidiaries (collectively, the “Foundation Indemnified Parties”) from and against one-half (50%) of all Member Proceeding Indemnifiable Losses incurred by the Foundation Indemnified Parties.

(c) if and from such time that the Foundation has incurred Member Proceeding Indemnifiable Losses (whether under Section 8.2(a) or otherwise) in excess of the Member Proceeding Indemnification Cap, the Purchaser and Parent shall each indemnify, defend and hold harmless the Foundation Indemnified Parties from and against all (100%) of the Member Proceeding Indemnifiable Losses in excess of the Member Proceeding Indemnification Cap.

Section 8.3 Indemnification Related to Tax Claims. Following the Closing and subject to the terms and conditions of this Article VIII, the Foundation shall indemnify, defend and hold harmless the Purchaser Indemnified Parties from and against one-half (50%) of all Losses suffered, incurred or paid, directly or indirectly, by any Purchaser Indemnified Party as a result of, arising out of or related to any Taxes imposed on the Company and any of its Subsidiaries as a result of the Transactions (including, the Reorganization).

Section 8.4 Limitation on Indemnification. Notwithstanding anything to the contrary contained in this Agreement:

(a) the first \$50,000,000 of Member Proceeding Indemnifiable Losses incurred in the aggregate by the Purchaser Indemnified Parties and the Foundation Indemnified Parties (the “Deductible”) shall be borne by Purchaser and Parent and, to the extent incurred by any Foundation Indemnified Party shall be promptly reimbursed to such Foundation Indemnified Party upon demand; provided, however, that any such reimbursed amounts shall, for the avoidance of doubt, count towards and proportionally reduce the Deductible.

(b) the maximum aggregate amount of Member Proceeding Indemnifiable Losses for which the Foundation Indemnified Parties shall be liable pursuant to Section 8.2(a) or for which the Foundation shall be primarily liable and not indemnified against under Section 8.2(b) and (c), shall be, in the aggregate, an amount equal to the Member Proceeding Indemnification Cap, regardless of which party or parties may be named in, or held liable in any Member Proceeding.

Section 8.5 Indemnification Procedures for Claims Relating to Member Proceedings.

(a) Notice. Following the initiation of a Member Proceeding that could be reasonably expected to give rise to any Member Proceeding Indemnifiable Loss, the applicable Indemnified Party seeking indemnification under this Article VIII shall, within 30 days thereafter, provide written notice to the applicable Indemnifying Party setting forth the specific facts and circumstances, in reasonable detail, for the bases of the claim of indemnification, the amount of any Indemnifiable Losses to which the applicable Indemnified Party is entitled to indemnification if such amount is capable of reasonable calculation (an “Indemnification Notice”); provided, that an Indemnified Party’s failure to provide an Indemnification Notice within the time period specified above shall not relieve the applicable Indemnifying Party from its indemnification obligations with respect to the subject of the Indemnification Notice, except to the extent the applicable Indemnifying Party is prejudiced as a result of such failure. The applicable Indemnifying Party shall have 30 days from receipt of such notice to object in writing to such indemnification claim; provided, that failure of the applicable Indemnifying Party to object within such 30-day period shall not affect the Rights of the applicable Indemnifying Party hereunder, except to the extent

the applicable Indemnified Party is prejudiced as a result of such failure. If the applicable Indemnifying Party agrees that it has an indemnification obligation but objects that it is obligated to pay only a lesser amount, the applicable Indemnified Party shall be entitled to recover promptly from the applicable Indemnifying Party the lesser amount, without prejudice to the applicable Indemnified Party's claim for the difference.

(b) Defense of Member Proceedings. The applicable Indemnified Party shall (i) defend against the Member Proceeding with a nationally-recognized counsel of the applicable Indemnified Party's choice, subject to the Indemnifying Party's approval in its reasonable discretion (which approval shall not be unreasonably withheld, conditioned or delayed), (ii) consult (and cause its counsel to consult) as regularly as practicable with designated representatives of the applicable Indemnifying Party regarding the status of such matter, including making the applicable Indemnified Party's legal counsel available for such consultation, and otherwise to reasonably cooperate with and inform such designated representatives of the applicable Indemnifying Party with respect to the conduct of the defense of and any significant decisions with respect to such Member Proceeding, and (iii) endeavor, to the extent practicable, to permit active participation of the designated representatives of the applicable Indemnifying Party and its counsel in Member Proceedings, including, as mutually agreed by the applicable Indemnified Party and applicable Indemnifying Party in light of tactical considerations. The applicable Indemnified Party and the applicable Indemnifying Party shall enter into a joint defense agreement as mutually agreed by such parties.

(c) The applicable Indemnifying Party may retain separate co-counsel at its sole cost and expense to represent it in connection with the Member Proceeding and the applicable Indemnified Party shall, and shall cause its legal counsel to, cooperate with such co-counsel in connection with the response, defense and/or settlement of such Member Proceeding. The applicable Indemnified Party shall not, without the prior written consent of the applicable Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to any admission or the entry of any judgment with respect to the matter, or enter into any settlement which, in any case, imposes monetary damages to be indemnified by the applicable Indemnifying Party pursuant to this Agreement.

Section 8.6 Indemnification Procedures for Certain Tax Claims.

(a) Notice. If any Taxing Authority makes a claim against any Purchaser Indemnified Party that, if successful, might result in an indemnity payment pursuant to Section 8.3 (a "Transaction Tax Claim"), such Purchaser Indemnified Party shall promptly (in any event within 15 days) notify the Foundation thereof in writing; provided, however, that the failure to so notify the Foundation shall not affect the Rights of the Purchaser Indemnified Party hereunder, except to the extent the Foundation is prejudiced by such failure.

(b) Defense. Purchaser, Parent, and the Company (as applicable) will diligently and effectively control and administer the Proceedings related to any Transaction Tax Claims with the objective of preserving the Intended Tax Treatment to the greatest extent possible. In connection therewith, the Foundation (on the one hand) and each of Purchaser, Parent, and the Company (on the other hand) shall cooperate with each other in good faith as is necessary for the administration of any Transaction Tax Claims, including the production of all necessary information or documents, the execution of limited powers of attorney, or other authorizations, documents or filings, and the performance of any other actions as are reasonably requested by the other Party. Purchaser, Parent or the Company (as applicable) shall (i) keep the Foundation timely informed of the progress of any Proceedings related to Transaction Tax Claims, (ii) allow the Foundation to participate, at the Foundation's sole expense, in such Proceedings and to employ counsel of the Foundation's choice for such purpose at the Foundation's sole expense, (iii) permit the Foundation to attend any meetings or conferences with the relevant Taxing Authority pertaining to any Transaction Tax Claim, (iv) promptly provide the Foundation with copies of all material documents (including material submissions, notices, protests, briefs, written rulings and determinations and

correspondence) pertaining to any Transaction Tax Claim, (v) permit the Foundation to comment on any material submissions to the relevant Taxing Authority pertaining to any Transaction Tax Claim, and (vi) not agree to any settlement, compromise, adjustment, making any Tax election or otherwise resolving any Proceedings related to any Transaction Tax Claim, without the Foundation's prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed).

(c) **Other Tax Claims.** Any indemnification relating to the Outstanding Tax Refund and Credit Claims and the Corporate Income Tax Claims shall be governed by Section 5.4(e) and not by this Section 8.6.

Section 8.7 Recovery Under Insurance Policies. Any Indemnified Party seeking indemnification hereunder shall use commercially reasonable efforts to pursue and collect any insurance proceeds available with respect to any Indemnifiable Losses. The amount of any recovery which an Indemnified Party seeking indemnification hereunder shall be entitled to receive shall be offset by the amount of insurance or other third party proceeds, if any, actually recovered (net of all costs of recovery, including increased premiums and net of any Taxes imposed on amounts recovered) by such Indemnified Party in respect of such Indemnifiable Losses, and there shall be no obligation under this Agreement for any party to indemnify the other party for the amount of such Indemnifiable Losses so reduced by such payment by the applicable party's insurer to such party. If, following the payment to the Purchaser Indemnified Party or Foundation Indemnified Party, as applicable, of any amount under this Article VIII, such Indemnified Party recovers any such insurance proceeds in respect of the claim for which such indemnification payment was made, such Indemnified Party shall promptly pay an amount equal to the amount of such proceeds (net of all costs of recovery, including increased premiums, and net of any Taxes imposed on amounts recovered, but not exceeding the amount of such net indemnification payment) to the applicable Indemnifying Party.

Section 8.8 Net of Tax Benefits. The amount of any Indemnifiable Losses of any Indemnified Party shall be reduced to the extent of any Tax Benefit recognized by such Indemnified Party or any of their Affiliates or Affiliated Groups (a "Tax Benefit Party") in the taxable year in which such Indemnifiable Loss is incurred and with respect to such Indemnifiable Losses. If subsequent to the making of an indemnity payment in respect of an Indemnifiable Loss, a Tax Benefit is recognized with respect to such Indemnifiable Loss and is recognized within the first taxable year following the taxable year in which the indemnity payment is made, the amount of such reduction, less any costs, expenses, Taxes or premiums incurred in connection therewith (together with interest thereon from the date of payment thereof to the date of repayment at the "prime rate" as published in The Wall Street Journal) shall promptly be repaid by the applicable Indemnified Party to the applicable Indemnifying Party.

Section 8.9 Sole Recourse. The sole recourse and exclusive remedy of the Purchaser Indemnified Parties and the Foundation Indemnified Parties with respect to any and all Member Proceeding Indemnifiable Losses and any other Losses of any kind or nature whatsoever that relate to any Member Proceeding shall be the indemnification provisions provided for pursuant to this Article VIII. In furtherance of the foregoing, Purchaser and Parent, on the one hand, and the Foundation and the Company, on the other hand, each hereby waive (on their own behalf and on behalf of each of the applicable Purchaser Indemnified Parties, on the one hand, and the applicable Foundation Indemnified Parties, on the other hand), to the fullest extent permitted by Law, any and all Rights, claims and causes of action of any kind or nature whatsoever that may be brought by any Purchaser Indemnified Party, on the one hand, or Foundation Indemnified Party, on the other hand, against any Foundation Indemnified Party, on the one hand, or Purchaser Indemnified Party, on the other hand, in connection with any Member Proceeding, except pursuant to the indemnification provisions provided for pursuant to this Article VIII (the "Sole Recourse Waiver"), and in addition to such Sole Recourse Waiver, the Purchaser Indemnified Parties, on the one hand, and the Foundation Indemnified Parties, on the other hand, covenant not to sue or otherwise initiate any Proceeding against any Foundation Indemnified Party, on the one hand, or Purchaser Indemnified Party,

on the other hand, for any of the matters waived by the Sole Recourse Waiver set forth in this Section 8.9. Notwithstanding the foregoing, nothing in this Section 8.9 shall limit any Party's right to seek injunctive relief pursuant to Section 9.10 or in the case of fraud pursuant to Section 8.1.

ARTICLE IX

Miscellaneous

Section 9.1 No Survival. None of the representations, warranties, covenants and other agreements in this Agreement or any certificate or instrument delivered pursuant to this Agreement, including any Rights arising out of any breach of any such representations, warranties, covenants and other agreements, shall survive the Closing or the termination of this Agreement, except as otherwise provided in Section 7.2 or Section 8.1 and except for those covenants and agreements contained herein that by their terms apply or are to be performed in whole or in part after the Closing.

Section 9.2 Fees and Expenses. Except as set forth herein, all costs and expenses incurred in connection with this Agreement and the consummation of the Transactions shall be paid by the Party incurring such costs and expenses.

Section 9.3 Amendment and Waiver.

(a) This Agreement may not be amended, altered or modified except by a written instrument executed by Purchaser and the Company. No course of dealing between or among any Persons having any interest in this Agreement will be deemed effective to modify, amend or discharge any part of this Agreement or any Rights or obligations of any Person under or by reason of this Agreement. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute, a waiver of any other provisions, whether or not similar, nor shall any waiver constitute a continuing waiver or estoppel with respect to any subsequent or other failure.

(b) Subject to Section 9.3(a) and in compliance with applicable Law, this Agreement may be amended by the Parties at any time before or after the Member Approval; provided, however, that after the Member Approval has been obtained, there may not be, without further Member Approval, any amendment, extension or waiver of this Agreement which changes or otherwise modifies or amends the amount or the form of the Eligible Member Payment or allocation thereof contemplated by this Agreement.

Section 9.4 Notices. All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given only (a) one Business Day after being delivered by hand, (b) five Business Days after being mailed certified return receipt requested with postage paid, (c) one Business Day after being couriered by overnight receipted courier service, (d) if by electronic mail, on the day on which such electronic mail was sent, or (e) on the date of rejection or refusal of any attempted delivery by one of the preceding methods:

If to the Foundation or, prior to Closing, the Company, then to:

Louisiana Health Service and Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana
5525 Reitz Avenue
Baton Rouge, Louisiana 70809
Attention: I. Steven Udvarhelyi, M.D.
Louis Patalano, IV
Email: steven.udvarhelyi@bcbsla.com
lou.patalano@bcbsla.com

with copies (which shall not constitute notice) to:

Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103-2921
Attention: Stephen A. Jannetta
Michael N. Baxter
Email: stephen.jannetta@morganlewis.com
michael.baxter@morganlewis.com

If to Parent, Purchaser, or, after the Closing, the Company, then to:

Elevance Health, Inc.
220 Virginia Avenue
Indianapolis, IN, 46204
Attention: Blair Todt (Executive Vice President, General Counsel)
Jay H. Wagner (Vice President, Counsel)
Email: blair.todt@anthem.com
jay.wagner@anthem.com

with copies (which shall not constitute notice) to:

White & Case LLP
1221 Avenue of the Americas
New York, New York 10020
Attention: Daniel G. Dufner, Jr.
Michael A. Deyong
Email: daniel.dufner@whitecase.com
michael.deyong@whitecase.com

If to the Foundation, then to:

The Accelerate Louisiana Initiative, Inc.
5525 Reitz Avenue
Baton Rouge, Louisiana
Attention: Tim Barfield
Penny Martin
Email: tim.barfield@bcbsla.com
penny.martin@bcbsla.com

with copies (which shall not constitute notice) to:

Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103-2921
Attention: Stephen A. Jannetta
Michael N. Baxter
Email: stephen.jannetta@morganlewis.com
michael.baxter@morganlewis.com

Any Party may give any notice, request, demand, or other communication hereunder using any other means (including personal delivery, expedited courier, messenger service, ordinary mail, or electronic

mail), but no such notice, request, demand or other communication shall be deemed to have been duly given unless and until it actually is received by the Party for whom it is intended.

Section 9.5 Assignment. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of each of the Parties and their respective successors and permitted assigns. Neither this Agreement nor any Rights, benefits or obligations set forth herein may be assigned by any of the Parties without the prior written consent of Purchaser and the Company, any attempted assignment without such prior written consent shall be void; provided, that Purchaser may assign its Rights under this Agreement to any Affiliate of Purchaser without the prior written consent of the Company; and provided, further, that Purchaser continues to remain responsible for its obligations hereunder.

Section 9.6 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law in any jurisdiction, such provision will be ineffective only to the extent of such prohibition or invalidity and only in such jurisdiction, without invalidating the remainder of such provision or the remaining provisions of this Agreement in such jurisdiction or any provision of this Agreement in any other jurisdiction.

Section 9.7 Construction and Interpretation. Unless the context otherwise requires, any reference in this Agreement to words imparting the singular number also include the plural and vice versa. References to Articles, Sections, Schedules, Exhibits, Sections of the Company Disclosure Letter, the Preamble and Recitals are references to articles, sections, schedules, exhibits, disclosure schedules, the preamble and recitals of this Agreement, and the descriptive headings of the several Articles and Sections of this Agreement and the Company Disclosure Letter (as applicable) are inserted for convenience only, do not constitute a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. Schedules, Exhibits and the Company Disclosure Letter are incorporated into and form an integral part of this Agreement. Unless the context otherwise requires, any reference to this Agreement or any other agreement or document shall be construed as a reference to this Agreement or such other agreement or document, as the case may be, as the same may have been, or may from time to time be, amended, varied, novated or supplemented. Unless the context otherwise requires, the words “hereby,” “herein,” “hereinafter,” “hereof,” and “hereunder” refer to this Agreement as a whole and not merely to the provision in which such words appear. The use of the masculine, feminine or neuter gender herein shall not limit any provision of this Agreement. Unless the context requires otherwise, the use of the terms “including” or “include” shall in all cases herein mean “including, without limitation,” or “include, but not limited to,” respectively. The word “or” is disjunctive but not necessarily exclusive. The phrase “to the extent” means “the degree by which” and not “if” for all purposes of this Agreement. References to “Dollars,” “dollars” or “\$”, without more are to the lawful currency of United States of America. References to any statute, rule, or regulation are to the statute, rule, or regulation as amended, modified, supplemented or replaced from time to time (and, in the case of statutes, include any rules and regulations promulgated under the statute) and all references to any section of any statute, rule, or regulation include any successor to the section. References to any Governmental Authority or Law shall mean and include any successor or replacement Governmental Authority or Law, as the case may be, to the referenced one. The terms “furnished” or “made available” shall mean that the information referred to has been physically or electronically delivered to the relevant parties (including, in the case of “made available” to Purchaser, material that has been posted, retained and thereby made available to Purchaser or its Representatives through the virtual data room titled established by the Company at least three Business Days prior to the date hereof). All references to dates and times herein, except as otherwise specifically noted, shall refer to New York City time. References to “days” means calendar days unless Business Days are expressly specified. If the last day for the giving of any notice or the performance of any act required or permitted under this Agreement is a day that is not a Business Day, then the time for the giving of such notice or the performance of such action shall be extended to the next succeeding Business Day.

Section 9.8 Purchaser Deliveries. Purchaser agrees and acknowledges that all documents or other items delivered or made available to Purchaser and Purchaser's Representatives by posting to the virtual data room (including in that certain "clean room" portion thereof) to which Purchaser or, in the case of the "clean room" portion, the applicable Purchasers' Representatives have access shall be deemed to be delivered or made available, as the case may be, to Purchaser for all purposes hereunder.

Section 9.9 No Third-Party Beneficiaries. Section 5.3 shall be enforceable by each of the current and former officers, directors, and similar functionaries and equityholders of the Company Entities and his or her heirs and Representatives and Section 5.5(f) shall be enforceable by each Director Emeritus (including a director who retires or resigns from the Company Board as of or in connection with the Closing). Except as otherwise expressly provided herein, nothing expressed or referred to in this Agreement will be construed to give any Person other than the Parties any legal or equitable right, remedy, or claim under or with respect to this Agreement or any provision of this Agreement.

Section 9.10 Specific Performance; Damages. The Parties agree that the aggrieved Party or Parties would suffer irreparable damage prior to a termination of this Agreement in the event that the Closing is not consummated in accordance with the terms of this Agreement, and that money damages or other legal remedies would not be an adequate remedy for any such damages. Accordingly, the Parties acknowledge and hereby agree that in the event of any breach or threatened breach by any Party of their covenants or obligations set forth in this Agreement, the aggrieved Party or Parties will be entitled to an injunction or injunctions to prevent or restrain such breaches or threatened breaches of this Agreement, and to specifically enforce the terms and provisions of this Agreement to prevent such breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of such Party under this Agreement, in addition to any other remedy to which the aggrieved Party or Parties are entitled at law or in equity, including the right to terminate this Agreement pursuant to Article VII and to seek money damages. The Parties each hereby agree not to raise any objections to the availability of the equitable remedy of specific performance to prevent or restrain breaches or threatened breaches of this Agreement. The Parties each hereby waive (i) any defenses in any Proceeding for specific performance, including the defense that a remedy at law would be adequate and (ii) any requirement under any Law to post a bond or other security as a prerequisite to obtaining equitable relief.

Section 9.11 Complete Agreement. This Agreement, together with the schedules and exhibits referred to herein, contains the complete agreement among the Parties and supersedes any prior understandings, agreements, representations or warranties by or among the Parties, whether written or oral, which may have related to the subject matter hereof or thereof in any way. Each Party agrees that, except for the representations and warranties contained in this Agreement, any Related Agreement to which the Company or Purchaser, as applicable, is or will be a party at the Closing, the certificate delivered pursuant to Section 1.5(b)(i) in the case of the Company, and the certificate delivered pursuant to Section 1.5(a)(i) in the case of Purchaser, neither Party makes any other representations or warranties, and each hereby disclaims any other representations or warranties, express or implied, as to the accuracy or completeness of any other information made by, or made available by, itself or any of its Representatives, with respect to, or in connection with, the negotiation, execution or delivery of this Agreement or the Transactions, notwithstanding the delivery or disclosure to the other or the other's Representatives of any documentation or other information with respect to any one or more of the foregoing. The representations and warranties in this Agreement are the product of negotiations among the Parties and are for the sole benefit of the Parties. Any inaccuracies in such representations and warranties are subject to waiver by the Parties in accordance with Section 9.3 without notice or liability to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the Parties of risks associated with particular matters regardless of the Knowledge of any of the Parties. Consequently, Persons other than the Parties may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date hereof or as of any other date.

Section 9.12 Counterparts. This Agreement and any Related Agreement may be executed by electronic transmission (i.e., facsimile or electronically transmitted portable document format (PDF) or DocuSign or similar E-Sign compliant electronic signature) and in counterparts, any one of which need not contain the signatures of more than one Party, but all such counterparts taken together shall constitute one and the same instrument.

Section 9.13 Governing Law. This Agreement shall be governed by and construed in accordance with the domestic Laws of the State of Delaware except to the extent that the Laws of the State of Louisiana are applicable to the LDI Approval without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.

Section 9.14 Waiver of Jury Trial. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. EACH PARTY (i) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (ii) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS Section 9.14.

Section 9.15 Exclusive Jurisdiction and Venue. WITHOUT LIMITING ANY PARTY FROM ENFORCING ANY JUDGMENT OR SEEKING SPECIFIC PERFORMANCE AS AN INTERIM MEASURE IN ANY APPROPRIATE JURISDICTION AND VENUE, EACH OF THE PARTIES IRREVOCABLY AGREES THAT ANY PROCEEDING BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT BETWEEN OR AMONG SUCH PARTIES, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE DELAWARE COURT OF CHANCERY AND ONLY STATE APPELLATE COURT THEREFROM WITHIN THE STATE OF DELAWARE (UNLESS THE DELAWARE COURT OF CHANCERY SHALL DECLINE TO ACCEPT JURISDICTION OVER A PARTICULAR MATTER, IN WHICH CASE, IN ANY STATE OR FEDERAL COURT LOCATED IN THE STATE OF DELAWARE). EACH OF THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF SUCH COURTS FOR SUCH PURPOSE. EACH OF THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH PROCEEDING BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

Section 9.16 Non-Recourse. This Agreement may only be enforced against, and any claim or suit based upon, arising out of, or related to this Agreement, or the negotiation, execution or performance of this Agreement, may only be brought against the named parties to this Agreement and then only with respect to the specific obligations set forth herein with respect to the named parties to this Agreement. No Person who is not a named party to this Agreement, including any past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney or Representative of the Company or of any of its Affiliates, will have or be subject to any liability or indemnification obligation (whether in contract or in tort) to Purchaser or any other Person resulting from (nor will Purchaser have any claim with respect to) (i) the distribution to Purchaser, or Purchaser's use of, or reliance on, any information, documents, projections, forecasts or other material made available to Purchaser in certain "data rooms," confidential information memoranda or management presentations in expectation of, or in connection with, the Transactions, or (ii) any claim based on, in respect of, or by reason of, the sale and purchase of the

Company, including any alleged non-disclosure or misrepresentations made by any such Persons, in each case, regardless of the legal theory under which such liability or obligation may be sought to be imposed, whether sounding in contract or tort, or whether at law or in equity, or otherwise; and each Party waives and releases all such liabilities and obligations against any such Persons.

Section 9.17 No Presumption Against Drafter. Each of the Parties has jointly participated in the negotiation and drafting of this Agreement. In the event of any ambiguity or if a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by each of the Parties and no presumptions or burdens of proof shall arise favoring any Party by virtue of the authorship of any of the provisions of this Agreement.

Section 9.18 Time of Essence. With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

Section 9.19 No Right of Set-Off. Purchaser, for itself and its successors and permitted assigns, hereby unconditionally and irrevocably waives any rights of set-off, netting, offset, recoupment, or similar Rights that Purchaser or any of its respective successors and permitted assigns has or may have with respect to any payments to be made by Purchaser pursuant to this Agreement or any other document or instrument delivered by Purchaser in connection herewith.

Section 9.20 Parent Guarantee. Parent hereby absolutely, irrevocably and unconditionally guarantees to the Company and the Foundation, and becomes surety for, the prompt payment and performance of all obligations of Purchaser to the Foundation and its Affiliates under this Agreement, including, without limitation, Purchaser's payment obligations under Section 1.6 and Section 1.7 (if applicable) of this Agreement, and including, without limitation, all costs and expenses of the Company or the Foundation incurred in the enforcement or collection of the foregoing (collectively, the "Guaranteed Obligations"). The Guaranteed Obligations shall continue in full force and effect until the final and irrevocable payment and performance in full of all of the Guaranteed Obligations. The guaranty set forth in this Section 9.20 is not conditioned upon any event or contingency, or any requirement that the Company or the Foundation (i) endeavor to first obtain payment of the Guaranteed Obligations from Purchaser or any other Person including, without limitation, any requirement that the Company or the Foundation make demand upon Purchaser, or pursue any of its Rights against Purchaser for collection of the Guaranteed Obligations whether through the commencement of legal Proceedings or otherwise, or (ii) pursue any Rights which may be available to the Company or the Foundation with respect to any other Person who may be liable for the payment of the Guaranteed Obligations, before seeking payment from Parent for payment of the Guaranteed Obligations. This is an absolute, unconditional, irrevocable and continuing guaranty and will remain in full force and effect until all of the Guaranteed Obligations have been indefeasibly paid in full. Parent's obligations hereunder shall not be affected, modified or impaired by any counterclaim, set-off, deduction or defense based upon any claim that Parent may have against Purchaser, except payment or performance of the Guaranteed Obligations. With respect to its obligations hereunder, Parent waives diligence, presentment, demand of payment, protest and all notices whatsoever.

Section 9.21 Representation of Foundation; Privilege. Purchaser and Parent each agree, on their own behalf and on behalf of their Affiliates (including, after the Closing, the Company), the Purchaser Indemnified Parties, any Person providing debt financing to Purchaser in connection with the Transactions, and their respective directors, officers, managers, members, partners, direct or indirect equityholders and controlling Persons, employees, owners, advisors and representatives, and the heirs, executors, administrators, estates, successors and assigns of any of the foregoing (collectively, the "Purchaser Related Parties"), that, following the Closing, Morgan, Lewis & Bockius LLP ("Morgan Lewis") may serve as counsel to the Foundation in connection with any matters related to this Agreement and the transactions contemplated hereby, including any litigation, claim or obligation arising out of or relating to this Agreement or the Transactions notwithstanding any representation by Morgan Lewis prior to the Closing

Date of the Company. Effective upon the Closing, Purchaser and Parent, on behalf of themselves, the Purchaser Related Parties and the Company, hereby (a) waives any claim they have or may have that Morgan Lewis has a conflict of interest or is otherwise prohibited from engaging in such representation and (b) agrees that, if a dispute arises after the Closing between Purchaser and/or Parent and/or the Company, on the one hand, and the Foundation, on the other hand, Morgan Lewis may represent the Foundation in such dispute even though the interests of the Foundation may be directly adverse to Purchaser and/or Parent and/or the Company and even though Morgan Lewis may have represented the Company in a matter substantially related to such dispute. Each of Purchaser and Parent represents to the Foundation that Purchaser's and Parent's own attorney has explained and helped Purchaser and Parent evaluate the implications and risks of waiving the right to assert a future conflict against Morgan Lewis, and Purchaser's and Parent's consent with respect to this waiver is fully informed. Purchaser and Parent, on behalf of themselves and the Purchaser Related Parties, also each further agree that, as to all privileged communications among Morgan Lewis, on the one hand, and the Company, the Foundation, or any of their respective representatives, on the other hand, that relate in any way to the Transactions, the attorney-client privilege and the expectation of client confidence shall belong to the Foundation and may be controlled by the Foundation and will not pass to or be claimed by Purchaser, Parent or the Company. In addition, if the Closing occurs, all of the privileged client files and records in the possession of Morgan Lewis related to this Agreement and the transactions contemplated hereby will continue to be property of (and be controlled by) the Foundation. Notwithstanding the foregoing, if after the Closing a dispute arises between Purchaser or Parent or the Company and a third party that is not a party to this Agreement, the Company may assert the attorney-client privilege to prevent disclosure of privileged communications by Morgan Lewis to such third party; provided that the Company shall not waive such privilege without the prior written consent of the Foundation.

ARTICLE X

Definitions

“ACO” means any accountable care organization to which any Company Entity is a member, including any accountable care organization under the Medicare Shared Savings Program and any accountable care organization participating in the Next Generation ACO Model established by the Center for Medicare & Medicaid Innovation.

“Advisory Board” has the meaning set forth on Schedule 3.

“Advisory Board Charter” has the meaning set forth on Schedule 3.

“Advisory Board Side Letter” means those certain side letter agreements to be entered into by and between the Company and each initial member of the Advisory Board regarding certain matters relating to the establishment of the Advisory Board, in each case, substantially in the form set forth in Section 10.1 of the Company Disclosure Letter.

“Affiliate” of any particular Person means any other Person controlling, controlled by or under common control with such Person, where “control” means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, Contract or otherwise.

“Affiliated Group” means an affiliated group as defined in Section 1504 of the Code (or any analogous combined, consolidated, unitary or similar group under state, local or non-U.S. Law).

“Affiliated Parties” means (i) the officers and directors of the Company Entities, (ii) the family members of any of the Persons described in clause (i) (where “family member” means such Person's

spouse, lineal ancestors and descendants (whether natural or adopted), siblings and any trust for the benefit of one or more of such Persons and such Person's spouse, lineal ancestors and descendants and siblings) and (iii) any Affiliate of any of the Persons described in clause (i) or clause (ii) (other than the Company Entities).

“Agreement” has the meaning set forth in the Preamble.

“Alternative Transaction” means, whether or not proposed in writing, any transaction or series of related transactions pursuant to which any Third Party or group of Third Parties would, directly or indirectly (i) acquire or participate in a merger, consolidation, or other business combination involving the Company, directly or indirectly, (ii) acquire a substantial equity interest in the Company, including the right to vote 25% or more of the capital stock (following a reorganization or conversion) of the Company or a resulting parent company of the Company, (iii) acquire 25% or more of the assets of the Company, other than in the Ordinary Course of Business, (iv) acquire in excess of 25% of the outstanding capital stock (following a reorganization or conversion) of the Company or a resulting parent company of the Company, other than as contemplated by this Agreement, (v) acquire control (as defined under the Insurance Laws) of the Company, or (vi) effect any transaction similar to the foregoing.

“Anti-Corruption Laws” means all U.S. and non-U.S. Laws relating to the prevention of corruption and bribery, including, without limitation, the Foreign Corrupt Practices Act of 1977, as amended.

“Antitrust Law” means the Sherman Act, 15 U.S.C. §§ 1-7, as amended; the Clayton Act, 15 U.S.C. §§ 12-27, 29 U.S.C. §§ 52-53, as amended; the HSR Act; the Federal Trade Commission Act, 15 U.S.C. §§ 41-58, as amended; and all other federal, state and foreign Laws, Orders, administrative and judicial doctrines, and other Laws that are designed or intended to prohibit, restrict, or regulate actions having the purpose or effect of monopolization or restraint of trade.

“Approved Excess Surplus” means an amount equal to the Statutory Capital of the Company in excess of 500% of the authorized control level risk based capital of the Company as of the Closing Date, or such other amount as approved by the Commissioner.

“ASOP” means actuarial standards of practice promulgated by the Actuarial Standards Board for use by actuaries when providing professional services in the United States.

“Balance Sheet Date” means December 31, 2021.

“Base Purchase Price” means \$2,500,000,000.00.

“BCBSA” means the Blue Cross and Blue Shield Association.

“BCBSA Plan” means an insurer, health maintenance organization or similar type entity that is a member of the BCBSA.

“Blue Plan Transaction” means any acquisition of a BCBSA Plan by Purchaser, Parent or any of Purchaser's other Affiliates (whether by merger, acquisition, consolidation, combination, acquisition of equity interests or assets, or otherwise), excluding any joint venture that does not result in the acquisition of all or a majority of the assets or equity interests of any BCBSA Plan.

“Burdensome Term or Condition” has the meaning set forth in Section 4.5(e).

“Business Day” means any day other than a Saturday or Sunday or any other day on which commercial banks in Baton Rouge, Louisiana, or New York, New York, are authorized or required by Law to close.

“CARES Act” means the Coronavirus Aid, Relief and Economic Security Act, as amended, and the related rules and regulations promulgated thereunder.

“Closing” has the meaning set forth in Section 1.3.

“Closing Balance Sheet” has the meaning set forth in Section 1.7(a).

“Closing Date” has the meaning set forth in Section 1.3.

“Closing Foundation Amount” means an amount equal to (i) the Foundation Amount, plus (ii) the Estimated Closing Surplus (which may be a negative number), minus (iii) the Estimated Company Transaction Expenses to the extent not included in the calculation of the Estimated Closing Surplus, minus (iv) the Estimated Closing Indebtedness to the extent not included in the calculation of the Estimated Closing Surplus.

“Closing Indebtedness” means the amount of Indebtedness of the Company Entities as of the Closing Date, as finally determined in accordance with Section 1.7 which, for the avoidance of doubt, shall include the Closing Repaid Indebtedness.

“Closing Repaid Indebtedness” has the meaning set forth in Section 1.4.

“Closing Surplus” means, as applicable, the amount by which either (i) the Statutory Capital exceeds the Minimum Regulatory Capital, each as of immediately prior to the Closing, or (ii) the Minimum Regulatory Capital exceeds the Statutory Capital, in each case as of immediately prior to the Closing and accounting for and after taking into account the payment or transfer, as applicable, of the Approved Excess Surplus to the Foundation (provided that for the avoidance of doubt, “Minimum Regulatory Capital” for purposes of calculating “Closing Surplus” shall continue to mean 375% of the authorized control level risk based capital of the Company as of the Closing Date (as further set forth in the definition of “Minimum Regulatory Capital”), notwithstanding any reference to 500% in the definition of “Approved Excess Surplus”), provided, however, that if the Minimum Regulatory Capital exceeds the Statutory Capital, such amount shall be expressed as a negative number for purposes of the calculation of the Closing Foundation Amount and the Final Foundation Amount.

“CMS” means the Centers for Medicare and Medicaid Services.

“Code” means the Internal Revenue Code of 1986, as amended.

“Commissioner” means the Louisiana Commissioner of Insurance.

“Company” has the meaning set forth in the Preamble.

“Company 401(k) Plan” has the meaning set forth in Section 5.5(e).

“Company Assets” has the meaning set forth in Section 2.7.

“Company Benefit Plans” has the meaning set forth in Section 2.14(a).

“Company Board” means the Board of Directors of the Company.

“Company Disclosure Letter” means the disclosure letter delivered concurrently with the execution of this Agreement by the Company to Purchaser.

“Company Entities” means each of the Company and its Subsidiaries.

“Company Intervening Event” means any Event with respect to the Company Entities, taken as a whole, that (a) is material, (b) was not known or reasonably foreseeable (with respect to substance or timing)

to the Company Board as of or prior to the date of this Agreement (and which could not have become known through any further reasonable investigation, discussion, inquiry or negotiation with respect to any fact, change, condition, occurrence, effect, event, circumstance or development known to the Company Board as of or prior to the date of this Agreement), (c) first becomes known to the Company Board after the execution of this Agreement, and (d) does not relate to or involve any Alternative Transaction; provided, however, that none of the following shall constitute a Company Intervening Event: (i) any Event relating to the business, assets, results of operations or condition (financial or otherwise) of Purchaser and its Affiliates, unless such Event has had or would reasonably be expected to have a material adverse effect on Purchaser, (ii) the receipt, existence or terms of an Alternative Transaction or a Superior Proposal or any inquiry or communications or matters relating thereto, or (iii) any action taken by any Party pursuant to and in compliance with the affirmative covenants set forth in Section 4.5 or the consequences of any such action.

“Company Permits” has the meaning set forth in Section 2.20(a).

“Company Shares” has the meaning set forth in the recitals hereto.

“Company Software” has the meaning set forth in Section 2.18(i).

“Company Systems” means any and all Computer Systems that are owned, leased, or licensed by, or under the control of, or used (or held for use) by or for any Company Entity, including any outsourced or cloud based platforms, systems and processes that are operated or maintained by any Person that is not a Company Entity for the benefit of any Company Entity.

“Company Termination Fee” has the meaning set forth in Section 7.3(a).

“Company Transaction Expenses” means all unpaid expenses of the Company Entities incurred or to be incurred prior to and through the Closing in connection with (a) the negotiation, preparation and execution of this Agreement, the Proposed Plan of Reorganization and the other agreements, documents and instruments contemplated hereby, and the consummation of the Transactions and the Closing and any transaction with other potential purchasers, including, in each case, out-of-pocket costs, fees, commissions and disbursements of financial advisors, attorneys, fiduciaries, accountants and other advisors and service providers, severance payments to directors, officers and employees, sale bonuses, retention payments and any other change-of-control or similar payments payable as a result of or in connection with (either alone or in combination with any other event) the Transactions, including the amount of any employer-side withholding, employment, or payroll Taxes imposed with respect to any such payments made before, on or after the Closing Date under the terms of agreements in effect at Closing (even if the due date of remittance is deferred under the CARES Act) and any amounts payable to gross up or make whole any Person for income or excise Taxes imposed with respect to such payments, (b) any amounts payable by the Company (prior to and through and including the Closing Date) pursuant to Section 9.2 and which have not been paid as of the Closing, (c) any outstanding accrued bonuses (including, without limitation, the actual amount of the Minimum Annual Bonus payments, if any), retention bonuses or severance payments (including, without limitation, the retention bonuses and severance payments listed on Section 9 of the Company Disclosure Letter) (including the amount of any employer-side withholding, employment, payroll, or similar Taxes imposed with respect to any such payments made before, on or after the Closing Date under the terms of agreements in effect at Closing (even if the due date of remittance is deferred under the CARES Act) and any amounts payable to gross up or make whole any Person for income or excise Taxes imposed with respect to such payments), (d) any Retiree Benefit Obligations that have accrued at or prior to the Closing, (e) 50% of the fees, charges and expenses payable to the Paying Agent, to the extent not paid by the Company prior to Closing and (f) any fees, charges and expenses payable in connection with the transfer of Marketable Securities to the Foundation in accordance with Section 1.6(b).

“Computer Systems” means any and all Software, (including firmware), computer hardware (whether general or special purpose), electronic data processing and storage systems and platforms,

information technology, information systems, record keeping systems, communications systems, telecommunications systems, networks, network equipment, interfaces, platforms, servers, peripherals, computer systems, and information contained therein or transmitted thereby.

“Contaminants” has the meaning set forth in Section 2.18(n).

“Contested Adjustment” has the meaning set forth in Section 1.7(b).

“Continuation Period” has the meaning set forth in Section 5.5(a).

“Continuing Employee” has the meaning set forth in Section 5.5(a).

“Contract” means any written contract, agreement, indenture, note, bond, guaranty, loan, lease, sublease, conditional sales contract, mortgage, license, sublicense, or other legally binding arrangement, commitment, or undertaking (in each case, whether written or oral), together with all amendments or supplements thereto.

“Copyleft Terms” means any terms of a license commonly referred to as an open source, free Software, copyleft, or community source code license (including any Software licensed under the GNU General Public License (GPL), the GNU Lesser General Public License (LGPL), the Mozilla Public License, the GNU Affero General Public License, the Eclipse Public License, the MIT license, the Common Public License, the CDDL, the Artistic License, the Netscape Public License, the Sun Community Source License, the Sun Industry Standards License (SISL), or any other public source code license arrangement) or any similar license, in each case that require, as a condition of or in connection with any use, modification, reproduction, or distribution of any Software licensed thereunder (or any Company Software or other Owned Intellectual Property that is used by, incorporated into or includes, relies on, is linked to or with, is derived from, or is distributed with such Software), any of the following: (a) the disclosing, making available, distribution, offering or delivering of source code or any information regarding such Company Software or other Owned Intellectual Property for no or minimal charge; (b) the granting of permission for creating modifications to or derivative works of such Company Software or other Owned Intellectual Property; (c) the granting of a royalty-free license, whether express, implied, by virtue of estoppel or otherwise, to any Person under Intellectual Property Rights (including patents) regarding such Company Software or other Owned Intellectual Property (whether alone or in combination with other hardware or Software); or (d) the imposition of restrictions on future patent licensing terms, or other abridgement or restriction of exercise or enforcement of any Intellectual Property Rights through any means.

“Copyrights” has the meaning set forth in the definition of “Intellectual Property”.

“Corporate Income Tax Claim” means any pending claim of any of the Company Entities at the Louisiana State Board of Tax Appeals that relates to a potential refund of Louisiana State corporate income Taxes paid under protest for Tax years 2017 through 2021 and further relates to additional Taxes that may be owed by any of the Company Entities with respect to a Pre-Closing Tax Period as determined in connection with or related to the resolution of such claim at the Louisiana State Board of Tax Appeals.

“COVID-19” means the SARS-Cov2 or COVID-19 pandemic, including any future resurgence or evolutions or mutations thereof and any related or associated disease outbreaks, epidemics and pandemics.

“COVID-19 Actions” means all reasonable actions taken, or planned to be taken, by the Company Entities in response to events, occurrences, conditions, circumstances, or developments arising directly or indirectly as a result of COVID-19 or any COVID-19 Measures, that are, in each case, in compliance with applicable Law or COVID-19 Measures.

“COVID-19 Measures” means any quarantine, “shelter in place”, “stay at home”, workforce reduction, social distancing, shut down, closure, sequester, safety or any other Law, Order, directive,

guidelines or recommendations promulgated by any Governmental Authority, including the Centers for Disease Control and Prevention and the World Health Organization, in each case, in connection with or in response to COVID-19, including the CARES Act and Families First Act.

“Data Security Requirements” means, collectively, all of the following to the extent relating to Data Treatment or otherwise relating to privacy, security, or security breach notification requirements and applicable to the Company, or to any of the Computer Systems: (i) the Company’s own rules, policies, and procedures; (ii) all applicable Laws; (iii) industry standards that the Company is required to follow by virtue of operating in the applicable industry (including, if applicable, the Payment Card Industry Data Security Standard (PCI DSS)); and (iv) Contracts into which the Company has entered or by which it is otherwise bound.

“Data Treatment” means the access, collection, use, processing, storage, sharing, distribution, transfer, disclosure, security, destruction, or disposal of any personal, sensitive, health, or confidential information or data (whether in electronic or any other form or medium).

“Demutualization Statutes” has the meaning set forth in the recitals hereto.

“Director Benefit Provisions” has the meaning set forth in Section 5.5(g).

“Eligible Member” has the meaning given to such term in the Plan of Reorganization.

“Eligible Member Payment” has the meaning given to such term in the Plan of Reorganization.

“Enforceability Exceptions” means (i) any applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws of general applicability affecting creditors’ rights and remedies generally and (ii) general principles of equity.

“Environmental Law” has the meaning set forth in Section 2.17.

“ERISA” has the meaning set forth in Section 2.14(a).

“Estimated Closing Balance Sheet” has the meaning set forth in Section 1.6(a).

“Estimated Closing Indebtedness” means a good faith estimate by the Company of the Closing Indebtedness as of immediately prior to the Closing.

“Estimated Closing Statement” has the meaning set forth in Section 1.6(a).

“Estimated Closing Surplus” means a good faith estimate by the Company of the Closing Surplus.

“Estimated Company Transaction Expenses” means a good faith estimate by the Company of the Company Transaction Expenses as of immediately prior to the Closing.

“Estimated UTP Accrual” means a good faith estimate by the Company of the UTP Accrual as to a particular Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim immediately prior to the Closing.

“Event” has the meaning set forth in the definition of “Material Adverse Effect”.

“Extension Date” has the meaning set forth in Section 7.1(d).

“Final Foundation Amount” means an amount equal to (i) the Foundation Amount, plus (ii) the Closing Surplus (which may be a negative number), minus (iii) the Company Transaction Expenses to the extent not included in the calculation of the Closing Surplus, minus (iv) the Closing Indebtedness to the extent not included in the calculation of the Closing Surplus.

“Final Determination” means (i) an Order by any court of competent jurisdiction, which Order has become final after all allowable appeals by either party to the action have been exhausted, the time for filing such appeal has expired or the applicable party has no right to request an appeal, or (ii) a final and binding written settlement or compromise.

“Final Resolution” means, with respect to an Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim, any of the following (as applicable): (i) if in favor of the relevant Company Entity, the resolution of a particular Tax year by the relevant Taxing Authority at the administrative level (including the completion of all administrative level appeals made by the relevant Company Entity) if not subject to subsequent amendment by the Taxing Authority or (ii) if with respect to the prior payment of Tax refunds (or credits against Tax) that a Company Entity received (or claimed and reflected in a Tax Return) and for which the relevant Taxing Authority was entitled to subsequently challenge such receipt at the administrative level, the expiration of the statute of limitations for such challenge if no such challenge was made.

“Final Resolution Amount” means, with respect to an Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim, any of the following (as applicable): (i) the amount of any cash Tax refund received after the Closing Date by any of the Company Entities, net of the amount of any Taxes, penalties, interest or other fees or charges arising due to the entitlement to receive or the receipt of such Tax refund, related to the Final Resolution of a particular Tax year and Tax jurisdiction of the Outstanding Tax Refund and Credit Claim or the Corporate Income Tax Claim, including applicable interest and (ii) the amount that the relevant Company Entity may retain to the extent that such amount is included in the UTP Accrual (as finally scheduled pursuant to Section 1.7 of this Agreement) as a result of the Final Resolution of a particular Tax year and Tax jurisdiction.

“Financial Statements” has the meaning set forth in Section 2.9(a).

“Foundation” has the meaning set forth in the Preamble.

“Foundation Amount” means an amount equal to (i) the Base Purchase Price, minus (ii) the Eligible Member Payment.

“Foundation Indemnified Party” has the meaning set forth in Section 8.2(b).

“Fundamental Representations” means the representations and warranties set forth in the first and second sentences of Section 2.1, Section 2.3, Section 2.4, Section 2.5, Section 2.7(a) (solely with respect to Organizational Documents), Section 2.8 and Section 2.26.

“GAAP” means the generally accepted accounting principles of the United States of America consistently applied, as in effect from time to time.

“Governmental Authority” means: (i) any federal, state, local, municipal, foreign or international government or governmental authority, quasi-governmental entity of any kind, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private) or any body or subdivision exercising or entitled to exercise any administrative, executive, judicial, quasi-judicial, legislative, police, regulatory, or Taxing Authority or power of any nature, (ii) any self-regulatory organization or (iii) any political subdivision of any of the foregoing.

“Guaranteed Obligations” has the meaning set forth in Section 9.20.

“Hazardous Substances” means: (i) any substance, material or waste that is listed, classified or regulated under any Environmental Law, (ii) any petroleum product or by-product, asbestos or asbestos-containing material, lead-containing paint or plumbing, polychlorinated biphenyls, radioactive material,

urea formaldehyde, medical waste, per-and polyfluoroalkyl or related substances or radon or (iii) any other substance, material or waste that is or may become the subject of regulatory action, or for which liability or standards of conduct may be imposed, under any Environmental Law.

“Health Care Law Filings” has the meaning set forth in Section 2.23(e).

“Health Care Laws” means all Laws pertaining to health care legal or regulatory matters applicable to the Company Entities, including, to the extent applicable, but not limited to, all Laws relating to: (i) the licensure, certification, qualification or authority to transact business in connection with, or the operation of business in connection with, the provision of, payment for, or arrangement of, health care services, health benefits or health insurance, including Laws that regulate ACOs, Providers, Provider networks, medical centers or clinics, pharmacy services (including operating pharmacies, and the sale, distribution and delivery/transportation of controlled substances or prescription drugs), managed care, third-party payors and Persons bearing the financial risk for the provision or arrangement of health care services and, without limiting the generality of the foregoing, the Medicare Program Laws and Laws relating to Medicaid programs; (ii) the offer, solicitation, receipt or acceptance of improper inducements or incentives involving Persons operating in the health care industry, including Laws prohibiting or regulating fraud and abuse, patient referrals or Provider incentives generally, and including the following statutes: the Federal anti-kickback law (42 U.S.C. § 1320a-7b(b)), the Federal physician self-referral law (42 U.S.C. § 1395nn), the Federal False Claims Act (31 U.S.C. §§ 3729, *et seq.*), the Federal Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the Federal Program Fraud Civil Remedies Act (31 U.S.C. § 3801 *et seq.*) and any similar state Laws; (iii) the administration of health care claims or benefits for, or processing or payment for, health care services, treatment or supplies furnished by Providers, including such administration and processing or payment activities conducted by third-party administrators, utilization review agents and Persons performing quality assurance, credentialing or coordination of benefits; (iv) billings to insurance companies, health maintenance organizations and other managed care plans or Health Care Programs or otherwise related to insurance fraud; (v) the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended; (vi) the Health Insurance Portability and Accountability Act of 1996, as amended; (vii) any state or federal Laws governing the privacy, security, integrity, accuracy, transmission, breach notification, storage or other protection of information about or belonging to actual or prospective members or patients treated by the ACOs and their Providers, including the Privacy Laws; (viii) any state insurance, health maintenance organization or managed care Laws (including Laws relating to Medicaid programs) applicable to any of the Company’s Subsidiaries; (ix) the Medicare Program Laws; (x) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; (xi) the Medicare Improvements for Patients and Providers Act of 2008; (xii) ERISA; (xiii) the Patient Protection and Affordable Care Act (Pub. L. 111-148) as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152), and (xiv) the Medicare Shared Savings Program, 42 U.S.C. § 1395jjj, and the Next Generation ACO Model or any other Model of the Center for Medicare and Medicaid Innovation established pursuant to 42 U.S.C. § 1315a.

“Health Care Programs” means any health care program (as such term is defined in Section 1128B of the Social Security Act (42 U.S.C. §1320a-7b(f)) and 42 C.F.R. §1001.2), the Medicare Shared Savings Program (42 U.S.C. § 1395jjj) and the regulations applicable thereto, and the Next Generation ACO Model (42 U.S.C. § 1315a and the regulations applicable thereto), and any other health program, whether of a Governmental Authority, commercial plan, employer-sponsored plan, or private plan that provides health benefits directly, through insurance, or otherwise.

“HIPAA” means the Health Insurance Portability and Accountability Act of 1996, as amended from time to time, including by the Health Information Technology for Economic and Clinical Health Act (HITECH), and any rules or regulations adopted by the U.S. Department of Health and Human Service (HHS) implementing HIPAA.

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

“Indebtedness” means the unpaid principal amount of, and accrued or unpaid interest on, (i) all indebtedness or incurred in substitution or exchange for indebtedness for borrowed money by any or all of the Company Entities, (ii) indebtedness evidenced by any notes (including surplus notes), bonds, debentures, mortgages or other debt securities, debt instrument or similar instruments, (iii) indebtedness secured by a Lien on assets or properties of such Person (iv) obligations or commitments to repay deposits or other amounts advanced by and owing to any Person that is not a Company Entity, (v) indebtedness for the deferred purchase price of property, securities, assets or services, as obligor or otherwise, including all earn-out payments whether or not matured, seller notes and other similar payments (whether contingent or otherwise) (other than trade payables incurred in the Ordinary Course of Business), (iv) any obligations of the Company Entities owed under leases that are recorded as capital or finance leases in the Financial Statements or required by GAAP to be characterized as capital or financial leases, (v) any payment obligations under any commodity, swap, derivative, currency, interest rate, call, hedge, or similar agreement, (vi) to the extent drawn upon, obligations in respect of performance bonds, letters of credit, bankers’ acceptances or similar interests, (vii) any accrued nonqualified deferred compensation obligations as of the Closing that are owed or that are not cancelable by unilateral action of any Company Entity under agreements or arrangements existing as of the Closing, (viii) any deferred rent obligations, (ix) all indebtedness for the deferred purchase price or property or services, (x) any obligations of any kind referred to in clauses (i) to (ix) above guaranteed or secured, directly or indirectly, in any manner by the Company Entities, (xi) current unpaid Taxes of the Company Entities with respect to a Pre-Closing Tax Period, determined in accordance with Section 5.4(a) but also by excluding any Transfer Taxes as well as any other Taxes of the Company Entities attributable to the Reorganization, the payment or transfer, as applicable, of the Approved Excess Surplus to the Foundation, or any other of the Transactions, (xii) all principal, interest, premiums, penalties, pre-payment penalties, fees, costs, expenses, indemnities, and breakage costs to the extent associated with any of the foregoing, (xiii) without duplication of any amounts included in Company Transaction Expenses, any Taxes deferred pursuant to the CARES Act or the Presidential Memorandum Deferring Payroll Tax Obligations dated August 8, 2020, including the employer portion of any payroll, social security or unemployment Taxes, and (xiv) any Transfer Taxes arising in connection with the Transactions, including the Reorganization.

“Indemnifiable Losses” means (i) with respect to Purchaser, all Member Proceeding Indemnifiable Losses for which a Purchaser Indemnified Party may be entitled to indemnification pursuant to Section 8.2(a) and all other Losses for which a Purchaser Indemnified Party may be entitled to indemnification pursuant to Section 8.3, and (ii) with respect to the Foundation, all Member Proceeding Indemnifiable Losses for which a Foundation Indemnified Party may be entitled to indemnification pursuant to Section 8.2(b).

“Indemnified Party” means either one or more of the Purchaser Indemnified Parties or Foundation Indemnified Parties, as applicable.

“Indemnifying Party” has the meaning set forth in Section 8.2(a) and (b), as applicable.

“Independent Accountant” has the meaning set forth in Section 1.7(c)(i).

“Information Statement” has the meaning set forth in Section 4.6(a)(i).

“Insurance Laws” has the meaning set forth in Section 2.22(a).

“Insurance Policies” has the meaning set forth in Section 2.21.

“Intellectual Property” means any and all intellectual or industrial property and rights, title and interests therein and thereto in any jurisdiction throughout the world, including: (i) patents, patent

applications and statutory invention registrations, and inventions and all improvements thereto (whether or not patentable or reduced to practice) and all reissues, continuations, continuation in part, revisions, divisional, substitutions, provisionals, renewals, extensions, and reexaminations in connection therewith (collectively, “Patents”); (ii) pending or registered trademarks, service marks, trade dress, corporate or trade names, designs, logos, slogans and other indicia of source, and all registrations, applications, and renewals in connection therewith (together with the goodwill associated therewith) (collectively, “Trademarks”); (iii) domain names, uniform resource locators, social media usernames, accounts, identifiers and handles; (iv) registered and unregistered copyrights, mask works, and all works of authorship (whether or not copyrightable), and all registrations, applications, and renewals in connection therewith (collectively, “Copyrights”); (v) trade secrets, know-how, technologies, databases, processes, techniques, protocols, methods, improvements, formulas, algorithms, technical information, proprietary information, customer and supplier lists, pricing and cost information, business and marketing plans, invention disclosures and confidential information (collectively, “Trade Secrets”); (vi) rights in Software and related technology; (vii) moral and economic rights; (viii) rights of privacy and publicity and in social media usernames, accounts, and handles; (ix) all other forms of intellectual property recognized under applicable Law; and (x) all rights relating to any of the foregoing, including all causes of action, judgments, settlements, claims and demands related thereto, and rights to prosecute and recover damages for any past, present or future infringements, dilutions, misappropriations and other violations thereof.

“Intended Tax Treatment” has the meaning set forth in Section 5.4(c).

“IRS” means the United States Internal Revenue Service.

“Knowledge” means (i) in the case of the Company, the actual knowledge of I. Steven Udvarhelyi, Darrell Langlois, Adam Short, Bryan Camerlinck, Mary Saporito, Korey Harvey, and Michele Calandro, after such inquiry as such individuals would normally conduct in the ordinary course of their duties to the Company, and (ii) in the case of Purchaser, the actual knowledge of Blair Todt, Kyle Weber, Bryony Winn, Gail Boudreaux, Pamela Williams, and Bryant Aaron in each case after such inquiry as such individuals would normally conduct in the ordinary course of their duties to Purchaser.

“LA Form A Filing” has the meaning set forth in Section 4.5(b).

“Law” means any federal, state, local, municipal, foreign or other law, statute, regulation, code, ordinance, rule, constitution, treaty, convention, principle of common law, edict, ruling, requirement or ordinance issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority, and any Orders.

“LDI Approval” means the final order or decision issued by the Commissioner pursuant to §236.4 of the Louisiana Insurance Code (LSA-R.S. 22:236.4), approving the LDI Filing and the Plan of Reorganization.

“LDI Filing” has the meaning set forth in Section 4.5(b).

“Leased Real Property” has the meaning set forth in Section 2.19(b).

“Liability” means any and all Indebtedness, liabilities and obligations, whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured or determined or determinable, including any liabilities for Taxes.

“Licensed Intellectual Property” means all Intellectual Property that is owned by any Person that is not a Company Entity and licensed or sublicensed to any Company Entity and used in its respective business, as the case may be, pursuant to a Material Contract.

“Liens” means any mortgages, deeds of trust, hypothecations, charges, licenses, liens, pledges, security interests, claims, options, rights of first offer or refusal, easements, encumbrances, leases, preemptive rights, grants, charges or other encumbrances or title defects in respect of any property or asset.

“Look-Back Date” means January 1, 2020.

“Loss” or “Losses” means, without duplication, all assessments, losses, penalties, fines, damages, Liabilities, Taxes, debts, charges, costs or expenses, including interest, and court costs and reasonable and documented attorneys’ fees, costs and expenses reasonably incurred in connection with the defense of any matter, or the investigation of any matter, whether or not relating to any matter for which any indemnity obligation is payable, or with respect to asserting or enforcing its Rights under this Agreement; provided, however, that in no event shall “Losses” include any special damages, consequential damages, lost profits, any costs or expenses for the procurement of substitute services, or any other indirect damages, whether arising in contract, tort (including negligence) or otherwise, even if the possibility thereof may be known in advance to one or more parties.

“Louisiana Insurance Code” shall mean Title 22 of the Louisiana Revised Statutes (LSA-R.S. 22:1 *et seq.*), and the rules, regulations, judgments, Orders, rulings, opinions, and guidance promulgated thereunder.

“Marketable Securities” means any securities that are (a) of a class that are traded on an established securities exchange, reported through an established over-the-counter trading system or otherwise traded over-the-counter and (b) freely tradeable (as defined below); and “Marketable Securities” shall include, for the avoidance of doubt, corporate and government bonds. “Freely tradeable” for this purpose shall mean securities that are not subject to any contractual restrictions on transfer and that are transferable pursuant to applicable securities Laws.

“Material Adverse Effect” means any event, fact, change, occurrence, action, development or effect (collectively, “Events”) that, individually or in the aggregate, has had or would reasonably be expected to have a material and adverse effect upon (a) the business, assets, results of operations or condition (financial or otherwise) of the Company Entities, taken as a whole, or (b) the ability of the Company to perform its obligations under this Agreement or consummate the Transactions; provided, that, for the purposes of clause (a) only, none of the following shall in and of itself constitute, and no Event resulting solely from any of the following shall constitute, a Material Adverse Effect: (i) general business, industry or economic conditions (or changes in such conditions) related to the business of the Company Entities or the industry in which the Company Entities operate, or conditions in the global economy generally, (ii) national or international political or social conditions (or changes in such conditions), including the engagement by the United States or any other country or group in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack or other acts of war, sabotage or terrorism, including any cyberattacks (including any escalation or general worsening of any such acts of war, sabotage or terrorism) upon the United States or any other country, or any of their respective territories, possessions, or diplomatic or consular offices or upon any military installation, equipment or personnel of the United States or any other country or group, (iii) changes (or proposed changes) in GAAP or other accounting standards or the interpretations thereof occurring after the date hereof, (iv) changes (or proposed changes) in Law (or the interpretation thereof) occurring after the date hereof, (v) compliance by Parent or any of its controlled Affiliates with Parent’s obligations, agreements and covenants contained in, or the taking of any action required by, this Agreement, or the failure to take any action prohibited by this Agreement, (vi) general conditions (or changes in such conditions) in the securities markets, capital markets, credit markets, currency markets or other financial markets in the United States or any other country or region in the world, including (A) changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and (B) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on

any securities exchange or over-the-counter market operating in the United States or any other country or region in the world, (vii) any “act of God,” including, but not limited to, weather, natural disasters, earthquakes, epidemics, pandemics or disease outbreaks (including COVID-19), hurricanes, tsunamis, tornadoes, floods, mudslides, and wild fires in the United States or any other country or region in the world, (viii) the announcement of the execution of this Agreement or the Transactions or the pendency thereof, or (ix) the failure of the Company Entities to meet or achieve the results set forth in any internal projection or forecast; provided, that this clause (ix) shall not prevent a determination that any change or effect underlying such failure to meet projections or forecasts has resulted in a Material Adverse Effect (to the extent such change or effect is not otherwise excluded from this definition of Material Adverse Effect). Notwithstanding the foregoing, solely to the extent any matter described in clauses (i), (ii), (iii), (iv), (vi) and (vii) of this paragraph has or would reasonably be expected to have a disproportionate effect on the businesses, assets, operations, condition (financial or otherwise) or operating results of the Company Entities, taken as a whole, relative to other participants in the industry, markets or geographical areas in which the Company Entities conduct their respective businesses, then the impact of such matter shall be taken into account for the purposes of determining whether a Material Adverse Effect has occurred. Notwithstanding anything to the contrary set forth above and for the avoidance of doubt, a Member Proceeding or any Proceeding made or brought by any former or current Member or other interested Person seeking to enjoin the Transactions shall not constitute a Material Adverse Effect.

“Material Contracts” has the meaning set forth in Section 2.13.

“Medicare Program Laws” means Title XVIII of the Social Security Act as well as any final rules and final regulations adopted pursuant to such Act (including Parts 422, 423 and 425 of Title 42 of the Code of Federal Regulations), any memoranda, written directives, instructions, guidelines, bulletins, manuals, requirements, policies, standards and frequently asked questions issued by CMS pursuant to such Act, and the terms of any Contract between CMS and the Company Entities.

“Member” has the meaning given to such term in the Plan of Reorganization.

“Member Approval” means the approval of the Plan of Reorganization by no less than two-thirds of the Qualified Voters at the Special Meeting pursuant to § 236.5 of the Louisiana Insurance Code (LSA-R.S. 22:236.5) and subject to the quorum and other requirements set forth in the Louisiana Insurance Code.

“Member Proceeding” means any claim, action, suit, charge, complaint, demand, petition or litigation of any former or current Member of the Company or other interested Person that alleges or asserts that such Member is entitled to any payment or additional consideration in connection with the Reorganization or the other Transactions that is not expressly provided for in this Agreement or the Plan of Reorganization, irrespective of the legal theory upon which such alleged entitlement is predicated.

“Member Proceeding Indemnifiable Losses” means, without duplication, all assessments, penalties, fines, damages and judgments resulting from a Final Determination with respect to a Member Proceeding, and all related court costs and reasonable and documented attorneys’ and expert witness fees, costs and expenses reasonably incurred with respect thereto, to the extent such amounts constitute a direct payment by or payment obligation of an Indemnified Party to any unaffiliated third party; provided, however, that in no event shall “Member Proceeding Indemnifiable Losses” include any special damages, consequential damages, lost profits, any costs or expenses for the procurement of substitute services, or any other indirect damages, whether arising in contract, tort (including negligence) or otherwise, even if the possibility thereof may be known in advance to one or more parties.

“Member Proceeding Indemnification Cap” means an amount equal to (i) the sum of (A) the Approved Excess Surplus plus (B) the Closing Surplus, each as finally determined in accordance with Section 1.7, minus (ii) the Eligible Member Payment.

“Minimum Annual Bonus” has the meaning set forth in Section 5.5(d).

“Minimum Regulatory Capital” means 375% of the authorized control level risk based capital of the Company as of the Closing Date prepared in accordance with the risk based capital formula for health insurance organizations as prescribed by the NAIC, utilizing inputs from the Estimated Closing Balance Sheet and the financial results from the 12 calendar months immediately preceding the Closing Date calculated in accordance with SAP applied on a basis consistent with the preparation of the audited Financial Statements and statutory reporting with the applicable domiciliary insurance Governmental Authorities to the extent not inconsistent with SAP.

“Morgan Lewis” has the meaning set forth in Section 9.21.

“MSSP ACOs” has the meaning set forth in Section 2.23(j).

“Mutual Termination Fee” has the meaning set forth in Section 7.3(b).

“New Plans” has the meaning set forth in Section 5.5(a).

“Nondisclosure Agreement” means that certain Nondisclosure Agreement by and between the Company and Parent, dated May 3, 2021.

“Note” has the meaning set forth in the recitals hereto.

“Note Amount” means an amount equal to the Closing Foundation Amount.

“OFAC” means the U.S. Department of the Treasury Office of Foreign Assets Control.

“Officers” means any employees of the Company Entities with the following management-levels as indicated in the employee census provided by the Company to Purchaser prior to the date hereof: Chief Executive Officer, Executive Vice President, Senior Vice President, and Vice President.

“Opelousas Settlement” means the Final Order and Judgment, dated December 21, 2022, issued by the 27th Judicial District Court for the Parish of St. Landry, regarding the matter Opelousas General Hospital Authority, a Public Trust, d/b/a Opelousas General Health System versus Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana.

“Open Source Software” means any Software that is licensed pursuant to: (i) any license that is a license now or in the future approved by the Open Source Initiative and listed at <http://www.opensource.org/licenses>, which licenses include all versions of the GNU General Public License (GPL), the GNU Lesser General Public License (LGPL), the GNU Affero GPL, the MIT license, the Eclipse Public License, the Common Public License, the CDDL, the Mozilla Public License (MPL), the Artistic License, the Netscape Public License, the Sun Community Source License (SCSL), and the Sun Industry Standards License (SISL); or (ii) any license to Software that is considered “free” or “open source software” by the Open Source Foundation or the Free Software Foundation.

“Orders” means any orders, decisions, judgments, writs, injunctions, decrees, awards, rulings, verdicts, sentences, stipulations, determinations, settlement agreements, deferred prosecution agreements, corporate integrity agreements, binding agreements, or assessments issued, promulgated, made, rendered or entered or otherwise put into effect by, with or under the authority of any Governmental Authority (including any judicial or administrative interpretations, guidance, directives, policy statements or opinions with respect thereto).

“Ordinary Course of Business” means, with respect to any Person, the ordinary course of the operations of such Person that is consistent with the past practices of such Person.

“Organizational Documents” means, with respect to any Person that is an entity, whether or not written, such Person’s organizational documents, including the certificate of organization, incorporation or partnership, bylaws, operating agreement or partnership agreement, joint venture and trust agreements, and any similar governing documents of any such Person and any amendment to any of the foregoing.

“Outstanding Tax Refund and Credit Claim” (i) means each claim that the Company is entitled to a potential refund of Federal income Tax or credits against Tax (including, for the avoidance of doubt, a credit that offsets U.S. Federal income Tax liability or a direct cash refund and including any interest received as a refund or credit) related to or arising from the amendment of the Company’s U.S. Federal income Tax Returns for Tax years 2015, 2016, and 2017 (as reduced by the amount of Federal income Tax benefit agreed to by the IRS exam related to Tax years 2015 and 2016) with respect to claiming a deduction under Section 833(b) of the Code on any such U.S. Federal income Tax Return and (ii) further includes any additional Taxes (including, for the avoidance of doubt, any penalties and interest related thereto) that may be owed by any of the Company Entities with respect to or arising from the Company’s U.S. Federal income Tax Returns for Tax years 2013 (as amended), 2018, and 2019 with respect to (x) claiming a deduction under Section 833(b) of the Code on any such U.S. Federal income Tax Return or (y) utilization of Tax credits or other tax attributes generated by the Tax Returns identified in this definition.

“Owned Intellectual Property” means any and all Intellectual Property that is owned (or purported to be owned), in whole or in part, by any Company Entity, and includes all Company Software.

“Owned Real Property” has the meaning set forth in Section 2.19(a).

“Parent” has the meaning set forth in the Preamble.

“Party” has the meaning set forth in the Preamble.

“Patents” has the meaning set forth in the definition of “Intellectual Property”.

“Paying Agent” means a paying agent mutually agreed to by the Parties prior to Closing, who shall serve as paying agent pursuant to the terms of the Paying Agent Agreement.

“Paying Agent Agreement” means a paying agent agreement to be entered into by and among Purchaser, the Company and the Paying Agent, in the form mutually agreed to by the Parties prior to Closing.

“Permits” has the meaning set forth in Section 2.20(a).

“Permitted Lien” means (i) such non-monetary Liens or other imperfections of title, if any, that do not impair in any material respect the current use of the applicable asset, including (A) easements, overlaps, encroachments and any matters of record that, individually or in the aggregate, do not impair in any material respect the use or occupancy of any Real Property and (B) title to any portion of the premises lying within the right of way or boundary of any public road or private road, (ii) Liens imposed or promulgated by Laws with respect to real property and improvements, including zoning regulations, in each case that, individually or in the aggregate, do not interfere in any material respect with or otherwise or impair in any material respect the use or occupancy of title of the real property subject thereto, (iii) non-monetary Liens disclosed on existing title insurance policies, title reports or existing surveys which have (together with all documents creating or evidencing such Liens) been delivered to Purchaser and which do not or would not materially impair the use or occupancy of such Real Property in the operation of the business of any Company Entity conducted therein, (iv) mechanics’, carriers’, workmen’s, repairmen’s and similar Liens incurred in the Ordinary Course of Business for amounts not yet due and payable or which are being contested in good faith by appropriate proceedings and for which appropriate reserves have been established and are being maintained in accordance with GAAP, (v) in the case of Leased Real Property, any Lien to which the fee or any other interest of the landlord in the Leased Real Property is subject, (vi) end user agreements that

grant non-exclusive licenses of Company Software to end users in the Ordinary Course of Business on terms in all material respects the same as the form end user Contracts that have been previously provided to Purchaser, and (vii) restrictions on transfer under applicable Securities Laws.

“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated association, corporation, limited liability company, entity or Governmental Authority.

“Plan of Reorganization” means the Proposed Plan of Reorganization, as the same may be amended or modified in accordance with its terms, and finally approved pursuant to the LDI Approval.

“PLR Request Submission” means, collectively, the private letter ruling requests to be submitted to the IRS by each of Parent and the Company (including all attachments, addendums, supplemental submissions and similar materials and documents related thereto, whether submitted along with the initial submission to the IRS or submitted at a later time) with respect to certain U.S. federal income Tax consequences related to the Transactions and that are to be prepared a manner consistent with that certain “Pre-Submission Memorandum Pertaining to Request by Elevance Health, Inc. for a Private Letter Ruling” submitted to the IRS on October 7, 2022 jointly by Parent and the Company with respect to the Transactions and as informed by the subsequent presubmission conference held with the IRS and representatives of Parent and the Company on October 20, 2022.

“Post-Closing Tax Periods” means all taxable years or other taxable periods beginning after the Closing Date and the portion of any Straddle Period beginning after the Closing Date.

“Pre-Closing Tax Period” shall mean all taxable years or other taxable periods that end on or before the Closing Date and, with respect to any Straddle Period, the portion of such Straddle Period ending on and including the Closing Date.

“Privacy Laws” means all applicable Laws pertaining to data protection, data privacy, data security, data breach notification, and cross-border data transfer, including without limitation HIPAA; the Health Information Technology Standards, Implementation Specifications, and Certification Criteria and Certification Programs for Health Information Technology, 45 C.F.R. Part 170; the 21st Century Cures Act and the information blocking regulations thereunder at 45 C.F.R. Part 171; the CAN-SPAM Act of 2003, 15 U.S.C. § 7701, *et seq.*; the Telephone Consumer Protection Act, 47 U.S.C. § 227, *et seq.*; the Fair Credit Reporting Act, 15 U.S.C. § 1681, *et seq.*; the Electronic Communications Privacy Act, 18 U.S.C. §§ 2510-22; the Stored Communications Act, 18 U.S.C. §§ 2701-12, *et seq.*; U.S. state and federal Laws that prohibit unfair or deceptive acts and practices, such as the Federal Trade Commission Act, 15 U.S.C. § 45, *et seq.*; and all other Laws and binding regulations relating to data protection, information security, cybercrime, cybersecurity incident notification, social security number protection, outbound communications and/or electronic marketing, use of electronic data and privacy matters (including online privacy) in any applicable jurisdictions.

“Proceeding” means any claim, action, suit, charge, complaint, demand, petition, litigation, arbitration or mediation, inquiry, investigation, audit, proceeding, prosecution or hearing (including any civil, criminal, administrative, or appellate proceeding, at law or in equity, public or private).

“Proposed Plan of Reorganization” means the Plan of Reorganization pursuant to which the Company shall reorganize from a mutual insurance company to a stock insurance company as adopted by not less than two-thirds of the entire Company Board on or prior to the date hereof in the form attached hereto as Exhibit B.

“Providers” means, collectively, all physicians, physician or medical groups, independent practice associations, preferred provider organizations, exclusive provider organizations, specialist physicians, dentists, optometrists, audiologists, pharmacies and pharmacists, radiologists or radiology centers,

laboratories, mental health professionals, chiropractors, physical therapists, nurses, nurse practitioners, physician's assistants, any hospitals, skilled nursing facilities, extended care facilities, community health centers, surgicenters, accountable care organizations, other health care or services facilities, durable medical equipment suppliers, opticians, home health agencies, alcoholism or drug abuse centers and any other specialty, ancillary or allied medical, health or wellness professional, facility or supplier that furnishes health care items or services.

“Public Hearing” means the public hearing(s) to be convened by the Commissioner and the LDI to hear evidence concerning the Reorganization and the Plan of Reorganization in accordance with §236.4 of the Louisiana Insurance Code (LSA-R.S. 22:236.4).

“Purchaser” has the meaning set forth in the Preamble.

“Purchaser Indemnified Party” has the meaning set forth in Section 8.2(a).

“Purchaser Related Parties” has the meaning set forth in Section 9.21.

“Purchaser Termination Fee” has the meaning set forth in Section 7.3(c).

“Qualified Voters” means the Members of the Company eligible to vote at the Special Meeting in accordance with the Plan of Reorganization.

“Real Property” means the Owned Real Property and the Leased Real Property.

“Real Property Leases” has the meaning set forth in Section 2.19(b).

“Regulated Entities” has the meaning set forth in Section 2.22(a).

“Regulated Entity Statements” has the meaning set forth in Section 2.9(b).

“Related Agreements” means the Plan of Reorganization, the Paying Agent Agreement and each of the other documents, certificates and instruments to be delivered hereunder or thereunder.

“Reorganization” has the meaning set forth in the recitals hereto.

“Representative” means, with respect to any Person, any director, officer, manager, member, direct or indirect equityholder, partner (whether limited or general), principal, attorney, employee, agent, advisor, consultant, accountant, or any other Person acting in a representative capacity for such Person, and, with respect to the Company at any time prior to Closing, shall include the Foundation.

“Required Approval” means each of the approvals, consents and waivers, and the expiration or termination of all statutory waiting periods in respect thereof, of Governmental Authorities and Third Parties required to consummate the Transactions that are set forth in Schedule 2.

“Retiree Benefit Obligations” means the aggregate amount of accrued benefit obligations under the Louisiana Health Service and Indemnity Company Postretirement Benefit Program, the Louisiana Health Service and Indemnity Company Supplemental Retirement Program for PJ Mills, and any other post-retirement health and welfare benefit obligations of the Company Entities, excluding coverage mandated by COBRA or Section 4980B of the Code, or any similar state group health plan continuation Law or that otherwise accrues after the Closing.

“Rights” means any rights, title, interest or benefit of whatever kind or nature.

“Sanctioned Country” means any country or region that is, or has been in the last five years, the target of a comprehensive embargo under Sanctions Laws (namely, Cuba, Iran, North Korea, Syria,

Venezuela, the Crimea region of Ukraine and the so-called Donetsk Republic and Luhansk People's Republic region of Ukraine).

“Sanctioned Person” means any Person that is the target of sanctions or restrictions under Sanctions Laws, including: (i) any Person listed on any applicable U.S. or non-U.S. sanctions restricted party list, including the OFAC Specially Designated Nationals and Blocked Persons List; (ii) any entity that is, in the aggregate, 50% or greater owned, directly or indirectly, or otherwise controlled by a Person or Persons described in clause (i); or (iii) any Person resident, based or organized in a Sanctioned Country.

“Sanctions Laws” means all Laws relating to economic or trade sanctions administered or enforced by the United States (including by OFAC or the U.S. Department of State), Canada, the European Union, Her Majesty's Treasury or the United Nations Security Council.

“SAP” means statutory accounting principles as set forth by the NAIC as applied by the appropriate insurance Governmental Authorities of the jurisdiction in which the relevant entity is domiciled or commercially domiciled.

“SAP Statements” has the meaning set forth in Section 2.22(a).

“Securities” has the meaning set forth in Section 2.8(c).

“Securities Laws” means securities Laws of any state, federal or national entity, whether domestic or foreign, and the rules and regulations promulgated thereunder, including the Securities Act of 1933, the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Investment Company Act of 1940, the Investment Advisers Act of 1940, Title V of the Gramm-Leach-Bliley Act.

“Security Audit” has the meaning set forth in Section 4.2(a).

“Security Auditor” has the meaning set forth in Section 4.2(a).

“Software” means any and all computer software (in object code, source code, firmware or other format) and databases, and related documentation and materials, including (a) software, compilers, middleware, tools, firmware, operating systems and specifications, platforms, algorithms, heuristics, interfaces, APIs, modules, test specifications and scripts, source code and object code, (b) databases and other data collections, and (c) all versions, updates, releases, patches, corrections, enhancements and modifications thereto and all documentation, developer notes, instructions, comments and annotations related to any of the foregoing; including all cloud and Software-as-a-Service based offerings.

“Sole Recourse Waiver” has the meaning set forth in Section 8.10.

“Special Meeting” means the meeting of the Qualified Voters convened in accordance with the Louisiana Insurance Code, the Amended and Restated Articles of Incorporation of the Company and the Amended and Restated Bylaws of the Company for the purposes of obtaining the Member Approval.

“Statutory Capital” means the admitted assets over the liabilities of the Company, prepared in accordance with SAP applied on a basis consistent with the preparation of the audited Financial Statements and statutory reporting with the applicable domiciliary insurance Governmental Authorities to the extent not inconsistent with SAP, as illustrated on Schedule 1. Statutory Capital will be adjusted to the extent that the net admitted deferred Tax asset (after taking into account deferred Tax liabilities) is greater than zero.

“Straddle Period” means any taxable year or other taxable period beginning on or before and ending after the Closing Date.

“Subsidiary” means, with respect to any Person, any partnership, limited liability company, corporation or other business entity of which (i) if a corporation, a majority of the total voting power of

shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a partnership, limited liability company or other business entity, a majority of the partnership, limited liability company or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a partnership, limited liability company or other business entity if such Person or Persons shall be allocated a majority of partnership, limited liability company or other business entity gains or losses or shall be or control the managing director or general partner of such partnership, limited liability company or other business entity.

“Superior Proposal” means a bona fide written proposal made to the Company by any Third Party which did not result from a breach of Section 4.4 with respect to any Alternative Transaction, (a) that is on terms that the Company Board determines in good faith (after consultation with its financial advisors and outside legal counsel) would result in a transaction that, if consummated, is (i) more favorable to the Eligible Members, as a group, and (ii) no less favorable to the Foundation, in each case of (i) and (ii), from a financial point of view, than the Transactions and this Agreement (taking into account any proposal by Purchaser to amend the terms of this Agreement), (b) with respect to which the cash consideration and other amounts (including costs associated with the proposed acquisition) payable at closing are subject to fully committed financing from recognized financial institutions, and (c) which is reasonably likely to receive all required governmental approvals, including by the LDI and the Qualified Voters, on a timely basis and otherwise reasonably capable of being completed within a reasonable period of time on the terms proposed, taking into account all financial, regulatory, legal and other aspects of such proposal, as is the Transactions and this Agreement.

“Tax” or “Taxes” means any and all federal, state, local or non-U.S. taxes, levies, fees, imposts, duties, and other similar governmental charges (including any interest, fines, assessments, penalties or additions to tax imposed in connection therewith or with respect thereto), whether payable directly or by withholding, whether or not requiring the filing of a Tax Return, whether disputed or not, and however denominated, including (i) taxes imposed on, or measured by, income, franchise, profits or gross receipts and (ii) ad valorem, alternative or add-on minimum, value added, capital gains, sales, goods and services, use, real or personal property, capital stock, license, branch, payroll, estimated, withholding, employment, social security (or similar), unemployment compensation, utility, severance, production, excise, stamp, occupation, disability, premium, windfall profits, transfer and gains taxes, escheat, unclaimed property, environmental, and customs duties.

“Tax Benefit” shall mean any reduction in any cash Tax liability for any given taxable year as a result of an Indemnifiable Loss equal to the positive difference, if any, between: (i) the applicable Tax Benefit Party’s liability for Taxes payable in the relevant taxable year computed not taking into account such Indemnifiable Loss; and (ii) the applicable Tax Benefit Party’s liability for Taxes payable in the relevant taxable year computed taking into account the Indemnifiable Loss.

“Tax Benefit Party” has the meaning set forth in Section 8.8.

“Taxing Authority” means a Governmental Authority charged with the administration of Taxes.

“Tax Purposes” has the meaning set forth in Section 5.4(c).

“Tax Returns” means any and all reports, returns, declarations, claims for refund, elections, disclosures, forms, estimates, information reports or returns or statements, including any other documents or amendments thereto, relating to the determination, assessment or collection of any Tax, filed or required

to be filed with any Governmental Authority in connection with Taxes, including any schedule or attachment thereto or amendment thereof.

“Termination Date” has the meaning set forth in Section 7.1(d).

“Termination Fee” means, as applicable, the Company Termination Fee, the Purchaser Termination Fee and/or the Mutual Termination Fee.

“Third Party” means any Person other than the Company, Purchaser, or any of their respective Subsidiaries or Affiliates.

“Total UTP Accrual” means the sum of all UTP Accruals as set forth in the Estimated Closing Balance Sheet and then finalized on the Closing Balance Sheet and scheduled hereto pursuant to Section 1.6 and Section 1.7, respectively, but calculated in the case of a Corporate Income Tax Claim by removing the offset for the deductibility of state and local income Taxes against Federal income Taxes. For the avoidance of doubt, the Total UTP Accrual shall be as finalized on the schedule prepared pursuant to Section 1.7 of this Agreement.

“Trade Control Laws” means all U.S. and non-U.S. Laws relating to (i) economic, trade, and financial sanctions, including, without limitation, those administered and enforced by the U.S. Department of Treasury’s Office of Foreign Asset Controls, the U.S. Department of State, and the United Nations; (ii) export, import, re-export, transfer, and retransfer controls, including, without limitation, the Export Administration Regulations, the International Traffic in Arms Regulations, the EU Dual-Use Regulation (Council Regulation (EC) No 428/2009, as amended) and the customs and import Laws administered by U.S. Customs and Border Protection; and (iii) U.S. anti-boycott requirements administered by the U.S. Department of Commerce and the U.S. Internal Revenue Service.

“Trade Secrets” has the meaning set forth in the definition of “Intellectual Property”.

“Trademarks” has the meaning set forth in the definition of “Intellectual Property”.

“Transaction Tax Claim” has the meaning set forth in Section 8.3(a).

“Transfer Taxes” has the meaning set forth in Section 5.4(b).

“Treasury Regulations” means the income Tax regulations, including temporary and proposed regulations, promulgated under the Code by the United States Treasury Department.

“UTP Accrual” means, for each Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim, the amount established as a net liability reserve pursuant to ASC 740-10 in the Financial Statements, as updated on the Estimated Closing Balance Sheet and then finalized on the Closing Balance Sheet (as estimated with respect to 11:59 p.m. on the Closing Date) and scheduled hereto pursuant to Section 1.6 and Section 1.7, respectively (including, for the avoidance of doubt, a reasonable estimate of any anticipated interest and penalties), related to such Outstanding Tax Refund and Credit Claim or Corporate Income Tax Claim.

“WARN Act” means the Worker Adjustment and Retraining Notification Act.

[Signature pages follow.]

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above-written.

ELEVANCE HEALTH, INC.

DocuSigned by:
By: John E. Gallina
Name: John E. Gallina
Title: Executive Vice President and Chief Financial Officer

ATH HOLDING COMPANY, LLC

DocuSigned by:
By: John E. Gallina
Name: John E. Gallina
Title: President

THE ACCELERATE LOUISIANA INITIATIVE, INC.

By: _____
Name:
Title:

LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY

By: _____
Name:
Title:

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above-written.

ELEVANCE HEALTH, INC.

By: _____
Name:
Title:

ATH HOLDING COMPANY, LLC

By: _____
Name:
Title:

**THE ACCELERATE LOUISIANA
INITIATIVE, INC.**

By: 
Name: Thomas A. Barfield, Jr.
Title: President

**LOUISIANA HEALTH SERVICE &
INDEMNITY COMPANY**

By: _____
Name:
Title:

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above-written.

ELEVANCE HEALTH, INC.

By: _____
Name:
Title:


ATH HOLDING COMPANY, LLC

By: _____
Name:
Title:

**THE ACCELERATE LOUISIANA
INITIATIVE, INC.**

By: _____
Name:
Title:

**LOUISIANA HEALTH SERVICE &
INDEMNITY COMPANY**

By: 
Name: I. Steven Udvarhelyi, M.D.
Title: President and Chief Executive
Officer

Schedule 1

Statutory Capital Schedule

See attached.

Schedule 1
Statutory Capital Schedule

	LHSIC
Total adjusted capital 12/31/2019	1,453,804,266
2020 net income	122,797,820
Change in net unrealized capital gains (losses) less capital gains tax	75,166,960
Change in net deferred income tax	15,690,940
Change in nonadmitted assets	4,885,990
Aggregate write-ins for gains or (losses) in surplus	44,860,766
Total adjusted capital 12/31/2020	1,717,206,742
2021 net income	81,677,894
Change in net unrealized capital gains (losses) less capital gains tax	26,510,088
Change in net deferred income tax	3,632,553
Change in nonadmitted assets	(6,801,397)
Aggregate write-ins for gains or (losses) in surplus	(3,955,152)
Total adjusted capital 12/31/2021	1,818,270,728
2022 net income thru 9/30/2022	(32,745,409)
Change in net unrealized capital gains (losses) less capital gains tax	(157,253,917)
Change in net deferred income tax	27,079,836
Change in nonadmitted assets	(5,734,207)
Aggregate write-ins for gains or (losses) in surplus	(5,712,243)
Total adjusted capital 9/30/2022	1,643,904,788
Authorized Control Level	\$192,663,662
500% RBC	500% \$963,318,310
375% RBC	375% \$722,488,733
Approved Excess Surplus	680,586,478
Estimated Closing Surplus	240,829,578
<u>UTP Accruals</u>	
Federal UTP Accrual	- 209,699,741
State UTP Accrual	- 7,507,220

Schedule 2

Required Approvals

1. The Antitrust Filings.
2. The LDI Approval.
3. The LA Form A Filing.
4. Approval by the Louisiana Commissioner of Insurance of the Pre-acquisition Notification/Form E Exemption Request Letter.
5. Approval by the Arkansas Commissioner of Insurance of the Application for Change of Control of a Domiciled Insurer
6. Approval by the Mississippi Commissioner of Insurance of the Application for Change of Control of a Domiciled Insurer.
7. Approval by the Arkansas Commissioner of Insurance of the Pre-acquisition Notification/Form E Exemption Request Letter.
8. Approval by the Mississippi Commissioner of Insurance of the Pre-acquisition Notification/Form E Exemption Request Letter
9. Approval by the Blue Cross and Blue Shield Association Board of Directors of the Application for Larger Controlled Affiliate.

Schedule 3

Commitments

1. Local Plan President – Local Plan President to be appointed by the Board of Directors of the Company subject to Parent approval.
2. Local employment levels – Parent and Purchaser commit to maintaining average aggregate employment levels in Louisiana at or above current employment levels for 2 years, which shall include offering future employment opportunities for open positions at Parent that can be based in Louisiana or fully remote, offering greater room for growth for the Company’s employees.
3. Center of Excellence – Parent and Purchaser commit to exploring the establishment of a Center of Excellence (e.g., MSO, analytics) in Louisiana that serves Parent corporate-wide and addresses local needs.
4. Whole Health Capabilities – Parent and Purchaser will commit to explore the development of specific Whole Health capabilities (to be specified) in Louisiana within the next 1-2 years (except for PBM which will take longer). Additionally, the Company will be provided the reasonable opportunity to deploy future capabilities according to local market need and timing.
5. Post-Transaction Advisory Board – Establishing an advisory board of the Board of Directors of the Company (the “Advisory Board”) with an agreed upon charter (the “Advisory Board Charter”) substantially in the form attached hereto as Exhibit E specifying duration, governance, responsibilities, etc. Such Advisory Board is to be comprised of Louisiana residents and provide the Company with advice, support and insight on matters relating to the Company’s business and operations in Louisiana, including monitoring integration with Purchaser and its enterprise-wide operations.
6. Operating Model – Commitment to proposed operational destination and timeline that enables scaled operations, increased competitiveness in Medicare Advantage and ASO and proposed unique management structure, providing strong local market with key leadership contacts to retain competitive advantage currently enjoyed.

Schedule 4

Hypothetical Scenarios for Tax Claims

See attached.

Schedule 4 – Illustrative examples of the operation of Section 5.4(d) and Section 5.4(e) of Agreement and Plan of Acquisition under various hypothetical scenarios

*The “Total UTP Accrual” used below is a notional Total UTP Accrual as adjusted pursuant to Section 5.4(d). The adjustments of the Total UTP Accrual pursuant to Section 5.4(d) may differ from the accounting practice, and such adjusted notional Total UTP Accrual is used solely for the calculation of the amount of payments under Section 5.4.

Scenario 1		Event	Company Obligation	Foundation Obligation	Beginning *Total UTP Accrual	Adjustment to *Total UTP Accrual Pursuant to Section 5.4(d)	Ending *Total UTP Accrual	Aggregate Taxes, interest, penalties suffered by Company related to LA CIT and/or 833(b) matters
	Day 0	Closing			Assume the Total UTP Accrual = \$100 as of the Closing.		\$100	
	Day 10	Company received a Tax refund of \$100 related to prevailing on the Louisiana CIT.	Company pays \$100 to Foundation under Section 5.4(e).		\$100	\$0 (tax refunds are just received and paid through)	\$100	\$0
	Day 20	Company required to pay \$50 based on rejection of 833(b) position	Company pays \$50 to government.	None (\$50 owed does not exceed adjusted Total UTP Accrual.)	\$100	\$0 (payments to taxing authority do not result in adjustment to Total UTP Accrual)	\$100	\$50
	Day 30	Company required to pay \$200 based on rejection of 833(b) position	Company pays \$200 to government.	Foundation pays \$150 to Company under 5.4(d).	\$100	+\$150 (increased due to payment by Foundation under 5.4(d))	\$250	\$250
	Day 40	Company prevails on LA CIT claim and is entitled to retain \$25 that had been included in Total UTP Accrual	None (Obligation to make payment pursuant to Section 5.4(e) turns off because payment would result in reduction in Total UTP Accrual, which would result in Company being entitled to indemnity payment because aggregate Taxes, interest,	None	\$250	Net \$0 (\$25 decrease because of theoretical requirement to pay \$25 to Foundation fully offset by \$25 increase by theoretical right to indemnity payment for excess of damages over reduced Total UTP Accrual)	\$250	\$250

			penalties Company suffered would exceed adjusted Total UTP Accrual)					
Day 50	Company required to pay \$25 based on rejection of 833(b) position	Company pays \$25 to government.	Foundation pays \$25 to Company under 5.4(d).	\$250	+\$25	\$275	\$275	

Scenario 2	Event	Company Obligation	Foundation Obligation	Beginning *Total UTP Accrual	Adjustment to *Total UTP Accrual Pursuant to Section 5.4(d)	Ending *Total UTP Accrual	Aggregate Taxes, interest, penalties suffered by Company related to LA CIT and/or 833(b) matters	
	Day 0	Closing			Assume the Total UTP Accrual = \$100 as of the Closing.	\$100		
	Day 10	Company required to pay \$100 based on clawback of 2018 tax refund	Company pays \$100 to government	None (\$100 owed does not exceed adjusted Total UTP Accrual.)	\$100	\$0 (payments to taxing authority do not result in adjustment to Total UTP Accrual)	\$100	\$100
	Day 20	Company prevails on LA CIT claim and is entitled to retain \$100 that had been included in Total UTP Accrual.	None (obligation to make payment pursuant to Section 5.4(e) turns off because Aggregate Taxes, interest, penalties Company suffered equals adjusted Total UTP Accrual)	None	\$100	Net \$0 (\$100 decrease because of theoretical requirement to pay \$100 to Foundation fully offset by \$100 increase by theoretical right to indemnity payment for excess of damages over reduced Total UTP Accrual)	\$100	\$100
	Day 30	Company required to pay \$250 based on rejection of 833(b) position	Company pays \$250 to government.	Foundation pays \$250 to Company under 5.4(d).	\$100	+\$250	\$350	\$350

Scenario 3		Event	Company Obligation	Foundation Obligation	Beginning *Total UTP Accrual	Adjustment to *Total UTP Accrual Pursuant to Section 5.4(d)	Ending *Total UTP Accrual	Aggregate Taxes, interest, penalties suffered by Company related to LA CIT and/or 833(b) matters
	Day 0	Closing			Assume the Total UTP Accrual = \$100 as of the Closing.		\$100	
	Day 10	Company prevails on 833(b) claim and is entitled to retain \$50 that had been included in Total UTP Accrual.	Company pays \$50 to Foundation under 5.4(e).	None	\$100	-\$50 (decreased due to payment by Company under 5.4(e))	\$50	\$0
	Day 20	IRS claws back the \$50 that Company was entitled to retain on Day 10.	Company pays \$50 to government.	None (\$50 owed does not exceed adjusted Total UTP Accrual.)	\$50	\$0 (payments to taxing authority do not result in adjustment to Total UTP Accrual)	\$50	\$50
	Day 30	Company prevails on LA CIT claim and is entitled to retain \$50 that had been included in Total UTP Accrual.	None (obligation to make \$50 payment pursuant to Section 5.4(e) turns off because Aggregate Taxes, interest, penalties Company suffered equals adjusted Total UTP Accrual)	None	\$50	Net \$0 (\$50 decrease because of theoretical requirement to pay \$50 to Foundation fully offset by \$50 increase by theoretical right to indemnity payment for excess of damages over reduced Total UTP Accrual)	\$50	\$50
	Day 40	Company required to pay \$250 based on rejection of 833(b) position	Company pays \$250 to government.	Foundation pays \$250 to Company under 5.4(d).	\$50	+\$250	\$300	\$300

Scenario 4

	Event	Company Obligation	Foundation Obligation	Beginning *Total UTP Accrual	Adjustment to *Total UTP Accrual Pursuant to Section 5.4(d)	Ending *Total UTP Accrual	Aggregate Taxes, interest, penalties suffered by Company related to LA CIT and/or 833(b) matters
Day 0	Closing			Assume, as of Closing, Total UTP Accrual = \$100, \$30 of which is for LA CIT claims and \$70 of which is for federal claims.		\$100	
Day 10	Company settles all LA CIT claims and is 1) required to pay \$20 to LA and 2) entitled to retain \$10.	1) Company pays \$20 to LA DOR. 2) Company pays \$10 to Foundation under 5.4(e).	None (\$20 owed does not exceed adjusted Total UTP Accrual.)	\$100	Net -\$10 ((1) payments to taxing authority do not result in adjustment to Total UTP Accrual; (2) \$10 decrease due to payment by Company under 5.4(e))	\$90	\$20
Day 20	Final Resolution of all federal claims that had been included in Total UTP Accrual has been reached, and Company 1) receives \$40 of Tax refund and 2) is entitled to retain \$70 that had been included in Total UTP Accrual	Company pays total \$110 to Foundation under 5.4(e).	None	\$90	Net -\$70 ((1) \$40 of refund is Tax refund described in clause (i) of the definition of the term "Final Resolution Amount" that is just received and paid through, not resulting in adjustment to Total UTP Accrual; (2) \$70 decrease due to payment by Company under 5.4(e))	\$20	\$20
Day 100	Company required to pay \$200 based on rejection of 833(b) position with respect to 2018 tax year.	Company pays \$200 to IRS.	Foundation pays \$200 to Company under 5.4(d).	\$20	+\$200 (increased due to payment by Foundation under 5.4(d))	\$220	\$220

Exhibit A

Form of Note

See attached.

EXHIBIT A**FORM OF PROMISSORY NOTE**

\$[●]

[●], 2023

FOR VALUE RECEIVED, the undersigned Louisiana Health Service & Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana), a limited liability company organized and existing under the laws of Louisiana (the “Payor”), hereby promises to pay to The Accelerate Louisiana Initiative, Inc., a Delaware nonprofit nonstock corporation (the “Payee”), in lawful money of the United States of America, in immediately available funds, the principal sum of [●] (\$[●])¹ on the terms and conditions set forth in this senior promissory note (this “Note”), payable as set forth herein.

**ARTICLE I.
DEFINITIONS; CONSTRUCTION**

Each capitalized term used and not otherwise defined herein shall have the meaning assigned to such term in the Purchase Agreement (as defined below).

**ARTICLE II.
OBLIGATION AND INTEREST**

2.1 Reference is made to that certain Agreement and Plan of Acquisition, dated as of January 23, 2023, by and among ATH Holding Company, LLC, an Indiana limited liability company (“Purchaser”), Payor, Payee and Elevance Health, Inc., an Indiana corporation (“Parent”) (as further amended, restated, amended and restated or otherwise modified from time to time, the “Purchase Agreement”), pursuant to which, among other things, Purchaser agrees to indirectly acquire one hundred percent (100%) of the issued and outstanding shares of capital stock of Payee in accordance with the Purchase Agreement and the Plan of Reorganization.

2.2 In connection with the Transactions (including the Plan of Reorganization) contemplated by the Purchase Agreement, Payor agrees to pay to Payee a sum of \$[●]², and, as a result, Payor hereby (a) acknowledges and agrees that Payor shall owe Payee an amount of [●] (\$[●]) (the “Principal Amount”) as of the date hereof, and (b) promises to pay to Payee, in lawful money of the United States of America, in immediately available funds, (i) the Principal Amount, *plus* (ii) all outstanding accrued and payable interest on the Principal Amount and any fees and expenses related thereto, which amounts, unless sooner paid in full in accordance with Article III, shall be due and payable immediately following the Closing without demand, and without set-off, defense or counterclaim of any kind.

2.3 Interest shall accrue on the outstanding Principal Amount at a rate per annum of [●] percent ([●]%) on a daily basis and compound daily from the first day following the Closing until this Note is repaid in full in cash or otherwise converted or cancelled.

¹ Amount to be equal to the Note Amount.

² Amount to be equal to the Note Amount.

2.4 Notwithstanding anything to the contrary contained in this Note, at no time shall the Payor be obligated or be required to pay interest on the outstanding principal amount of this Note at a rate of interest that would be in excess of the maximum rate which the Payor is permitted by applicable law to contract or agree to pay. If the Payor would at any time be required or obligated to pay interest on such outstanding principal amount under this Note at a rate in excess of such maximum rate, then the rate of interest under this Note shall be deemed to be immediately reduced to such maximum rate. Interest payable hereunder shall be computed at such maximum rate and any prior interest payments made in excess of such maximum rate shall be applied and shall be deemed to have been payments made in reduction of the outstanding principal amount of this Note and thereafter the Payee shall refund any remaining excess to the Payor or as a court of competent jurisdiction may otherwise order.

2.5 In relation to any payment hereunder, the Payee agrees to comply with any information reporting and withholding requirements with respect to Taxes under applicable Law, and the Payee shall, to the extent legally entitled to do so, provide to the Payor appropriate Internal Revenue Service Form W-9 or W-8, as applicable, and such other forms and documents that the Payor may reasonably request in connection with its reporting and withholding obligations under applicable Law. The Payor shall withhold any Taxes required to be withheld by applicable Law with respect to any payments to the Payee hereunder and shall timely remit such withheld amounts to the appropriate Taxing Authorities.

ARTICLE III. PREPAYMENT AND REPAYMENT

3.1 Payor may prepay this Note at any time, in whole or in part, without notice, penalty, or premium. Any partial payment will be applied *first*, to accrued and unpaid interest hereon (if any) and then to the outstanding Principal Amount.

ARTICLE IV. EVENTS OF DEFAULT; EXERCISE OF REMEDIES.

4.1 Events of Default. Each of the following events shall be an event of default (an “Event of Default”):

- (a) the Payor shall have failed to make a payment hereunder when due; and
- (b) the Payor or any of its subsidiaries shall have become Bankrupt.

4.2 Exercise of Remedies. If any Event of Default occurs and is continuing, the Payee may (i) declare all or any portion of the unpaid principal balance of this Note and any interest thereon to be immediately due and payable, whereupon all such amounts shall become and be forthwith due and payable, without presentment, demand, protest or other notice of any kind, all of which are expressly waived by the Payor; *provided* that, upon the occurrence of an Event of Default described in clause (b), the unpaid principal balance of this Note and any interest thereon shall automatically become and be due and payable, without presentment, demand, protest or any notice of any kind, all of which are hereby expressly waived by the Payor and (ii) take any other action to the extent permitted under applicable law (each an “Enforcement Action”).

**ARTICLE V.
MISCELLANEOUS.**

5.1 Notices. Except as otherwise provided herein, all notices, requests, demands, consents, instructions or other communications to or upon Payor and Payee under this Note shall be in writing and delivered by facsimile, hand delivery, overnight courier service or certified mail, return receipt requested to each party at the address set forth below (or to such other address most recently provided by such party to the other party). All such notices and communications shall be effective (a) when sent by overnight service on the business day following the deposit with such service, (b) when mailed, by registered or certified mail, first class postage prepaid and addressed as aforesaid through the United States Postal Service, upon receipt, (c) when delivered by hand.

If to the Payor, prior to the Closing, to:

Louisiana Health Insurance and Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana
5525 Reitz Avenue
Baton Rouge, Louisiana 70809
Attention: I. Steven Udvarhelyi, M.D.
Louis Patalano, IV
Email: steven.udvarhelyi@bcbsla.com
lou.patalano@bcbsla.com

with copies (which shall not constitute notice) to:

Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103-2921
Attention: Stephen A. Jannetta
Michael N. Baxter
Email: stephen.jannetta@morganlewis.com
michael.baxter@morganlewis.com

If to the Payor, after the Closing, to:

Louisiana Health Insurance and Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana
c/o ATH Holding Company, LLC
220 Virginia Avenue
Indianapolis, IN 46204
Attention: Blair Todt (Executive Vice President, General Counsel)
Jay H. Wagner (Vice President, Counsel)
Email: blair.todt@elevancehealth.com
jay.wagner@elevancehealth.com

with copies (which shall not constitute notice) to:

White & Case LLP

1221 Avenue of the Americas
New York, New York 10020
Attention: Daniel G. Dufner, Jr.
Michael A. Deyong
Email: daniel.dufner@whitecase.com
michael.deyong@whitecase.com

If to the Payee, to:

The Accelerate Louisiana Initiative, Inc.
5525 Reitz Avenue
Baton Rouge, Louisiana
Attention: Tim Barfield
Penny Martin
Email: tim.barfield@bcbsla.com
penny.martin@bcbsla.com

with copies (which shall not constitute notice) to:

Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103-2921
Attention: Stephen A. Jannetta
Michael N. Baxter
Email: stephen.jannetta@morganlewis.com
michael.baxter@morganlewis.com

5.2 Assignment. This Note and the rights, interests or obligations hereunder may not be assigned by either Payor or Payee without the prior written consent of the other party; provided, that Payee may assign this Note to a Transferee as set forth in the Purchase Agreement. Any purported assignment of this Note in violation of this Section shall be null and void and shall be ineffective to relieve any party of its obligations hereunder. This Note shall inure to the benefit of and be binding upon Payor and Payee and their respective legatees, heirs, successors and assigns of the parties.

5.3 Amendments and Waivers. No amendment, supplement or waiver of any provision of this Note, nor consent to any departure by any of the parties hereto from any provision of this Note, shall in any event be effective unless the same shall be in writing, signed by each of Payor and Payee. Any such amendment, supplement, waiver or consent shall be effective only in the specific instance and for the specified purpose for which given.

5.4 Governing Law. This Note and all disputes or controversies arising out of or relating to this Note or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the [State of New York], without regard to conflicts of law provisions that would result in the application of laws of a State other than the [State of New York].

5.5 Counterparts. This Note may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Note by facsimile transmission or electronic transmission in “.pdf” format shall be as effective as delivery of a manually signed original.

[Remainder of page left intentionally blank.]

IN WITNESS WHEREOF, the undersigned has executed this Note effective as of the date first above written.

**LOUISIANA HEALTH SERVICE &
INDEMNITY COMPANY**

By: _____
Name:
Title:

ACKNOWLEDGED AND AGREED:

THE ACCELERATE LOUISIANA INITIATIVE, INC.

By: _____

Name:

Title:

Exhibit B

Proposed Plan of Reorganization

See attached.

Exhibit C

Example Estimated Closing Statement

See attached.

Exhibit C

Estimated Closing Statement (\$ in Dollars)		
Item	SPA Clause	Amount
Estimated Closing Indebtedness (Not Included in Calculation of Estimated Closing Surplus)	1.6 (a)(ii)(a)	1,987,318
Company Transaction Expenses	1.6 (a)(ii)(b)	1,350,000
Estimated Closing Surplus	1.6 (a)(ii)(c)	240,829,578

Notes

Estimated Closing Indebtedness			
	Not Included in Calculation of Estimated Closing Surplus	Included in Calculation of Estimated Closing Surplus	Repayment?
Vantage Notes Payable	-	28,626,245	N
Nonqualified Deferred Compensation Obligations	-	19,148,445	N
Capital Lease Obligations - BCBSLA	1,860,350	-	N
Capital Lease Obligations - Vantage	126,968	-	N
Total	\$1,987,318	\$47,774,690	

Estimated Closing Indebtedness	\$1,987,318
---------------------------------------	--------------------

Estimated Closing Repaid Indebtedness	\$ -
--	-------------

Eligible Member Payment	
Eligible Member Payment Amount	1.6(c) 180,000,000
Total Eligible Member Payment Amount	\$180,000,000

Estimated Closing Sellers Transaction Expenses	
Cain Brothers	1,350,000
MLB	-
Deloitte	-
Chaffe	-
McKinsey	-
Employees and Officers	-
Total Estimated Closing Sellers Transaction Expenses	\$1,350,000

Plan of Acquisition (POA) Definitions (\$ in Dollars)

<u>Payment</u>	<u>Amount</u>	<u>Notes</u>
Base Purchase Price	\$2,500,000,000	
Eligible Member Payment	(180,000,000)	
Foundation Amount	\$2,320,000,000	
Foundation Amount	\$2,320,000,000	
Plus: Estimated Closing Surplus	240,829,578	
Less: Amount to pay transaction expenses	(1,350,000)	
Less: Estimated Closing Indebtedness	(1,987,318)	
Closing Foundation Amount	\$2,557,492,259	
Note Amount	2,557,492,259	

Estimated Closing Balance Sheet (\$ in Dollars)

Balance Sheet - Example as of Sept 2022

September 2022

Assets

Current Assets:

Cash and cash equivalents	\$314,573,579
Short Term Investments	1,487,031
Subscription Income and Other A/R	582,590,662
Inventory	2,367,341
Deferred tax asset	110,247,458

Total Current Assets **\$1,011,266,071**

Investments:

Bonds (at market value)	\$1,017,122,984
Stocks	784,178,525
Pledged Certificates of Deposit	-
Real Estate and Other	120,338,273
Investments in Subsidiaries	0

Total Investments **\$1,921,639,783**

Property, buildings and equipment, net: \$147,982,558

Intangible Assets, net: \$47,914,418

Goodwill, net of amortization \$71,434,742

Total Assets **\$3,200,237,571**

Liabilities and Shareholders' Equity

Policy Liabilities:

Claims payable	\$151,408,735
Incurred but not reported claims	375,712,348
Unpaid claims adjustment expense	870,472
Aggregate health policy reserves	123,784,476
Liability for Uninsured Plans	8,995,366

Total Policy Liabilities **\$660,771,398**

Accounts Payable and Accrued Expenses: \$814,311,287

Unearned Subscription Income: 132,833,789

Deferred Tax Liability 2,992,569

Total Liabilities **\$1,610,909,043**

Shareholders' Equity:

Common stock	\$0
Dividend	-
Minimum Suplus	300,000
Unrealized Gain (Loss) on Securities	(65,102,543)
Additional paid-in capital	0
Retained earnings	1,654,131,071
Noncontrolling interest	(0)

Total Shareholders' Equity **\$1,589,328,528**

Total Liabilities and Shareholders' Equity **\$3,200,237,571**

Exhibit D

Advisory Board Charter

See attached.

**LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY
D/B/A BLUE CROSS AND BLUE SHIELD OF LOUISIANA**

ADVISORY BOARD CHARTER

**ARTICLE I
FORMATION OF THE ADVISORY BOARD**

Pursuant to and in accordance with law and the governing documents of Louisiana Health Service & Indemnity Company (the “Company”), the Board of Directors (the “Board”) of the Company is establishing an advisory board (the “Advisory Board”) as of [●], 2023.

**ARTICLE II
TERM**

SECTION 2.1. *Term.* The Advisory Board shall exist from the date hereof until the later of the (a) tenth anniversary of the date hereof and (b) date on which the Board terminates the Advisory Board (the “Term”).

**ARTICLE III
ADVISORY BOARD MEMBERSHIP**

SECTION 3.1. *Membership.* The number of members that shall constitute the Advisory Board shall be established by the Advisory Board from time to time but shall not be less than five (5) members nor more than twelve (12) (such members, the “Advisory Board Members”). Each member shall be a Qualified Representative and shall serve for one (1) year terms and at the discretion of the Advisory Board. “Qualified Representative” means a natural person who is a resident of Louisiana who would contribute to the goals and mission of the Advisory Board. Qualified Representatives shall bring diverse perspectives to their roles as Advisory Board Members, whether through diversity of thought, experience, culture, race, age, gender or otherwise. No Advisory Board Member shall serve as a member of the board of directors (or similar governing body) of The Accelerate Louisiana Initiative, Inc., a Louisiana nonprofit nonstock corporation, or as an officer thereof; provided, however, that nothing herein shall limit or restrict any Advisory Board Member from simultaneously serving as a member of the board of Blue Cross and Blue Shield of Louisiana Foundation, a Louisiana non-profit corporation.

SECTION 3.2. *Observers.* Observers may be appointed from time to time by the Advisory Board (each, an “Observer”). Observers may be recommended for consideration for appointment from time to time by the Board, Elevance Health, Inc. (“Elevance”) or the President of the Company (the “President”). As provided in Section 5.1, the President shall be invited to each meeting of the Advisory Board and shall participate as an Observer. Observers shall be excused from any portion of a meeting of the Advisory Board when the Chairperson determines that it is advisable or appropriate to meet in executive session.

SECTION 3.3. *Nomination and Appointment.* The initial Advisory Board Members are set forth on Exhibit A (such Qualified Representatives, the “Initial Members”). Upon the resignation or removal of an Initial Member pursuant to Section 3.4 hereof, or to otherwise fill a vacancy of the Advisory Board, the remaining Advisory Board Members shall have the sole right to nominate and appoint replacement or additional Advisory Board Members.

SECTION 3.4. *Resignation & Removal.*

(a) Any Advisory Board Member may resign by giving the Advisory Board thirty (30) calendar days' advance written notice or on such other date as agreed by the Chairperson and such Advisory Board Member. Upon the death or resignation of an Advisory Board Member, the Advisory Board shall have the sole right to appoint a replacement Advisory Board Member.

(b) An Advisory Board Member will be deemed removed (i) at the expiration of the term during which he or she attains the age of seventy-five (75), (ii) if the Advisory Board Member breaches (A) the provisions of this Charter, (B) in any material respect, any internal policy of the Company or Elevance applicable to members of similar boards, fiduciary or otherwise, within the Elevance corporate organization, or any other agreement to which the Company and such Advisory Board Member are party or (iii) if, unless excused by the Advisory Board, the Advisory Board Member has three (3) consecutive absences from regular meetings of the Advisory Board. Any finding of fact regarding an Advisory Board Member being deemed removed pursuant to any of the foregoing clauses (ii) and (iii) shall require, (x) for a period of four years from the date of adoption of this Charter, the affirmative vote of 66²/₃% of the then-serving Advisory Board Members who are not also employed or engaged as an employee, officer, or subject matter consultant by the Company or by Elevance (the "Supermajority Vote") and, (y) thereafter, the affirmative vote of a majority of the Advisory Board Members. Upon removal, the Advisory Board shall have the sole right to appoint a replacement Advisory Board Member.

(c) An Advisory Board Member shall be removed by the Advisory Board in the event the Advisory Board and the President determine such Advisory Board Member is no longer a Qualified Representative. Any finding of fact regarding an Advisory Board Member being removed pursuant to the Advisory Board's and the President's determinations that such Advisory Board Member is no longer a Qualified Representative shall require, (x) for a period of four years from the date of adoption of this Charter, the Supermajority Vote and, (y) thereafter, the affirmative vote of a majority of the Advisory Board Members.

SECTION 3.5. *Indemnification.* The Advisory Board Members shall be indemnified and held harmless by the Company, to the fullest extent permitted by law with respect to the members of the board of directors of a Louisiana business corporation, for actions taken pursuant to and in accordance with their duties on the Advisory Board.

ARTICLE IV SCOPE OF AUTHORITY

SECTION 4.1. *Duties and Responsibilities of the Advisory Board.* The Advisory Board shall be advisory only in nature. Notwithstanding anything to the contrary contained herein, the Advisory Board will not have any power or authority to bind, act for or on behalf of the Company, Elevance or their respective affiliates and no Advisory Board Member shall have any such power or authority as a result of being an Advisory Board Member. Responsibility for the management of the Company and Elevance will rest with the board of directors and officers of each such entity. The following shall be the principal duties and responsibilities of the Advisory Board:

(a) Review and advise upon strategies relevant to the Company, as an affiliate of Elevance.

(b) Review and consult with Company and Elevance management regarding materials provided from time to time to the Advisory Board, including but not limited to, (i) strategic plans, (ii) financial performance, (iii) operational performance reports (iv) customer satisfaction reports, (v) provider satisfaction reports, (vi) employee engagement satisfaction reports, and (vii) status reports on adherence to the commitments made in the Plan of Reorganization Regarding the Conversion from a Mutual Insurance Company to a Stock Insurance Company governing the Company's demutualization approved by the Louisiana Department of Insurance on [●], 2023 and the Form A (Statement Regarding the Acquisition of Control of or Merger with a Domestic Insurer) filed by the Company on [●], 2023.

(c) Perform such other functions and duties as may reasonably be delegated to the Advisory Board by Elevance from time to time.

(d) Provide the Company and Elevance management with market information, stakeholder input and feedback (including from members/policyholders, providers, members of the community, public officials, etc.) and other information regarding the performance, market position, market perception, competitive landscape, community relations, government relations and other relevant matters affecting the Company.

(e) Provide additional guidance as requested by Elevance.

ARTICLE V ADVISORY BOARD STRUCTURE AND OPERATIONS

SECTION 5.1. *Meetings.* The Advisory Board may meet as often as it reasonably deems appropriate; provided, however, that it shall meet no less than one (1) time per quarter. The President shall be invited to attend each such meeting of the Advisory Board and participate as an Observer. A meeting of the Advisory Board may be called at the request of three (3) Advisory Board Members. A quorum for a meeting will be a majority of the total voting members. Advisory Board Members may participate in a meeting by means of conference telephone or similar communications by means of which all persons participating in the meeting can hear and be heard.

SECTION 5.2. *Agenda.* The Chairperson, in consultation with the President of the Company will provide the members of the Advisory Board with an agenda of matters to be discussed at each meeting sufficiently in advance of any scheduled meeting.

SECTION 5.3. *Chairperson.* The Advisory Board shall appoint a Chairperson, who shall be an Advisory Board Member. The Chairperson will chair each meeting of the Advisory Board and set the agenda for Advisory Board meetings.

SECTION 5.4. *Voting.*

(a) Each Advisory Board Member will be a voting member of the Advisory Board and each voting member will be entitled to one (1) vote. Except as otherwise provided in this Charter, the Advisory Board will act by a majority of the voting members. Actions taken by the unanimous consent of the Board may be taken by unanimous written consent in lieu of a meeting. Observers will not be voting members.

(b) An Advisory Board Member will be recused from any actions of the Advisory Board in respect of any matter where the Advisory Board Member has an actual or potential conflict of interest as further discussed in Article X.

SECTION 5.5. *Minutes.* The Chairperson or its designee will take minutes of each Advisory Board meeting, which shall be distributed to all Advisory Board Members and to the Company upon request.

ARTICLE VI COMMITTEES

SECTION 6.1. *Designation of Sub-Committees.* The Advisory Board may designate one (1) or more sub-committees. Sub-committees will be composed only of Advisory Board Members and Observers that are appointed in accordance with this Charter. Each sub-committee will serve at the pleasure of the Advisory Board.

SECTION 6.2. *Sub-Committee Authority, Etc.* All sub-committees will be advisory only in nature. The Advisory Board may create and dissolve sub-committees as it deems appropriate. The Advisory Board will appoint the members of each sub-committee. A sub-committee will consult with and provide advice to the Advisory Board. No sub-committee will have any authority to act for or in the name of or otherwise bind the Advisory Board, the Company or Elevance.

SECTION 6.3. *Sub-Committee Actions and Meetings.*

(a) A quorum for a meeting will be a majority of the members. Any action required or permitted to be taken by a sub-committee may be taken without a meeting and without notice if the sub-committee consents in writing to such action. Each sub-committee will act by a majority of its members. Actions taken by the unanimous consent of the applicable sub-committee may be taken by unanimous written consent in lieu of a meeting.

(b) Each sub-committee will take minutes of each sub-committee meeting, which shall be distributed to the Advisory Board and to the Company upon request.

(c) Members of a sub-committee may participate in a meeting by means of conference telephone or similar communications by means of which all persons participating in the meeting can hear and be heard.

(d) Information given to members of a sub-committee is to be kept confidential in the same manner as provided in Article IX.

ARTICLE VII COMPENSATION AND EXPENSE REIMBURSEMENT

SECTION 7.1. *Compensation.* In consideration for their services to the Advisory Board and for so long as they remain an Advisory Board Member, each Advisory Board Member shall be paid an annual retainer. In addition, the Chairperson of the Advisory Board shall receive an additional annual retainer for serving as Chairperson. Such amounts shall be paid quarterly to each Advisory Board Member and the Chairperson. The annual retainer amounts paid to each Advisory Board Member and the Chairperson shall be reasonable in relation to the services to be rendered and the commitment to be made as an Advisory Board Member and, where applicable, the Chairperson, and shall be as set forth in a written agreement

to be entered into among the Company, Elevance and the Advisory Board Member. The President, based on input from the Advisory Board, shall communicate to Elevance any recommendations and/or requests that the Advisory Board may have regarding compensation matters, and Elevance shall determine how to respond to such recommendations or requests in its sole discretion.

SECTION 7.2. *Expenses.* Each voting member of the Advisory Board will be reimbursed by the Company for reasonable and documented out-of-pocket expenses incurred in attending in-person meetings of the Advisory Board.

SECTION 7.3. *Reimbursement.* Requests for reimbursements should include: (a) details (e.g., date and place) of the relevant Advisory Board meeting for which the expense reimbursement is sought, (b) details of the underlying expenses that should clearly differentiate between different types of expenses (e.g., travel, lodging, meals), and (c) appropriate documentation such as receipts or bills. All requests for reimbursement must be submitted in writing to the Company. Any reimbursement will be paid to the Advisory Board Member.

SECTION 7.4. *Exceptions.* Only the expenses incurred by Advisory Board Members will be reimbursed. Expenses by any other individuals accompanying such persons will not be reimbursed unless otherwise agreed by the Company. The Company reserves the right to reject any request for reimbursement if, in the reasonable determination of the Company, such reimbursement, whether in whole or in part, would violate any applicable statute, law, rule, regulation, order, writ, judgment, decree, or internal policy governing Advisory Board expense reimbursement applicable to the Company.

ARTICLE VIII AMENDMENT

Any amendments to this Charter shall require, (a) for a period of four (4) years from the date of adoption of this Charter, the Supermajority Vote and, (b) thereafter, the affirmative vote of a majority of the Advisory Board Members; provided that, no amendment may be made to this Charter that would conflict with the governing documents of the Company; and provided, further, that no amendment to this Charter shall be valid without the Company's written consent, which consent is not to be unreasonably withheld, conditioned or delayed.

ARTICLE IX CONFIDENTIALITY

All information received by any person in connection with the Advisory Board shall be subject to strict confidentiality and use restrictions, which shall be no less strict than those applicable to members of the Board.

ARTICLE X CONFLICTS OF INTEREST

SECTION 10.1. In accepting the appointment to the Advisory Board, each Advisory Board Member and each Observer agrees that its acceptance and service to the Advisory Board is not in conflict with any other contractual or other obligation to which such person is otherwise bound. Annually, as directed by the Chairperson, each Advisory Board Member and each Observer will complete the Conflicts of Interest questionnaire set forth on Exhibit B and return such completed questionnaire to the Chairperson. In addition, each Advisory Board

Member and each Observer will promptly inform the Chairperson upon the occurrence or discovery of any facts and circumstances that could reasonably give rise to a question regarding, the appearance of, or the existence of a conflict of interest with respect to any matter on which the Advisory Board receives information or may reasonably be expected to deliberate (each of the foregoing, including any conflict of interest included in a Conflicts of Interest questionnaire, a “Conflict Circumstance”).

SECTION 10.2. Each Advisory Board Member and each Observer will be recused from receiving any information or taking part in any discussions or actions of the Advisory Board in respect of any Conflict Circumstance. An Advisory Board Member must recuse itself from the Advisory Board’s deliberation and voting on any matter for which a Conflict Circumstance is present. In addition to the foregoing, the Chairperson may move to exclude an Advisory Board Member from deliberation and voting on any matter for which the Chairperson reasonably believes a Conflict Circumstance may exist, and such Advisory Board Member will be excluded as a voting member on such matter unless objected to by a majority vote of the remaining voting Advisory Board Members

Exhibit A

Initial List of Advisory Board Members

1. Judy P. Miller
2. Stephanie A. Finley
3. Michael B. Bruno
4. Robert T. Lalka
5. J. Kevin McCotter
6. Thad Minaldi
7. Carl Luikart, M.D.

Exhibit B
Conflicts of Interest Questionnaire¹

[•]

¹ To be confirmed prior to closing.

EXHIBIT D
Fairness Opinion

[See attached]



January 12, 2023

Board of Directors of Louisiana Health Service & Indemnity Company,
d/b/a Blue Cross and Blue Shield of Louisiana ("BCBSLA")
5525 Reitz Avenue
Baton Rouge, Louisiana 70809

Ladies and Gentleman:

Chaffe & Associates, Inc. ("Chaffe") understands that BCBSLA, a licensee of the Blue Cross Blue Shield Association ("BCBS"), is considering a proposed demutualization pursuant to La. R.S. 22:236, *et seq.* It is also proposed that, simultaneously with the demutualization, BCBSLA would be sold to another licensee of BCBS (the "Sale Transaction") that would make the demutualization, in effect, a "sponsored" demutualization. As a result of the demutualization and Sale Transaction, BCBSLA will be converted to a stock company and the membership interests of existing BCBSLA members would be extinguished. The newly issued shares of stock sold pursuant to the Sale Transaction would be treated under the Internal Revenue Code as if they had been issued directly to BCBSLA members in exchange for their pre-existing membership interests. A private letter ruling has been requested from the Internal Revenue Service confirming the propriety of such treatment for tax purposes.

In order to effectuate the conversion, BCBSLA will submit a proposed plan of reorganization that meets with the requirements of La. R.S. 22:236.2, a draft of which dated January 12, 2023 has been provided to Chaffe. The plan of reorganization is required to be adopted by action of not less than two-thirds of BCBSLA's members present and voting in person or represented by proxy at a special meeting of members and two-thirds of BCBSLA's directors and, following a public hearing, approved by the Louisiana Commissioner of Insurance.

One of the requirements for the plan of reorganization is to provide for the distribution of consideration, in a fair and equitable manner, to all eligible members upon extinguishment of their membership interests. The reorganizing mutual must obtain an opinion addressed to the board of directors of the reorganizing mutual from a qualified investment bank that "the provision of consideration upon the extinguishment of the membership interests pursuant to the plan of reorganization is fair to the eligible members, as a group, from a financial point of view." BCBSLA has retained Chaffe for the exclusive purpose of rendering an opinion that "the provision of consideration" to BCBSLA's Eligible Members upon the extinguishment of their membership interests pursuant to the plan of reorganization is fair to the Eligible Members, as a group, from a financial point of view. Accordingly, Chaffe's opinion is limited to the fairness, from a financial point of view, of the methodology under which the aggregate amount of consideration to be paid to the Eligible Members as a group is determined.

As used in this letter, the term “Eligible Member” has the same meaning as in the January 12, 2023 draft of the plan of reorganization.

La. R.S. 22:236(9) defines “membership interest” to mean:

. . . with respect to a mutual insurer, all rights and interests of a policyholder as a member arising under the mutual insurer’s articles of incorporation and bylaws, by law or otherwise, which rights include but are not limited to the right, if any, to vote and the right, if any, with regard to the surplus of the mutual insurer not apportioned or declared by the board of directors for policyholder dividends.

BCBSLA’s articles of incorporation grant its members the right to vote, but they provide that BCBSLA shall issue no dividends. Moreover, the articles are silent with regard to any right of the members to BCBSLA’s surplus or the proceeds of its liquidation, and BCBSLA and its legal counsel are unaware of any provision of law providing such rights.

In light of the above, BCBSLA’s proposed methodology is to allocate a portion of the consideration to the existing Eligible Member group according to the percentage obtained by dividing the total number of “member months” that an Eligible Member was covered by an insurance policy issued by BCBSLA, as adjusted to account for member months attributable to employees only (not including dependents) for group policies, by the total number of “member months” all members covered by an insurance policy issued by BCBSLA or one of its subsidiaries since its formation in 1975 (excluding member months attributable to self-insured members).

Chaffe’s opinion expressed in this letter is limited to the fairness, from a financial point of view, of the above methodology. Chaffe expresses no opinion as to the fairness, from a financial point of view or otherwise, of any other matter.

Chaffe also does not express an opinion on any other matter, including, but not limited to the following:

- (1) the value or range of values of BCBSLA, and the fairness from a financial point of view of such value, range of values, any point within such range, and the value of a member month;
 - (2) the total amount of consideration to be paid in the demutualization and Sale Transaction or its fairness from a financial point of view, and Chaffe understands that the total amount of consideration may be based upon a valuation performed by another investment bank and/or will be the subject of a fairness opinion rendered by such bank;
 - (3) the accuracy or completeness of the information used by BCBSLA to compute the total member months of all members since BCBSLA’s formation and of the number of member months attributable to existing Eligible Members individually or as a group, and the accuracy of and methodology underlying such calculations;
 - (4) the methodology and underlying assumptions for the allocation of consideration among Eligible Members;
-

- (5) the decision by BCBSLA to employ the methodology stated above for the allocation of the transaction consideration to the Eligible Member group as compared to any other methodology;
- (6) the form of the consideration to be distributed to the Eligible Members;
- (7) the structure, form and conditions of the plan of reorganization under which the demutualization will be effected, or the structure, form and conditions of the Sale Transaction or any other arrangement or agreement contemplated by the plan of reorganization;
- (8) the rationale underlying the business decision of BCBSLA to effect the plan of reorganization, the resulting demutualization or the Sale Transaction; and
- (9) the correctness, soundness or fairness of the decision of the Louisiana Commissioner of Insurance with respect to the plan of reorganization, the Sale Transaction or any other matter.

Chaffe has not been engaged to make, and does not make, a recommendation to the members of BCBSLA or any other person whether to vote to approve or not approve the plan of reorganization or the Sale Transaction or as to how such person should otherwise act with respect to the plan of reorganization of Sale Transaction.

In this assignment, Chaffe used the professional care and diligence of investment bankers in its review of material provided to it or developed by it and in its consideration of the factors there presented. Chaffe's opinion is based upon a review and analysis of the allocation of consideration consistent with the standards of the investment banking industry.

In addition, Chaffe has, to the extent it deemed relevant in accordance with the standards of the investment banking industry, considered other factors in rendering its opinion, including but not limited to the views of the Louisiana Commissioner of Insurance and the rights associated with a membership interest in BCBSLA, which do not include a right to dividends or surplus pursuant to its articles of incorporation, and other factors customarily considered in a transaction of the type being addressed by Chaffe in this letter.

It should be understood that developments subsequent to this date may affect this opinion, but Chaffe is under no obligation to, and will not, update, revise or reaffirm its opinion.

Chaffe, as part of its investment banking business, is regularly engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, financings, and fairness opinions for corporate and various other purposes. Chaffe will receive a fee upon delivery of this opinion. Chaffe's compensation for this opinion is not dependent or contingent upon the completion of the any transaction and is not related to or based upon the nature of the findings made herein. BCBSLA has agreed to reimburse Chaffe for its expenses related to this assignment. BCBSLA has also agreed to indemnify Chaffe for certain liabilities that may arise in connection with the engagement.

Chaffe has not provided services to BCBSLA prior to this assignment. Chaffe confirms that none of its subsidiaries, affiliates; officers, directors, shareholders, or employees are Eligible Members.

Chaffe has not provided services to Elevance Health, Inc or its affiliates and Chaffe confirms that none of its subsidiaries, affiliates; officers, directors, shareholders, or employees are Elevance Health, Inc. policyholders.

For the purpose of rendering this opinion, Chaffe has reviewed and relied upon, with your consent, the following written materials provided by the management of BCBSLA, some of which contain the estimates and judgments of the management of BCBSLA:

- Draft Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana Plan of Reorganization to a Stock Insurance Company, as of January 12, 2023 (inclusive of Exhibit E, dated January 12, 2023);
 - Draft Agreement and Plan of Acquisition by and among Elevance Health, Inc., as Parent, ATH Holding Company, LLC, as Purchaser, The Accelerate Louisiana Initiative, Inc., as the Foundation, and Louisiana Health Service & Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana), as the Company, as of January 5, 2023;
 - Draft Project River Step Plan, prepared by PwC, dated October 7, 2022;
 - Draft Memorandum Re: Request of Elevance, Inc. and Blue Cross and Blue Shield of Louisiana for a Private Letter Ruling, dated December 22, 2022;
 - Project River – Member Months and Policyholder Consideration Spreadsheet, including but not limited to estimates of assumptions by BCBSLA of cumulative member months since inception of BCBSLA, accumulated member months for active members (as of 8/31/2022), voting right adjustment to member month calculation for group related members, and adjustment to member month calculation for group related members assuming that employer portion of policy cost is 75% and 50%, dated November 17, 2022;
 - Memorandum from Korey Harvey to Vanessa Brown Claiborne, Re: Engagement & Management Recommendation, dated September 30, 2022;
 - Memorandum from McGlinchey Stafford PLLC to Korey Harvey, Re: Conversion of Louisiana Health Service & Indemnity Company d/b/a Blue Cross Blue Shield of Louisiana from a Mutual Insurer to a Stock Insurer, dated July 27, 2022;
 - Bylaws of Louisiana Health Service & Indemnity Company, adopted May 21, 2019;
 - Third Amendment to the Amended and Restated Articles of Incorporation of Louisiana Health Service & Indemnity Company, dated February 19, 2019;
 - Second Amendment to the Amended and Restated Articles of Incorporation of Louisiana Health Service & Indemnity Company, dated February 16, 2016;
 - Articles of Amendment to the Amended and Restated Articles of Incorporation of Louisiana Health Service & Indemnity Company, dated February 21, 2007;
 - Authentic Act of Amended and Restated Articles of Incorporation of Louisiana Health Service & Indemnity Company, dated February 18, 2003;
-

- Memorandum from Korey Harvey to Vanessa Brown Claiborne, Re: Engagement & Management Recommendation, dated August 24, 2022;
- Annual Statements of The HMO Louisiana, Inc. for the years ended December 31, 1988-1997, 2000-2004, 2014-2018, and 2020-2021; and
- Annual Statements of the Louisiana Health Service and Indemnity Company for the years ended December 31, 1987, 1996-2006, and 2008-2021.

Chaffe has further relied upon the assurances of the management of BCBSLA that they are not aware of any facts that would render the above information inaccurate, incomplete or misleading. Chaffe has also assumed, at BCBSLA's direction, that the estimates of BCBSLA's management reflected in the information and materials supplied to Chaffe have been reasonably prepared on bases reflecting the best currently available estimates and judgments of management as to the matters covered thereby, and Chaffe has relied, at BCBSLA's direction, on the same. Chaffe also participated in discussions with members of BCBSLA's management regarding their assessment of the materials listed above and other internal data relied upon them in recommending the methodology by which BCBSLA proposes to allocate consideration to the Eligible Members.

Chaffe has not taken responsibility for the independent verification of, and has not independently verified, and Chaffe expresses no view or opinion of, any information considered in connection with rendering its opinion, whether publicly available or furnished or otherwise made available to it, by BCBSLA or others, including without limitation, any financial information. For purposes of its opinion, Chaffe has, with BCBSLA's permission, assumed and relied upon the accuracy, completeness, and fair presentation of all such information reviewed by it. Chaffe has not made an independent evaluation or appraisal of the value of any of BCBSLA's assets or liabilities (contingent or otherwise), and Chaffe has not been furnished with any such evaluation or appraisal. Chaffe is not an actuary. In that regard, Chaffe has made no analysis of, and expresses no opinion as to, the adequacy of policy reserves, future policy benefits, other policyholder funds or other related actuarial items.

In rendering this opinion, Chaffe has, with your consent, assumed that in all respects material to its analysis, the Sale Transaction will be consummated in accordance with the terms described in the Draft Memorandum Re: Request of Elevance, Inc. and Blue Cross and Blue Shield of Louisiana for a Private Letter Ruling, dated December 22, 2022, without any material waiver, amendment or delay of any term, condition or agreement. Chaffe has also assumed, with your consent, that all governmental, regulatory, or other consents and approvals necessary for the consummation of the Sale Transaction will be obtained without any effects that would be material to Chaffe's analysis.

This fairness opinion has been approved and authorized for issuance by Chaffe's fairness opinion review committee. This opinion is provided solely for the benefit and use of Board of Directors of BCBSLA in connection with and for the purposes of their consideration of the methodology used to allocate consideration to Eligible Members, as a group, in the proposed demutualization. Chaffe has not been asked to, nor does it express any view on, and its opinion does not address, any other term or aspect of the plan of reorganization. Chaffe's opinion will be referenced and included as an exhibit in the BCBSLA plan of reorganization and filed with the Louisiana Insurance Commissioner and the insurance commissioners of Arkansas and Mississippi and the National Association of Insurance Commissioners. Chaffe's opinion may be provided to the Antitrust Division of the U.S. Department of Justice or the Federal Trade Commission, as

applicable, upon its request in connection with its review of the Sale Transaction under the Hart-Scott -Rodino Antitrust Improvements Act of 1976, as amended. In addition, Chaffe's opinion will be referenced in and included as an exhibit to the materials provided to BCBSLA's members in connection with the special meeting of members held to consider approval of the plan of reorganization. Otherwise, Chaffe's opinion may not be reproduced, summarized, described or referred to or given to any other person without Chaffe's prior written consent.

Based upon and subject to the foregoing, including the various factors considered, assumptions made, qualifications to the opinion and limitations on the scope of the review undertaken and opinions given as set forth herein, and based upon such other matters as Chaffe considered relevant, it is Chaffe's opinion, as of the date hereof, that BCBSLA's proposed methodology to allocate the consideration to the existing Eligible Member group according to the percentage obtained by dividing the number of "member months" that an Eligible Member was covered by an insurance policy issued by BCBSLA, as adjusted to account for member months attributable to employees only (not including dependents) for group policies, by the total number of "member months" all members covered by an insurance policy issued by BCBSLA or one of its subsidiaries since its formation in 1975 (excluding member months attributable to self-insured members) upon the proposed demutualization is fair, to the existing Eligible Members, as a group, from a financial point of view.

Very truly yours,

CHAFFE & ASSOCIATES, INC.

Chaffe & Associates, Inc

H:\DATA\B\Blue Cross Blue Shield\FOP Letter\BCBSLA FOP Letter Final 1-12-2023.docx

EXHIBIT E
Eligible Member Payment Methodology

[See attached]

Exhibit E - Eligible Member Payment Methodology

Current values shown are estimates and will be reconciled and provided as of the required dates determined by the transaction process.

Valuation Calculations

Cumulative Member Months*	322,215,815
Eligible Member Months	16,544,837
Eligible Member Months %	5%
Transaction Valuation	\$ 3,500,000,000
Total Voting Member Consideration	\$ 179,417,729

Number of Eligible Members (as of 12/15/22)	94,802
Consideration per Eligible Member	\$ 1,896

Definitions For Purposes of Exhibit E Only

Cumulative Member Months means total number of months an individual was covered by an insurance policy issued by BCBSLA or one of its subsidiaries since BCBSLA was established in 1975.

Eligible Member means a fully insured group or individual policyholder of an active (not terminated) BCBSLA insurance policy as of the date of adoption of the Plan of Reorganization by the Board of Directors. Each insurance policy is permitted one vote.

Eligible Member Months means the total number of months an individual was covered by an insurance policy issued by BCBSLA to an Eligible Member. Group Eligible Member Months are reduced by 50% to account for member months attributable to employees only (not including dependents) of the policyholder. Cumulative Member Months are not reduced by the 50% factor above. The BCBSLA marketing economist determined that the group policy multiplier was 50% (i.e. average group subscriber policy has 2 covered individuals, but only 1 employee of the policyholder). The individual policy multiplier was 100% (i.e. 1 voting right per contract).

Transaction Valuation means the aggregate of the Base Purchase Price under the Acquisition Agreement plus the estimated Closing Surplus plus the estimated Approved Excess Surplus

Comments/Notes

** Member months are currently estimates based on available and summarized data. The total member months will be recalculated by members of the BCBSLA actuarial team utilizing current member data as of the record date.*

EXHIBIT F
Actuarial Opinion

[See attached]



Deloitte Consulting LLP

111 S. Wacker Drive
Chicago, IL 60606-4301
USA

Tel: +1 312 486 3535

Fax: +1 312 247 3535

www.deloitte.com

Date: January 12, 2023

To: Board of Directors of Louisiana Health Service & Indemnity Company
d/b/a Blue Cross and Blue Shield of Louisiana ("BCBSLA")
5525 Reitz Avenue
Baton Rouge, Louisiana 70809

Statement of Actuarial Opinion Allocation of Policyholder Consideration for Proposed Demutualization

IDENTIFICATION

I, Brian M. Collender, am associated with the firm of Deloitte Consulting LLP. I am a Fellow of the Society of Actuaries and member of the American Academy of Actuaries. I meet the education, experience, and other qualification requirements promulgated by the American Academy of Actuaries for rendering this opinion.

I have been retained, as of June 23, 2022, by BCBSLA to render this opinion regarding the allocation of consideration among eligible members under the proposed demutualization of BCBSLA.

SCOPE

I have examined BCBSLA's methodology and underlying assumptions for allocation of consideration among eligible members as provided by BCBSLA and as outlined in Exhibit E in BCBSLA's Plan of Reorganization.

This opinion rendered solely assesses the allocation of consideration among eligible members. This opinion is not intended to offer comment or recommendation regarding the exact number of members eligible to receive consideration, the form of the consideration to be distributed to eligible members, nor the proposed methodology for valuation of the total consideration to be distributed, including any calculations or components related to the development of the total consideration amount.

Additionally, this opinion is rendered from an actuarial perspective and should not be construed as legal advice or any opinion related to the structure, form and conditions of the plan of reorganization and demutualization, or decisions of BCBSLA or state regulators with respect to the plan of reorganization. This opinion also provides no recommendation with regard to whether or not the members of BCBSLA should vote to approve the plan of reorganization.

I have made no analysis of the adequacy of policy reserves, future policy benefits, other policyholder funds or any other related actuarial financial statement items, as such items which are outside the scope of this opinion.

MY UNDERSTANDING

I understand that BCBSLA, a licensee of the Blue Cross Blue Shield Association ("BCBS"), is considering a proposed demutualization pursuant to La. R.S. 22:236, and it is also proposed that, simultaneously with the demutualization, BCBSLA would be sold to another licensee of BCBS. As a result of the demutualization, BCBSLA will be converted to a stock company and the membership interests of existing BCBSLA members would be extinguished.

BCBSLA has provided drafts of their proposed plan of reorganization dated December 12, 2022 and December 29, 2022. BCBSLA has also provided a draft of an opinion from a qualified investment banker, Chaffe & Associates, Inc., addressing the fairness of BCBSLA's proposed methodology for determining the total consideration to existing eligible members, as a group, from a financial point of view.

As represented by BCBSLA, my understanding is that BCBSLA's articles of incorporation grant its members the right to vote, but they provide that BCBSLA shall issue no dividends. Moreover, according to BCBSLA, the articles are silent with regard to any right of the members to BCBSLA's surplus or the proceeds of its liquidation, and my understanding is that BCBSLA and its legal counsel are unaware of any provision of law providing such rights.

ANALYSIS

In developing my opinion related to the Scope as previously outlined, my analysis consisted of reviewing documents provided and developed by BCBSLA and having discussions with BCBSLA representatives around the development of the allocation of the consideration.

My review included analysis of the following documents provided by BCBSLA:

- Estimation of per member policyholder considerations found in "Project River – Member Months and Policyholder Consideration 11.17.22.xlsx";
- Details and information found in the draft plan of reorganization, "116697_113352904v7_Project River – Plan of Reorganization (MLR draft 12.12.2022.DOCX";
- BCBSLA Articles of Incorporation, "LHSIC – Articles of Inc -2-2019, 2-2016, 2-2007 Amend, 3-2003 articles.pdf";
- BCBSLA bylaws, "LHSIC BYLAWS -Approved 4-15-19.pdf";
- Sample BCBSLA member contracts including, "2023 GF IND CSD PLAN G CONTRACT – FINAL V1.pdf", "2023 IND CONTRACT PREF ESSEN DENTAL – FINAL V1.pdf", "2023 NGF IND BLUE SAVER CONTRACT – FINAL DMSR.pdf", "2023 NGF SM GRP PREMIER BLUE BP – FINAL DMSR.pdf"

I reviewed the above documents for reasonableness and consistency with BCBSLA's methodology and underlying assumptions for allocation of consideration among eligible members, including the fact that BCBSLA does not pay dividends and that the key right of policyholders is limited to a voting right.

ACTUARIAL CONSIDERATIONS

Actuarial standards of practice in this area are not prescriptive with regard to allocation of consideration among eligible members, and industry practices vary. Moreover, BCBSLA's proposed demutualization is unique in that none of BCBSLA's policies provide for dividends to be paid (i.e. none are participating insurance policies), in contrast to what is typically seen in mutual insurance companies.

In typical demutualizations, consideration is allocated partly on a per policy or per policyholder basis (called the fixed portion) and, for participating policies, partly on the basis of policyholders' actuarial contribution to the company's surplus (called the variable portion). In theory, the fixed portion compensates the policyholder for loss of membership rights (e.g., voting rights) upon demutualization, while the variable portion, if applicable, compensates participating policyholders for the loss of any rights to a distribution of excess assets in the event of liquidation.

The concept of fixed or variable components of consideration, depending on the specific circumstances, is also discussed in Louisiana statutes for reorganizing mutual insurance companies¹.

In BCBSLA's proposed plan of reorganization, BCBSLA has determined that the allocation of consideration among eligible members should consist of a fixed component on a per policy basis to compensate policyholders for the loss of voting rights. Furthermore, BCBSLA has determined that since all of its policies are non-participating, paying no dividends and providing no rights to surplus, shares of stock or liquidation proceeds, there is no variable component to the allocation of consideration among eligible members.

Practices commonly used by actuaries for the allocation of the fixed component of consideration compensate policyholders for the loss of membership rights associated with owning an in-force policy (e.g. voting rights). As outlined in Exhibit E of BCBSLA's proposed plan of reorganization, BCBSLA's allocation method for the proposed demutualization includes a fixed component to compensate policyholders for the loss of voting rights. The same amount will be allocated to each eligible member for each available vote.

Actuarial Standards of Practice (ASOP) No. 37 notes that in determining the reasonableness of the allocation, the actuary may consider the company's voting policy and that the actuary may determine that the fixed component can be allocated based on each eligible policy (regardless of the size of the policy) or each eligible policyholder (regardless of the number of policies or size of policies)². The allocation methodology utilized by BCBSLA conforms to this guidance as the fixed component is allocated based on each policy that has a voting right.

Under BCBSLA's methodology, there is no variable portion of consideration being allocated to eligible members. According to the American Academy of Actuaries Practice Note titled, "Distribution of Policyholder Equity in a Demutualization", a variable portion is generally allocated to policyholders that are participating on its face³. Since BCBSLA's policies are all non-participating, it is reasonable that there is not a variable portion being allocated.

BCBSLA has represented that the final counts of eligible members and final total consideration amount for eligible members as of the date of the board's adoption of the plan of reorganization are not expected to change materially from the amounts provided by BCBSLA in a spreadsheet dated December 20, 2022, and as summarized in Exhibit E, with current estimates as of that date and which underlie this opinion.

RELIANCE

In forming my opinion on the allocation of consideration among eligible members, I have relied upon information provided by BCBSLA.

I have evaluated BCBSLA's information, data and analysis for reasonableness and consistency. I have not performed any reconciliations of the provided data to any other data sources, nor have I performed any independent verification, recalculations or reconciliations of values provided. Therefore, the opinion that follows is contingent upon the accuracy and completeness of the

¹LA Rev Stat § 22:236.3 (2021), subsection B(1) states "The method shall provide for each eligible member to receive: (a) a fixed component of consideration or a variable component of consideration, or both; or (b) any other component of consideration acceptable to the commissioner"

²*Actuarial Standards of Practice No. 37 – Allocation of Policyholder Consideration in Mutual Life Insurance Company Demutualizations*, Actuarial Standards Board, Effective May 1, 2011

³*Distribution of Policyholder Equity in a Demutualization*, American Academy of Actuaries Practice Note, July 1999

January 12, 2023

Page 4

information I have received and reviewed; I am not aware of any facts or circumstances that would suggest that the provided information may be inaccurate, misleading, or incomplete.

My examination included review of actuarial and related guidance regarding allocation of consideration among eligible members consequent to the demutualization of a mutual insurance company.

OPINION

In my opinion, BCBSLA's proposed methodology and underlying assumptions for allocation of consideration among eligible members are reasonable and appropriate and the resulting allocation, as summarized in Exhibit E, is fair and equitable.

SIGNATURE

This Statement of Actuarial Opinion is intended to satisfy the requirement for such an opinion under *LA Rev Stat § 22:236.3 (2021), subsection 2B⁴*, and is intended for use by BCBSLA, the Board of Directors of BCBSLA, and the regulators of BCBSLA.

Actuarial considerations and analyses used in forming my opinion conform to the relevant Standards of Practice as promulgated by the Actuarial Standards Board, whose standards form the basis of this statement of opinion.



Brian M. Collender, FSA, MAAA
Deloitte Consulting LLP
111 S. Wacker Dr.
Chicago, IL 60606
(312) 486-4505

January 12, 2023

⁴LA Rev Stat § 22:236.3 (2021), subsection B(2) states: "The reorganizing mutual shall obtain an opinion addressed to the board of directors of the reorganizing mutual from an actuary who is a member of the American Academy of Actuaries that the methodology and underlying assumptions for allocation of consideration among eligible members are reasonable and appropriate and the resulting allocation is fair and equitable."

EXHIBIT G

Foundation Board Members

1. C. Richard Atkins, D.D.S.
2. Thomas A. Barfield, Jr.
3. Jerome K. Greig
4. Charles Brent McCoy

Advisory Board Members

1. Judy P. Miller
2. Stephanie A. Finley
3. Michael B. Bruno
4. Robert T. Lalka
5. J. Kevin McCotter
6. Thad Minaldi
7. Carl Luikart, M.D.

EXHIBIT H
Note Amount Calculation

“Note Amount” means an amount equal to the Closing Foundation Amount.

“Closing Foundation Amount” means (i) the Foundation Amount, *plus* (ii) the Estimated Closing Surplus (which may be a negative number), *minus* (iii) the Estimated Company Transaction Expenses to the extent not included in the calculation of the Estimated Closing Surplus, and *minus* (iv) the Estimated Closing Indebtedness to the extent not included in the calculation of the Estimated Closing Surplus.

- “Foundation Amount” means an amount equal to (i) the Base Purchase Price, *minus* (ii) the Eligible Member Payment.
 - “Base Purchase Price” means \$2,500,000,000.00.
 - “Eligible Member Payment” is defined in Article V of this Plan of Reorganization.
- “Estimated Closing Surplus” means a good faith estimate by BCBSLA of the Closing Surplus.
 - “Closing Surplus” means, as applicable, the amount by which either (i) the Statutory Capital exceeds the Minimum Regulatory Capital, each as of immediately prior to the Closing, or (ii) the Minimum Regulatory Capital exceeds the Statutory Capital, in each case as of immediately prior to the Closing and accounting for and after taking into account the payment or transfer, as applicable, of the Approved Excess Surplus to the Foundation (provided that for the avoidance of doubt, “Minimum Regulatory Capital” for purposes of calculating “Closing Surplus” shall continue to mean 375% of the authorized control level risk based capital of BCBSLA as of the Closing Date (as further set forth in the definition of “Minimum Regulatory Capital”), notwithstanding any reference to 500% in the definition of “Approved Excess Surplus”), provided, however, that if the Minimum Regulatory Capital exceeds the Statutory Capital, such amount shall be expressed as a negative number for purposes of the calculation of the Closing Foundation Amount and the Final Foundation Amount.
 - “Statutory Capital” means the admitted assets over the liabilities of BCBSLA, prepared in accordance with SAP applied on a basis consistent with the preparation of the audited Financial Statements (as defined in the Acquisition Agreement) of BCBSLA and statutory reporting with the applicable domiciliary insurance Governmental Authorities (as defined in the Acquisition Agreement) to the extent not inconsistent with SAP, as illustrated on Schedule 1 to the Acquisition Agreement. Statutory Capital will be adjusted to the extent that the net admitted deferred Tax (as defined

in the Acquisition Agreement) asset (after taking into account deferred Tax liabilities) is greater than zero.

- “Minimum Regulatory Capital” means 375% of the authorized control level risk based capital of BCBSLA as of the Closing Date prepared in accordance with the risk based capital formula for health insurance organizations as prescribed by the NAIC, utilizing inputs from the Estimated Closing Balance Sheet (as defined in the Acquisition Agreement) and the financial results from the 12 calendar months immediately preceding the Closing Date calculated in accordance with SAP applied on a basis consistent with the preparation of the audited Financial Statements and statutory reporting with the applicable domiciliary insurance Governmental Authorities to the extent not inconsistent with SAP.
- “Approved Excess Surplus” means an amount equal to the Statutory Capital of BCBSLA in excess of 500% of the authorized control level risk based capital of BCBSLA as of the Closing Date, or such other amount as approved by the Commissioner.
- “Regulated Entities” has the meaning set forth in Section 2.22(a) of the Acquisition Agreement.
- “Final Foundation Amount” means an amount equal to (i) the Foundation Amount, *plus* (ii) the Closing Surplus (which may be a negative number), *minus* (iii) the Company Transaction Expenses (as defined in the Acquisition Agreement) to the extent not included in the calculation of the Closing Surplus, *minus* (iv) the Closing Indebtedness (as defined in the Acquisition Agreement) to the extent not included in the calculation of the Closing Surplus.
- “SAP” means statutory accounting principles as set forth by the NAIC as applied by the appropriate insurance Governmental Authorities of the jurisdiction in which the relevant entity is domiciled or commercially domiciled.
- “Estimated Company Transaction Expenses” means a good faith estimate by BCBSLA of the Company Transaction Expenses as of immediately prior to the Closing.
- “Estimated Closing Indebtedness” means a good faith estimate by BCBSLA of the Closing Indebtedness as of immediately prior to the Closing.

Amendment No. 1 to the Plan of Reorganization

[See attached]

**AMENDMENT NO. 1 TO PLAN OF REORGANIZATION REGARDING THE
CONVERSION FROM A MUTUAL INSURANCE COMPANY TO A STOCK
INSURANCE COMPANY**

This Amendment No. 1 (this “Amendment”) to the Plan of Reorganization Regarding the Conversion From a Mutual Insurance Company to a Stock Insurance Company (as amended hereby, the “Plan of Reorganization”) was approved and made effective by the Board of Directors of Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (the “Company”) on July 18, 2023.

WHEREAS, on January 23, 2023, the Board of Directors of the Company (the “Board”) adopted the Plan of Reorganization Regarding the Conversion From a Mutual Insurance Company to a Stock Insurance Company (the “Original Plan”);

WHEREAS, the Original Plan provided that the Company shall reorganize from a mutual insurance company to a stock insurance company in accordance with LSA-R.S. § 22:72, LSA-R.S. § 22:236 *et seq.* and the other applicable provisions of the Louisiana Insurance Code;

WHEREAS, the Board deemed it desirable and appropriate to amend the Original Plan as set forth herein; and

WHEREAS, in accordance with applicable law and the terms and provisions of the Original Plan, more than two-thirds of the members of the Board have approved of this Amendment.

NOW, THEREFORE, in consideration of the foregoing recitals and the agreements contained herein, and for other good and valuable consideration, the Original Plan is hereby amended as follows:

1. Eligible Member Payment.

Article V of the Original Plan is hereby amended and restated in its entirety to read as follows:

“

**ARTICLE V.
Form and Amount of Consideration to be Distributed**

The Board has received the Fairness Opinion confirming the fairness of the method for the provision of aggregate consideration to the Eligible Members, as a group, from a financial point of view, consistent with LSA-R.S. § 22:236.3(A). The aggregate consideration to be distributed to the Eligible Members in exchange for the extinguishment of their Membership Interests will be cash in an amount equal to approximately \$307,755,241, subject to adjustment in respect of the reconciliation of the member months in between the Adoption Date and the Closing Date and the methodology and conditions set forth on Exhibit E hereto (the “Eligible Member Payment”). The aggregate value of the Eligible Member Payment was determined by tabulating the total number of months that an Eligible Member was covered by an insurance policy issued by BCBSLA, divided by the number of member months of all Members and all members of BCBSLA’s

subsidiaries since BCBSLA’s corporate formation in 1975, in accordance with the methodology set forth on Exhibit E hereto. The tabulation does not take into account the member months attributable to self-insured customers, which currently constitutes a majority of BCBSLA’s Members and customers and related member months, and is a significant contributor to the value of BCBSLA. The exclusion of self-insured customer member months in the tabulation increases the value that is attributable to Eligible Members to the benefit of the Eligible Members (as compared to the value if the self-insured customer member months were included).”

2. Section 9.1.

The following sentence is hereby added to the end of Section 9.1 of the Original Plan:

“In addition to the Public Hearing and approval of the Proposed Reorganization under LSA-R.S. § 22:236.4, the Commissioner must also conduct a public hearing and approve the change of control pursuant to LSA-R.S. § 22:691.4.”

3. Exhibit E.

Exhibit E to the Plan of Reorganization is hereby amended and restated in its entirety as set forth don Schedule 1 attached hereto and made a part hereof.

4. Miscellaneous.

4.1 Full Force and Effect. As amended by the terms hereof, the Plan of Reorganization remains in full force and effect and is hereby ratified and confirmed in all respects.

4.2 Capitalized Terms. All references to the “Plan of Reorganization” shall now refer to the Plan of Reorganization as amended by this Amendment.

4.3 Governing Law. The terms of this Amendment will be governed by and construed in accordance with the laws of the State of Louisiana.

+++++

SCHEDULE 1

EXHIBIT E

Eligible Member Payment Methodology

See attached.

Exhibit E - Eligible Member Payment Methodology

Values shown are based on available data and good faith estimates as of the record date of January 23, 2023. This Exhibit will be updated with revised values as of the Reorganization Effective Time.

Valuation Calculations

Cumulative Member Months ¹	391,210,584
Eligible Member ² Months	35,276,035
Eligible Member Months ³ as a % of Cumulative Member Months	9.02%
Transaction Valuation ⁴	\$ 3,413,000,000
Total Eligible Member Consideration	\$ 307,755,241

Number of potential Eligible Member as of Record Date (1/23/23)	101,617
Consideration per Eligible Member per Eligible Policy	\$ 3,029

Definitions For Purposes of Exhibit E Only

- 1) Cumulative Member Months means total number of months an individual was covered by an insurance policy issued by BCBSLA or one of its subsidiaries since BCBSLA was established in 1975.
- 2) Eligible Member means a fully insured group or individual policyholder of an active (not terminated) BCBSLA insurance policy as of the date of adoption of the Plan of Reorganization by the Board of Directors. Each insurance policy is permitted one vote.
- 3) Eligible Member Months means the total number of months an individual was covered by an insurance policy issued by BCBSLA to an Eligible Member since BCBSLA was established in 1975.
- 4) Transaction Valuation means the aggregate of the Base Purchase Price under the Acquisition Agreement plus the estimated Closing Surplus plus the estimated Approved Excess Surplus.

Comments/Notes

Cumulative Member Months and Eligible Member Months are based on available data beginning in 2010, and good faith estimates derived from data trends in enrollment and statutory filings with the Louisiana Department of Insurance prior to 2010. The values shown here represent data for potential Eligible Members as of the Record Date (January 23, 2023) and in accordance with the methodology reviewed and determined fair by the consulting investment banker and actuarial experts.

Amendment No. 2 to the Plan of Reorganization

[See attached]

AMENDMENT NO. 2 TO PLAN OF REORGANIZATION REGARDING THE CONVERSION FROM A MUTUAL INSURANCE COMPANY TO A STOCK INSURANCE COMPANY

This Amendment No. 2 (this “Amendment”) to the Plan of Reorganization Regarding the Conversion From a Mutual Insurance Company to a Stock Insurance Company (as amended by that Amendment No. 1, dated as of July 18, 2023 (“Amendment No. 1”), and as further amended hereby, the “Plan of Reorganization”) was approved and made effective by the Board of Directors of Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (the “Company”) on August 23, 2023.

WHEREAS, on January 23, 2023, the Board of Directors of the Company (the “Board”) adopted the Plan of Reorganization Regarding the Conversion From a Mutual Insurance Company to a Stock Insurance Company (as amended by the Amendment No. 1, the “Current Plan”);

WHEREAS, the Current Plan provided that the Company shall reorganize from a mutual insurance company to a stock insurance company in accordance with LSA-R.S. § 22:72, LSA-R.S. § 22:236 *et seq.* and the other applicable provisions of the Louisiana Insurance Code;

WHEREAS, the Board deemed it desirable and appropriate to further amend the Current Plan as set forth herein; and

WHEREAS, in accordance with applicable law and the terms and provisions of the Current Plan, more than two-thirds of the members of the Board have approved of this Amendment.

NOW, THEREFORE, in consideration of the foregoing recitals and the agreements contained herein, and for other good and valuable consideration, the Current Plan is hereby further amended as follows:

1. **Section 9.2.** Section 9.2 of the Current Plan is hereby amended and restated in its entirety to read as follows:

“Written notice of the Public Hearing, in a form satisfactory to the Commissioner, will be mailed by first class mail at BCBSLA’s expense at least 30 days prior to the Public Hearing to BCBSLA’s Members. Such notice will be mailed to the address of each Member of BCBSLA as such address is shown on BCBSLA’s records on the Record Date (or such other address as may be provided in writing to BCBSLA by the Member within a reasonable period of time prior to the mailing of the notice). Such notice of Public Hearing will include a brief statement of the subject of the Public Hearing, the date, time and location of the Public Hearing, and such additional information as the Commissioner may require.”

2. **Section 9.4.** Section 9.4 of the Current Plan is hereby amended and restated in its entirety to read as follows:

“In the event that the Commissioner approves this Plan, the Proposed Reorganization and the Acquisition (such approval, the “Commissioner’s Order”), notice of the Commissioner’s Order will be mailed by first class mail following the issuance of the Commissioner’s Order to BCBSLA’s Members. Such notice will be mailed to the address

of each Member of BCBSLA as such address is shown on BCBSLA’s records on the Record Date (or such other address as may be provided in writing to BCBSLA by the Member within a reasonable period of time prior to the mailing of the notice).”

3. Section 10.1(a). Section 10.1(a) of the Current Plan is hereby amended and restated in its entirety to read as follows:

“

(a) BCBSLA will hold a special meeting of Members (the “Special Meeting”) within a time period that complies with LSA-R.S. § 22:236.5, which shall occur after the Public Hearing. At the Special Meeting, the Members qualified to vote will be entitled to vote in person or by proxy on this Plan. The Members eligible to vote at the Special Meeting (the “Voting Members”) will be the Members of BCBSLA entitled to vote as of the record date for the Special Meeting established by the Board pursuant to the Current Articles and currently effective Amended and Restated Bylaws of BCBSLA (the “Record Date”).”

4. Section 10.2(a). Section 10.2(a) of the Current Plan is hereby amended and restated in its entirety to read as follows:

“

(a) BCBSLA will mail or cause to be mailed notice of the Special Meeting by first class mail at BCBSLA’s expense to all of the Voting Members. The notice will comply with the Current Articles and LSA-R.S. § 22:236.5 and set forth the date, time and place of the Special Meeting. Such notice will be mailed, at least 30 days prior to the Special Meeting, to the address of each Voting Member as it appears on the records of BCBSLA on the Record Date (or such other address as may be provided in writing to BCBSLA by the Voting Member within a reasonable period of time prior to the mailing of the notice). The notice will be in a form satisfactory to the Commissioner.”

5. Defined Term. The following defined term is hereby added to Section 12.2 of the Current Plan in appropriate alphabetical order:

“Record Date” shall have the meaning specified in Section 10.1(a).”

6. Miscellaneous.

6.1 Full Force and Effect. As amended by the terms hereof, the Plan of Reorganization remains in full force and effect and is hereby ratified and confirmed in all respects.

6.2 Capitalized Terms. All references to the “Plan of Reorganization” shall now refer to the Plan of Reorganization as amended by this Amendment.

6.3 Governing Law. The terms of this Amendment will be governed by and construed in accordance with the laws of the State of Louisiana.

+++++

Amendment No. 3 to the Plan of Reorganization

[See attached]

AMENDMENT NO. 3 TO PLAN OF REORGANIZATION REGARDING THE CONVERSION FROM A MUTUAL INSURANCE COMPANY TO A STOCK INSURANCE COMPANY

This Amendment No. 3 (this “Amendment”) to the Plan of Reorganization Regarding the Conversion from a Mutual Insurance Company to a Stock Insurance Company (as amended by the Amendment No. 1, dated as of July 18, 2023 (“Amendment No. 1”) and Amendment No. 2, dated as of August 23, 2023 (“Amendment No. 2”), and as further amended hereby, the “Plan of Reorganization”) was approved and made effective by the Board of Directors of Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (the “Company”) on December 12, 2023.

WHEREAS, on January 23, 2023, the Board of Directors of the Company (the “Board”) adopted the Plan of Reorganization Regarding the Conversion from a Mutual Insurance Company to a Stock Insurance Company (as amended by the Amendment No. 1 and Amendment No. 2, the “Current Plan”);

WHEREAS, the Current Plan provided that the Company shall reorganize from a mutual insurance company to a stock insurance company in accordance with LSA-R.S. § 22:72, LSA-R.S. § 22:236 *et seq.* and the other applicable provisions of the Louisiana Insurance Code;

WHEREAS, the Board deemed it desirable and appropriate to further amend the Current Plan as set forth herein; and

WHEREAS, in accordance with applicable law and the terms and provisions of the Current Plan, more than two-thirds of the members of the Board have approved this Amendment.

NOW, THEREFORE, in consideration of the foregoing recitals and the agreements contained herein, and for other good and valuable consideration, the Current Plan is hereby further amended as follows:

1. Amendments to Current Plan.

(a) **Affirmations**. Affirmation A(2) of the Current Plan is hereby amended and restated in its entirety to read as follows:

“prior to the effectiveness of the Reorganization (as defined below) and in furtherance of the purposes and policies set forth in the currently existing Second Amended and Restated Articles of Incorporation of BCBSLA (the “Current Articles”) (including promoting the health and welfare of the constituencies to be served pursuant to such Current Articles), the contribution by BCBSLA of the Approved Excess Surplus to The Accelerate Louisiana Initiative, Inc., a newly formed Louisiana nonprofit nonstock corporation organized to work to improve the health and lives of the people of the State of Louisiana which has qualified as a Code Section 501(c)(4) social welfare organization (the “Foundation”) and, in connection therewith, the issuance by BCBSLA, and acceptance and agreement thereto by the Foundation, of a funding agreement which requires the Foundation, subject to the satisfaction of certain conditions, to donate the amounts it receives pursuant to the Reorganization (less amounts for applicable taxes and expenses) to the Trust (as defined herein), as further provided for in Section 1.2 hereof;”

(b) **Section 1.2**. Section 1.2 of the Current Plan is hereby amended and restated in its entirety to read as follows:

“The Foundation has been formed by BCBSLA in connection with the Proposed Reorganization. Prior to the effectiveness of the Reorganization, in furtherance of the purposes delineated in the Current Articles to work to improve the health and lives of the citizens of the State of Louisiana, and in accordance with the Louisiana Demutualization Law and subject to the approval of the Commissioner, and in exchange for the right to become a stock insurance company under the Louisiana Demutualization Law with the approval of the Commissioner, BCBSLA shall (a) donate or transfer the Approved Excess Surplus to the Foundation and (b) issue the Note to the Foundation. Immediately following the Closing, Purchaser shall (i) contribute, or cause to be contributed, to BCBSLA an amount equal to the Note Amount, and (ii) cause BCBSLA to donate to the Foundation the Note Amount and thereby satisfy its obligations under the Note. In connection with the payment of the Note Amount and the donation or transfer of the Approved Excess Surplus to the Foundation, BCBSLA will issue, and the Foundation will accept and agree to the terms of, a funding agreement which requires the Foundation, subject to the satisfaction of certain conditions, to donate the amount it receives in connection with the Proposed Reorganization (less amounts for applicable taxes and expenses) to a newly established special charitable trust (the “Trust”), which would be established under the laws of the State of Louisiana and would have the same purpose of improving the health and lives of the people of the State of Louisiana.”

(c) **Section 1.4.** Section 1.4 of the Current Plan is hereby amended and restated in its entirety to read as follows:

“This Plan and the amendment and restatement of the Current Articles contemplated by Section 1.1 (the “Articles Amendment”) will become effective upon the date and time of filing of appropriate Articles of Amendment by the Recorder of Mortgages for the Parish of East Baton Rouge, Louisiana, and a Certificate of Compliance with the Louisiana Department of Insurance as provided in the Louisiana Demutualization Law unless a later date and time are specified in the Articles Amendment, in which event this Plan and the Articles Amendment will become effective and take place at the later date and time (which shall not be later than the tenth day after the Articles Amendment is recorded in accordance with LSA-R.S. § 22:236.8.(C)). The effectiveness of this Plan is conditioned upon, among other things, (1) approval of this Plan, which includes the Acquisition, by the Commissioner, (2) approval of this Plan by the Members at the Special Meeting, as further described in Article X, and (3) the satisfaction of the conditions set forth in Article VI of the Acquisition Agreement (a copy of which is attached hereto as Exhibit C).”

(d) **Section 9.1.** Section 9.1 of the Current Plan is hereby amended and restated in its entirety to read as follows:

“This Plan and the Proposed Reorganization, which includes the Acquisition, are subject to the approval of the Commissioner. The Commissioner will hold a public hearing on these matters pursuant to LSA-R.S. 22:236.4 (the “Public Hearing”).

(e) **Section 9.4.** Section 9.4 of the Current Plan is hereby amended and restated in its entirety to read as follows:

“In the event that the Commissioner approves this Plan and the Proposed Reorganization, which includes the Acquisition (such approval, the “Commissioner’s Order”), notice of the Commissioner’s Order will be mailed by first class mail following the issuance of the Commissioner’s Order to BCBSLA’s Members. Such notice will be mailed to the address of each Member of BCBSLA as such address is shown

on BCBSLA's records on the Record Date (or such other address as may be provided in writing to BCBSLA by the Member within a reasonable period of time prior to the mailing of the notice)."

(f) Section 11.5. The following sentence is added to the end of Section 11.5 of the Current Plan:

"All directors of the Foundation will also become members of the board of trustees of the Trust pursuant to the organizational documents of the Trust."

(g) Defined Term. The following defined term is hereby added to Section 12.2 of the Current Plan in appropriate alphabetical order:

"Trust" shall have the meaning specified in Section 1.2."

(h) Exhibit E. Exhibit E to the Current Plan is hereby amended and restated in its entirety as set forth on Schedule 1 attached hereto and made a part hereof.

2. Full Force and Effect. As amended by the terms hereof, the Plan of Reorganization remains in full force and effect and is hereby ratified and confirmed in all respects.

3. Capitalized Terms. All references to the "Plan of Reorganization" shall now refer to the Plan of Reorganization as amended by this Amendment.

4. Governing Law. The terms of this Amendment will be governed by and construed in accordance with the laws of the State of Louisiana.

Schedule 1

Exhibit E

See attached.

Exhibit E - Eligible Member Payment Methodology

Values shown are based on available data and good faith estimates as of the Adoption Date January 23, 2023. This Exhibit will be updated with revised values as of the Reorganization Effective Time.

Valuation Calculations

Cumulative Member Months ¹	391,210,584
Eligible Member ² Months	35,276,035
Eligible Member Months ³ as a % of Cumulative Member Months	9.02%
Transaction Valuation ⁴	\$ 3,413,000,000
Total Eligible Member Consideration	\$ 307,755,241

Number of potential Eligible Policies as of the Adoption Date (1/23/23)	101,617
Consideration per Eligible Member per Eligible Policy	\$ 3,029

Definitions For Purposes of Exhibit E Only

- 1) Cumulative Member Months means total number of months an individual was covered by an insurance policy issued by BCBSLA or one of its subsidiaries since BCBSLA was established in 1975.
- 2) Eligible Member means a fully insured group or individual policyholder of an active (not terminated) BCBSLA insurance policy as of the date of adoption of the Plan of Reorganization by the Board of Directors. Each insurance policy is permitted one vote.
- 3) Eligible Member Months means the total number of months an individual was covered by an insurance policy issued by BCBSLA to an Eligible Member since BCBSLA was established in 1975.
- 4) Transaction Valuation means the aggregate of the Base Purchase Price under the Acquisition Agreement plus the estimated Closing Surplus plus the estimated Approved Excess Surplus.

Comments/Notes

Cumulative Member Months and Eligible Member Months are based on available data beginning in 2010, and good faith estimates derived from data trends in enrollment and statutory filings with the Louisiana Department of Insurance prior to 2010. The values shown here represent data for potential Eligible Members as of the Adoption Date (January 23, 2023) and in accordance with the methodology reviewed and determined fair by the consulting investment banker and actuarial experts.

First Amendment to the Agreement and Plan of Acquisition

[See attached]

AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF ACQUISITION

This Amendment No. 1, dated as of December 13, 2023 (this “Amendment”), to the Agreement and Plan of Acquisition, dated as of January 23, 2023 (the “Agreement”), is made and entered into by and among Elevance Health, Inc., an Indiana corporation (“Parent”), ATH Holding Company, LLC, an Indiana limited liability company (“Purchaser”), Louisiana Health Service & Indemnity Company (d/b/a Blue Cross and Blue Shield of Louisiana), a Louisiana mutual insurance company (the “Company”), and The Accelerate Louisiana Initiative, Inc. (the “Foundation” and, together with Parent, Purchaser and the Company, the “Parties”).

WHEREAS, pursuant to Section 9.3 of the Agreement, the Parties desire to amend the Agreement and the Company Disclosure Letter to (1) reflect that the Foundation has redomiciled from Delaware to Louisiana, (2) reflect the entry into a funding agreement by the Company and the Foundation as outlined below, (3) updates of a technical nature regarding the regulatory filing/review process, and (4) updates to certain provisions related to the fact that the closing would occur in 2024 rather than 2023.

NOW, THEREFORE, in consideration of the foregoing recitals and the agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1. Redomicile.

The word “Delaware” in the Preamble of the Agreement and in Exhibit A - Form of Promissory Note, is hereby replaced with the word “Louisiana”, to reflect the fact that the Foundation has redomiciled from Delaware to Louisiana.

2. Funding Agreement.

- (a) Section 1.6 of the Agreement is hereby amended to include a new subsection (g) to read in its entirety as follows:

“(g) At the Closing, in connection with the Company’s payment to the Foundation of the Note Amount in satisfaction of its obligations to the Foundation under the Note, as well as the payment or transfer of the Approved Excess Surplus to the Foundation, the Company and the Foundation shall execute and deliver a funding agreement containing the terms outlined in Exhibit F.”

- (b) A new exhibit shall be added to the Agreement as Exhibit F, which new exhibit shall be as set forth on Exhibit A attached hereto.

3. Employee Benefits and Executive Compensation-Related Matters.

- (a) Section 5.5(a) of the Agreement is hereby amended and restated to read in its entirety as follows:

“(a) From the Closing Date through the date that is the one-year anniversary of the Closing Date (the “Continuation Period”), Purchaser shall, or shall cause one of its

Affiliates (including the Company Entities) to, provide each employee of each Company Entity who continues to be employed by a Company Entity, Purchaser or any of their respective Affiliates following the Closing (a “Continuing Employee”) with (i) a salary or hourly wage rate not less than equal salary or hourly wage rate as provided to such employee immediately prior to the Closing Date; (ii) a target annual bonus opportunity, and a target long-term bonus opportunity that are substantially comparable in the aggregate to the target cash annual bonus opportunity and the target cash long-term bonus opportunity provided to such Continuing Employee immediately prior to the Closing Date (for the avoidance of doubt such opportunities may be provided in the form of either cash or equity, or a combination thereof); and (iii) other employee benefits (excluding any severance, annual and long term cash bonuses and equity or equity-based awards) that substantially comparable in the aggregate to those provided to such Continuing Employee immediately prior to the Closing Date. From the Closing Date through the date that is the two-year anniversary of the Closing Date, Purchaser shall, or shall cause its Affiliates (including, for the avoidance of doubt, the Company Entities) to provide, each Continuing Employee with severance cash and benefits (excluding any equity or equity-based awards) entitlements and protections no less favorable than those set forth on Section 5.5(a) of the Company Disclosure Letter. The Parties acknowledge and agree that, following the date of this Agreement and effective at Closing, the Company shall offer and enter into retention and severance agreements with the officers of the Company identified on Section 4.1(c) of the Company Disclosure Letter, containing the terms and conditions set forth in Section 4.1(c) of the Company Disclosure Letter.”

(b) Section 5.5(d) of the Agreement is hereby amended to remove references to 2023 and replace such references to references to 2024.

(c) Section 5.5(e) of the Agreement is hereby removed and to be left “RESERVED”.

(d) Section 4.1(c) of the Company Disclosure Letter (Compensation and Benefits) is hereby amended and to read in its entirety as set forth on Exhibit B hereto.

4. MISCELLANEOUS

4.1 Full Force and Effect. As amended by the terms hereof, the Agreement remains in full force and effect and is hereby ratified by the Parties. Nothing herein shall be deemed to be a waiver of any provisions of the Agreement or cure any breaches under the Agreement. Each Party represents and warrants to the other Parties that this Amendment has been duly and validly executed and delivered by such Party and constitutes the valid and legally binding obligations of such Party enforceable in accordance with its terms.

4.2 Acknowledgement. The parties acknowledge and agree that the LA Form A Filing, and approval of such, may not be required as the information required for a change of control may be filed as part of the LDI Filing and the approval of the change of control may be accomplished in conjunction with and as a part of the LDI Filing.

4.3 Capitalized Terms. Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Agreement. All references to the “Agreement” shall now refer to the Agreement as amended by this Amendment.

4.4 Binding. This Amendment shall be binding upon and inure to the benefit of the Parties, their heirs, personal representatives, successors and assigns.

4.5 Entire Agreement. This Amendment (together with the Agreement) contains the entire agreement of the Parties with respect to the subject matter hereof, and may not be amended or modified except by an instrument executed in writing in accordance with the terms of the Agreement.


4.6 Counterparts. This Amendment may be executed in counterparts, each of which (or any combination of which) when signed by all of the Parties shall be deemed an original, but all of which when taken together shall constitute one agreement. Executed copies hereof may be delivered by facsimile or other electronic means such as by transfer of a PDF file by electronic mail and upon receipt shall be deemed originals and binding upon the Parties.

[Signature page follows.]

IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed, as of the date first above written.

COMPANY:

**LOUISIANA HEALTH SERVICE &
INDEMNITY COMPANY,
D/B/A BLUE CROSS AND BLUE SHIELD OF
LOUISIANA**

By: 
Name: I. Steven Udvarhelyi, M.D.
Title: President and Chief Executive Officer

PURCHASER:

ATH HOLDING COMPANY, LLC

By:  _____
Name: Mark Kaye
Title: President

PARENT:


ELEVANCE HEALTH, INC.

By:  _____
Name: Mark Kaye
Title: Executive Vice President &
Chief Financial Officer

FOUNDATION:

**THE ACCELERATE LOUISIANA
INITIATIVE, INC.**

By: _____



Name: Thomas Barfield, Jr.

Title: President

Exhibit A:

Exhibit F

Terms of Funding Agreement

If certain conditions are satisfied, as outlined further below, the Foundation would donate or contribute the funds it receives in connection with the Reorganization to a newly established special charitable trust (as referred to herein, the “Trust”). The Trust would have the same general purpose as the Foundation of improving the health and lives of the people of the State of Louisiana. The Trust would be established under the laws of the State of Louisiana and it is intended that the Trust will be exempt from federal income tax as an organization described in Section 501(c)(4) of the Code.

Until the earlier of the initial twelve years of its existence or the achievement of certain milestones or criteria (to be established by the board of trustees of the Trust, after consultation with the Louisiana Department of Health and the Louisiana Department of Children & Family Services, and other such state departments as appropriate to properly develop milestones and criteria), the Trust would have primary areas of focus within that general purpose, which would be related to:

- helping move Louisianians from dependence to independence, with a priority of assisting individuals and families to move from depending on government programs to a life of independence through jobs, coaching, and assistance in the transition,
- improving health outcomes by addressing chronic illnesses, disabilities and health concerns through a focus on diabetes, maternal/infant health, and mental health,
- health care workforce development through programs designed to match the demand for the health care workforce in Louisiana while addressing the excess demand on training institutions and risk of out-of-state migration, which may include, without limitation, marrying training for Certified Nurse Assistants (CNAs) with high school curricula and graduation schedules to expedite the process of earning CNA qualifications, balancing the demand for nurses with the limited pipeline of nurses from Louisiana universities, creating more practical and flexible ways for nursing capacities to be increased, augmenting dedicated resources to attract high quality faculty to university nursing programs, and exploring ways to increase funding, commitment, and employment opportunities for in-state health care jobs, and
- optimizing government performance (in particular, state health care, workforce, and social service agencies), which may include, without limitation, providing expertise and structured training academies for senior level executives in specific state agencies, providing bench training for the future leaders of Louisiana state government, providing technical resources to assist state agencies in integrating eligibility systems and modernizing customer-facing interfaces through mobile devices, and surfacing best practices and technical assistance to supercharge agency performance and program optimization.

For each of the Priority Areas outlined above, the Trust may allocate a relatively small portion of its resources to innovation, research and development, and pilot programs designed to improve the health, health outcomes, and social determinants of health in Louisiana. Other than Pennington Biomedical Research Center, educational institutions and institutions of higher education shall not be eligible to receive these resources. The Trust would comply with the restrictions that apply to public charities

described in Code Section 501(c)(3) with respect to influencing legislation and participating in political campaign activity.

The Trust will be organized and operated exclusively for the social welfare purpose of improving the health and lives of the people of Louisiana. The Trust will also be prohibited from the amendment of certain provisions regarding government oversight and the purpose and disposition of the assets of the Trust without the consent of a court of competent jurisdiction.

The board of trustees of the Trust would consist of nine to eleven members, which would include the existing four board members of the Foundation (C. Richard Atkins, D.D.S., Thomas A. Barfield, Jr., Jerome K. Greig and Charles Brent McCoy), one member selected by the Governor of the State of Louisiana (which will not be an employee or official of the government of the State of Louisiana unless the Trustees consent to the appointment of such individual), and the remaining board members would be selected by the then current members of the board of trustees (i.e. self-perpetuating board members). It is also expected that the Louisiana Commissioner of Insurance would be offered an observer role on the board of the Trust (which would be a non-voting and non-compensated position).

It is expected that new legislation in the State of Louisiana will be needed to create this special charitable trust, as existing laws in Louisiana do not provide sufficient flexibility for a private charitable trust of this magnitude to operate in a commercially reasonable manner. In particular, existing trust law does not allow for sufficient delegation of organizational management to traditional governance structures such as committees, executives, and employees, nor does it provide for market-standard indemnification of board-level leadership, which are crucial to recruiting appropriate personnel to the organization in trustee and management roles.

If the Closing occurs, the Foundation would retain as a custodian the funds it receives in connection with the Plan of Reorganization until the date that is 12 months from the Closing (the “Expiration Date”). During that period, the Foundation will not make any grants and will only deploy funds for the purposes of recruiting staff, initiating start-up operations, and paying for applicable taxes and other expenses. It is expected that during this 12-month period, the conditions below will be satisfied; however, if they are not satisfied, then the Foundation will seek to convert from an organization exempt under Code Section 501(c)(4) to an organization exempt under Code Section 501(c)(3), and upon such conversion, the Foundation would be free to operate in accordance with its organizational documents. If the conditions are satisfied by the Expiration Date, the Foundation would donate or contribute to the Trust all of the funds it has received in connection with the Plan of Reorganization (less any amounts paid as required by applicable law for taxes or otherwise paid pursuant to the Agreement or as operating expenses).

As described above, the Foundation shall receive the Approved Excess Surplus at the Closing and Note Amount immediately following Closing, and the Adjustment, if applicable, following the Closing, and shall, following and subject to the satisfaction of the following conditions, promptly donate the total amount it has received (less any amounts paid as required by applicable law for taxes or otherwise paid pursuant to the Agreement or as operating expenses) to the Trust, subject to the following conditions: (a) the Trust will adopt and have in place a trust agreement and bylaws containing the material terms and conditions that are summarized below under “Summary of Material Terms of Trust”; (b) the initial Board of Trustees of the Trust will include those individuals identified above, and the remaining trustees will be selected as described above; (c) the Trust will have received an affirmative determination from the IRS of

the Trust's status as exempt from federal income tax under Code Section 501(c)(4); (d) the Trust will have agreed to assume all debts and liabilities of the Foundation; and (e) new legislation will be enacted and in force in the State of Louisiana ("Proposed Legislation") that is in substantial conformance with the summary set forth below under "Proposed Legislation."

As referenced above, in the event that each of the above conditions are not satisfied by the Expiration Date, the Foundation will retain the funds and deploy them in accordance with its organizational documents and will be obligated to seek to convert from an organization exempt under Code Section 501(c)(4) to an organization exempt under Code Section 501(c)(3), and to take such other actions as shall be necessary and advisable to achieve said result, as soon as reasonably practicable following the Expiration Date.

Summary of Material Terms of Trust

The Trust will be organized and operated exclusively for the social welfare purpose of improving the health and lives of the people of Louisiana. The Trust will provide for the composition of the Board of Trustees of the Trust as outlined above. The Trust will also be prohibited from the amendment of certain provisions regarding government oversight and the purpose and disposition of the assets of the Trust without the consent of a court of competent jurisdiction.

Proposed Legislation

The Proposed Legislation, as enacted, must provide for delegation of authority of the Board of Trustees of the Trust to officers, employees, and agents, the indemnification of trustees, officers, agents and third parties, limitations on the liabilities of trustees, officers, and agents, and the assumption of liabilities in connection with or related to donations or contributions, in each case in a manner that is no less than the corresponding standards under Louisiana law for nonprofit corporations. The Proposed Legislation, as enacted, must also permit the trust instrument to be amended by the trustees without court involvement, except certain provisions regarding government oversight and the purpose and disposition of the assets of the Trust. In addition, the Proposed Legislation, as enacted, must not (i) change the purpose of the Trust, (ii) require amounts be paid to specific recipients or causes or (iii) change the board of trustees of the Trust. Finally, no amendments to the Proposed Legislation that are enacted that materially alter the terms above would be allowable.

Exhibit B:

Company Disclosure Letter – Section 4.1

(c) Compensation and Benefits.

1. The Company has entered, and shall continue to enter, into a new retention arrangement (“New Retention Agreements”) with each Officer of the Company who is not currently party to an individual retention agreement and each Officer that is hired consistent with the Agreement and this Schedule 4.1(c), and each New Retention Agreement shall be substantially similar to the form provided by the Company to Purchaser.
2. The Company has provided, and shall continue to provide, each Officer of the Company, other than the Chief Executive Officer of the Company, with a new CIC Severance Agreement that shall be substantially similar to the CIC Severance Agreement provided by the Company to Purchaser.
3. As part of its 2023 year-end annual review, the Compensation Committee will adopt, and the Board subsequently will approve, its ordinary course annual compensation and performance reviews and merit increase cycle, with an expected general increase of 5.25% for employee compensation with the pool for merit increases and such pay increases to be implemented to be effective on or before March 1, 2024; provided that the Company shall consult with Purchaser for any such increases for Officers which exceed 7.5% individually.
4. For all open cycles of the Company LTIP, awards under the Company LTIP shall continue to be paid according to the schedule applicable to such awards, subject to the following:
 - a. For the 2021-2023 cycle of the Company LTIP, the Company will determine the value of awards in the ordinary course of business and consistent with past practice and based on actual performance, and such awards will be paid at a date determined by the Company in the ordinary course of business and consistent with past practices, which shall be no later than March 15, 2024.
 - b. For the 2022-2024 cycle, 2023-2025 cycle and 2024-2026 cycle of the Company LTIP, contingent on the Closing, the Company will set the value of awards under the applicable cycle based on the target level of performance. Such awards will vest based on continued employment through the end of the applicable performance period (subject to earlier prorated vesting (based on employment during the performance period) and payment upon retirement, death, disability, involuntary termination without cause, or good reason termination).
5. For awards under the Company AIP for 2023, awards will be determined based on actual performance by the Company in the ordinary course of business and consistent with past practice, and such awards will be paid at a date determined by the Company in the ordinary course of business and consistent with past practices, which shall be no later than March 15, 2024.
6. For awards under the Company AIP for the pre-Closing period of 2024, effective as of the Closing, the Company shall set the value of each such individual award to be the target value applicable to the individual award for such period (each, a “2024 Stub Period Bonus”). Company AIP awards for 2024 will be paid at a date determined by the Company in the ordinary course of business and consistent with

past practices, which shall be no later than March 15, 2025, and consistent with applicable employment or severance agreements.

7. Notwithstanding Section 4.1(c)(vi) of the Agreement, the Company may, following 3-day advance notice to Purchaser, make offers of employment to, engagement of services of, or terminate (other than for cause, which shall not require advance notice) the employment or services of any Officers. Following receipt of the notice described in the preceding sentence, Purchaser shall have opportunity to review and consult with the Company on any such proposed hire who would be an Officer for the applicable 3-day period.
8. The Company may make changes in broad-based health and welfare plans in the ordinary course of annual review of such plans consistent with past practice; provided that such changes do not materially increase the costs of such health and welfare plans.
9. The Company adopted a new incentive plan for eleHealth Holdings, a managed services organization, as well as its subsidiaries, in February 2023, in a form provided to the Purchaser prior to the date hereof.